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Abstract 
Many people seek individualised homeopathic treatment, however its use 
remains controversial. There have been suggestions that any improvement 
of the symptoms of those seeking individualised homeopathic treatment is 
solely down to the time and attention given to the patient by the homeopath. 
This aim of this thesis is to explore the question “is homeopathic treatment 
involving a homeopathic consultation and a homeopathic remedy any 
different to spending time with an empathetic practitioner, in the treatment of 
irritable bowel syndrome?” 
This study involved a systematic review of homeopathic treatment for 
irritable bowel syndrome and a randomised controlled trial comparing 
individualised homeopathic treatment to supportive listening and usual care. 
The primary outcome measure was the change in irritable bowel symptom 
severity score at 26 weeks. Differences between the three arms were 
assessed using independent t-tests and ANCOVA. 
A qualitative study nested within the randomised controlled trial involved 
qualitative interviews with a proportion of the participants in both the 
homeopathic treatment and supportive listening arms. This was to explore 
participants’ experiences of the treatment they received, and what, if 
anything about the treatment they felt led to any improvements. 
The systematic review of homeopathic treatment for irritable bowel 
syndrome identified two eligible RCTs, a meta-analysis of the results of 
these trials indicated a benefit of homeopathic treatment over placebo. 
However the results of this review should be viewed with caution as it is 
possible that there was a degree of bias associated with these two trials.  
In the randomised controlled trial, no significant differences were found 
between homeopathic treatment and supportive listening, when using t-tests 
or ANCOVA to compare mean change in IBS-SSS between baseline and 26 
weeks.  
The qualitative interviews identified four different typologies that explained 
what patients believed to have led to changes in their general health and/or 
irritable bowel symptoms.
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1  
1 Introduction  
This thesis reports a study of the effectiveness of homeopathy in the 
treatment of irritable bowel syndrome (IBS). The aim of this thesis is to 
evaluate whether or not homeopathic treatment involving a homeopathic 
consultation and a homeopathic remedy (hereafter referred to as 
individualised homeopathic treatment or IHT), is effective in the treatment of 
IBS.  
The idea for this thesis began in 2005 following the publication of a meta-
analysis of trials of homeopathy that concluded that homeopathy was no 
better than placebo (Shang et al. 2005). This publication led the author to 
consider previous trials of homeopathy and their strengths and weaknesses. 
The author has worked as both a professional homeopath, and as a chemist 
in commercial research. This combined experience led her to question 
whether or not it was possible to carry out a study into the effectiveness of 
IHT that was acceptable to both homeopaths and the scientific community. 
The validity of studies designed to test the effectiveness of IHT have in the 
past been criticised by homeopaths for not being a true reflection of how IHT 
is delivered in practice, and by the scientific community for methodological 
weaknesses, in particular being biased towards IHT. The author therefore 
wanted to explore whether it was possible to design a trial of IHT that was 
true to how homeopathic treatment is delivered in practice, without the 
methodological weaknesses that have in the past been associated with trials 
of homeopathy.  
One of the criticisms of homeopathy is that it is the time and attention given 
to the patient by the homeopath that leads to any improvement in patient 
outcomes (McKie 2005). Considering this criticism led to the question “is 
homeopathic treatment involving a homeopathic consultation and a 
homeopathic remedy any different to spending time with an empathetic 
practitioner?” In an attempt to answer this question this thesis has three 
components, a systematic review into the effectiveness of IHT for IBS, a 
randomised controlled trial (RCT) of IHT and nested within the RCT, a 
qualitative study exploring RCT participants’ beliefs about the treatment they 
received. A qualitative element was included in the study because, whilst the 
RCT would be able to give information about the effectiveness of IHT, it 
would not be able to give information about what it was about IHT that led to 
any improvements in IBS and/or general health. This thesis therefore 
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describes the three components of the study, with this chapter providing an 
overview of the thesis and its structure. 
Chapter 2 lays out the conceptual issues and details the complexity that had 
to be tackled before proceeding. It also provides an explanation of what 
homeopathy is and the different types of homeopathic treatment. Chapter 3 
describes the systematic review of homeopathy for IBS, giving information 
on the methods used, search strategies and results found. Using the MRC 
framework for complex interventions, IHT can be thought of as a complex 
intervention (Medical Research Council 2000). Complex interventions are 
interventions comprising of a number of elements, which may operate both 
independently and inter-dependently. These elements appear to be essential 
to the functioning of the intervention, however it is difficult to precisely 
identify the active ingredient of the intervention (Medical Research Council 
2000). IHT can be thought of as complex intervention with two components; 
the homeopathic consultation and the homeopathic remedy, in addition to 
which, is the possibility of an interaction between these two components. 
This means that, as with all complex interventions, there are inherent 
challenges in designing trials of IHT. These challenges are discussed in 
Chapter 4 along with the types of trials that have so far been used to explore 
the effectiveness of IHT and other forms of homeopathy. In light of these 
difficulties Chapter 5 considers to how to construct an attention control for 
IHT as an alternative to the traditional placebo-controlled trial, defining a 
potential attention control for IHT, namely supportive listening. Chapter 6 
explains the methodology for both the RCT and the qualitative study and 
Chapter 7 describes the methods used in these studies. Due to the belief 
held by some, that homeopathy is nothing more than a placebo and it is 
unethical to carry out trials of placebo treatments (Smith 2012), there are 
ethical concerns associated with carrying out a trial of homeopathy. 
Therefore Chapter 8 focuses on this and other ethical concerns associated 
with both the RCT and qualitative study. Also contained within this chapter is 
a discussion on the potential for author bias and how this was dealt with. 
Details of the results of the RCT are given in Chapter 9, whilst results from 
the qualitative study are given in Chapter 10. Finally Chapter 11 gives a 
discussion of the results of each of the components of the thesis before 
discussing what the combined results say about the effectiveness of 
homeopathic treatment for IBS. Chapter 10 also discusses strengths and 
limitations and some of the challenges involved in conducting this study. 
Implications for practice and policy, along with recommendations for future 
study are made in Chapter 11. 
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This thesis contributes to the literature on the design of trials for assessing 
the effectiveness of IHT. It provides information on the feasibility of carrying 
out a trial comparing the effectiveness of IHT to an attention control for 
patients with IBS, which may be used to inform the design of future trials. In 
addition it contributes to the literature base on the effectiveness of 
homeopathy for IBS. The qualitative study contributes to the knowledge 
regarding patients perceptions of what, if anything about IHT that leads to 
any improvements in IBS symptoms and general health.
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2 Homeopathy and placebo 
This chapter sets out to describe the contextual issues that underpin this 
thesis. Knowledge of these contextual issues is necessary to understand not 
only why the evaluation of homeopathy is important but also why the 
evaluation of homeopathy is not straightforward. The chapter opens with a 
brief explanation of complementary and alternative medicine (CAM) before 
moving on to discuss homeopathy, in terms of the history of homeopathy 
and the different types of homeopathy available. Although homeopathy is 
available on the NHS, its inclusion is contentious (House of Commons 
Science and Technology Commitee 2010). Therefore, the reasons why 
homeopathy is so contentious, and the relevance of evidence based 
medicine to the debate about whether or not to include homeopathy on the 
NHS is explored. Much of the controversy surrounding homeopathy is due to 
the view that it is a placebo treatment (Ernst 2010), consequently the 
chapter concludes with an exploration of the nature of placebos and different 
understandings of what a placebo is.  
2.1 Complementary and alternative medicine 
CAM is a broad and constantly changing discipline, which makes it difficult to 
define. The website for the United States National Center for 
Complementary and Alternative Medicine (NCCAM) defines CAM as “a 
group of diverse medical and healthcare systems, practices and products 
that are not generally considered part of conventional medicine.” (National 
Center for Complementary and Alternative Medicine 2012). This quote 
reflects the diversity of treatments that could be considered to be CAM. The 
fact that the quote mentions that CAM treatments are not “generally” 
considered part of conventional medicine highlights the fact that there is no 
consensus as to whether some treatments should be considered to be part 
of CAM, or whether they should be considered to be part of conventional 
medicine. It is this uncertainty that leads to the difficulty in providing an 
absolute definition for what is, and what isn’t, a CAM treatment.  
CAM has been a growing field in the UK (House of Lords 2000; Ernst 2008) 
since the 1980’s.There was little research into its exact usage until the end 
of the 20th century when studies showed that 15-20% of UK citizens used 
CAM in some form each year (Thomas, Nicholl and Coleman 2001; Thomas, 
Coleman and Nicholl 2003). A questionnaire-based survey found that this 
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was due to patients’ dissatisfaction with the results of conventional medicine 
(Astin 1998). Furthermore interviews with CAM users found that 
conventional medicine was viewed as lacking in holism, where the body is 
treated as separate parts rather than being viewed as a whole system 
(Barrett et al. 2003). CAM is viewed by some as being more individual than 
conventional medicine, prioritising the doctor-patient relationship and 
promoting wellbeing rather than healing illness (Veeramah and Holmes 
2000; Bishop, Yardley and Lewith 2006), along with seeing the body as a 
whole system (Barrett et al. 2003). The majority of CAM treatments seek to 
treat the whole person rather than the diseased part and involve a much 
longer consultation time than that provided in the NHS. The bulk of CAM 
consultations are paid for out of pocket (Thomas, Nicholl and Coleman 
2001), which gives an indication of the values that people place on CAM. 
This thesis is concerned with homeopathy, a form of CAM. To put 
homeopathic treatment into context the basic principles of homeopathy are 
explained below. 
2.2 Homeopathy 
Homeopathy (also spelt homoeopathy) can be thought of as a system of 
medicine based on treating the individual, by giving medicines known as 
remedies, prepared from substances that have been highly diluted and 
succussed (shaken). It was first developed by Samuel Hahnemann in the 
18th century in Germany and works on the principle of “like cures like” - that 
is, a substance that would cause symptoms in a healthy person cures those 
same symptoms in illness. For example, one remedy which might be used in 
a person suffering from insomnia is coffea, a remedy made from coffee.  
Hahnemann originally trained as a medical doctor but became disillusioned 
by the brutal medical practices at the time and because of this started 
working as a translator (Blackie 1990). Dissatisfied with the explanation that 
the reason cinchona relieved malaria symptoms was because it was bitter, 
he decided to take some himself. He found that he then developed some of 
the symptoms of malaria and came up with the theory that “like cures like”, 
i.e. something that causes symptoms in a well person will cure those same 
symptoms in a sick person (Vithoulkas 1998). Following on from this he 
began to test more substances, some of which were poisons, leading to his 
decision to dilute and succuss them prior to taking them (Blackie 1990). He 
claimed that, from his observations, the more dilute a substance was, the 
more powerful its effects as long as it was succussed (Hahnemann 1996). It 
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is these high dilutions, many of which are beyond Avogadro’s number which 
is 6 x 10-23 (meaning none of the original substance is left), that have led to 
scepticism about homeopathy and questions over how something diluted 
beyond Avogadro could exert any physical effect. Many detractors of 
homeopathy see it as implausible and there has been a number of calls for 
the end of homeopathy, such as the editorial in the Lancet in 2005 entitled 
“The End of Homeopathy” (Anonymous 2005a). Yet homeopathy is more 
than just the remedy, the consultation and the tailoring of the remedy to the 
individual person were key aspects of Hahnemann’s Organon, (the book 
written by Hahnemann explaining homeopathy and its philosophy). 
Therefore criticising homeopathy on the grounds of the implausibility of the 
remedy fails to take into account whether or not there is any effectiveness 
specific to the homeopathic consultation and remedy matching process.  
Despite the controversy surrounding homeopathy, it is a popular 
complementary medicine which has been available on the NHS since its 
inception in 1948. Not only is it integrated into the NHS in parts of the UK, it 
is also integrated into the health systems of other countries such as 
Pakistan, India, Sri Lanka and Mexico (World Health Organization 2002). It 
is one of the five most used CAM based therapeutic systems in the world 
(World Health Organisation 2001) and is popular in the UK, continental 
Europe, Asia and North America. A UK survey has shown that 1.2% of the 
population had consulted a homeopath in the 12 months prior to the survey 
and 8.6% had bought an over-the-counter homeopathic remedy (Thomas, 
Nicholl and Coleman 2001). It is possible that there may be a response bias 
to this survey, as the data was collected via a postal questionnaire, which 
would require that respondents be English speaking and literate. 
Furthermore those people who had used homoeopathy may be more likely 
to respond to a survey about CAM than people who had no interest in CAM. 
Therefore these results should be thought of as relating to the adult, literate 
English speaking population. Despite this a further survey, where 
supplementary questions about CAM usage were added to a National 
Omnibus Survey, found that 1.9% of the population had visited a homeopath 
in the past 12 months. The National Omnibus survey is carried out by the UK 
Office for National Statistics on behalf of the government, public and not for 
profit bodies, and aims to give a nationally representative estimate about 
individuals and households. Therefore whilst the possibility of a response or 
sampling bias cannot be ruled out, an Omnibus sample has been found to 
be comparable to Census data (Thomas and Coleman 2004). 
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2.2.1 Types of homeopathy and homeopaths 
The issue of whether “homeopathy” is more than placebo is compounded by 
the fact that the term “homeopathy” is used to describe several different 
styles of homeopathic treatment, classical, clinical and complex (Relton, 
O'Cathain and Thomas 2008). Classical also called individualised 
homeopathic treatment (IHT) (Katz et al. 2005) is the form most commonly 
practised in the UK.  
IHT involves a detailed case taking where the homeopath seeks to 
understand the patient’s symptoms and their experience of their symptoms, 
and from this prescribes a remedy individualised to that patient. The ideal of 
IHT is to identify one remedy that fits the totality of the patient’s symptoms 
and thus aims to address all that person’s problems. In contrast to this, in 
continental Europe, practitioners practice clinical homeopathy (sometimes 
known as therapeutic homeopathy or therapeutic prescribing), where 
prescriptions involve the use of specific remedies for individual diseases. It is 
of note that clinical homeopathy’s model of homeopathic prescribing is more 
aligned with the biomedical model of health and disease than the model 
used in IHT. For example if a person with irritable bowel syndrome and 
migraines were to go to a homeopath who used clinical homeopathy, they 
would usually receive two remedies, one thought to have an affinity with the 
gastrointestinal tract, and another thought to be one of the “headache” 
remedies. The consultation time would be relatively short because clinical 
prescribing does not require a complete picture of the patient to make a 
prescription, rather it merely requires the symptoms of the irritable bowel 
syndrome and those of the migraines. However if the same person went to a 
homeopath who prescribed according to the principles of IHT, the 
homeopath would ask questions not only about the irritable bowel syndrome 
and the migraines, but also about any other problems the person may be 
having, along with more general questions about the type of person they are, 
their likes and dislikes etc. The homeopath would then try to find one remedy 
that covers all the patient’s symptoms and also fits their general state. This 
one remedy would aim to address all the patient’s problems rather than 
breaking them up and prescribing for each problem, as is the way in 
conventional medicine. Thus homeopaths using the IHT model are less 
concerned with biomedical diagnoses and more concerned with the person’s 
symptoms picture. Looking to treat the whole person and not a disease 
label. 
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The final type of homeopathy is complex homeopathy, so called because it 
involves the use of homeopathic “complexes”, which are a combination of 
remedies and sometimes herbal medicines as well. These complexes are 
often available over the counter such as Pollena™, a homeopathic complex 
sold in the UK for hay fever. Complex homeopathy tends to be practised by 
practitioners trained in a variety of CAM therapies, rather than by 
homeopaths, and does not require a detailed description of symptoms.  
Another form of treatment known as isopathy is sometimes confused with 
homeopathy. This confusion arises because the substances prescribed in 
isopathy are diluted in the same way as homeopathic remedies. However, 
isopathy is not concerned with enquiring about symptoms but merely 
involves the prescribing of the thing thought to have caused the problem in 
the first place i.e. in poison ivy rash isopathy would advocate prescribing 
rhus tox a homeopathic medicine made from poison ivy (Coulter and Dean 
2007), whereas in IHT a homeopathic medicine would be prescribed based 
on the persons symptoms.  
In the UK there are two types of qualified homeopaths, professional 
homeopaths who have completed a three to four year course in homeopathy 
but are not trained doctors, and medical homeopaths who are trained 
doctors, vets or dentists with additional training in homeopathy. As it is the 
most common form of homeopathic treatment for chronic complaints, this 
thesis focuses on IHT (McCarney, Linde and Lasserson 2004). 
To provide a context for the debate surrounding the inclusion of homeopathy 
in the NHS, the next section will discuss evidence based medicine, the 
National Institute for Health and Clinical Excellence and how they relate to 
the inclusion of homeopathy within the NHS.  
2.3 Evidence based medicine 
The National Institute for Health and Clinical Excellence (NICE) is the 
independent organisation responsible for providing guidance on the 
prevention and treatment of ill health and the promotion of good health. 
NICE guidance aims to ensure that people living in England and Wales have 
the same access to medicines that are considered to be clinically effective 
and cost effective, and to reduce uncertainty about which treatments should 
be used (National Institute for Health and Clinical Excellence 2012). It should 
be noted that there is a difference between efficacy and effectiveness, with 
efficacy being whether the drug or procedure generates the required clinical 
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outcome under ideal conditions and effectiveness being; does the drug or 
procedure work under usual circumstances (Compher 2010).  
Evidence based medicine (EBM) arose as a consequence of variations in 
medical practice, with some treatments being used that had no evidence of 
effectiveness. The practice of EBM therefore requires the “conscientious, 
explicit and judicious use of current best evidence in making decisions about 
the care of individual patients” (Sackett et al. 1996) page 71. However this 
definition fails to take into account patient choice, therefore Evidence Based 
Nursing Practice suggests a definition by Muir Gray, which seems more 
helpful, "an approach to decision making in which the clinician uses the best 
evidence available, in consultation with the patient, to decide upon the option 
which suits the patient best" (Evidence Based Nursing Practice 2003). When 
thinking about individual patients, EBM means integrating the best available 
evidence with clinical expertise and patient choice. This means that, for the 
practice of EBM, research to judge the efficacy of treatments is needed, with 
the strongest evidence for effectiveness being the randomised controlled 
trial (RCT) or preferably systematic reviews of a number of high quality 
RCTs (Lohr, Eleazer and Mauskopf 1998). The rise in EBM has led to the 
demand that CAM therapies be subjected to the same rigorous assessment 
as conventional medicine, particularly with the use of RCTs to assess CAM 
(Miller et al. 2004). If a treatment is recommended by NICE the NHS is 
expected to fund that treatment, hence the need for evidence of the 
effectiveness of CAM therapies for them to be provided by the NHS. Where 
a CAM treatment is not available on the NHS, people who want it have to 
pay for it out of their own pocket, thus limiting patient choice to only those 
who can afford to pay. At the same time, it would be clearly undesirable for 
ineffective treatments to be paid for by the NHS. This means that there is a 
need for treatments to be evaluated, so that those treatments found to be 
beneficial, can be made available to all who desire, and would potentially 
benefit from, that treatment. 
2.4 Homeopathy and the NHS 
Historically homeopathy has been available on the NHS since the NHS was 
founded, and it has been up to individual doctors and PCTs to decide as to 
whether or not their patients can access it on the NHS. Although there are 
currently no NICE guidelines for homeopathic treatment, at present 
approximately 30 per cent of NHS primary care Trusts (PCTs) continue to 
fund homeopathic treatment (Moberly 2011). There are also three 
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homeopathic hospitals (Bristol, Glasgow and London), which provide 
outpatient treatment. However homeopathy’s availability on the NHS 
remains contentious: a recent report from the House of Commons Science 
and Technology committee stated that “the government should stop allowing 
the funding of homeopathy on the NHS” (House of Commons Science and 
Technology Committee 2010) page 45 paragraph 110. Much of the criticism 
levelled at homeopathy is that the remedy is no more than a placebo and it 
is the long consultation time with an empathetic practitioner that leads to any 
perceived effectiveness of homeopathic treatment (McKie 2005). This led 
the House of Commons report to conclude, “Placebos should not routinely 
be prescribed on the NHS. The funding of homeopathic hospitals – hospitals 
that specialise in the administration of placebos – should not continue” 
(House of Commons Science and Technology Committee 2010) page 45 
paragraph 111. The government’s response to this was thus, “our continued 
position on the use of homeopathy within the NHS is that the local NHS and 
clinicians, rather than Whitehall, are best placed to make decisions on what 
treatment is appropriate for their patients – including complementary and 
alternative treatments such as homeopathy - and provide accordingly for 
those treatments” (Cabinet Office 2010) page 4 paragraph 8. This statement 
appears to be in some conflict with EBM which relies heavily on evidence 
rather than clinical judgement. However the government may have political 
reasons for not wanting to completely remove homeopathic treatment from 
the NHS, such as not wanting to be seen to be limiting patient choice. 
Furthermore, although EBM requires that one seeks out evidence, the 
practice of EBM does not suggest that clinical judgement should be 
disregarded altogether, rather the four elements of: evidence, resource 
constraints, patient’s choice and clinical judgement should be used in 
decision making.  
Despite the government’s response to the Science and Technology 
Committee, there remains a strong lobby against CAM, and homeopathy in 
particular, as evidenced by Simon Singh’s recent campaign against Radio 
Surrey’s inclusion of a feature on homeopathy (Singh 2012). The focus of 
the anti-CAM lobby’s argument is that there is no evidence to prove CAM’s 
efficacy, and in the case of homeopathy, the implausibility of how the 
homeopathic remedy could act given current scientific understanding. The 
anti-homeopathy lobby and the movement against the inclusion of 
homeopathy on the NHS, has resulted in a number of PCTs discontinuing 
funding for homeopathy and the closure of the Tunbridge Wells 
Homeopathic Hospital. The reason for discontinuing funding for homeopathy 
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has been cited as being due to the lack of evidence as to its efficacy (NHS 
Wirral 2011). This reasoning is flawed, and does not explain the whole 
picture, as 46% of commonly used treatments have unknown effectiveness 
(Garrow 2007). However the lack of evidence of efficacy could be being 
used as a convenient excuse by some, to hide more political and economic 
reasons for not wishing to include CAM in the NHS.  
Whatever the reasoning, the refusal of some PCTs to fund homeopathy has 
had an impact on patients’ choice. It is therefore important to understand 
whether or not homeopathy works in terms of its continuing provision on the 
NHS. However how best to determine this has been the topic of much 
debate (Bell 2005). In addition it is also important to know whether or not 
homeopathy is a safe treatment. In light of this the next section discusses 
the ethical implications of homeopathy and trials of homeopathy. 
2.4.1 Ethics of trials of homeopathy 
In addition to the debate about whether homeopathy should remain available 
on the NHS, there have been questions raised over whether or not 
homeopathic treatment is ethical. In one of the most recent articles on the 
ethics of homeopathy Smith (Smith 2012) goes as far as to suggest that the 
implausibility of homeopathy makes it ethically unacceptable and that it is 
the moral duty of citizens to reject it. Furthermore there have been 
suggestions that trials of homeopathic treatment are unethical “There has 
been enough testing of homeopathy and plenty of evidence showing that it is 
not efficacious…” (House of Commons Science and Technology Committee 
2010) page 21 paragraph 77. “It is also unethical to enter patients into trials 
to answer questions that have been settled already” (House of Commons 
Science and Technology Commitee 2010) page 21 paragraph 78. However, 
stating that homeopathy as a whole is not efficacious is disingenuous, as 
there have been RCT trials and systematic reviews that have shown 
homeopathy to have been efficacious in certain conditions, such as 
childhood diarrhoea (Jacobs et al. 2003) and rheumatic disease (Jonas, 
Linde and Ramirez 2000). Writing these studies off without proper critique is 
not beneficial to people with these conditions who could potentially benefit 
from homeopathic treatment. In addition, given these results, it would be 
useful to understand further what it is about homeopathic treatment that 
leads to these apparent benefits. Whilst it is possible that the results of these 
trials are anomalies, and differences found where none really existed, this 
can be true of any studies where the results have not been replicated. 
Therefore until there is a definitive answer as to whether or not homeopathic 
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treatment works, there is justification in continuing to explore whether or not 
homeopathic treatment is beneficial. Furthermore research carried out into 
“ultra high dilutions” of substances diluted beyond Avogadro’s number has 
found some evidence of differences between ultra high dilutions made using 
a substance and distilled water and distilled water alone. This research is 
briefly discussed in section 2.5. Despite this, in a discussion of homeopathy 
from a utilitarian perspective, Smith (Smith 2012) goes even further by 
suggesting that because homeopathy is implausible then any positive results 
would necessarily be false positive results and these results, if reported, 
could lead to misinterpretation and unjustifiable credibility being given to 
homeopathy.  
The questions over the ethics of homeopathy have been compounded by an 
influential meta-analysis conducted by Shang (Shang et al. 2005). This 
meta-analysis was accompanied by an editorial in the Lancet questioning 
whether this was the end of homeopathy (Anonymous 2005a) because it 
had been unable to conclude that homeopathy was more effective than 
placebo. However, of the five systematic reviews that reviewed all RCTs for 
homeopathic treatment regardless of condition, four have concluded that 
homeopathic treatment is different to placebo (Kleijnen, Knipschild and 
Terriet 1991; Boissel et al. 1996; Linde et al. 1997; Cucherat et al. 2000). 
These systematic reviews did not specify a condition which they were 
studying, rather they identified all RCTs of homeopathic treatment for all 
conditions (that a RCT had been carried out for) and then carried out their 
review. It is questionable as to the relevance of these systematic reviews as 
they have tried to review homeopathy for all conditions and it may be that 
whilst homeopathy is effective for one condition it is ineffective for another, 
thus combining all conditions together could lead to erroneous or confusing 
results. In addition it is likely that there would be a high degree of 
heterogeneity between the trials, again leading to the possibility of erroneous 
conclusions. In fact some of the criticism of the Shang study (Shang et al. 
2005) lies in the high degree of heterogeneity between their included studies 
and the fact that their conclusions on the effectiveness of homeopathy 
depend on the set of analysed trials (Ludtke, Rutten and Rutten 2008). 
Hence, if they had chosen to analyse, from the trials they identified, a 
different set of trials than they chose, the results would be different. This is 
primarily due to the inclusion of one negative trial on preventing muscle 
soreness in long distance runners (Tveiten et al. 1998). Due to the high 
heterogeneity between the studies included in the meta-analyses carried out 
13  
as part of these five systematic reviews of homeopathy, it is difficult to 
ascribe any meaning to the results of these meta-analyses.  
Regardless of this controversy, the frequency with which people consult 
homeopaths may be some indication of the value which they place on the 
homeopathic approach (Spence and Thompson 2005) and hence the need 
to identify if it is effective, in order to inform patients.  
The view that homeopathy is a placebo, and therefore should not be used, 
feeds into a wider debate on the use of placebos and indeed the debate 
about what constitutes a placebo. This debate is reviewed in the following 
sections, however an overview of the research into ultra high dilutions is 
discussed first, some of which has found intriguing results.  
2.5 Ultra high dilutions 
This section provides a brief overview of some of the research that has been 
carried out into Ultra high dilutions (UHD’s). Whilst the area of study in this 
PhD is not about the basic science of UHDs, a brief summary is given here 
to give an outline of what UHD research might tell us about the nature of 
ultra-highly diluted solutions, such as those that form the basis of 
homeopathic remedies.  
Research into ultra-high dilution (also known as serial dilution and agitation), 
is concerned with the basic science behind homeopathy and the properties 
of UHDs. A systematic review published in 2007 (Witt et al. 2007) assessed 
the evidence base for laboratory studies of UHDs. These were not studies 
carried out on people or animals but studies exploring the physical 
properties of UHDs. Of 67 published studies that were evaluated, 75% found 
ultrahigh dilutions to have an effect, where an effect was taken to be any 
observed difference between the UHD and water, as measured by nuclear 
magnetic resonance (NMR), calorimetry and thermoluminecence. However it 
should be noted that there were large number of different experimental 
approaches used and that in a subject as controversial as homeopathy a 
publication bias is not unlikely. It is possible that studies that did not show 
any difference between UHD’s and water have not been published, and 
were therefore not included in Witt’s review i.e. there may be an element of 
publication bias at play. 
Studies carried out by independent laboratories measuring the physical 
properties of ultra-highly diluted solutions using techniques such as 
calorimetry, spectroscopy and thermoluminecence have been conducted 
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(Rey 2003; Elia et al. 2004; Roy et al. 2005; Rao et al. 2007). Such studies 
have found differences between homeopathically prepared solutions and 
control samples (such as water or other solvents). Whilst not giving 
information as to how homeopathic medicines may work, these experiments 
demonstrate that it is possible that ultra-high dilutions have specific physical 
properties, despite not containing any of the original molecules. The 
knowledge that UHDs may have specific physical properties and future 
exploration of these properties may lead to a greater understanding of how 
homeopathy may or may not work.  
The focus of this chapter will now move on to placebos and the placebo 
effect, beginning with a discussion on the nature of placebo.  
2.6 The nature of placebo 
The Oxford English Dictionary online gives the following definition of 
placebo: 
“a medicine or procedure prescribed for the psychological benefit to the 
patient rather than for any physiological effect. 
 a substance that has no therapeutic effect, used as a control in 
testing new drugs. 
 a measure designed merely to humour or placate someone: pacified 
by the placebos of the previous year, they claimed a moral victory 
Origin: late 18th century: from Latin, literally 'I shall be acceptable or 
pleasing', from placere 'to please'” (Oxford Dictionaries 2011), online source. 
This definition sets the scene for the idea that placebos inherently involve 
the deception of patients. Through giving the patient a substance or 
treatment that the patient believes will help them, it actually will help them, 
despite the fact that there is no evidence that the substance or treatment in 
question has any biological effect. This definition is not comprehensive in 
that it fails to take account of the fact that placebos can be effective in terms 
of reduction of symptoms and can lead to a therapeutic effect, which will be 
discussed later on in this section. Firstly, however, it is useful to provide a 
brief overview of the history of placebo to set the scene for current thinking.  
Prior to world war II, when paternalistic attitudes to the ethics of medicine 
prevailed, (i.e. before the era of informed consent where patients are now 
given all the facts and no attempts are made to deceive patients), placebos 
were routinely given as a means of granting patients peace of mind 
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(Kaptchuk 1998). Placebo was given to people as a kind of benign 
deception, in the thought that it would not harm the patients and the action of 
giving something to take may make them feel better. Thus they were given 
to humour patients rather than because they were thought to be effective. 
However things began to change during the 1950’s and placebos became 
commonly acknowledged as powerful following an estimate by Beecher that 
treatment with a placebo leads to an improvement in symptoms in 
approximately one third of cases (Beecher 1955). Beecher based this 
estimate on an analysis of 15 studies that had used a placebo, calculating 
the average percentage of patients who were satisfactorily relieved by a 
placebo across the 15 studies. The 15 studies comprised nine different 
conditions. However in his study Beecher didn’t take into account regression 
to the mean, natural history of the condition or concurrent interventions, 
which also have the potential of leading to an improvement. Therefore 
despite its wide acceptance, the figure of around 30% response to placebo 
may be misleading. Regression to the mean is the term used to describe the 
phenomenon that occurs when variables “regress to the mean”. If on first 
measurement a variable is found to be at either of the extreme ends of a 
scale, then it is likely that on a second measurement it will have moved 
closer to the average score i.e. those at the extreme ends of the scale will 
regress towards the mean (Torgerson and Torgerson 2008). Despite the 
problems with Beecher’s study the results remained unquestioned, with few 
medical researchers interested in quantifying the placebo effect, either in 
terms of investigating possible mechanisms of action or confirming 
Beecher’s results (Wampold et al. 2005). In addition to this, although 
Beecher surmised that the mechanism by which the placebo effect occurs 
deserved more study, until recently there had been little, if any interest in 
exploring this mechanism or mechanisms. 
It wasn’t until a publication in 2001 by Hróbjarsson and Gøtzche 
(Hrobjartsson and Gotzsche 2001) that people began to question Beecher's 
results. Hróbjarsson and Gøtzche claimed that there was little evidence to 
suggest that placebos had powerful clinical effects except possibly in 
treatments for pain (Hrobjartsson and Gotzsche 2001). Hróbjarsson and 
Gøtzche based this claim on a meta-analysis that they carried out to 
estimate the placebo effect. Hróbjarsson and Gøtzche identified trials 
published before 1999 that compared active treatment, placebo treatment 
and no treatment and compared the results of the placebo arm to the no 
treatment arm. Inclusion was not limited by condition; therefore a wide 
variety of conditions was included in this study. An update to this study was 
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published in 2004 with similar findings (Hrobjartsson and Gotzsche 2004). 
Hróbjarsson and Gøtzche 2004 concluded that they were unable to find 
evidence for a large effect for placebos in general. However there was the 
possibility of a small effect in pain studies that used a patient measured 
continuous outcome, but this could not be clearly distinguished from bias. 
The overall conclusion from both Hróbjarsson and Gøtzche’s studies, that 
there was little evidence to suggest that placebos had powerful clinical 
effects, fails to take into account of the fact that different disorders may have 
lesser or greater placebo effects (Wampold et al. 2005).  
Although overall estimates of the placebo effect may indicate that the 
placebo effect is not large, it could be that there is a large placebo effect for 
some conditions/situations and a smaller effect for others. Furthermore, 
Hróbjarsson and Gøtzche’s studies (Hrobjartsson and Gotzsche 2001; 
Hrobjartsson and Gotzsche 2004) failed to take into account the fact that the 
patients’ expectations regarding the efficacy of the treatment may differ for 
different treatments and/or different conditions. Patients’ expectations are 
important because they are part and parcel of the “placebo effect,” and it is 
through these expectations that placebos “work.” It is likely that factors such 
as how impressive the treatment is, how invasive it is, its plausibility, its cost 
and its perceived mechanism of action, will all play a part in patient’s 
expectations (Ernst and Resch 1995). Therefore it is possible that 
Hróbjarsson and Gøtzche’s 2001 and Hróbjarsson and Gøtzche’s 2004 
studies did not lead to an accurate estimate. Indeed in Hróbjarsson and 
Gøtzche 2001 it was admitted that there was significant heterogeneity in the 
outcomes produced by placebo in the studies they identified. This 
heterogeneity could be the result of variables other than the placebo effect, 
such as regression to the mean, which may not have been consistent across 
all studies. Alternatively it could be that there are different mechanisms for 
different conditions/settings i.e. the placebo effect is not heterogeneous in 
size or mechanism. However if the placebo effect genuinely varies across 
different conditions, then placebo must exist in some form or another. If it 
didn’t exist it would be impossible for one placebo to be more effective than 
another placebo (Kirsch 2005), and therefore placebo must exert some form 
of an effect. Whether or not this effect results from a single mechanism of 
action or whether different mechanisms of action occur in different situations 
is important. However of more importance is the fact that the placebo effect 
can vary because this signifies that it must exist. The studies used in 
Hróbjarsson and Gøtzche’s 2001 study have been reanalysed by Wampold 
(Wampold et al. 2005). In his reanalysis Wampold categorised each study as 
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to whether the design of the study was adequate to estimate the placebo 
effect and the degree to which it was expected that a placebo would help the 
disorder being studied. A study was considered to be adequate to estimate 
the placebo effect if it was; double blind, the participants were aware that 
they may receive a placebo and the placebo was not administered 
surreptitiously, and the treatment and the placebo were indistinguishable. 
The decision regarding the degree by which a placebo was expected to help 
was made through deciding whether the condition was amenable to 
psychological factors, with the theory that conditions amenable to 
psychological factor would be amenable to placebo. Wampold found that 
when the results from Hróbjarsson and Gøtzche’s 2001 meta-analysis were 
disaggregated on the two categories described above, evidence for a 
placebo effect was found. In fact a relatively large effect was observed in 
adequately performed studies where the condition was amenable to placebo 
effects and a continuous outcome was used (Wampold et al. 2005). 
However if the placebo effect varies according to condition, patients 
expectations, mode of delivery etc, then it is not something that is readily 
quantifiable (in terms of a single number that is true across all conditions and 
situations). In fact the placebo effect may not result from one single 
mechanism of action, therefore trying to tie it down to a specific figure is not 
particularly useful in furthering the understanding of how and why the 
placebo effect works. “Indeed, the construct itself remains an enigma to this 
day”, (Borkovec and Sibrava 2005) page 806. More useful perhaps would be 
an understanding of the mechanism through which an inactive drug may 
lead to an improvement.  
To add further uncertainty as to what exactly is the “placebo effect” and its 
definition, it has been found that, between 1981 and 2000 the percentage of 
people suffering from depression who have responded to placebo 
medication (and genuine anti-depression medication) has increased by 
around 7% per decade (Walsh et al. 2002; Khan et al. 2005). Responding to 
placebo was defined as a reduction of at least 50% on the Hamilton Rating 
Scale for Depression (Williams 1988) and/or a Clinical Global Impression 
(Guy 1976) rating of markedly or moderately improved. This figure may be 
skewed by the fact that only published studies were included in the analysis, 
however it is thought unlikely that unpublished studies would have found a 
higher figure for the placebo effect than found in published studies. 
Therefore it possible that the figure may be higher than the 7% quoted. This 
increase leads to the notion that some factor of placebo response must have 
changed over the years. It is possible that clinically important characteristics 
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of patients involved in treatment studies and/or the definition of “depression” 
has changed over the years, the exact reason for the increase remains 
unclear. It is also possible that a change in people’s beliefs around anti-
depression medication, and an increased acceptance that medication is the 
best treatment for depression, has also in part prompted this change. 
Therefore, it may be a difference in the meaning that people attribute to anti-
depression medication, that has led to this increase.  
It is not just the meaning that people attribute to a tablet that is capable of 
having an effect. An example of the meaning people attribute to the mode of 
delivery of a medication is shown in a study that compared placebo 
injections to placebo tablets (de Craen et al. 2000). In de Craen’s study 
placebo injections were found to be more effective than placebo tablets. This 
cannot be due to the injection being more effective than the tablet as neither 
included an active ingredient, rather it is to do with the meaning people 
attach to injections that led to the effect. In addition the colour of the tablet 
and the number of tablets given has been shown to affect the placebo 
response (Blackwell, Bloomfied and Buncher 1972). This study found that 
blue capsules produced a greater sedative effect than pink capsules and the 
effect of two capsules was greater than the effect of one capsule. Blackwell 
and de Craen’s studies provide a useful insight into some of the complexities 
of the placebo effect. 
Practitioners style of delivery can also influence the impact of the placebo 
effect (Thomas 1987). This is of particular relevance to treatments such as 
homeopathy, where the practitioner may be perceived to be a major 
contributor to any effectiveness. A study was carried out in 1984 (Thomas 
1987) where patients visiting a GP surgery with symptoms, but without 
abnormal physical signs, were randomised to one of four consultations: a 
consultation carried out in a positive style (with or without treatment) or a 
consultation carried out in a in a “non-positive” style (with or without 
treatment). A positive style involved the GP giving the patients a firm 
diagnosis and assuring them that they would get better within a few days. If 
the patient was given a medication they were told that it would definitely 
make them better. If they were not given a medication they were told that in 
the doctor’s opinion they did not require any medication. The negative style 
consultation was an artificial consultation where the GP stated; “I cannot be 
certain what is the matter with you”, and if no prescription was given the GP 
added; "And therefore I will give you no treatment." If however a prescription 
was given GP added, "I am not sure that the treatment I am going to give 
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you will have an effect" (Thomas 1987) page 1200. The consultation closed 
with the GP telling the patient to return if they were not better in a few days. 
In all cases the treatment given was a placebo tablet, i.e. no one in the study 
received an active medication. After the consultation with the doctor, patients 
were asked to fill in a patient satisfaction survey, answering four questions 
designed to gauge patient satisfaction (the exact questions are not 
reported). Two weeks after the consultation patients were sent a 
questionnaire asking the following three questions: Did you get better? How 
many days after seeing the doctor did you get better? Did you require any 
further treatment? The study found that patients who received a positive 
consultation were more likely to get better than those who didn’t. In this 
study only one doctor, who was also the researcher, delivered the 
consultations. In addition, the outcome measures used were not validated. 
This leads to the possibility that the findings are not generalisable. Whether 
or not the patient was prescribed a tablet made no difference to whether or 
not the patient got better (53 out of 100 who received a tablet, compared to 
50 out of 100 who didn’t receive a tablet), which is interesting in itself. 
However the tablet was not the focus of the article and the effect of being 
prescribed a tablet is only briefly discussed. Despite this, this study does 
show that, in the case of this particular doctor, varying the style of 
consultation, led to differing patient outcomes. Thomas’s study provides an 
example of how the meanings attached to a treatment, such as the hope 
instilled in the patient by the practitioner, can have a strong effect. Each 
patient-practitioner interaction is unique, and therefore the strength of the 
patient-practitioner interaction, and what it means to the patient is impossible 
to determine in advance. Furthermore the meaning the patient attaches to 
the interaction and therefore the so called “placebo effects” of the 
consultation, will depend on the attitude of the prescriber towards the 
treatment and towards the patient, along with the attitude of the patient 
towards the prescriber, the treatment and towards their own health 
(Moerman 2002).  
Therefore although placebo medications are inert substances that cannot do 
anything biologically themselves, it is feasible that the meaning that people 
attach to them is capable of having an effect (Moerman and Jonas, 2002). In 
light of this the next section moves away from the term placebo and 
discusses other possible ways of viewing the placebo effect. 
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2.6.1 Meaning response 
With the term placebo comes the connotations of deception and 
hypochondria, connotations that are unhelpful in understanding how and 
why something inactive should have an effect. In addition, the lack of 
coherence in defining the nature of what placebo is and isn’t only leads to 
contradictions and confusion (Gotzsche, 1994). Moving away from the term 
“placebo”, with all its connotations of deception and lack of effectiveness, 
coupled with the lack of theorising about placebo’s mechanism of action, 
seems helpful when thinking about complex interventions such as 
homeopathic treatment. Instead of the terms “placebo” and “placebo effect”, 
Moerman uses the term “meaning response”, implying that it is the meanings 
that people attribute to things that lead to any effects. “Meaning response” is 
a more helpful term because it is starting to provide an explanation as to why 
something apparently “inactive” should have an effect; that is, because of 
the meanings people attribute to it. Paterson and Dieppe, however prefer the 
terms characteristic and incidental effects (Paterson and Dieppe 2005). 
Characteristic or specific effects are those that are unique to a specific 
therapy and believed to cause the outcome. Incidental or non-specific effects 
are other factors that are thought to affect the outcome e.g. patient 
expectations, credibility of treatment, therapeutic alliance etc. (Paterson and 
Dieppe 2005). It is also possible to think not of placebo and placebo effects 
but of context effects (Di Blasi et al. 2001). Context effects are factors that 
may influence a patient’s response to a treatment such as the setting, 
aspects of the practitioner (personality, status, sex etc.), treatment 
characteristics (mode of delivery, colour or shape of tablet etc.) or patient’s 
characteristics (beliefs about illness, degree of anxiety etc.). Thinking in 
terms of context effects allows for the fact that context effects will vary 
depending on the context of the treatment, and that there is not a single 
mechanism of action for these effects. For example the strength of the 
context effects for a given treatment will depend on who is providing the 
treatment, their manner and demeanour, what the treatment is like, is it a 
tablet or an injection, what colour is it, where is it delivered, in a GP surgery, 
in hospital or at home. All these factors can influence the context effects and 
lead to different outcomes (Moerman 2002). The terms context effects, 
meaning response and non-specific effects, provide a more accurate 
portrayal of effects that are non-specific to the treatment than the terms 
“placebo” and “placebo effect.” This is because these alternative terms do 
not have the unhelpful connotations of deception and lies associated with 
the word placebo. Such connotations can lead to the belief that a person 
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who gets better after receiving a placebo is likely to be a hypochondriac, and 
thus to the conclusion that there is little value in investigating the “placebo 
effect” and possible mechanisms of action. However, non-specific factors 
can lead to an improvement in a person’s condition or illness despite their 
not having any intrinsic biological activity, and although they do not have an 
intrinsic biological activity, it does not mean that biological effects will not be 
observed (Moerman 2002).  
In order to isolate what is unique to a therapy and what is not, it is helpful to 
look at the terms “unique elements”, and “essential but not unique 
elements”. Waltz used these terms in her work on assessing adherence to 
treatment and therapist competence in psychological therapies (Waltz et al. 
1993). Although Waltz used the terms as a means to describe therapist 
behaviours when conducting a treatment, they can equally be applied to 
elements of the treatment itself rather than solely therapist behaviours. An 
example of an essential but not unique aspect of a treatment would be in the 
case of IHT, the interaction with an empathic practitioner. Many treatments 
involve a consultation with an empathetic practitioner, therefore it is not 
unique, however without the interaction with an empathetic practitioner it 
would be difficult, if not impossible, to obtain the information needed to 
prescribe a homeopathic remedy.  
To summarise, placebos and the placebo effect are labels used to describe 
the observation that biologically inactive treatments can lead to an 
improvement in symptoms. Simply using the label “placebo” does not explain 
how these improvements occur. It is more meaningful to use other terms 
such as “context effects”, “meaning response”, “specific” and “non-specific” 
effects or “unique” and “essential but non-unique” elements rather than 
“placebo” because these terms do not have any of the negative connotations 
associated with the term “placebo”. 
2.7 ‘Unique’ and ‘essential but non-unique’ elements of 
homeopathic treatment 
In order to explore the concept that homeopathic treatment is a placebo 
treatment, it is useful to understand what the “unique” or specific effects and 
the “essential but non-unique” or “non-specific” effects of homeopathic 
treatment are. To do this a search was carried out in October 2009; this 
search was repeated in May 2010 and June 2012.  
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The search was carried out in Web of Science (1898-2012), AMED (Allied 
and Complementary Medicine) 1985 to June 13 2012, Embase (1947 to 
June 13 2012), Ovid MEDLINE(R) (1950 to June Week 1 2012), and a 
database of homeopathy trials up to 1995 (Dean 2004), using the key words 
“specific effect”, “context effect”, “non specific effect”, “homeopath*” and the 
MeSH term homeopathy, (full details given in Appendix 1). 
The titles and abstracts of the studies identified by the searches were read 
to determine whether they were exploring the specific, and/or non-specific, 
effects of homeopathic treatment. The full text of all studies that mentioned 
specific or non-specific effects in relation to homeopathic treatment were 
accessed. Studies which talked about non-specific or specific effects with 
relation to plants, animals or laboratory research into ultra high dilutions 
were excluded. There were twelve potentially relevant studies, however only 
one of these had attempted to classify the non-specific and specific 
elements of homeopathic treatment. This was a study by Thompson 
(Thompson 2006), which on reading was found to be reporting the results of 
an earlier study (Thompson and Weiss 2006) that looked into the active 
ingredients in homeopathic treatment. Three of the other studies were RCTs 
(Brien, Lachance and Lewith 2004; Fisher et al. 2006; Adler et al. 2011), 
these RCTs attempted to measure specific and/or non-specific effects of 
homeopathic treatment rather than characterising these effects and are 
discussed in Chapter 4. Also identified were five discussion pieces on trials 
of homeopathic treatment and how to explore whether homeopathic 
treatment exerted a specific effects (Vickers 2000; Weatherley-Jones, 
Thompson and Thomas 2004; Ernst and Canter 2005; Mathie 2006; Ernst 
2011), two reviews of the effectiveness of homeopathic treatment (Shang et 
al. 2005; Clausen, van Wijk and Albrecht 2011) and a trial assessing a 
homeopathic complex for menopausal symptoms (Wasilewski 2004).  
In Thompson’s study participants were offered a package of care which 
consisted of five homeopathic consultations. Prior to the initial consultation, 
and following the final consultation, participants were interviewed. At the 
initial consultation the interviews focused on patient expectations and the 
final interview focused on understanding patients’ experiences. All 
consultations were recorded and transcribed. At the end of treatment, data 
such as questionnaires (disease specific, Measure Yourself Medical 
Outcome Profile, Glasgow, Homeopathic Hospital Outcome Profile and 
Consultation and Relational Empathy Scale) and a report from a “significant 
other" were collected. In addition to this, participants were asked to produce 
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a piece of artwork that depicted their treatment. Textual data was analysed 
using thematic analysis, with themes being either pre-existing, derived from 
previous theoretical study, or emerging from the data. Triangulation of the 
interview data, questionnaires, artwork and report from significant other was 
used to create an informal composite measure which the author termed 
“global outcome assessment.” Whilst triangulating the data in this way 
provides a useful way of assessing patients in terms of taking all the 
available data into account, no discussion is provided on how conflicting 
views were dealt with. This leads to a question over the thoroughness of the 
triangulation, as it is unlikely that all the data would be in agreement. The 
global assessment placed each participant into one of three categories; 
major, some or none. These categories related to the degree of 
improvement each participant had experienced in relation to their health 
status over the treatment period. The exact details of the analysis and 
triangulation are not reported and nor is how the active ingredients were 
identified, save to say that the analysis process was guided by a text by 
Mason (Mason 1996).  
The focus of the report is on the active ingredients of interest that emerged 
though the analysis process. Some of these active ingredients can be 
thought of as generic, such as consultational empathy and some specific to 
homeopathic treatment, such as the remedy matching process. Whilst not 
trying to propose that the effects covered identified all the different modes of 
action, Thompson’s study provides a framework for exploring the potentially 
therapeutic factors of homeopathic treatment. Whilst, there is a lack of detail 
given on the analysis method, there is a detailed description of the results for 
two of the patients is given by Thompson, one of whom achieved a major 
improvement and one who remained the same. The description used 
illustrations from the different data generated for these patients to show how 
the data fitted together and how it fitted with the overall global assessment 
for each of the two patients. These illustrations provided a convincing 
account of how these patients improved or didn’t improve through treatment. 
This, coupled with the detailed descriptions of the active ingredients, backed 
up by examples from a variety of the 18 patients who took part in this study 
and an honest description of the study’s limitations, lead to the decision that 
this is a credible study. This is one of the first studies to open the “black box” 
of homeopathic treatment and whilst it may not have identified all the 
potential therapeutic effects, it gives a useful overview of what these effects 
may potentially be. Specific effects of homeopathic treatment were 
characterised by Thompson et al as; 
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 In depth enquiry into bodily complaints and idiopathic symptoms  
 Homeopathic remedy  
 Remedy matching process.  
Non-specific effects can be characterised as; 
 Consultational empathy 
 Openness to mind body connection 
 Disclosure 
Exactly how these effects were categorised is not entirely clear. Despite this 
the above lists provide a useful framework for looking at what is specific or 
non-specific to homeopathic treatment. This is because the elements are 
clearly defined and can thus be used when exploring what is specific and 
non-specific to homeopathic treatment. 
In summary, this chapter has explored some of the concepts relevant to 
homeopathic treatment such as placebo, specific and non-specific effects. It 
has also explained why evaluating the effectiveness of homeopathic 
treatment is important within the context of homeopathic treatment remaining 
available on the NHS. In light of the importance in evaluating the 
effectiveness of homeopathic treatment the next chapter describes a 
systematic review into the effectiveness of homeopathic treatment for 
irritable bowel syndrome.  
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3 Systematic review of homeopathic treatment for irritable 
bowel syndrome 
The previous chapter highlighted the reasons why it was important to 
evaluate the effectiveness of homeopathic treatment. However before 
deciding whether or not a trial of homeopathic treatment for irritable bowel 
syndrome (IBS) is needed, it is useful to review the current evidence for 
homeopathic treatment for IBS. In light of this a scoping search was carried 
out to assess the current available information, prior to carrying out a 
systematic review. This chapter discusses the reasons why a systematic 
review of the effectiveness of homeopathic treatment for IBS was carried out 
and the methodology and methods used, before moving on to discuss the 
results of the systematic review.  
3.1 Introduction 
The Cochrane systematic review reported in this PhD thesis was carried out 
simultaneously with the RCT trial. Ideally the systematic review would have 
been carried out in advance of the RCT and the results of the systematic 
review used to inform the development of the RCT. However due to time 
limitations this was not possible. Instead an early scoping search was 
carried out prior to the RCT to assess the available information on 
homeopathic treatment for IBS. This scoping search is described in the next 
section. It is necessary to conduct a search of the literature prior to carrying 
out a research project because it would be unethical to conduct research in 
an area where there was already a clear answer in the literature (World 
Medical Association 2008). This means that it is necessary to demonstrate 
that there is a clear need for a study prior to its commencement. Hence a 
scoping search to assess the available information on homeopathic 
treatment for irritable bowel syndrome was carried out prior to conducting 
the RCT. The aim of the scoping search was to determine what the available 
evidence was of the effectiveness of homeopathic treatment for IBS to allow 
a decision to be made as to whether or not there was need for a trial 
exploring the effectiveness of homeopathic treatment for IBS. If it had been 
found that there was conclusive evidence for or against the effectiveness of 
homeopathic treatment for IBS, then there would have been no need for 
another trial. 
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3.2 Scoping search on homeopathic treatment for irritable 
bowel syndrome 
The scoping search was initially carried out in November 2009, repeated in 
May 2010 and again in June 2012. The search was initially carried out in 
2009 to determine whether there was a need of a trial of IHT for IBS. It was 
repeated in 2010 to ensure that the results were accurate and up to date for 
the application to the research ethics committee. It was repeated again in 
2012 for the purpose of writing this thesis, to ensure that up to date results 
were included. 
Searches were carried out in Web of Science (1898-2012), AMED (Allied 
and Complementary Medicine) (1985 to June 2012), Embase Classic + 
Embase (1947 to 2012 June 27) and Ovid MEDLINE (1946 to June week 3 
2012), a database of homeopathy trials up to 1995 (Dean 2004) and Hom-
Inform (the database of the British Homoeopathic Library) using the key 
words “Irritable bowel syndrome”, “irritable bowel disease”, “irritable colon”, 
“homeopath*” and the MeSH terms homeopathy and irritable bowel 
syndrome.  
The search strategies are shown in Appendix 2. 
References in systematic reviews of homeopathic treatment were also 
searched.  
The abstracts of the identified papers were read, to determine whether or not 
they were a study on the use of homeopathy in the treatment of IBS. The full 
text of those that appeared to be relevant was then skim read.  
These scoping searches identified many discussion papers, single case 
reports e.g. a clinical audit (Treuherz 1998), one consecutive case series 
(Gray 1998) and three randomised controlled trials (Owen 1990; Rahlfs and 
Mossinger 1976; Rahlfs and Mossinger 1979).  
In the consecutive patient case series (Gray 1998), 20/25 patients reported 
an improvement and 14/25 reported marked improvement, judged by 
decreasing intensity and frequency of their symptoms. A small pilot 
pragmatic randomised controlled trial (RCT) of homeopathic treatment alone 
compared to usual care alone (Owen 1990) found no difference between the 
two arms (n=23). Two RCTs comparing homeopathic medicines to placebo 
of homeopathic medicines (Rahlfs and Mossinger 1976; Rahlfs and 
Mossinger 1979) reported positive results. Rahlfs (Rahlfs and Mossinger 
1979) found that 32/42 (76%) of those in the homeopathic medicine arm 
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reported significant relief compared to 18/43 (42%) of those in the placebo 
arm. Despite these findings as yet no systematic review has been carried 
out on homeopathy for IBS. As it stands the existing evidence, although 
patchy, does suggest a need for further research into the clinical 
effectiveness of homeopathic treatment for patients with IBS. Furthermore 
there was no Cochrane review registered to study this question. 
3.3 Rationale for carrying out the systematic review 
One of the reasons for carrying out a systematic review is to summarise the 
available evidence of effectiveness on a specific topic. Systematic reviews of 
effectiveness aim to bring together all the evidence of effectiveness (for a 
treatment(s)), that correspond with predefined exclusion/inclusion criteria for 
a particular question (Wider and Boddy 2009), e.g.; “Does homeopathic 
treatment work for irritable bowel syndrome?” Often systematic reviews 
contain meta-analyses. Meta-analyses involve the use of statistical methods 
to give an estimate of the overall result by combining the results of individual 
studies (Glass 1976). This allows a more precise estimate of the overall 
effect of the intervention to be given rather than simply quoting the results 
from individual studies (Deeks, Higgins and Altman 2011).  
The use of strategies to limit bias and random error mean that systematic 
reviews are less prone to bias than traditional narrative reviews (Cook, 
Mulrow and Haynes 1997). Traditional reviews are at risk of providing 
incomplete or biased information through conscious or unconscious bias in 
the search procedure and sources used in the review, whereas systematic 
reviews have several key features aimed at minimising bias and random 
error. These are: 
 They address a clearly stated question 
 Search criteria are made explicit and stated in advance  
 They use comprehensive searching and retrieval procedures, defined 
in advance  
 Decisions regarding studies relevance and how and why studies were 
selected for inclusion are clearly given and correspond to predefined 
criteria 
 A rigorous critical appraisal is given of the included studies 
A biased review process in an effectiveness review can lead to an over or 
under estimation of the treatment effect. Furthermore if a review is not 
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rigorous or clearly reported it can be difficult to assess how useful the results 
of the review are in practice, and the validity of the results (Cook, Mulrow 
and Haynes 1997). In a systematic review explicit systematic methods are 
used with the intention of minimising bias, meaning that decisions are made 
based on pre-defined criteria. These criteria and methods are stated prior to 
conducting the systematic review to allow an accurate and objective 
conclusion to be drawn (Oxman and Guyatt 1993).  
There are a number of means by which bias can occur when conducting a 
systematic review of a CAM intervention, these include; failure to establish a 
protocol in advance, including studies that only give the desired answer, 
failure to identify all relevant studies, failing to address the issue of 
publication bias and imposing language restrictions on included studies. In 
addition the studies included in the review may themselves be biased, 
therefore the validity of the findings from each of the included studies should 
be assessed by assessing their risk of bias and quality of reporting (Green 
and Higgins 2011), this is discussed in detail in Section 3.6.4.  
To minimise the impact of bias by the author, it is vital that the methods used 
when conducting a systematic review are transparent, documented in 
advance and the planned methods peer reviewed (Green and Higgins 2011). 
When the reasons for judgements are not made explicit it is difficult to 
assess the validity of the methods used and it is possible for the reviewer to 
intentionally or unintentionally introduce bias. For example by only including 
studies that provide their desired answer and excluding studies that do not 
(Oxman and Guyatt 1993). Furthermore it is likely that errors in judgement 
will be made if results are informally synthesised and methods not made 
explicit and documented in advance. Oxman and Guyatt found poor 
consistency of expert ratings of journal articles when systematic and explicit 
methods were not used (Oxman and Guyatt 1993). 
In a systematic review, appropriate steps should be taken to ensure that as 
far as possible all relevant studies are identified. This is especially important 
in areas where there is limited research, such as CAM interventions where 
one missing RCT can significantly affect the overall result (Wider and Boddy 
2009). In addition there is the issue of publication bias, where positive 
results are more likely to get published than negative results (Easterbrook et 
al. 1991). Publication bias occurs in both conventional and CAM journals 
(Ernst 2007). Some of the means by which publication bias can be 
minimised is to, as far as possible, locate unpublished works or works 
situated in the grey literature (Conn et al. 2003). Grey literature is literature 
29 
 
that cannot easily be found through conventional channels, such as 
searching bibliographic databases. This can be because it is not indexed 
and therefore not picked up by searching of bibliographic databases, or 
because it is not made widely available. Examples include documents 
produced and published by governmental agencies and working groups 
(Alberani, Pietrangeli and Mazza 1990). Possible means of identifying 
articles in the grey literature are discussed in section 3.5.2. As already 
mentioned, limiting language of publication can lead to bias (Pham et al. 
2005) due to failure to include all relevant studies. This can be a particular 
problem for CAM where a large portion of studies of some interventions, 
such as acupuncture, are published in languages other than English (Wider 
and Boddy 2009). This issue is further explored in relation to the systematic 
review of homeopathic treatment for IBS in Section 3.5.1. 
To summarise, the validity of systematic reviews are based on the inclusion 
of an unbiased sample of relevant studies using a priori, transparent, explicit 
and well document methodology (Juni et al. 2002). 
Consequently to update the knowledge base of the effects of homeopathic 
treatment for IBS, on a more robust basis, it was decided to carry out a 
systematic review. The advantages of a systematic review, over a literature 
review are those stated above, in that systematic reviews provide an explicit, 
structured and transparent means of reviewing the literature. This means 
that they are likely to be freer from bias than a less formal literature review 
(Oxman and Guyatt 1993). Furthermore there may be trials that had not 
been picked up by the scoping literature review, and when the evidence 
base in small, as is often the case for homeopathic treatment, even one 
missing RCT can change the findings of the review leading to skewed 
conclusions (Wider and Boddy 2009). A Cochrane systematic review was 
chosen because it would offer a structured format for carrying out the review 
and Cochrane also provide training for those carrying out Cochrane reviews. 
Furthermore a Cochrane review on homeopathic treatment for IBS had not 
already been carried out and nor was a protocol registered. Therefore this 
was an opportunity to fill that gap. The protocol for this review has been 
published (Peckham et al. 2012). 
3.4 Aim of the review 
The aim of the review was to identify and assess previous trials of 
homeopathic treatment for IBS, to gauge whether or not homeopathic 
treatment provides an effective means of treating IBS. I.e. does homeopathic 
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treatment for IBS work. It was also planned to carry out a meta-analysis to 
combine the result from previous studies and give an estimated effect size. 
However this would only be possible if sufficiently similar studies were 
identified. This is discussed in more detail in Section 3.6.5. In addition, if 
sufficient studies were identified, a sub-group analysis comparing different 
forms of homeopathic treatment would be carried out. This is discussed in 
Section 3.6.5.The role of this systematic review in the context of this thesis 
was to determine whether or not a trial of homeopathic treatment for IBS 
was needed. 
3.5 Methodology 
3.5.1 Rationale for inclusion criteria  
When considering how to determine which studies to include in the 
systematic review, The Cochrane Handbook of Systematic Reviews was 
consulted (Higgins and Green 2011). From reading this and previous 
systematic reviews of other interventions for IBS (Liu et al. 2006; Zijdenbos 
et al. 2009), it was decided that there were five criteria that needed to be 
defined. These were: the types of studies to be included, the outcome 
measures to report, the types of participants in the studies, study design and 
the interventions delivered in the studies.  
The initial scoping search only identified three RCTs of homeopathic 
treatment for IBS, two were published in German (Rahlfs and Mossinger 
1976; Rahlfs and Mossinger 1979) and one in English (Owen 1990). From 
these findings it was not expected that a large number of studies of 
homeopathic treatment for IBS would be identified. Since two of the 
previously identified RCTs were in German (Rahlfs and Mossinger 1976; 
Rahlfs and Mossinger 1979), it is likely that there may be other RCTs 
published in languages other than English. Since it is desirable to identify as 
many eligible studies as possible to obtain the most precise result, studies in 
languages other than English were included in this review. This is because, 
as already stated, it is possible that even one missing study can lead to a 
skewed result (Wider and Boddy 2009). Furthermore excluding studies 
because of their language of publication can lead to language bias (Egger et 
al. 1997). This is particularly the case if positive studies in one language are 
more likely to be published than negative studies. It has been found that, for 
CAM interventions, restricting the language of publication can substantially 
alter the results (Pham et al. 2005). In addition to this there can be a 
difference between countries, in terms of what gets published. It has been 
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shown that CAM articles published in the highest impact European journals 
are more likely to have positive outcomes than those published in the 
highest impact US journals (Sood et al. 2007). It is therefore important not to 
exclude on the basis of where the study was conducted, rather to assess 
and report whether the study meets the inclusion criteria and then assess its 
risk of bias and its quality of reporting (Higgins and Green 2011).  
In this systematic review it was suggested by the editor for the inflammatory 
bowel disease and functional bowel disorders review group that non-
randomised studies (NRS) should be included. In enthusiasm for conducting 
the review it was agreed that cohort studies would be included. To be 
considered as eligible for inclusion, cohort studies needed to be non-
randomised comparative cohort studies where IBS patients treated with 
homeopathy were compared to IBS patients who hadn’t been treated with 
homeopathy and their progress followed. This review did not include 
retrospective case-series. However on deciding whether solely RCTs and 
quasi RCTs should be included in a review information on including (NRS) 
should be sought (Higgins and Green 2011; Reeves et al. 2011). The 
Cochrane Non-Randomised Studies Methods Group (NRSMG) gives the 
following reasons for including NRS: 
 To provide evidence of benefit/harm for interventions where it is 
impossible to carry out RCTs or where it is extremely unlikely that 
RCTs have been carried out. 
 To provide evidence/harm for interventions where the effects cannot 
be effectively studied by RCTs because of rare outcomes or 
outcomes that were not known to be important when existing RCTs 
had been carried out. 
 To explore the evidence for carrying out an RCT by evaluating 
existing NRS or use the finding of NRS to inform the design of a 
randomised trial. 
In retrospect the reasons listed above are not met, and it may therefore have 
been wise not to have included NRS in this review, as there are downsides 
to their inclusion. The main issue with NRS is that biases are likely to be 
greater than for randomised studies. The principal source of bias in NRS 
which have comparison groups is selection bias. This occurs when there are 
differences in the baseline characteristics of individuals in the different 
intervention groups. It may be these baseline differences that lead to any 
observed differences in outcomes rather than the intervention; this means 
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that it is possible to conclude that there is an intervention effect, when really 
there is not one. It was therefore important for NRS to consider any 
weakness of the study design, how the study was conducted, and the 
possibility for selective reporting of outcomes. Of particular concern are NRS 
studies which do not report having a protocol. It is believed that such studies 
are more prone to reporting biases. However their inclusion had already 
been agreed. 
Consequently a narrative description will be given of any cohort studies 
eligible for inclusion; however they will not be included in any meta-analyses. 
This is because the Cochrane NRSMG recommends that NRS and 
randomised studies are not combined and that the results are presented 
separately. This is because results from different study designs are expected 
to systematically differ, which results in greater heterogeneity between 
studies (Reeves et al. 2011). It was decided at the outset not to carry out a 
meta-analysis of included NRS alone because there is a greater risk of 
heterogeneity between NRS than between randomised studies. This is due 
to NRS being more likely to be methodologically diverse and therefore not 
suitable for combining (Reeves et al. 2011). 
In terms of the interventions offered, trials were included where one arm 
received homeopathic treatment and the other received a placebo or an 
active comparator treatment, such as usual care. Homeopathic treatment 
was defined as a treatment which involved the delivery of a homeopathic 
remedy; where the remedy was given by a homeopath following a 
consultation or where a homeopathic remedy was given outside of a 
consultation. It is possible that effectiveness of homeopathic treatment may 
be related to the type of homeopathic treatment used i.e. classical 
homeopathic treatment involving a consultation plus a homeopathic remedy 
may be more effective than when a homeopathic remedy is given without a 
consultation. Therefore it was planned that if sufficient studies of high 
enough quality were identified a subgroup analysis comparing these two 
forms of homeopathic treatment would be carried out. See Section 3.6.5: 
Data analysis, for more details. It was deemed unlikely that any trials that 
directly compared different forms of homeopathic treatment would be 
identified, however if any such trials were identified they would be eligible for 
inclusion.  
Trials of IBS use a variety of outcome measures such as IBS Severity 
Scoring System (Francis, Morris and Whorwell 1997), Adequate Relief 
Measure (Mangel et al. 1998) and GI Symptom rating Scale (Svedlund, 
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Sjodin and Dotevall 1988). There is no consensus as to which is the best 
outcome measure (Bijkerk et al. 2003). The majority of the outcome 
measures used are self-reported and because of the nature of IBS there is 
not a physical test that indicates its presence or severity. It was therefore 
decided that to be considered for inclusion, the study must have reduction of 
global symptoms of IBS as measured by a global IBS symptom score as one 
of its outcomes. Examples of global IBS symptom measures are (but not 
limited to): IBS Severity Scoring System (Francis, Morris and Whorwell 
1997), GI Symptom rating Scale (Svedlund, Sjodin and Dotevall 1988) or 
Functional Bowel Disorder Severity Index (Drossman et al. 1995).  
For the purposes of this systematic review a global IBS symptom score was 
defined as an outcome measure that asked “overall how would you rate your 
IBS?” or an outcome measure that asked patients to rate two or more 
aspects of their IBS (pain, bloating, constipation or diarrhoea symptoms or 
satisfaction with bowel habit). The rating could either be on a visual 
analogue scale or through grading the symptoms as good, adequate or poor 
or similar. It was not required for the scale used to be validated; this is 
because the earliest published validated global IBS measure is the 
Functional Bowel Disorder Severity Index (Drossman et al. 1995), and 
therefore requiring the scale to be validated would preclude all studies 
carried out prior to 1995, which could potentially lead to the exclusion of 
relevant studies and a subsequent effect on results.  
3.5.2 Searches 
It was decided to search the following electronic databases, after 
consultation with a research librarian and the Cochrane IBD and Functional 
Bowel Disorders Group editor, as being databases likely to contain studies 
of IBS and/or studies of complementary and alternative medicine: 
MEDLINE Ovid (1948-May 2012), EMBASE classic + EMBASE (1947-May 
2012), the Cumulative Index to Nursing and Health (CINAHL) and Allied and 
Complementary Medicine Database (AMED) (1985-May 2012), The 
Cochrane Central Register of Controlled Trials (CENTRAL) on the Cochrane 
Library, The Cochrane Complementary Medicine Field, The Cochrane 
IBD/FBD Group Specialised Register, Hom-Inform (2012) (a homeopathy 
specific database.) 
It was anticipated that there would be a significant amount of grey literature 
on the subject of homeopathic treatment for IBS. The reason for the 
abundance of grey literature on homeopathy is that often studies of 
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homeopathic treatment are published in publications that are not included in 
the major bibliographic databases (Wider and Boddy 2009). This means that 
there may be studies that are eligible for inclusion into this review that can 
not be identified via electronic databases such as MEDLINE alone (Benzies 
et al. 2006). Therefore care needs to be taken to maximise the ability to 
locate such studies. For this purpose other resources that were used for 
searching included:  
 Reference searching where the reference lists for all included studies 
were scrutinised for more trials. 
 Conference abstracts from Digestive Disease Week (DDW) (2007-
2011) and the United European Gastroenterology Week (UEGW) 
(2007-2011) 
 A database of the trials of homeopathy (Dean 2004). This database 
contains studies of homeopathic treatment from 1821 to 1995.  
 Personal contact. Where possible the first author of all included 
studies will be contacted for information regarding any unpublished 
trials. 
 The Homeopath and Homeopathic Links will be hand searched 
between 2008 - 2011 to determine the likely yield of these journals. 
3.5.3 Missing data 
The Cochrane Handbook’s guidelines for dealing with missing data were 
followed (Higgins, Deeks and Altman 2011). In the first instance missing 
data was requested from study authors. When this was not possible 
because the authors did not have the missing data or the author was not 
contactable, the assumptions of the methods used to deal with the missing 
data were explained, i.e. if the methods used to input the missing data 
required the data to be assumed to be missing at random this was made 
clear. 
In this review missing continuous data was dealt with by using the last result 
carried forward method (Pocock 1983) and assumptions explained. However 
where dichotomous data was missing an available case analysis was 
performed. An available case analysis is where the analysis is confined to 
those people for whom no data is missing in the variables required for the 
analysis (Raghunathan 2004). The potential impact of the missing data on 
the results of the review is discussed in Section 3.5.3.  
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3.6 Methods 
3.6.1 Inclusion criteria 
Types of studies and interventions 
To be eligible for inclusion into this review studies needed to be randomised 
controlled trials (RCTs) or quasi-randomised studies that compared 
homeopathic treatment with placebo or an active comparator e.g. usual care. 
Or in the case of cohort studies, where a group of people are followed over 
time, to be eligible studies needed to explore the association between 
having homeopathic treatment and subsequent outcome by comparing 
people with IBS who received homeopathic treatment with those who didn’t 
receive homeopathic treatment. The rationale for these inclusion criteria is 
given in 3.5.1  
Rationale for inclusion criteria 
All such studies were evaluated for inclusion regardless of publication 
language and publication status (full / abstract etc). For the purpose of this 
review quasi-randomised studies were defined as studies that have been 
randomised using “quasi-random” methods, such as alternation between 
treatment arms, year of birth or month entered into study (Torgerson and 
Torgerson 2008). 
A narrative description was given of any cohort studies eligible for inclusion; 
however they were not included in any meta-analyses for the reasons given 
in 3.5.1. 
Types of participant 
Participants needed to have been diagnosed with IBS using either the 
ROME criteria (Drossman 2006) or through clinical symptoms. Trials where 
greater than 10% of the participants had ulcerative colitis, Crohn's disease or 
bowel cancer were not included in the review. This was because the 
symptoms of ulcerative colitis, Crohn's disease and bowel cancer can be 
similar to the symptoms of IBS leading to the possibility of people being 
diagnosed with IBS before subsequently going on to being diagnosed with 
ulcerative colitis, Crohn’s disease or bowel cancer. There is no test that 
confirms a diagnosis of IBS, rather it is diagnosed through the Rome criteria 
or though physical symptoms in the absence of alarm signs (Drossman 
2006). Therefore the symptoms that were supposed as being down to IBS 
may not have in fact have been down to IBS and there is a possibility that 
such patients do not, and potentially never did have, IBS.  
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Outcome measures 
The study must report the outcome of global symptoms of IBS as measured 
by a global IBS symptom score, as one of its outcomes. Examples of global 
IBS symptom measures are (but not limited to): IBS Severity Scoring System 
(Francis, Morris and Whorwell 1997), Adequate Relief Measure (Mangel et 
al. 1998), GI Symptom rating Scale (Svedlund, Sjodin and Dotevall 1988), 
Functional Bowel Disorder Severity Index (Drossman et al. 1995) or IBS 
Symptom Questionnaire (Goka and Sandy 1999). What will constitute a 
global outcome measure, for the purpose of this review, has been defined in 
section 3.5.1. 
As long as a study had a suitable primary outcome (i.e. a measurement of 
global symptoms of IBS as defined in section 3.5.1), it was suitable for 
inclusion regardless of secondary outcomes; however data from eligible 
studies was also collected on the following secondary outcomes, where 
possible. 
The following were secondary outcomes of interest in the review:  
 Quality of life as measured by validated quality of life measure e.g. 
EQ-5D (Williams 1990), SF36 (Ware and Sherbourne 1992) , IBS 
Quality of Life Measure (Patrick et al. 1998), IBS Quality of Life 
Questionnaire (Hahn et al. 1997), Functional Digestive Disorder 
Quality of Life Questionnaire (Chassany et al. 1999), IBS Health 
Related Quality of Life Questionnaire (Wong et al. 1998); 
 Abdominal pain, discomfort and distension 
 Stool frequency, bowel transit time 
 Stool consistency – self report 
 Other global rating scales such as the EQ-5D visual analogue scale 
 Adverse events, such as an undesirable event associated with the 
use of the homeopathic medicine in the study i.e. breathing problems 
or skin irritation. 
 Costs 
3.6.2 Searches and search strategy 
The following electronic databases were searched in May 2012. 
MEDLINE Ovid (1946-May week 2 2012), EMBASE classic + EMBASE 
(1947-2012 May 24), the Cumulative Index to Nursing and Health (CINAHL) 
and Allied and Complementary Medicine Database (AMED) (1985-May 
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2012), The Cochrane Central Register of Controlled Trials (CENTRAL) on 
the Cochrane Library, The Cochrane Complementary Medicine Field, The 
Cochrane IBD/FBD Group Specialised Register, Hom-Inform (2012) (a 
homeopathy specific database.) 
MEDLINE was searched using the following terms which were modified and 
then applied to other databases 
#1 colonic diseases/ OR irritable bowel syndrome/ OR colonic diseases, 
functional/ OR irritable bowel[tw] OR irritable colon[tw] OR spastic colon[tw] 
OR functional bowel disease*[tw] OR functional colonic disease*[tw] 
#2 homeopathy/ OR homeopath*[tw] OR homoeopath*[tw] 
#3 #1 AND #2 
The search strategy did not include a filter for RCTs, or cohort studies. This 
was because it was not expected that a large number of studies would be 
identified, and it would thus be feasible to search through all identified 
studies.  
The following sources were also searched: 
1. Reference searching. The reference lists for all included studies were 
scrutinised for more trials. 
2. Conference abstracts. Conference abstracts from Digestive Disease 
Week (DDW) (2007-2011) and the United European Gastroenterology Week 
(UEGW) (2007-2011) were searched. 
3. Other databases. A database of the trials of homeopathy was also 
searched (Dean 2004). This database contained studies of homeopathic 
treatment from 1821 to 1995.  
4. Personal contact. Where possible the first author of all included studies 
was contacted for information regarding any unpublished trials. 
5. Handsearching. The Homeopath and Homeopathic Links were hand 
searched between 2008 - 2011 to determine the likely yield of these 
journals. 
3.6.3 Data collection  
Studies identified by the literature search were independently reviewed by 
two people, (the author and a colleague). First we discarded any studies with 
titles that were obviously not relevant e.g. titles such as homeopathic 
treatment for ulcerative colitis. Following this we assessed the remaining 
titles and abstracts against the inclusion criteria. Figure 3-1 shows a flow 
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diagram of this process. Any disagreements were resolved by a third party 
(the author’s supervisors). 
 
 
Exclude Unclear Include 
Yes 
Exclude Go to question 2  
Unclear No 
Participants in the study 
Q2: Were the participants 
assessed as having IBS either 
using the ROME criteria or 
through clinical diagnosis? 
Yes 
Exclude Go to question 3 
Unclear No 
Interventions in the study 
Q3: Did the study contain at 
least two groups; at least 
one of which received 
homeopathic treatment 
compared to placebo, usual 
care or another 
intervention?  
Yes 
Exclude Go to question 4 
Unclear No 
Interventions in the study 
Q4: Was the difference in 
treatment the only planned 
difference between the two 
groups? 
Yes 
Exclude Go to question 5 
Unclear No 
Outcomes in the study 
Q5: Did the study report a 
measure of IBS?  
Yes 
Exclude Include, subject to 
clarification of unclear 
points 
Unclear No 
Final decision  
Type of study 
Q1: Is the study described 
as cohort or RCT or quasi 
RCT?  
Figure 3-1: Study eligibility flow diagram 
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Data was extracted from the included studies using a data extraction sheet 
prepared for this purpose, see Table 3-1 below. Authors were contacted to 
clarify any unclear data, where possible. The data extraction table was 
constructed through advice given at the Cochrane Workshop, on reading the 
Cochrane Handbook (Higgins and Deeks 2011) and the preferred reporting 
of items for systematic reviews and meta-analyses (PRISMA) (Moher et al. 
2009). The PRISMA statement was released in an attempt to improve the 
quality of reporting of systematic reviews. It is important that the data 
extraction form is transparent and reproducible to enable double checking. 
Data should be collected on aspects that may influence the outcome or 
magnitude of effect, such as the type of participants, how participants were 
diagnosed, setting or intervention used. Data is also required on factors that 
may introduce different biases such as study design. It is also useful to 
collect data on aspects of the study that allow others to make a judgement 
as to the applicability of the review such as, where the study was conducted 
(geographic location, setting) and details about the participants (age, 
gender, ethnicity). Finally information on the results obtained in the study 
needs to be collected to allow a summary to be made of the results of the 
included studies and if applicable to carry out a meta-analysis (Higgins and 
Deeks 2011). Table 3-1 was used as far as possible for any cohort studies 
identified as eligible, however a further table (Table 3-2) was constructed to 
allow data relevant to NRS to be collected. This table was compiled based 
on advice from the Cochrane Handbook chapter on non-randomised studies, 
(Reeves et al. 2011) and also the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) guidelines (von Elm et al. 
2008). The STROBE guidelines were complied in an attempt to improve the 
quality of reporting of observational studies. In Table 3-2 answers were 
reported as yes, no or can’t tell as per Cochrane guidelines (Reeves et al. 
2011). 
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  Study 1 Study 2 
Participants Description   
Geographic location   
Setting (e.g. hospital/private clinic etc)   
Age (mean, (SD) range)   
Gender (% female)   
Ethnicity   
Inclusion criteria   
Exclusion criteria   
Diagnostic criteria (e.g. 
ROME/clinical/other) 
  
Measurement of baseline IBS severity   
Study design (e.g. randomised controlled trial/cross 
over/cluster etc) 
  
 Duration of study   
 How was randomisation achieved (random 
numbers,  
  
 Masking (clinicians, patients, assessors)   
Intervention Description of intervention (e.g. type of 
homeopathy/details of remedies 
given/strength/dosage) 
  
 Details of control   
 Fidelity/integrity checked?   
Outcomes Primary outcome(s)   
 Secondary outcome(s)   
 Adverse events   
 Time points when outcomes were collected 
during the study 
  
 Notes   
Analysis Analysis method(s) used (intention to treat, 
per-protocol) 
  
Missing data Is missing data reported?   
 How was missing data dealt with?   
Other Author contacted (Y/N)   
 Power calculation given (Y/N)   
Table 3-1: Data extraction form for included studies 
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 Study 1 Study 2 
Was there a comparison: 
Between two or more groups of participants receiving 
different interventions? 
  
Were participants allocated to groups by: 
Actions of the researchers? (other than concealed 
randomisation or quasi-randomisation) 
Time differences? 
Location differences? 
Treatment decisions? 
Participants’ preferences? 
On the basis of outcome? 
Some other process? (specify) 
  
Which parts of the study were prospective/ retrospective 
(state which): 
Identification of participants? 
Assessment of baseline and allocation to intervention? 
Assessment of outcomes? 
Generation of hypotheses? 
  
On what variables was comparability between groups 
assessed: 
Potential confounders? 
Baseline assessment of outcome variables? 
  
Table 3-2: Data extraction form for NRS 
 
A separate table was used to capture information on the flow of participants 
through the trial as shown below in Table 3-3. This table was constructed 
based on the CONSORT guidelines laid out for the reporting of clinical trials 
of non-pharmacologic interventions (Boutron et al. 2005).  
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Number of participants Study 1 Study 2 
Intervention Control Intervention Control 
Eligible     
Excluded     
Refused to take part     
Randomised     
Excluded post randomisation     
Withdrawn     
Lost to follow up     
Died     
Included in analysis     
Notes     
Table 3-3: Information on flow of participants 
Outcome data was collected for each included study and recorded as shown 
in Table 3-4 (for dichotomous outcomes) and Table 3-5 (for continuous 
outcomes.) 
Outcome Timing Intervention Control Notes 
Observed Total Observed Total 
       
Table 3-4: Outcome data for dichotomous data 
 
Outcome Timing Intervention Control 
Mean Mean 
chge* 
Std 
dev** 
N Mean Mean 
chge 
Std 
dev 
N 
          
Table 3-5: Outcome data for continuous variables 
*Mean chge means mean change 
**Std dev means standard deviation 
The Cochrane Reviewers Handbook (5.1.0) (Higgins and Green 2011) was 
referred to for guidance regarding any assumptions made about results, e.g. 
missing standard deviation, misreporting standard error as standard 
deviation, and lack of information on withdrawal or loss to follow up. 
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3.6.4 Assessment of quality 
The methodological quality of the included RCT were assessed using the 
Cochrane risk of bias tool as described by the Cochrane Reviewers 
Handbook (5.1.0) (Higgins and Green 2011). Each of the sources of bias 
given below were assessed and graded as either low, high or unclear.  
 sequence generation (i.e. was allocation sequence adequately 
generated?) 
 allocation sequence concealment (i.e. was allocation adequately 
concealed?) 
 blinding (i.e. was knowledge of the allocated interventions adequately 
prevented during the study?) 
 incomplete outcome data (i.e. were incomplete outcome data 
adequately addressed?) 
 selective outcome reporting (i.e. are reports of the study free of 
suggestion of selective outcome reporting?)  
 other potential sources of bias (i.e. was the study apparently free of 
other problems that could lead to a high risk of bias e.g. baseline 
imbalances, evidence of carry-over in cross-over trials, comparability 
of groups in cluster trials). 
The results from this assessment were tabulated as shown in Table 3-6. 
Study ID Risk of bias Support for judgement 
Lead author and 
date 
(low/high/unclear) A brief description of why the grading 
was given e.g. If study was given a 
high risk of bias for blinding, this box 
could contain the following “ this study 
was not blinded” or “no description of 
blinding procedures was given.” To 
explain why the study had a high risk 
of bias. 
Table 3-6: Risk of bias table 
The quality of quasi-randomised, non-randomised trials and cohort studies 
was assessed using a quality instrument designed for assessing the quality 
of non-randomised studies (Downs and Black 1998). A review of instruments 
for assessing the quality of non-randomised studies (Deeks et al. 2003) 
concluded that the two most useful tools were those by Downs and Black or 
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the Newcastle-Ottawa Scale (Wells et al. 2008). On assessing the suitability 
of these two instruments the one by Downs and Black was chosen because 
it was more comprehensive, containing 27 elements compared to 8 in the 
Newcastle-Ottawa Scale. In the review by Deeks et al it was suggested that 
the Newcastle-Ottawa Scale would need some modifications to make the 
tool suitable for use in effectiveness studies. In addition, the criterion validity 
of the Newcastle-Ottawa Scale is currently being compared to more 
comprehensive tools (Ottawa Hospital Research Institute 2011), hence the 
more comprehensive Downs and Black tool was chosen.  
3.6.5 Data analysis 
Data was analysed in Review Manager (RevMan 5.1) using available case 
analysis, with missing data dealt with as described in section 3.5.3: Missing 
Data. It was intended that if the interventions, controls, outcomes and patient 
groups were sufficiently similar, then data from individual trials would be 
combined for meta-analysis. Meta-analysis would not be used if a high 
degree of heterogeneity (I2>75%) was detected (Higgins et al. 2003). 
Statistical heterogeneity was assessed using the Chi-square test and the 
quantity I2. Chi-square test was considered statistically significant if P≤0.10. 
Where meta-analysis was deemed appropriate, for continuous variables, 
when the same scales had been used, the weighted mean difference was 
calculated. If studies were deemed sufficiently similar but different scales 
had been used, then the standardised mean difference was calculated. In 
both cases results were quoted along with 95% confidence intervals. For 
dichotomous outcomes the pooled risk ratio with 95% confidence interval 
was calculated. In terms of combining the data, a fixed effect model was 
used to pool data in the absence of heterogeneity, as defined by an I2 < 50% 
and a p value of chi-square of less than 0.10. However, an I2≥ 50% and less 
than 75% was considered to represent moderate heterogeneity and in such 
cases a random effects model was used for pooling the data. When 
moderate heterogeneity was found to exist between studies for the primary 
outcome, reasons for this were explored. For each study, clinical 
heterogeneity was assessed through the description of the setting and 
homeopathic approach used (e.g. classical or clinical). Study data was 
summarised using Forest plots, regardless of whether meta-analyses were 
carried out. 
In terms of unit of analysis issues, it was not anticipated that there would be 
any issues arising from cluster randomisation. This was because the most 
common study mode for homeopathic treatment is randomisation of 
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individuals, and it was therefore unlikely that any trials involving cluster 
randomisation would be identified. Cluster randomisation is where groups of 
individuals are randomised to the different interventions, rather than the 
individuals themselves being randomised to the different interventions. 
Some examples of the groups that could be used in cluster randomisation 
are medical practice or school. In the case of cluster randomisation by 
medical practice, all the people attending a particular medical practice will be 
randomised to the same intervention (Torgerson and Torgerson 2008). 
However, a more likely scenario which could lead to unit of analysis issues 
in trials of homeopathic treatment was cross-over trials, which have been 
used to assess homeopathic treatment (Frei et al. 2005). In the case of 
cross-over trials data was extracted and analysed from the first period only. 
This is because it is thought that it is likely that there will be a carry-over of 
the effect of homeopathic treatment (Frei et al. 2007). A carry-over effect 
occurs when the difference between treatments is dependent on the order in 
which they were given. This can lead to a bias, usually towards the null 
hypothesis (Higgins, Deeks and Altman 2011). Another possibility where unit 
of analysis issues could have arisen was where results were reported at 
multiple time points (Deeks, Higgins and Altman 2011). In this case separate 
meta-analyses were carried out for each outcome at each time point, when 
possible. Time points were grouped as follows: less than 3 months and 
longer than 3 months. These time points were chosen because, through 
personal experience, and in consultation with other homeopaths, they 
represent time frames in which a difference in the likelihood of responding 
would be expected i.e. it is generally thought it will take at least three months 
to see an improvement in patients receiving homeopathic treatment. Finally 
in studies where there were multiple intervention groups each intervention 
group was analysed separately against the control group. In these instances 
the sample size for the control group was divided proportionately across 
each intervention group to avoid double counting of the participants in the 
control group. i.e. if participants in intervention one were compared to the 
entire control group and participants in intervention two were compared to 
the entire control group, then the participants in the control group have been 
analysed twice; once in the comparison between intervention one and the 
control group and once in the comparison between intervention two and the 
control group (Higgins, Deeks and Altman 2011). 
It was thought unlikely that there would be enough studies of sufficient 
quality for subgroup analyses to be carried out. However it was intended that 
if data was reported separately for the different forms of IBS (IBS-D, IBS-C 
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and IBS-M), then a subgroup analysis to explore whether effect sizes varied 
across the different IBS subtypes would be carried out. Other subgroup 
analyses that were intended to be carried out, where possible, were: 
different homeopathy interventions e.g. classical or clinical and different 
comparators (e.g. no/usual treatment, placebo, other treatment). Other 
subgroup analyses could have been considered such as randomisation 
method (i.e. quasi versus true randomisation). However the greater the 
number of sub group analyses carried out the greater the chance of a type 
two error, i.e. a difference is found when there is not really a difference. A 
fuller discussion on the dangers of multiple analyses can be found in 
Chapter 7. A sensitivity analysis by quality of studies and randomisation 
method was to be carried out if a sufficient number of trials were identified. 
This was to determine if the results of the primary analysis changed 
according to which trials are incorporated into the analysis, with the quality 
cut-off point being high risk of bias, i.e. those considered to be at a high risk 
of bias will be compared to those being of a low or medium risk of bias. 
Reporting biases were assessed using funnel plots when more than 10 
studies were identified for inclusion in the review (Rothstein, Sutton and 
Borenstein 2005). Funnel plots are used to check the existence of 
publication bias and involve plotting, in the form of a scatter plot, treatment 
effect versus measure of study size. If the plot has an inverted funnel shape 
then it is unlikely that there is publication bias. However if the shape is 
asymmetric then this indicates there may be publication bias or systematic 
differences between the small and large studies, and suggests that an 
exploration of the cause of this asymmetry is warranted.  
3.7 Results 
Searches were carried out during the week beginning 21st May 2012. The 
searches identified 269 studies. Figure 3-2 shows the flow of studies through 
the screening process.  
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After screening titles to remove duplicates 127 studies were left, the 
remaining titles were screened to remove studies that were obviously 
irrelevant, leaving 59 studies. Examples of titles of studies considered to be 
irrelevant were: “Children: young adults or a breed apart?” (Zajac 1998) , 
“Spring is in the air and the sneezing begins.” (Jones 2005). Of these 59 
studies, 26 studies had abstracts. These abstracts were screened and from 
this 2 of these studies were deemed potentially relevant. However 33 of the 
studies did not have available abstracts, four of which were written by the 
same author. This author was contacted and asked about the nature of her 
studies. They were found not to be relevant to this review being discussion 
Titles screened (n=269) 
Excluded (n= 210)  
Duplicate study (n=142) 
Not relevant (n=68) 
 
Excluded (n= 24)  
Not RCT or cohort study (n=24) 
Abstract available? 
Full text accessed (n= 31) 
I 
I 
 
Excluded (n= 29) 
Not RCT or cohort study (n=23) 
IBS global outcome measure not used (n=1) 
Same study reported twice (n=1) 
Incorrect reference (n=2) 
Included studies (n= 2) 
I 
I 
 
Studies identified (n=269) 
 
 
 
Abstract screened (n=26) 
Yes (n=26) No (n= 33) 
Author contacted and 
studies found not to be 
relevant (n=4) 
Figure 3-2: Flow of studies through the screening process 
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pieces and treatment strategies. This left 29 studies without abstracts, for 
which the full text was accessed. This meant that the full text of 31 studies 
was accessed, the 2 studies that were potentially relevant having read their 
abstract, and the 29 studies that did not have an abstract available. Having 
accessed the full text of all potentially relevant articles 3 RCTs were found. 
No cohort studies were located. Although Owen’s (Owen 1990) study was 
an RCT it did not use a global IBS outcome as its primary outcome. Instead 
patients were asked to grade their own worst four symptoms on a visual 
analogue scale. Patients scored the same four symptoms identified at 
baseline on each of their repeat questionnaires. As these symptoms did not 
have to be IBS related, this outcome was not a global IBS measure, and 
therefore this study was not eligible for inclusion. This left 2 RCT trials. Table 
3-7 gives details of the studies which were excluded after their full text was 
accessed along with reasons for their exclusion. 
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Author  Reasons for exclusion 
(Anonymous 2005b)  Not RCT, cohort or study 
(Anonymous 2009)  Not RCT, cohort or study 
(Aleem 2000) Not RCT, cohort or study 
(Bhagat 2010) Not RCT, cohort or study 
(Bhattacharjee 2010) Not RCT, cohort or study 
(Chimthanawala 2004) Not RCT, cohort or study 
(Diamond and Diamond 2005) Not RCT, cohort or study 
(Feldhaus 2000) Not RCT, cohort or study 
(Gamble 2008) Not RCT, cohort or study 
(Gebhardt 1988) Not RCT, cohort or study 
(Gray 1998) Case series with no comparison group 
(Greeson et al. 2008) Not RCT, cohort or study 
(Innes, Greenfield and Hunton 
2000) 
Discussion on the use of case study 
methodology with examples of its use 
using homeopathic treatment 
(Jagose 2004) Not RCT, cohort or study 
(Jones 1996) Not RCT, cohort or study 
(Jones 1997) Not RCT, cohort or study 
(Jones 1999) Not RCT, cohort or study 
(Krishendu 2010) Not RCT, cohort or study 
(Lecoyte et al. 1993) Reporting results of same study as 
reported by Owen 1990. 
(Lobo 2000) Not RCT, cohort or study 
(Master 2010) Not RCT, cohort or study 
(Mohan, Kishore and Ratna 2006) Not RCT, cohort or study 
(Owen 1990) RCT of homeopathic treatment 
compared to usual care. Outcome 
measure used was not a global IBS 
measure 
(Pinto 1999) Not RCT, cohort or study 
(Slade 2003) Not RCT, cohort or study 
(Turner 2008) Not RCT, cohort or study 
(White 1999) Not RCT, cohort or study 
Table 3-7: Characteristics of excluded studies 
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3.7.1 Included studies 
Two studies were identified as eligible for inclusion. They were both 
conducted by Rahlfs and Mössinger (Rahlfs and Mossinger 1976; Rahlfs 
and Mossinger 1979), both these studies were in German and therefore 
required translation from German into English, which was carried out by a 
colleague able to read in German. The 1976 study compared a homeopathic 
dilution of asafoetida (0.1%), a homeopathic dilution of asafoetida (0.1%) 
plus nux vomica (0.01%) and placebo. The 1979 study was a repeat of the 
1976 study, this time without the inclusion of the asafoetida plus nux vomica 
arm. It therefore compared asafoetida (0.1%) with placebo. Both of the 
studies were multi-centre randomised controlled trials carried out in 
Germany, recruiting patients from general practice who presented with 
symptoms indicative of IBS. Diagnosis was made through clinical symptoms. 
No baseline measurements were given, other than the number of males and 
number of females in each of the arms. The outcome measure for Rahlfs 
and Mössinger 1976 (Rahlfs and Mossinger 1976) was a global assessment 
of symptoms at 8 and 15 days. This was a three point scale with the patients 
scoring whether they were: no better, more than 50% improved, or free of 
symptoms. Other outcomes were: the day that they felt improvement and an 
index number generated from patients’ symptoms. The outcome measure for 
Rahlfs and Mössinger 1979 (Rahlfs and Mossinger 1979) was a global 
assessment of symptoms at 8 and 15 days based on a four point scale, with 
participants rating whether they were worse, no better, more than 50% 
improved or free of symptoms. Other outcome measures were the day they 
felt improvement. A summary of the study characteristics is given in Table 
3-8 and Table 3-9 for Rahlfs and Mössinger 1976 and Rahlfs and Mössinger 
1979 respectively.  
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Rahlfs and 
Mössinger 
1976 
  
Participants Description Patients presenting in general practice 
with symptoms indicative of IBS.  
Geographic location Germany 
Setting (e.g. 
hospital/private clinic etc) 
GP surgeries 
Age (mean, (SD) range) Asafoetida 42.81* 
Asafoetida + nux vom 33.00 
Placebo 44.61 
*SD and range not presented 
Gender (% female) 50.79% 
Ethnicity Not stated 
Inclusion criteria Age 20-60 
Pain in abdomen sensitive to palpation 
plus any three of the following: 
Pain cutting or stabbing 
Pain independent of food intake 
Pain occurring at intervals 
Flatulence 
Constipation or regular use of laxatives 
Emotional disturbance 
Respiratory problems due to pain in 
chest 
Sensitive to fruit, vegetables, legumes, 
onions or cabbage 
Exclusion criteria Pathological urine findings 
Suspected kidney stones 
Taking long term medication (sleeping 
tablets and laxatives allowed) 
Pregnant women 
Suffered with compliant less than 14 
days 
Diagnostic criteria (e.g. 
ROME/clinical/other) 
Clinical 
Measurement of baseline 
IBS severity 
No 
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Rahlfs 
1976 and 
Mössinger 
cont/... 
  
Study 
design 
(e.g. randomised 
controlled trial/cross 
over/cluster etc) 
RCT multi-centre 
Duration of study 15 days 
How was randomisation 
achieved (random 
numbers,  
Random balanced code given to each 
recruiting centre, the exact details of 
which are not stated. The method of 
allocation is not clearly described. 
Masking (clinicians, 
patients, assessors) 
Clinicians and patients masked for the 
allocation, not stated whether 
assessors were masked for the 
assessment. 
Intervention Description of intervention 
(e.g. type of 
homeopathy/details of 
remedies 
given/strength/dosage) 
Clinical homeopathy, either: 
Asafoetida 0.1% in alcohol 6 x 5 drops 
daily 
Mixture of Asafoetida 0.1% plus nux 
vomica 0.01% in alcohol 6 x 5 drops 
daily. 
Details of control Placebo solution 45% alcohol 6 x 5 
drops daily 
Fidelity/integrity checked? Not mentioned, however two centres 
were removed from analysis for not 
complying with the protocol. 
Outcomes Primary outcome(s) Self assessment on 3 point scale, 
no/negligible improvement, more than 
half improved or free of symptoms 
Secondary outcome(s) Day number they felt considerable 
improvement 
Patient’s individual symptoms from 
which an index number could be 
calculated, 
Adverse events None reported 
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Rahlfs 
1976 and 
Mössinger 
cont/... 
  
Outcomes Time points when 
outcomes were collected 
during the study 
8 days and 15 days 
Notes  
Analysis Analysis method(s) used 
(intention to treat, per-
protocol) 
Per-protocol 
Missing 
data 
Is missing data reported? Details of why people were not included 
in the analysis are given however which 
arm they were in and is not recorded 
How was missing data 
dealt with? 
No discussion on how the missing data 
was dealt with other than it was not 
included 
Other Author contacted (Y/N) N 
Power calculation given 
(Y/N) 
It is claimed in the publication that a 
power calculation carried out but details 
not given 
Table 3-8: Characteristics of Rahlfs and Mössinger 1976 
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Rahlfs and 
Mössinger 
1979 
  
Participants Description Patients presenting in general 
practice with symptoms indicative of 
IBS. 
Geographic location Germany 
Setting (e.g. 
hospital/private clinic etc) 
GP surgeries 
Age (mean, (SD) range) Asafoetida 42.75 (13.21) 
Placebo 42.33 (10.99) 
Gender (% female) 68.5% 
Ethnicity Not stated, although one of the 
exclusion criteria was being 
“Ausländer”. This can be translated as 
being a foreigner and can be used to 
include naturalised immigrants, 
therefore it is likely that participants 
were all German, however without this 
being specifically stated it cannot be 
certain.  
Inclusion criteria 20-60 years 
Pain in abdomen sensitive to 
palpation (pain sensitive site must be 
indicated) plus any three of the 
following: 
Pain cutting or stabbing 
Pain independent of food intake 
Pain occurring at intervals 
Flatulence 
Constipation or regular use of 
laxatives 
Emotional disturbance 
Respiratory problems due to pain in 
chest 
Sensitive to fruit, vegetables, 
legumes, onions or cabbage 
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Rahlfs and 
Mössinger 
1979 
  
Participants Exclusion criteria Migrant workers and foreigners 
Pathological urine findings 
Suspected kidney stones 
Taking long term medication (sleeping 
tablets and laxatives allowed) 
Pregnant women 
Gallstones and gall bladder problems 
 Diagnostic criteria (e.g. 
Rome/clinical/other) 
Clinical 
 Measurement of baseline 
IBS severity 
No 
Study 
design 
(e.g. randomised 
controlled trial/cross 
over/cluster etc) 
RCT multi-centre 
Duration of study 14 days 
How was randomisation 
achieved (random 
numbers,  
Not described 
Masking (clinicians, 
patients, assessors) 
Clinicians and patients masked for the 
allocation, not stated whether 
assessors were masked for the 
assessment. 
Intervention Description of intervention 
(e.g. type of 
homeopathy/details of 
remedies 
given/strength/dosage) 
Clinical homeopathy,  
Asafoetida 0.1% in alcohol 6 x 5 
drops daily 
Details of control Placebo solution 45% alcohol 6 x 5 
drops daily 
Fidelity/integrity checked?  
Outcomes Primary outcome(s) Self assessment on a four point scale; 
worse, not improved/negligible 
improvement, more than half 
improved, free of complaint 
 Secondary outcome(s) If they were improved day on which 
improvement was felt. 
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Rahlfs and 
Mössinger 
1979 cont/.. 
  
 Adverse events 1 person had Crohn’s disease 
1 person had heartburn and flatulence 
1 person had facial neuralgia 
1 person had diarrhoea 
1 person had unspecified 
incompatibility with medication 
1 person had severe pain and 
diarrhoea 
1 person complained of tiredness  
 Time points when 
outcomes were collected 
during the study 
8 days and 15 days 
 Notes  
Analysis Analysis method(s) used 
(intention to treat, per-
protocol) 
Per-protocol 
Missing 
data 
Is missing data reported? Details of why people were not 
included in the analysis is reported 
 How was missing data 
dealt with? 
No discussion on how the missing 
data was dealt with other than it was 
not included 
Other Author contacted (Y/N) N 
 Power calculation given 
(Y/N) 
Power calculation carried out but 
details not given 
Table 3-9: Characteristics of Rahlfs and Mössinger 1979 
The participant flow through the studies in shown in Table 3-10. It can be 
seen that the participant flow was not adequately reported in either of the 
trials. The number of eligible people is not reported at all, and of the number 
randomised, only the total number randomised is given. It is not stated how 
many people were originally randomised to each arm of the trial. These 
studies were carried out in the 1970s before the CONSORT statement was 
issued (Schulz et al. 2010), which may account in part for the lack of detail 
on participant flow through the studies.  
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Number of participants Study 1 Study 2 
Asa 
foetida 
Asa 
foetida 
+ nux 
vom 
Control Asa 
foetida 
Control 
Eligible NS* NS NS NS NS 
Excluded NS NS NS NS NS 
Refused to take part NS NS NS NS NS 
Randomised 72 in total** 119 in total** 
Excluded post 
randomisation 
9 in total** 24 in total** 
Withdrawn  3 3 
Lost to follow up 3 in total** 4 in total** 
Died 0 0 0 0 0 
Included in final analysis 21 19 23 42 43 
Table 3-10: Participant flow for included studies 
*NS = not stated 
** breakdown by allocation not given. 
3.7.2 Risk of bias 
As already stated the quality of reporting in the two included studies was 
poor, this led to difficulty in reporting the risk of bias because the information 
needed to determine the risk of bias was not available for the majority of 
areas of possible bias as shown in Table 3-11. 
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Study 
ID 
 Risk of 
bias 
Support for judgement 
R
a
h
lf
s
 1
9
7
6
 a
n
d
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ö
s
s
in
g
e
r 
Random sequence 
generation 
Unclear A chance code was used for the randomisation, the exact nature of which is not reported. 
Therefore its risk of bias cannot be determined. 
Allocation concealment Unlcear Medication was provided in sequentially numbered drug containers but method of allocation is not 
clearly described. 
Blinding of participants 
and personnel 
Unclear Study participants and recruiting doctors were blinded, however it is not clear whether or not the 
assessors were blinded. 
Blinding of outcomes Unclear It is not reported whether or not the outcome assessment was carried out blind. 
Incomplete outcome data Unclear Insufficient reporting of attrition, reasons for attrition but not details of allocation are given. 
Selective reporting Unclear Insufficient information provided. 
Other bias Unclear Insufficient information provided to assess whether the study is at risk from other bias. 
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Random sequence 
generation 
Unclear Although it is stated that this is a randomised trial no details are given as to how randomisation 
was achieved. 
Allocation concealment Unlcear Medication was provided in sequentially numbered drug containers but method of allocation is not 
clearly described. 
Blinding of participants 
and personnel 
Unclear Description is given as to blinding of participants and doctors, but it is not clear as to whether 
assessors were blinded. 
Blinding of outcomes Unclear It is not reported as to whether the outcome assessment was carried out blind. 
Incomplete outcome data Low Missing outcome data balanced in numbers and for missing for similar reasons across all groups. 
Selective reporting High 28 participants could not be evaluated because of violation of the protocol, however several 
patients older than the specified inclusion criteria were included in the analysis. 
Other bias Unclear Insufficient information provided to assess whether the study is at risk from other bias. 
Table 3-11: Risk of bias table for included studies
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The random sequence generation was not adequately reported in either of 
these two studies, although it is stated that a chance code was used in 
Rahlfs and Mössinger 1976 (Rahlfs and Mossinger 1976); what this entailed 
is not described. Rahlfs and Mössinger 1979 (Rahlfs and Mossinger 1979) 
states that it was a randomised trial, but the exact means by which 
randomisation was achieved is not mentioned. In terms of allocation 
concealment, in both studies it is stated that the medication was provided in 
sequentially numbered containers. In Rahlfs and Mössinger 1979 (Rahlfs 
and Mossinger 1979), the fact that the asafoetida solution had a slight 
garlicky after-taste is mentioned. It then goes on to describe how, even 
though the placebo solution doesn’t have this, it is unlikely that participants 
would be able to identify which arm they were in because of the after-taste. 
This was because asafoetida was not a known medicine at the time of the 
trial. Therefore participants would have no expectations as to whether or not 
the medication would have a taste. In addition this was not a cross over trial 
so participants were only given one medication and therefore would not 
know about the difference in taste. Finally it is claimed that participants 
would not have contact with each other during the study. However the 
possibility that people may have talked to each other while in the waiting 
room at the doctor’s surgery cannot be ruled out.  
This thorough description of the blinding of participants to the medication is 
in contrast to the rest of the reporting of the blinding of outcome assessment, 
of which nothing is mentioned about whether or not it was carried out blind. 
This was true of both studies. Although Rahlfs and Mössinger 1976 (Rahlfs 
and Mossinger 1976) reported some of the reasons for missing outcome 
data, this was not consistent, making it difficult to tell if the study was at risk 
of selective reporting bias. However Rahlfs and Mössinger 1979 (Rahlfs and 
Mossinger 1979) was more thorough in its reporting of missing outcome data 
and why some participants data was missing. Furthermore the missing data 
appeared to be evenly balanced across the groups, with a similar number 
and similar reasons for missingness across the two arms. It is stated in the 
Cochrane Handbook that an answer of “yes” to there being a similar number 
and similar reasons for missingness across all arms, can indicate a low risk 
of bias (Higgins, Altman and Sterne 2011). In terms of selective reporting, 
this could not be assessed for Rahlfs and Mössinger 1976 (Rahlfs and 
Mossinger 1976). However Rahlfs and Mössinger 1979 (Rahlfs and 
Mossinger 1979) was deemed to be at a high risk of bias because there 
appeared to be inconsistency in exclusion of participant data, in that, whilst 
some people were excluded for not meeting the inclusion criteria, people 
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who did not meet the inclusion criteria because they were too old were still 
included in the analysis. Finally the possibility of other sources of bias could 
not be determined again due to the inadequacy of reporting in these two 
studies. In terms of the overall risk of bias for the outcome of improvement in 
IBS symptoms it is unclear for Ralhfs and Mössinger 1976 (Rahlfs and 
Mossinger 1976) and high for Rahlfs and Mössinger 1979 (Rahlfs and 
Mossinger 1979), this is because the risk of bias was unclear for all the 
domains in Rahlfs and Mössinger 1976 (Rahlfs and Mossinger 1976). For 
Rahlfs and Mössinger 1979 (Rahlfs and Mossinger 1979) there was a high 
risk of bias because the risk of selective reporting was deemed to be high as 
already discussed (Higgins, Altman and Sterne 2011). 
3.8 Analysis of results 
Data was analysed in RevMan (The Cochrane Collaboration 2011).  
Rahlfs and Mössinger 1976 (Rahlfs and Mossinger 1976) and Rahlfs and 
Mössinger 1979 (Rahlfs and Mossinger 1979) reported outcomes at both 8 
and 15 days. For the data analysis, data was taken at the study endpoint of 
15 days. Although it was planned that where there was missing continuous 
data, a last value carried forward method would be used to input the missing 
data, in practice this could not be done. This was because baseline data was 
not given for any of the participants, and furthermore there was no way of 
matching up missing 15 day scores with their corresponding 7 day scores. In 
a further point, in the text of Rahlfs and Mössinger 1979 it states that data 
was collected at 7 and 14 days, however in the tables where the data is 
reported, it states that the data was collected at 8 and 15 days. Whilst this 
discrepancy was noted it was considered that whether or not the data was 
collected at 14 or 15 days would make little difference to the overall result.  
Rahlfs and Mössinger 1976 (Rahlfs and Mossinger 1976) was a three armed 
trial, with two different homeopathic treatments being compared to placebo. 
This could have led to unit of analysis issues. To prevent this the number of 
participants in the placebo arm was divided by two, as explained in Section 
3.6.5. This meant that two comparisons were entered into RevMan: 
asafoetida (0.1%) compared to placebo and asafoetida (0.1%) + nux vomica 
(0.01%) compared to placebo. The results for the outcomes are shown in 
Table 3-12.  
The two studies were deemed sufficiently similar to carry out a meta-
analysis. This was because they had used the same outcome, in addition 
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both studies were comparing homeopathic treatment to a placebo treatment. 
The results from the meta-analysis are shown in Figure 3-3. The 
standardised mean difference was used because although the outcome was 
the same, Rahlfs and Mössinger 1976 (Rahlfs and Mossinger 1976) 
measured the outcome on a three point scale and Rahlfs and Mössinger 
1979 (Rahlfs and Mossinger 1979) measure it on a four point scale. 
Heterogeneity was not significant as measured by I2< 50% and P of Chi2 > 
0.1. Therefore a fixed effect model was used. In Figure 3-3, Rahlfs et al 
1976a is the comparison of asafoetida with placebo and Rahlfs et al 1976b 
is the comparison of asafoetida + nux vom with placebo.
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Study  Outcome Timing Intervention 1 0.1% asa foetida Intervention 2 0.1% 
asafoetida + 0.1% nux 
vomica 
Control 
Mean Std dev** N Mean Std 
dev 
N Mean Std 
dev 
N 
Rahlfs and 
Mössinger 
1976 
Global 
improvement 
in IBS 
8 days 0.62 0.59 21 0.47 0.51 19 0.43 0.51 23 
15 days 0.90 0.77 21 0.82 0.69 19 0.65 0.71 23 
Rahlfs and 
Mössinger 
1979 
Global 
improvement 
in IBS 
8 days 2.70 0.70 44    2.36 0.61 45 
15 days 3.11 0.83 42    2.49 0.77 43 
Table 3-12: Results
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Figure 3-3: Results from a meta-analysis of included studies 
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The results from the meta-analysis show that homeopathic treatment using 
specified homeopathic remedies was more effective than placebo. However, this 
result must be interpreted with caution. This is because the quality of reporting in 
the including studies meant that it is difficult to assess whether or not these 
studies were carried out in a rigorous manner, and therefore how likely these 
results are to be a true reflection of the treatment effect. This, coupled with the 
fact that both the included studies assessed the effectiveness of pre-defined 
homeopathic remedies for IBS i.e. clinical homeopathy, suggests that more 
research is needed i.e. a study exploring the effectiveness of individualised 
homeopathic treatment would be useful. 
This chapter has reported on a systematic review of the effectiveness of 
homeopathic treatment for IBS, and concluded that a trial evaluating the 
effectiveness of individualised homeopathic treatment for IBS would be useful. 
However the design of such a trial is not simple, the next chapter explains why 
this is so, and discusses what can be learnt from the methodological literature 
regarding trials of homeopathic treatment.
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4 Trials of individualised homeopathic treatment 
The previous chapter concluded that a trial of individualised homeopathic 
treatment (IHT) for IBS was needed, however in order to design such a trial, 
the issues involved in designing randomised controlled trials (RCT) for 
complex interventions such as CAM treatments need to be explored. This 
chapter therefore sets out to do this before moving on to assess the 
strengths and weaknesses of previous trials exploring IHT. These previous 
trials were studied to assess whether any of the designs would provide an 
appropriate means of assessing the effectiveness of homeopathic treatment 
for IBS. On studying these designs it became apparent that to define a 
control for IHT (in the context a clinical trial), was not simple and that an 
alternative approach was needed.  
4.1 The suitability of randomised controlled trials for CAM 
Randomised controlled trials are considered to be the gold standard of 
evidence when assessing the effectiveness of an intervention (Akobeng 
2005). This is because the randomisation process seeks to prevent any 
systematic differences between the arms of the trial (Torgerson and 
Torgerson 2008). The lack of systematic differences aims to minimise a 
number of potential biases and create a situation whereby any differences in 
outcome are due to differences between the comparator interventions, rather 
than due to existing differences between the groups. RCTs can take two 
different approaches; explanatory or pragmatic (Schwartz and Lellouch 
2009). Explanatory trials are used to determine whether or not a treatment 
has any efficacy in an ideal experimental setting. They usually compare the 
experimental intervention with a placebo. Pragmatic trials seek to explore 
the effectiveness of an intervention as it would be applied in practice. 
Consequently, the results of pragmatic trials are more generalisable than the 
results of explanatory trials (MacPherson 2004). 
Despite the strengths of the RCT, its applicability for testing CAM has been 
questioned due to its reductionist nature, which results in a difference 
between how a CAM therapy is applied in a RCT and how the treatment 
would be delivered in everyday practice (Barry 2006). One of the issues in 
designing a CAM RCT is the difficulty in terming what the active ingredient in 
CAM is. This is because the therapeutic effect is often not solely confined to 
the acupuncture needles or the homeopathic remedy, but is an intertwined 
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process between the needling or remedy, the patient, the practitioner, and 
the diagnostic process (Carter 2003). In IHT the prescription of a 
homeopathic remedy requires an in-depth understanding of the patient and 
their illness, which cannot be achieved though the use of a formulaic 
process. Although any treatment can be holistic provided it is applied in a 
holistic manner, the theory underpinning many CAM treatments is that of 
viewing the body as a whole system. Therefore CAM treatments are often 
complex and multi-stranded. This leads to a difficulty in designing a RCT that 
adequately represents how the treatment is delivered in practice, due to the 
differing philosophical beliefs about health and disease in CAM. This is not 
unique to CAM and homeopathy, but can be the case with other complex 
interventions. 
In terms of homeopathic philosophy, symptoms are seen as a manifestation 
of a single disturbance rather than a group of unrelated symptoms caused 
by different disorders (Vithoulkas 1998). Thus although in conventional 
terms a person may have been given multiple diagnoses, in the practice of 
IHT those same symptoms would all be viewed as part of one single 
disturbance. The aim of IHT is to prescribe a single remedy to relieve all the 
symptoms of that single disturbance. Within the philosophy of IHT, as 
described by Hanhemann, symptoms are a manifestation of a disturbance 
within the “vital force” and as such cannot be separated into multiple 
diagnoses. This is one of the fundamental tenets of IHT (Hahnemann, 1996). 
Therefore a well-selected homeopathic remedy should lead to improvement 
in that single disturbance, and a reduction in all symptoms. When a remedy 
acts in this manner it is referred to as that person’s “constitutional” remedy.  
Whilst it is possible that some IHT practitioners prescribe more than one 
remedy at a time, this is due to uncertainty over which of a particular group 
of remedies to prescribe, or as an adjunct to the “constitutional” remedy to 
enhance its effectiveness. However the aim of IHT practitioners is to 
determine a single constitutional remedy through a detailed case taking. This 
differs from the conventional model whereby a person may be offered 
different treatments for each of the different conditions. This also leads to a 
difference in the understanding of symptoms, with homeopaths viewing the 
appearance and disappearance of symptoms in a different manner to that of 
conventional medicine. For example one of the indications of a well selected 
remedy is the return of old symptoms (symptoms a person has suffered with 
in the past). The return and subsequent disappearance of old symptoms is 
seen as indicative of a patient being restored to health (Vithoulkas 1998). 
Thus the prescription of homeopathic remedies requires a detailed 
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understand of the patient’s symptoms, any interruption to this understanding 
can lead to confusion and difficulty in knowing how to proceed with 
treatment. This can occur in trials where the homeopath is blinded to 
whether the patient has received placebo or not, as they are uncertain 
whether a lack of reaction is due to an ineffective remedy being chosen or 
due to placebo (Weatherley-Jones, Thompson and Thomas 2004), this is 
examined in more detail in Section 4.2.  
It is the different understanding of illness and disease that sets CAM apart 
from conventional medicine. The assumptions of EBM and the biomedical 
approach require evidence of the efficacy of CAM for biomedically 
diagnosed disorders. However, CAM often has its own diagnosis procedures 
that influence how the treatment will be conducted (Barry 2006), with 
healthcare advice often being varied to take into account new problems that 
may arise during treatment, whether physical or mental/emotional (Paterson 
and Dieppe 2005). This means that trials that follow strict protocols as to 
how the treatment will be conducted do not replicate how CAM is delivered 
in practice. Yet these issues do not mean that it is impossible to carry out an 
RCT of a CAM therapy, merely that there are problems that must be 
considered when designing a trial for a CAM therapy.  
The next section discusses some of the RCT designs that have been used 
to explore the effectiveness of homeopathy and discusses their strengths 
and weaknesses. An understanding of these previous trials was needed to 
determine whether or not they provided an appropriate design for assessing 
the effectiveness of IHT for IBS, and if not what kind of design would be 
appropriate. The strengths and weaknesses of explanatory and pragmatic 
trials for assessing homeopathic treatment is first explored, before moving 
on to assess the usefulness of factorial trials in assessing IHT. 
4.2 Explanatory trials 
A summary of RCT findings carried out by the British Homeopathic 
Association found that from 1950 to the end of 2010, 156 RCTs representing 
research in 75 medical conditions had been reported, 135 as full papers in 
peer reviewed journals (British Homeopathic Association 2010). These 
figures give an indication as to the number of studies and range of 
conditions in which the effectiveness of homeopathic treatment has been 
explored. The majority of homeopathy RCTs (n=120), are explanatory trials 
that have assessed the homeopathic remedy, rather than the whole package 
of IHT. This is done by comparing a homeopathic consultation, plus a 
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homeopathic remedy to a homeopathic consultation, plus a placebo remedy. 
Figure 4-1 shows a schematic diagram of the standard design for RCTs of 
homeopathic treatment.  
 
 
 
Trials comparing the homeopathic remedy (arm A) to a placebo (arm B) are 
exploring whether the homeopathic remedy has any efficacy and are not 
aiming to explore the effectiveness of the whole intervention of homeopathic 
treatment. In addition, they are unable to give information on the 
effectiveness of the homeopathic consultation, they can merely assess the 
efficacy of the homeopathic remedy. This type of trial has, in the past, been 
used to assess the effectiveness of IHT (Weatherley-Jones et al. 2004), 
clinical (Rahlfs and Mossinger 1979) and complex homeopathy (Jacobs et 
al. 2007). This type of trial is explanatory in nature and is designed to 
determine whether a treatment (in this case the homeopathic remedy), has 
any efficacy under ideal circumstances (Torgerson and Torgerson 2008). 
Explanatory trials have high internal validity as they control for known and 
unknown confounders through the intervention being precisely and rigidly 
described, and the use of tightly defined entry criteria. However care needs 
to be taken to ensure that the external validity of these trials is not 
compromised by the use of overly restrictive inclusion/exclusion criteria. This 
is because the use of strict criteria could lead to an unrepresentative sample 
that did not reflect the true population of the condition being studied and thus 
the results may not be generalisable.  
The usefulness of studies that compare homeopathic consultation plus 
homeopathic remedy, to homeopathic consultation plus placebo remedy, for 
assessing IHT as a complex intervention (rather than the remedy), is 
questionable. This is primarily due to the complex nature of IHT and the 
Patients 
A: Homeopathic 
consultation 
+ 
Homeopathic remedy 
B: Homeopathic 
consultation 
+ 
Placebo remedy 
Randomise 
Figure 4-1: Standard design for RCT of homeopathic treatment 
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interaction between the homeopath and the patient. In a trial of IHT for 
chronic fatigue (Weatherley-Jones et al. 2004) the homeopaths taking part in 
the trial found it difficult to determine how to proceed after the first and 
subsequent consultations. This was due to an uncertainty about the placebo, 
as a patients reaction or lack of reaction to a remedy can be very important 
in deciding on the next prescription (Henriques 1998). This means that the 
patient’s reaction to the homeopathic remedy can affect how the homeopath 
conducts the consultation. Therefore it is likely that the specific effects of the 
homeopathic remedy and the non-specific effects of the consultation are not 
independent of each other. The specific effects of the remedy are taken to 
be beneficial effects that would not be observed with placebo, whilst non-
specific effects of the consultation are taken to be effects that would occur 
within any consultation with a caring practitioner. If the specific effects of the 
remedy, and the non-specific effects of the consultation are interrelated, then 
this means that it would be impossible to separate out the effects of the 
remedy and the effects of the consultation. This means that the effects of the 
remedy and the effects of the consultation cannot be separated and may be 
more than the sum of their parts. In addition, comparing a homeopathic 
consultation plus a homeopathic remedy to a homeopathic consultation plus 
a placebo remedy means that both arms get a homeopathic consultation. 
This design fails to take into account whether or not there is a positive effect 
inherent to the homeopathic consultation. It could be that a benefit has 
arisen because of some element that is specific to a homeopathic 
consultation that would not be found in other consultations i.e. a specific 
effect of the homeopathic consultation, such as the remedy matching 
process. In such a design this would remain unknown. It is important 
therefore when conducting a study of homeopathic treatment to decide what 
it is that is being studied; is it solely the homeopathic remedy or is it IHT as a 
package (the consultation plus the homeopathic remedy). 
4.3 Pragmatic trials 
It has been suggested that pragmatic trials provide a means of assessing 
CAM as it is delivered in practice (MacPherson 2004). A pragmatic trial is a 
trial that assesses the effectiveness of a therapy as it is delivered in practice 
and the therapy is usually compared to usual care or no treatment. Four 
pragmatic trials comparing IHT to usual care have been identified, although 
there may be others (Owen 1990; Fixsen, Vickers and Harrison 1999; Relton 
et al. 2009; Thompson et al. 2011). Figure 4-2 shows a schematic diagram 
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of a pragmatic trial design for a RCT of homeopathic treatment that is setting 
out to compare homeopathic treatment as a whole, single intervention, with 
an alternative system of care. 
 
 
 
These trials aim to explore the effectiveness of homeopathic treatment as it 
is delivered in everyday practice. They compare the whole intervention of 
homeopathic treatment (arm A) with either no treatment or usual care (arm 
B), or sometimes another treatment. They can give information about the 
relative effectiveness of homeopathic treatment compared to no 
treatment/usual care or another treatment depending on what arm B 
comprises of. What they can’t do is give information about exactly what 
components within the intervention have led to any effects, therefore when 
assessing homeopathic treatment pragmatic trials cannot be used to 
determine the effectiveness of the remedy alone. This fact has led them to 
be criticised for being bound to find a positive result (Ernst and Lee 2008; 
Perry, Terry and Ernst 2010). This is because one arm of the trial is getting 
time and attention that the other arm isn’t getting, and it may be that this time 
and attention is leading to a benefit rather than an inherent effect of the 
treatment itself. Whilst it is true that a trial comparing homeopathic treatment 
to usual care cannot give information about whether or not homeopathic 
treatment is any better than spending time with an empathetic practitioner, 
this type of trial can give information on the clinical effectiveness of 
homeopathic treatment compared to usual care. In addition, a pragmatic trial 
comparing homeopathic treatment to usual care for glue ear did not find a 
positive result (Fixsen, 1999). However some critics of homeopathic 
treatment believe that in order to decide whether or not homeopathic 
treatment is effective, there needs to be proof as to whether the 
homeopathic remedy is efficacious (Ernst 2011), which pragmatic trials of 
Patients 
A: Homeopathic 
consultation 
+ 
Homeopathic remedy 
B: Alternative approach to 
treatment – commonly 
usual care or no treatment 
Randomise 
Figure 4-2: Pragmatic trial design for a RCT of homeopathic treatment 
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homeopathic treatment are not able to do. In addition, it is possible, in a 
pragmatic trial, where practitioners are able to practice as they would in 
everyday practice, that there will be some variability due to practitioners. In a 
real world setting IHT prescribers (classical homeopaths) may not all 
prescribe in exactly the same manner.  It could be that some practitioners 
would adhere strictly to prescribing only one remedy at a time, whilst others 
prescribe more than one remedy, as described in Section 4.1. One of the 
strengths of pragmatic trials is that they allow practitioners to behave as they 
would in everyday practice and hence are often more generalisable than 
explanatory trials. In a pragmatic trial restricting their ability to prescribe as 
they would in everyday practice may lead to results that are less 
generalisable. It is inevitable that practitioner variation does exist.  However 
to explore the impact of this variability a specifically designed study would be 
required. 
4.4 Factorial trials 
Another method that could be used to evaluate different elements of a 
complex intervention is a factorial study design. Factorial designs aim to take 
into account the entangled nature of multiple elements of an intervention 
such as IHT (consultation and remedy) and enable the researcher to 
determine the relative contribution of the different parts (Torgerson and 
Torgerson 2008). The simplest type of factorial design is a 2x2 factorial 
design as shown in Figure 4-3 for IHT.  
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This design aims to break IHT into component parts and in the subsequent 
statistical analysis determine the relative contributions of each component 
part, along with detecting whether there is any synergy between the 
component parts (Torgerson and Torgerson 2008). Whilst in theory this 
design could potentially provide a means of assessing IHT, in practice there 
are some concerns. Some of these concerns are generic to factorial designs 
and others to a factorial design for IHT. One of the issues of factorial designs 
is their complexity. This is especially the case in designs of a higher order 
than 2x2, where the recruitment process can be confusing for participants 
and researchers alike. In addition, there can be a problem with the powering 
of such trials. This occurs particularly if there is a negative interaction 
between two of the components (i.e. the sum of the two treatments is less 
than their individual contributions), thus giving rise to a decrease in the effect 
size. If this interaction was unknown prior to the study, then it could result in 
an inadequately powered trial due to the actual effect size being lower than 
anticipated. Furthermore a large sample size is required to fully power a 
factorial trial that is able to detect interactions (Torgerson and Torgerson 
2008). Inevitably there will be an increase in cost associated with an 
increase in trial size.  
In terms of factorial designs applicability to IHT, the main problem lies with 
how to construct the different arms. The no consultation and no remedy arm 
(marked D in Figure 4-3) can be constructed as a usual care arm and the 
consultation and remedy arm (marked A in Figure 4-3) as a IHT arm. The 
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Figure 4-3: 2x2 Factorial design 
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other two arms are more problematic though. In terms of arm B, in practice a 
homeopath would not conduct a homeopathic consultation and then not give 
a remedy, unless the patient did not need a remedy because; a) they did not 
have any health problems or b) the homeopath felt that a previously given 
remedy was still working (Henriques 1998). A way round this would of 
course be to give a placebo remedy, but there are reasons why this is not 
desirable, such as the homeopath’s difficulty in assessing patient’s progress 
and therefore their ability to prescribe appropriate homeopathic remedies as 
already discussed in Section 4.1. In terms of the remedy only arm (marked C 
in Figure 4-3); it could be argued that it is impossible to deliver an 
individualised homeopathic remedy without a consultation as it is the 
consultation that provides the information needed to prescribe the most 
appropriate remedy. Yet there is the possibility of using internet based 
homeopathy, whereby the patient fills out a form on the internet which is 
mailed to the homeopath who then prescribes based on this. In this form of 
IHT there is a minimal interaction between the patient and the homeopath 
and this would provide a possible way of prescribing an individualised 
remedy without the consultation. However as this is a relatively recent 
development in homeopathic prescribing there are so far a very limited 
number of practitioners experienced in this approach. In addition there is still 
an interaction between the homeopath and the patient, although limited.  
4.5 Recent developments in homeopathic trial methodology 
In more recent years studies such as those by Brien (Brien, Lachance and 
Lewith 2004) and Steinsbekk (Steinsbekk et al. 2005a; Steinsbekk et al. 
2005b; Steinsbekk et al. 2007) have attempted to explore the effects 
attributable to the homeopathic consultation and/or the homeopathic 
remedy. Brien outlined a test model for separating the effects of the 
homeopathic consultation from the effects of the remedy, using a rheumatoid 
arthritis complex given to one group of people after having a homeopathic 
consultation, and another group without a consultation (Brien, Lachance and 
Lewith 2004). Figure 4-4 shows a schematic diagram of this trial.  
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Brien proposed making a number of comparisons.  
To establish the effect of the homeopathic consultation by comparing; 
 Arm A with arm D (homeopathic consultation + rheumatoid complex 
vs. rheumatoid complex).  
  Arm B with arm E (homeopathic consultation + placebo remedy vs. 
placebo remedy).  
To establish the effect of the individualised remedy by comparing; 
 Arm C with arm B (homeopathic consultation + homeopathic remedy 
vs. homeopathic consultation + placebo remedy). 
To establish the effect of the rheumatoid complex by comparing; 
 Arm A with arm C (homeopathic consultation + rheumatoid complex 
vs. homeopathic consultation + placebo remedy). 
 Arm D with arm E (rheumatoid complex vs. placebo). 
To establish the difference between IHT and the rheumatoid complex by 
comparing; 
 Arm C with arm A (homeopathic consultation + homeopathic remedy 
homeopathic consultation + rheumatoid complex). 
Brien’s trial therefore appears to be attempting to answer multiple questions 
(Brien, Lachance and Lewith 2004). The danger with trying to answer 
multiple questions is that it would require multiple comparisons. Without 
careful attention to how these multiple comparisons are adjusted for, it is 
highly likely that they will lead to a Type I error i.e. a difference is found 
E 
Placebo 
Patient
s 
Consultation No Consultation 
C 
Individualised 
treatment 
A 
Rheumatoid 
complex 
D 
Rheumatoid 
complex 
 
B 
Placebo 
Figure 4-4: Schematic diagram of Brien's trial 
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between the arms and a false null hypothesis is rejected in error (Benjamin 
and Hochberg 1995).  
The ability of Brien’s trial (Brien, Lachance and Lewith 2004) to answer 
these questions is debatable (Chatfield, Mathie and Fisher 2011). Trying to 
separate out the component parts of IHT into the consultation and the 
remedy, can be problematic in terms of constructing arms that adequately 
reflect IHT as it is delivered in practice (Weatherley-Jones, Thompson and 
Thomas 2004).  
In terms of Brien’s trial (Brien, Lachance and Lewith 2004) the question that 
the trial is most likely to be able to answer is, “is a homeopathic rheumatoid 
complex more effective than a placebo?” This comparison compares a 
homeopathic rheumatoid complex (with no consultation) to a placebo tablet. 
This comparison is more akin to the standard drugs trial, where the patient is 
receiving either a placebo or a genuine tablet. In this comparison nobody 
receives a homeopathic consultation and it is less likely that any additional 
effects will come into play.  
In addition to the issues over what questions Brien’s trial is able to answer, 
there is the question over multiple comparisons and adequate power. It was 
stated in Brien’s protocol (Brien, Lachance and Lewith 2004) that 110 
participants would be needed to detect a significant change in the primary 
outcome measure, however only 77 participants began treatment and only 
56 completed treatment. This could have led to a lack of power to detect an 
effect, although the author claimed that post-hoc calculations revealed the 
study not to be underpowered. However post-hoc power calculations can be 
problematic and are not recommended (Hoenig and Heisey 2001). 
Furthermore, Brien proposed making six comparisons. Five outcome 
measures are mentioned in the protocol for Brien’s trial, so if each 
comparison was made for each outcome measure, that would result in 30 
comparisons. It highly likely that one of these comparisons would show a 
significant result due to chance, rather than there genuinely being an effect. 
This is a multiple testing effect and should be accounted for by methods that 
seek to reduce type 1 error – one of these is the use of the Bonferroni 
correction (Bland and Altman 1995).  
In summary, this design is too complicated and tries to assess too many 
different complex variables at once. It is unlikely that this design will be able 
to give information on the effectiveness of IHT, as it is delivered in practice, 
or indeed the relative effectiveness of the homeopathic consultation or 
homeopathic remedy, as is claimed. 
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Steinsbekk (Steinsbekk et al. 2005a; Steinsbekk et al. 2005b; Steinsbekk et 
al. 2007) employed a different design to test the effect of the homeopathic 
consultation: homeopathic treatment was compared to self-prescribed 
medication in children. A schematic diagram of this trial is shown in Figure 
4-5.  
 
 
This was a four armed trial which compared usual care (arm A) to 
preventative treatment (placebo or genuine) for an upper respiratory tract 
infection. In this study the children were recruited because they had visited a 
medical doctor for an upper respiratory tract infection (time frame of visit not 
clearly reported). Arm B involved the prescription of an individualised 
remedy after a homeopathic consultation. In arms C and D the parents filled 
out a questionnaire designed to identify the best of a choice of three 
remedies for the child, who was then subsequently given the remedy 
identified by the questionnaire (arm C) or a placebo tablet (arm D).  
In this trial the comparisons made were: 
 Arm A and arm B, i.e. standard care vs. IHT (Steinsbekk et al. 2005b) 
 Arm B vs. arm C, IHT vs. self-prescribed remedy (Steinsbekk et al. 
2007) 
 Arm C vs. arm D self-prescribed vs. placebo (Steinsbekk et al. 2005a) 
Each comparison in this study was reported separately. 
Comparing arm B and arm C attempts to answer the question, “is IHT better 
than a self-prescribed remedy at preventing upper respiratory tract infections 
in children?” i.e. two different styles of homeopathic treatment are being 
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Wait list 
control using 
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B 
Individualised 
homeopathic 
treatment 
C 
 Self-treatment with 
homeopathic 
remedy chosen prior 
to randomisation 
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Self-treatment 
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tablet 
Patients 
Randomise 
Parents fill out questionnaire 
Figure 4-5: Schematic diagram of Steinsbekk's trial 
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compared. This allows the relative effectiveness of homeopathic treatment 
compared to a self-prescribed remedy, when prescribed to children for the 
prevention of upper respiratory tract infection. The intention of this arm was 
to determine whether the homeopathic consultation has an effect. However, 
the difference between the two arms is not just the difference between 
having a consultation, or not, because those in the self-prescribed arm were 
given one of a choice of three remedies, whereas those in the consultation 
arm were given one of a choice of any of the remedies in the homeopathic 
pharmacopeia. Furthermore dosage instructions were different in the self-
prescribed arm to the IHT arm. In the IHT arm the homeopaths varied the 
dosages according to the child, whereas in the self-prescribed arm all the 
children were given the same dosage. Therefore this comparison can give 
information about the two styles of homeopathy, but the reasons for any 
differences between the arms cannot solely be attributed to the consultation.  
Comparing arm A and arm B attempts to answer the question, “is IHT for the 
prevention of upper respiratory tract infections more effective than usual 
care?” This comparison does not give any indication as to the efficacy of the 
different constituents of IHT but merely explores the effectiveness of the 
whole intervention IHT. 
Comparing arm C versus arm D allows the effectiveness of a self-prescribed 
homeopathic remedy to be compared to a placebo treatment. These two 
arms were blinded, so that the child and their parents did not know whether 
the child was given the remedy they had chosen from the questionnaire or 
an identical placebo tablet. This comparison is thus designed to assess 
whether a self-prescribed homeopathic remedy is more effective than a 
placebo. However it cannot say whether a homeopathic remedy prescribed 
by a homeopath is more effective than a placebo.  
Whilst there was no direct comparison between IHT and placebo, the 
authors extrapolated that, in the context of their trial, it did not matter 
whether patients used IHT, self-prescribed remedies or placebo (Steinsbekk 
et al. 2007). This conclusion is problematic as there was no direct 
comparison between IHT and placebo. Whilst the authors concluded that the 
effects of the consultation in their study is negligible (Steinsbekk et al. 2007), 
this may not be the case. This study was carried out in children, and in 
homeopathic consultations with children it is the parent/adult that does most 
of the talking. Thus it could be that any effects associated with the 
consultation are reduced for children. (Steinsbekk et al. 2007). This would be 
important if the consultation plays a significant part of any benefit associated 
78 
 
with IHT. In summary Steinsbekk’s design has provided some interesting 
information, however it only gives information on homeopathic treatment for 
children, and it is likely that the experience of the homeopathic consultation 
will be different for adults.  
A feasibility study trying to look at the specific and non-specific effects of IHT 
(Fisher et al. 2006) has been carried out to try and determine the relative 
contributions of each, the aim being to assess whether any benefits of IHT 
were due to something specific to IHT (a specific effect i.e. the homeopathic 
remedy), or due to something generic to many treatments that involve a 
consultation (non-specific effect i.e. the time and attention of a caring 
practitioner). A fuller discussion on the meanings of specific and non-specific 
effects and their relationship with the placebo debate was given in Chapter 
2. In Fisher’s trial patients were randomised to open label treatment or 
blinded treatment. A schematic diagram of this trial is shown in Figure 4-6. 
 
 
 
The open label treatments were IHT (arm B) or wait list control (arm A) whilst 
the blinded treatments were IHT (arm C) or homeopathic consultation plus 
placebo (arm D). Whilst the aim of this study was to elucidate the relative 
contributions of the specific and non-specific effects of IHT, unless it is 
assumed that the only effect specific to IHT is the homeopathic remedy, this 
trial design is not able to meet its aim because all arms are receiving a 
homeopathic consultation. By giving everybody a genuine homeopathic 
consultation it is not possible to assess the effect of any effects specific to 
the homeopathic consultation. It is likely that there are effects specific to the 
homeopathic consultation, as discussed in Chapter 2, a study of the specific 
effects of IHT identified two elements of the homeopathic consultation as 
being specific to a homeopathic consultation, the remedy matching process, 
and an in-depth enquiry into bodily complaints (Thompson and Weiss 2006). 
Patients 
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Figure 4-6: Schematic diagram of Fisher's trial 
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Given this information, Fisher’s study would not have been able to assess 
the relative contributions of the specific and non-specific effects of IHT. In 
addition, in his conclusions, Fisher concluded that this trial design was 
unlikely to be able to identify the relative contributions of specific and non-
specific effects. This was because patients who were blinded to their 
treatment were more likely to drop out. In particular Fisher felt that blinded 
patients, who did not notice an improvement, were most likely to drop out, 
whilst patients who improved remained in the study, thus leading to an 
apparently positive effect of blinding. Unfortunately the reasons for dropouts 
were not reported, so although it is true that blinded patients were more 
likely to drop out, why this should have occurred can not be verified. It may 
be that Fisher’s suspicion is correct; however without knowing the reasons 
for the dropouts this cannot be confirmed.  
In summary, although Fisher’s study provides an alternative trial designed 
assess the specific and non-specific aspects of IHT, the design is fatally 
flawed in that it would not have been able to do what it set out to do for the 
reasons described above. Furthermore, in reality, it was found to be 
unfeasible to conduct such a trial due to poor recruitment rates and 
differential drop out. The reasons for the poor recruitment rate are unclear, 
even in the worst case scenario of being randomised to the placebo remedy 
arm, the patients would still get a genuine remedy once the trial was 
completed. In addition, this would have been in the same time scale that 
they would have received genuine treatment had they not taken part in the 
trial, i.e. they had nothing to lose by consenting to be in the trial. This was 
pointed out to potential participants in the invitation letter, therefore the 
reasons behind patients reluctance to be in the trial is difficult to understand 
without interviewing the patients to find out why this was so.  
Adler (Adler 2011) has proposed a novel study design, a schematic diagram 
of which is shown in Figure 4-7.  
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This trial is designed to assess the efficacy of IHT in treating depression. In 
this placebo controlled 4-armed trial participants are randomised to 
homeopathic case taking type I with a genuine remedy (arm A), 
homeopathic case taking type I with placebo (arm B), homeopathic case 
taking type II with a genuine remedy (arm C), or homeopathic case taking 
type II with placebo (arm D). All the patients in the trial are blinded to the 
treatment they receive, whilst the homeopaths delivering the treatment know 
which case history type they are following. However the homeopaths do not 
know whether the patients they are treating are receiving a genuine or a 
placebo homeopathic remedy. This is potentially an interesting design. 
Unfortunately to ensure patient blinding exactly what homeopathic case 
taking type I and type II entail has so far not been published. This means 
that exactly what this study is trying to ascertain about case taking remains 
unclear without further information about the case taking methods. For 
example the study could be trying to assess the contribution of talking to an 
empathetic practitioner by comparing a supportive case taking method to a 
more formal and “cold” case taking, as was the case in Kaptchuk’s 
acupuncture study (Kaptchuk et al. 2008). Or it could be contrasting two 
different schools of case taking, such as following a more traditional 
Hannemanian method to the newer Sankaran method1.  
                                            
1 The Hanemanian method involves an in-depth enquiry into bodily 
complaints coupled with an exploration of the characteristics of the person, 
whilst the Sankaran method also know as the “sensation method” aims to 
uncover a persons “vital sensation” through a more abstract case taking. A 
full discussion of this method can be found in Sankaran’s book “The 
Sensation.” SANKARAN, R. 2004. The Sensation in Homoeopathy. India: 
Homoeopathic Medical Publishers. 
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Figure 4-7: Schematic diagram of Adler's trial 
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4.6  Other studies of homeopathic treatment 
This section explores some of the other types of studies that have been 
carried out to assess homeopathic treatment, beginning with a discussion on 
observational studies and why their results cannot necessarily be directly 
attributed to homeopathic treatment. It then moves on to discuss studies that 
have looked in more depth at the homeopathic consultation, and the kind of 
information that they have been able to give.   
4.6.1 Observational studies 
Observational studies are non-randomised studies where data is gathered 
on people exposed to an intervention; this data may or may not be 
compared to data from people who have not been exposed to that 
intervention (Torgerson and Torgerson 2008). Observational studies can 
also give information about the natural history of a disease in a “real-world” 
situation, and it is possible to observe large numbers of people over a long 
time scales. In observational studies, where there is a comparator group, 
there is a weaknesses due to the lack of randomisation. This means that it is 
not known whether or not any differences observed are due to the effect of 
the intervention, or due to an inherent difference between the two groups. 
Furthermore for observational studies in which there is no comparator group 
(i.e. the data on those who received the intervention is not compared to data 
from people who didn’t receive it), it cannot be known whether any 
improvements observed are genuinely due to the treatment or to other 
factors such as regression to the mean. In the case of conditions such as 
IBS, it is likely that patients would consult the doctor when they were feeling 
at their worst and so were likely to improve (regress to the mean), whether 
they had treatment or not (Torgerson and Torgerson 2008).  
One of the largest observational studies of homeopathic treatment is a 6 
year study carried out by Bristol Homeopathic Hospital involving over 6 500 
consecutive patients and over 23 000 outpatient consultations from 1997 to 
2003 (Spence and Thompson 2005). This study aimed to assess the health 
changes of all patients who attended the hospital during this period. Patients 
were asked to rate the overall change in their health since their first visit, 
using the outcome scale shown in Table 4-1. 
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Outcome Score 
Much better +3 
Better +2 
Slightly better +1 
No change 0 
Slightly worse -1 
Worse -2 
Much Worse -3 
Table 4-1: Outcomes used in Bristol study 
The results found that following homeopathic treatment over 70% of patients 
reported some degree of improvement in their health and 50% reported a 
major improvement. However there is a potential for bias in that the outcome 
measure used was completed in the presence of the doctor and therefore 
the patients may not have been honest in their reporting, due to not wanting 
to disappoint the doctor, leading to a possible overestimation of the effect i.e. 
social desirability bias (Fisher 1993). It is also possible that there was a 
degree of recall bias in this study, where patients are more influenced by 
their current state than their previous state and find it difficult to remember 
how they were before, therefore comparisons to how they used to be may 
not be accurate (Schmier and Halpern 2004). Furthermore as there is no 
comparator group, it cannot be certain as to whether the patients would have 
improved to the same degree without treatment anyway. The large scale of 
the study and the fact that it reflected real-world circumstances are the 
strengths of the study.  
Another long term prospective, multi-centre cohort study involving 103 
homeopathic primary care practices (Witt et al. 2005) in Germany and 
Switzerland recorded data from all first time consulters (2,851 adults and 
1,130 children) and had similar findings. In this study all patients who 
consented to take part and were consulting the participating homeopathic 
doctor for the first time were included, regardless of their diagnosis; 103 
doctors took part in the study. The main outcome measures were patient 
and physician assessments and quality of life using the KITA questionnaire 
for children aged between 1 and 6 (completed by their parents), the KINDL 
questionnaire for children aged between 7 and 16 and the SF-36 for people 
aged over 16. These were completed at baseline and after 3, 12, and 24 
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months and returned to the study office in a sealed envelope, i.e. they were 
not completed in the presence of the doctor as was the case in Spence and 
Thompson’s study (Spence and Thompson 2005). Completing a 
questionnaire in the presence of a doctor as already mentioned, may lead to 
the patients overestimating how much they had improved, in an attempt to 
avoid disappointing the doctor (Fisher 1993). Witt calculated the 
improvement that could be expected due to regression to the mean, using a 
previously established method (Hannan et al. 1994). Comparing the 
calculated value with the results of her study she found that the 
improvements found in her study were greater than would be expected to be 
attributed to regression to the mean (assuming the subjects in the study 
were no more ill than a random sample from the general population). These 
were maintained up to the 24 month follow-up. The study therefore 
concluded that it is probable that users of homeopathic treatment will 
improve considerably. However as the authors acknowledged, this 
improvement cannot be attributed solely to homeopathic treatment. The 
uncontrolled nature of this type of study means that participants may at the 
same time have been seeking other treatments or doing other things that 
could have led to, or contribute to, their improvements. A subsequent follow-
up from Witt’s study which was carried out after 8 years has also been 
reported (Witt et al. 2008). The improvements found in the previous study 
continued to be maintained up to eight years after inclusion into the study. 
Again this improvement may not be due solely to homeopathic treatment. 
Despite this Witt’s study provides a good indication that people who seek 
homeopathic treatment will improve, however why they improve cannot be 
verified; whether it is due to a factor specific to homeopathic treatment, 
placebo effects, regression to the mean, withdrawal bias (where participants 
who do not perceive a benefit withdraw from the trial) or something else 
remains uncertain.  
4.6.2 Studies looking at the homeopathic consultation 
The homeopathic consultation is an integral part of IHT, and as such it is 
important to explore studies that have investigated the consultation, as these 
studies may shed light on factors to consider when designing a trial to 
assess the effectiveness of IHT, along with providing insights into how to 
design such a trial.  
Various studies have been carried out to determine the different elements 
involved in the homeopathic consultation, in terms of both what the 
consultation is like and attempting to understand what the active ingredients 
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of a homeopathic consultation may be. This section provides an overview of 
some of the studies that have examined, what the homeopathic consultation 
is like, and explores what they have been able to say about homeopathic 
treatment and in particular the homeopathic consultation.  
Eyles Eyles et al. 2010) looked into the homeopaths perception of the 
consultation which led to the formation of a model entitled, “a theoretical 
model of a UK classical homeopathic consultation”. This theoretical model 
identifies the different elements that play a part in the homeopathic 
consultation and how they are interrelated from the homeopaths perspective. 
The elements identified were; connecting, exploring the journey, finding the 
level, understanding self and responding therapeutically. The element 
“connecting” refers to the connection between the homeopath and the 
patients and covers areas such as empathy and rapport. “Exploring the 
journey” involves the patients disclosing information about themselves and 
their illness. The homeopath will then attempt to unravel this information, 
thus allowing them to gain an understanding of the patient. “Finding the 
level” involves evaluating the patient in terms of their illness, prognosis and 
most appropriate treatment. “Understanding self” refers to the need for the 
homeopath to understand themselves in order to be able to connect with the 
patients and provide effective treatment. Finally “responding therapeutically” 
refers to how the homeopath is able to respond to the patient’s needs and 
provide treatment fitting for the particular patient. Data from interviews with 
homeopaths, an examination of videos of homeopathic consultations and 
homeopaths diaries were triangulated. The model looks at the homeopathic 
consultation from a particular perspective of the homeopath, and therefore 
cannot tell us anything about how the patient views the homeopathic 
consultation. However the study states clearly that it is about homeopath’s 
perspectives, so although its generalisability to how the homeopathic 
consultation is viewed in the round could be questioned, its generalisability 
to the population studied is less questionable. Although a potential 
weakness of the study is the fact that no medical homeopaths were 
interviewed, it is unknown as to whether this group of homeopaths would 
have a different view of the homeopathic consultation and therefore how 
applicable the model would be to this group. However the final model was 
shown informally to medical homeopaths, (by Eyles), who agreed with its 
findings, therefore it is likely that medical homeopaths, to some degree, hold 
a similar view of the consultation to professional homeopaths. The fact that 
information was gathered from a variety of sources, interviews, videos and 
diaries gives added weight to the final model produced and is one of the 
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studies strengths. However only a limited number of homeopaths had 
agreed to be videoed and it may be that there are differences between how 
those who agreed to be videoed and those who didn’t agree to be videoed, 
conduct a consultation. It is also possible that the presence of a video 
camera may have affected how the consultation was conducted. In 
summary, whilst it is considered likely that the model gives a good 
representation of the homeopathic consultation from a homeopath’s 
perspective – which is what the study set out to do, it is also possible that 
patients would have a different view that would be worth exploring. Whilst 
this model doesn’t focus on what effects are specific and what are non- 
specific to IHT, it does reveal the interconnectedness of the specific and 
non-specific aspects of IHT and proposes that these parts cannot be 
separated from each other. 
Other studies have compared the homeopathic consultation to conventional 
consultations (Ruusuvuori 2005; Rise and Steinsbekk 2009). However these 
studies have not attempted to produce a framework or model of the 
constituents of the homeopathic consultation and so although they provide 
interesting comparisons, they have not tried to understand the constituents 
of the homeopathic consultation in terms of what is unique or not. For 
example Rise (Rise and Steinsbekk 2009) compared parents views of 
homeopathic consultations and conventional consultations and found that 
parents viewed homeopathic consultations to take a whole-person approach, 
whereas conventional medicine consultations were more symptom based. 
However what this “whole person” approach comprised was not elucidated 
(Rise and Steinsbekk 2009), and therefore what this study adds to the 
understanding of IHT and homeopathic consultations is questionable.  
Brien (Brien, Leydon and Lewith In press) carried out a study which involved 
interviewing participants who had taken part in the RCT described in Section 
4.5. The aim of the study was to explore rheumatoid arthritis (RA) patients’ 
perceptions of the homeopathic consultation and whether they perceived 
any benefits from the consultation. From the interviews a model was 
constructed as to how the homeopathic consultation may help RA patients. 
The main themes of this model were; gaining advice from the homeopath, 
exploring their illness, exploring themselves and gaining emotional support. 
No mention is made of the homeopathic remedy within the model; this 
seems to be an oversight in that the ultimate aim of a homeopathic 
consultation is to facilitate the prescription of a remedy. Patients would have 
been aware of this and it seems likely that they would have mentioned the 
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remedy with regard to the consultation. Participants who had completed all 
five treatment sessions were interviewed. This could have led to a biased 
sample, as it is unlikely that those who did not perceive any benefit would 
attend all five appointments. The conclusion that patients experience a 
benefit from the homeopathic consultation cannot therefore be generalised 
to mean that all patients with RA will benefit from a consultation. The author 
states that 16 of the people contacted agreed to be interviewed, and that 
data saturation appeared to have been reached from these 16 interviews. It 
seems convenient that data saturation was reached within the number of 
people eligible and who consented to be interviewed. However, the resulting 
model is explained in depth, with examples of how the conclusions were 
reached. Thus, although there are concerns about some of the conduct of 
this study, it is likely that the model does reflect how those patients 
interviewed perceived the homeopathic consultation.  
In summary these studies have provided some important information on 
what the homeopathic consultation is like. 
4.7 Choosing an appropriate study design  
The most important aspect of any research design is whether it is able to 
answer the question that is being asked. Thus when considering research 
designs the question should come first and the research design fitted to the 
question rather than the question fitted to the design, as is sometimes the 
case (Vickers et al., 1997). In this study the question posed is;  
• Is IHT, as it is delivered in practice, any different to spending time with 
an empathetic practitioner? 
In this chapter different designs of trials have been reviewed in terms of the 
information they are able to give about IHT. This PhD study aims to explore 
the effectiveness of IHT as it is delivered in practice. As already explained, 
pragmatic RCTs are able to explore treatments as they are delivered in 
practice (MacPherson 2004). However despite recent developments in IHT 
study design there have been no studies that have explored the whole 
package of IHT without trying to dismantle IHT into its component parts, or 
without comparing IHT to usual care. However comparing IHT to usual care 
is unable to answer the question posed in this PhD study as to whether IHT 
is any different to spending time with an empathetic practitioner. This is 
because the comparison of the IHT arm would get a consultation with an 
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empathetic practitioner, whilst the other would not. This leaves the question 
as to what to use as a comparator control for IHT.  
In clinical trials one of the key issues to consider is what to use as a control. 
Part of the reason for the lack of studies exploring IHT as a whole package 
has been due to the difficulty in identifying a control that would provide 
equivalent time and attention to the homeopathic consultation, therefore 
controlling for any “consultational” effects. The next chapter explores how to 
design a control that would control for the time and attention involved in IHT. 
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5 Designing of a trial to assess the effectiveness of 
individualised homeopathic treatment 
The purpose of this chapter is to determine how best to design a trial for 
individualised homeopathic treatment (IHT). In the previous chapter it was 
concluded that none of the designs that had been used in the past were able 
to determine whether or not IHT was any different to spending time with an 
empathetic practitioner. Thus a different approach was needed in designing 
such a trial. In the field of psychotherapy, due to the inherent difficulties in 
constructing a “control” arm for a treatment that involves a therapeutic 
interaction, researchers have spent time thinking about how to go about 
designing controls and what they should consist of.  
One type of control used in psychotherapy research is an attention control 
(AC) or attention placebo. That is a non-specific treatment aimed at 
controlling for the time spent with an empathetic practitioner. In this PhD 
study the term “attention control” will be used, rather than the term attention 
placebo, to reflect the fact that this type of control is a non-specific rather 
than an inactive treatment. With this in mind this chapter discusses attention 
controls and important considerations involved in designing such a control, 
and in doing so draws on the conceptual issues explored in Chapter 2. 
5.1 Attention control 
Controls have been used in trials of behavioural therapies to test whether 
any positive effects of the therapy are due to; the generic aspect of spending 
time with an empathetic person or a specific aspect of the experimental 
treatment. These “time and attention” controls are often also known as 
“attention placebo” or “attention control” (AC).  
ACs aim to give those in the control arm equivalent time and attention to that 
received by those in the active treatment arm(s). 
The first published study (that was found), that talked about the use of an 
AC, was published in 1965 (Koenig and Masters 1965), and used 
“supportive counselling” as an AC in a smoking cessation trial using a 
behavioural therapy to aid cessation, signifying that this concept is not a new 
one and that all searches in this area should all go back to1965. In this study 
supportive counselling was used to control for the effects of talking to 
someone who showed concern and interest in the person, along with what 
89 
 
was felt to be the possibly beneficial effect of a figure they held in regard 
encouraging them to stop smoking. The supportive counselling involved 
discussing smoking and the reasons for smoking, encouragement when the 
person refrained from smoking but understanding if the person was unable 
to stop i.e. providing the person with a supportive environment in which to 
discuss their habit and ways of breaking it. 
Before looking in more detail at ACs it was necessary to understand “what 
constitutes an “attention control?”” To this end a scoping search was carried 
out in Web of Science using the search term “attention placebo” (1898-
2009). “Attention placebo” is the term more commonly used to describe 
these “time and attention” controls, however, the author prefers to use the 
term “attention control”, believing this term more accurately reflects the fact 
that these controls are not necessarily an inactive treatment. The aim was 
not to have a definitive search for all studies that had used an AC but rather 
to find a range of studies to compare and contrast and gain an idea of “what 
constitutes an AC.” At this stage the search was restricted to trials to gain a 
perspective on attention placebos that was not coloured by having 
previously read opinion or discussion pieces.  
The search brought up 68 citations. Of these the “active” treatments involved 
a behavioural therapy, psychotherapeutic intervention, educational program, 
relaxation, exercise training or hypnosis. In order to better understand “what 
constitutes an “attention placebo?” it was desired to review in more detail a 
subsection of these 68 trials. To do this it was decided to choose one 
experimental treatment and extract data from all trials of that experimental 
treatment. The experimental treatment chosen was Cognitive Behavioural 
Therapy (CBT) because this was the experimental treatment most prevalent, 
with 9 of the available trials comparing Cognitive Behavioural Therapy (CBT) 
to AC. Data was extracted on: the condition treated, what the attention 
placebo comprised of, any rationale given for the AC, whether any checks 
were carried out to verify the integrity of the therapy delivery and whether or 
not it was the same person or group of people that delivered the CBT and 
the AC. Table 5-1 provides a summary of the results. The aim of this data 
extraction being to gain an understanding of some of the issues surrounding 
the choice of an AC, and ways in which these issues had been dealt with.  
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Table 5-1: Data extraction from nine trials that included an attention control 
Article Condition Treatment 1 Treatment 2 Attention Placebo Rationale for attention placebo Details of attention 
placebo 
Therapist Check of integrity of 
therapies/ credibility check 
Amigo 1991  Essential 
hypertension 
Cognitive 
behavioural 
program 
 Regular contacts 
between therapists 
and patient 
Control for regular interaction 
and relationship between 
subjects and examiners. 
Discussed daily 
experiences with therapist 
encouraging patients to 
overcome stress without 
telling them how to. 
Doesn’t 
say 
No 
Thackwray 
1993 
Bulimia 
Nervosa 
CBT Behavioural 
therapy 
Non-specific self 
monitoring 
No specific rationale given. Patient completed self-
monitoring form and spent 
time with therapist, aiming 
to instil positive 
expectancies without 
giving specific advice.  
Same Yes - subjects completed 
check lists to check 
therapists covered certain 
subjects. Some sessions 
were audio taped and 
checked. 
Heimberg 
1998 
Social phobia Cognitive 
behavioural 
group therapy 
phenelzine Educational 
supportive group 
therapy 
Use of appropriate control 
provides a stern test of the 
utility of the treatment. 
Topics relevant to social 
phobia were presented 
and discussed. 
Same 
group 
Yes - Credibility of 
treatment checked. 
Thomas 1999  Sickle cell 
disease 
(SCD) pain 
Cognitive 
behavioural 
group therapy 
No 
intervention 
Discussion group 
chaired by a 
psychologist 
Wanted plausible placebo that 
provoked similar expectancies 
to the treatment group.  
Discussion of the type of 
problems and feelings 
associated with living with 
SCD. 
Same No clear information. 
Lincoln 2003 Depression 
after stroke 
CBT Standard 
Care 
Conversation with 
community 
psychiatric nurse 
Results from previous studies 
may be due to having a 
supportive therapist to listen to 
problems. 
Conversation with 
community psychiatric 
nurse focusing on day-to-
day occurrences and 
physical effects of stroke 
and life changes. 
Same No 
Thieme 2006  Fibromyalgia Cognitive 
behavioural 
therapy 
Operant 
behavioural 
therapy 
General discussion No specific rationale given. Discussions centred on 
medical and psychosocial 
problems of Fibromyalgia. 
Same 
team 
No 
Blanchard 
2007  
Irritable 
bowel 
syndrome 
Cognitive 
behavioural 
group therapy 
Intensive 
symptom 
monitoring 
Psycho educational 
support groups 
Commonly available treatment 
that would control for 
attention and group meetings. 
Educational topics 
introduced by therapist 
and opportunity for 
members to share views 
and experiences. 
Same 
group 
Yes - doctoral student sat 
in on all groups as an 
observer.  
O’Conner 
2007  
Delusional 
Disorder  
Cognitive 
behavioural 
therapy 
 Individualised 
weekly meetings 
with one of the 
psychologists 
Cognitive behavioural therapy 
has been found more effective 
when compared to routine 
care than when compared to 
an AC. 
Individualised weekly 
meetings, involving non 
directive supportive 
discussion. 
Same 
group 
Yes - audio recorded and 
randomly selected for 
treatment integrity 
Zautra 2008  Rheumatoid 
Arthritis 
Cognitive 
behavioural 
therapy 
Mindfulness 
meditation 
Education only Control for non-specific 
treatment effects such as 
attention, expectation and 
group support. 
Information about 
rheumatoid arthritis and 
other health related topics 
given in a group setting.  
Same 
team 
Yes –audio recorded and 
listened to by treatment 
supervisor. 
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A variety of different ACs were used in these trials, all intending to control for 
the therapists’ time and attention. However despite differences in the way 
they were presented, all of the ACs involved some kind of discussion about 
the problems associated with the patient’s condition, either in a one-to-one 
format or in a group setting, depending on whether or not the trial was 
looking at group CBT. In all the trials it was the same person or group of 
people that delivered both the “genuine” therapy and the AC therapy. In five 
of the trials there was a check to confirm that in the AC arm an AC was 
being delivered rather than CBT. This data extraction provided a basis for 
further exploration of the notion of AC. 
Thus to further this understanding a search was carried out in Web of 
Science from 1965 to 2010, using the search terms “attention placebo” OR 
“attention control”. This was to identify articles explaining how and why 
particular ACs had been used to control against active interventions, the aim 
being to gain an understanding of the considerations that need to be made 
when considering what would be a suitable AC for IHT. 
This search identified 880 papers, the abstracts of which were scanned to 
determine if the paper involved a study that had used an AC or was a 
discussion piece on ACs, the references of relevant papers were also 
screened in an attempt to locate any additional relevant papers. From this 
literature it was found, as in the previous search, that a variety of different 
ACs were used. However, on inspection, despite the different name tags 
given to the ACs many of them appeared to be essentially the same 
treatment, involving a non-directive discussion, often referred to as 
supportive listening/therapy (Whorwell, Prior and Faragher 1984; Guthrie et 
al. 1993), although the terms non-directive counselling (Ward et al. 2000) 
and brief non directive psychotherapy (Friedli et al. 1997) have also been 
used to describe what appear to be very similar treatments. These 
treatments, which will be termed “supportive listening” for the purpose of this 
thesis, all involve a non-specific treatment whose aim was to develop a 
supportive relationship by providing emotional support based on rapport and 
unconditional regard (Tarrier et al. 1998). However supportive listening does 
not involve some of the more advanced Rogerian counselling skills, such as 
problem clarification. It should be borne in mind that non-specific is not the 
same as inactive, the term “non-specific” is used to mean that the elements 
this treatment consists of are generic rather than unique. Supportive 
listening is considered to be a therapy in its own right and is used by 
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organisations such as Macmillan as a means of providing support to people 
in difficult situations (University Hospital of North Staffordshire NHS Trust 
2012). 
Others ACs involved relaxation (Boyce et al. 2003), support groups 
(Blanchard et al. 2007) or one-to-one education and discussion (Drossman 
et al. 2003). One thing all these AC interventions had in common was that 
they were all “off the shelf” interventions i.e. they were treatments that had 
already been used previously although not necessarily as an AC. For 
example relaxation therapy has been used in trials as an active intervention 
in its own right (Yu, Lee and Woo 2010). Whilst disease-specific support 
groups, both internet based and face-to-face, are a readily encountered and 
popular phenomenon. 
Yet there were also trials found that had not used an “off the shelf” 
treatment, rather they had gone to considerable time and effort to design an 
AC specific to the treatment under investigation. The intention being to 
construct an AC that would be equivalent to the experimental intervention, 
with the therapeutically active factor(s) available only in the intervention 
group (Safer and Hugo 2006). This suggests that the AC should contain 
none of elements unique to the experimental treatment, whilst possessing 
the essential but non-unique elements to the same degree as the 
experimental treatment. 
Thus it became apparent that when using an AC there is a basic choice to 
be made; either to use an already established non-specific treatment or to 
design an AC specific to the treatment under investigation. However, when 
attempting to design a new and credible AC, there is always the possibility of 
creating an intervention that is effective in its own right. In one irritable bowel 
syndrome trial the author felt that failure to find a significant difference 
between the AC and active treatment was due to the participants in the AC 
(pseudo meditation and EEG alpha suppression bio-feedback group) 
converting it into an active and effective treatment (Blanchard et al. 1992). 
Whilst with some ACs it is difficult to see how this could be the case, such as 
one that involved listening to audio book segments (Jacobson et al. 2011), 
with other multifaceted ACs, such as the one described by Blanchard, it is 
possible that the different facets could interact, leading to an effective 
therapy. However it is also possible that this is wishful thinking on the part of 
the researcher when finding their “active” therapy to be no more effective 
than an AC. Using an AC that has already been used a number of times in 
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the past and whose effects are better understood would eliminate or reduce 
such concerns.  
5.2 Structural equivalence 
In addition to the thoughts about the contents of ideal comparison controls in 
respect to the specific and non-specific effects of the treatment being 
evaluated, the concept of structural equivalence has also been suggested as 
being important in preventing the introduction of bias (Baskin et al. 2003). 
Structural equivalence (Baskin et al. 2003) means that the structural aspects 
of the both the trial and control treatment are the same; all groups get the 
same number of sessions, with the same duration and over the same time 
frame. If any medication is given out then all groups would be given a 
medication, whether it be placebo or genuine. If tasks are given to do at 
home then all arms get tasks etc. Providing structural equivalence is 
important because any effectiveness observed in a trial where the arms are 
structurally non-equivalent may be down to the non-equivalence rather than 
any active effects of the treatment being assessed. For example, in a review 
of psychotherapy trials (Baskin et al. 2003) it was found that those where the 
control was structurally in-equivalent to the active treatment, there was a 
greater effect size compared to those that were structurally equivalent (i.e. 
same number of sessions, time spent with patient etc).  
Finally, the view that the AC should be a credible treatment option for the 
condition in question should also be explored. Borkovec and Nau (Borkovec 
and Nau 1972) have developed a questionnaire to assess how credible 
people perceive the treatment they are receiving/are going to receive will be 
for their condition. This questionnaire has been utilised in trials using an AC. 
Credibility is important for two reasons: (i) the credibility of a treatment has 
the potential to provide a powerful therapeutic effect (Wampold 2001), (ii) 
there is likely to be an increased dropout rate in the AC arm if people think it 
is not going to be of any benefit to them.  
Therefore from this review it can be summarised that an AC should: 
 Be a plausible treatment for the condition being treated 
 Not have a significant impact on the mechanism thought to explain 
the effectiveness of the investigational treatment.  
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 Be equivalent to the active treatment in terms of time spent with the 
patient.  
5.3 Attention controls in irritable bowel syndrome trials 
As already mentioned, one of the most important aspects when choosing an 
AC is that it is a credible treatment for the condition being treated 
(Whitehead 2004). Different ACs may appear credible for different illnesses. 
An AC that may be credible to a person with IBS may not be credible to a 
person with chronic fatigue; therefore it was felt that it was important to think 
carefully about the kinds of treatment that a person with IBS would believe 
may work. To this end a search was carried out to identify randomised 
controlled trials of IBS that used an AC. This was to allow exploration of the 
types of ACs used and their credibility to patients, with the aim of narrowing 
down suitable options for an AC in an IBS trial of IHT. The search was 
carried out in February 2010 and repeated in 2012, with the purpose of 
ensuring that up to date results were included in this thesis. 
The search was carried out in Embase (1947 – June 20 2012), MEDLINE 
(1950 – June week 2 2012) and PsychINFO (1806- June week 2 2012) and 
Web of Science (from 1965 to week 22 2012) using the search terms 
“attention placebo”, “attention control”, “supportive listening”, “supportive 
counselling”, “supportive therapy”, “relaxation”, “non-directive counselling”, 
“brief psychotherapy”, “irritable bowel syndrome”, “irritable bowel disease”, 
“irritable colon” and the Mesh term “irritable bowel syndrome.” Full details 
are given in Appendix 3. Systematic reviews identified in the search were 
used to identify any further papers that may also have included an AC. A 
further search was also carried out in Web of Science (from 1965 to week 22 
2012) to identify all the papers relating to IBS written by Whorwell or 
Blanchard, two researchers who are known to have used AC in IBS. A 
summary of the findings are shown in Table 5-2.
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Reference Experimental treatment Attention control/comparator Same 
contact time 
Comments 
(Whorwell, Prior and 
Faragher 1984) 
Hypnotherapy Psychotherapy and placebo Yes  
(Blanchard et al. 
1992) study 1* 
Multi component (relaxation, 
thermal biofeedback and 
cognitive therapy) treatment 
Pseudo meditation and EEG alpha 
suppression biofeedback 
Yes  Credibility and expectations assessed by 
questionnaire 
(Blanchard et al. 
1992) study 2* 
As above As above Yes Credibility and expectations assessed by 
questionnaire 
(Guthrie et al. 1993) Psychotherapy Supportive listening No  
(Payne and 
Blanchard 1995) 
Individualised cognitive 
treatment.  
 
Self-help support group. 
 
Yes  
(Fernandez et al. 
1998) 
As above Visualisation of bowel function  Yes High dropout rate in attention control arm 
(Boyce et al. 2003) Cognitive behavioural therapy 
 
Relaxation therapy  No  
(Drossman et al. 
2003) 
Cognitive behavioural therapy Educational support  Yes Credibility and expectations assessed by 
questionnaire 
(Simren et al. 2004) Hypnotherapy Supportive therapy, including dietary 
advice, telephone support and discussion 
with a consultant 
No  
(Fernandez and 
Amigo 2006) 
Training in stress management 
or contingency management 
Biofeedback control  Yes  
(Blanchard et al. 
2007) 
Group based CBT 
 
Psycho educational support groups. Yes  
(Vlieger et al. 2007) Hypnotherapy Supportive therapy discussing symptoms 
and triggers. 
No  
(Gaylord et al. 2009) Mindfulness  IBS support group Yes Credibility assessed by questionnaires. 
Adherence to protocol assessed by video 
(Craske et al. 2011) Cognitive behavioural 
treatment targeting visceral 
anxiety. 
Educational support Yes Credibility assessed by questionnaires. 
Adherence to protocol assessed by audio 
recordings 
(Flik et al. 2012) Individualised hypnotherapy Group educational supportive therapy Yes  
(Lindfors et al. 2012) Hypnotherapy Supportive therapy as per Simren’s study  No  
Table 5-2: Attention controls used in IBS trials 
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The ACs identified in this search comprised: supportive therapy, 
psychotherapy + placebo tablet, psycho-educational support group, self-help 
support group, pseudo-meditation and EEG alpha-suppression biofeedback, 
education, biofeedback and visualisation. The controls used were not 
designed to be inactive treatments, rather they were designed to control for 
the non-specific effects of the experimental treatment. It should also be 
borne in mind that what is considered a non-specific treatment by some is 
considered to be an active treatment by others. In this PhD study a control 
treatment is taken to be a treatment that contains only generic elements and 
no elements that are not found in other treatments. 
 Of the list of controls identified in the searches, only supportive 
therapy/listening, pseudo meditation and self-help support groups were used 
as a control in more than one trial (Blanchard et al. 1992; Guthrie et al. 1993; 
Payne and Blanchard 1995; Simren et al. 2004; Gaylord et al. 2009). 
However the supportive therapy was not the same in all trials. In one of the 
trials it comprised a one-to-one supportive conversation (Guthrie et al. 
1993), and in the other it comprised one-to-one discussions with four 
specialists in different areas, i.e. dietician, gastroenterologist etc. (Simren et 
al. 2004). Although relaxation therapy is shown in Table 5-2 as an attention 
placebo, in this trial there was a comparison of CBT and relaxation to test 
the hypothesis that CBT would be better than relaxation therapy. 
Furthermore, relaxation therapy for IBS appears to be a treatment in its own 
right and has been used as one of the active treatment options in two trials 
(Fernandez et al. 1998; Fernandez and Amigo 2006), see Table 5-2.  
From the ACs identified as having been previously used in IBS trials the 
following were considered as potentially suitable as an AC for IHT; relaxation 
therapy, supportive listening, an education program, support group or 
designing an AC specifically for IHT. Designing an AC specifically for IHT 
was decided against because it was felt that it would not be feasible in the 
time scale of this project to design, test for credibility and then run a RCT 
with a specifically designed AC. ACs that had been specifically designed to 
contain the non-specific effects of a particular treatment, such as EEG alpha 
suppression biofeedback, were not considered because they had elements 
that were not a part of IHT, such as carrying out physical treatment. To aid in 
the decision as to what would be the most suitable AC for IHT a table (Table 
5-3) of the specific and non-specific effects of IHT was constructed from 
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Thomson’s work, that was discussed in Chapter 2 (Thompson and Weiss 
2006). 
Specific effects of homeopathic 
treatment 
Non-specific effects of homeopathic 
treatment 
 In depth enquiry into bodily 
complaints and idiopathic 
symptoms  
 homeopathic remedy  
 Remedy matching process  
 Consultational empathy 
 Openness to mind body 
connection 
 Disclosure 
Table 5-3: Specific and non-specific effects of IHT 
Using Table 5-3 as a framework for identifying the non-specific aspects of 
IHT and considering the ACs chosen as being potentially suitable as an AC 
for IHT (relaxation therapy, supportive listening, an education program, 
support group), it was decided that an AC for IHT must contain a one-to-one 
interaction with an empathetic practitioner. This was because a one-to-one 
interaction would allow for the opportunity for disclosure along with providing 
consultational empathy. The opportunity for disclosure is important for IBS 
patients because, although IBS is perceived to be a physical condition, 
people with IBS are more likely to suffer with anxiety or depression than 
those in the general population (Ten Berg et al. 2006). Along with this is the 
fact that IBS is a condition that people often don’t talk about. This is because 
of embarrassment and feelings of stigma due to a lack of understanding by 
friends and family about the effects of IBS (Silk 2001; Drossman et al. 2009). 
In a focus group study carried out by Drossman one participant said 
(Drossman et al. 2009) page 1538 “I didn’t tell my husband, don’t tell my 
friends. I feel lots better now that I can talk about it.” This quote highlights 
the importance of being able to talk about IBS to IBS suffers. 
Although a support group is an attractive option and appears in the literature 
to have been credible it is was not chosen because it is not a one-to-one 
interaction. It was felt that the AC must be a one-to-one interaction to allow 
for the possibility for disclosure and consultational empathy.  
Despite relaxation therapy having been compared to cognitive behavioural 
therapy in an IBS study (Boyce et al. 2003) it was not chosen, because there 
is the potential that it could contain specific effects in its own right. 
Relaxation therapy comprises particular techniques aimed at releasing 
tensions in the body and promoting positive thinking, thereby helping the 
98 
 
 
 
person to cope in a stressful situation (Yu, Lee and Woo 2010). It has been 
shown to have physiological effects such as lowering the heart rate (Peveler 
and Johnston 1986), and for the purpose of this study is therefore 
considered to be an active treatment rather than a non-specific treatment. 
Another possibility was an education program as described in a cognitive 
behavioural therapy (CBT) trial (Drossman et al. 2003), whereby the 
participant reads a variety of educational materials and discusses them with 
the therapist. This appears to have been a credible therapy, is relatively 
easy to deliver and offers a one to one interaction. However the educational 
material may lead to some effectiveness of this intervention over and above 
spending time with an empathetic practitioner. It was therefore decided that 
supportive listening would provide the best AC for a trial of IHT because the 
non-specific aspects of IHT of consultation empathy and the opportunity for 
disclosure would be provided, without the specific elements of in depth 
inquiry into bodily symptoms, the remedy and remedy matching process. It 
was felt that although education could involve the same length of time spent 
with a practitioner, education doesn’t perhaps have the same opportunities 
for disclosure as does supportive listening and IHT. In addition education 
could also include specific effects that IHT doesn’t, thus introducing more 
variables.  
As already stated supportive listening has previously been used as an AC in 
IBS trials and is therefore thought to be a credible treatment option. 
Consequently supportive listening is considered to be the most appropriate 
AC to control for therapists’ time and attention in a trial of IHT because it is a 
non-specific therapy which can be used to give the same amount of time and 
attention to that received in a homeopathic consultation. Furthermore it has 
been used successfully in the past as a control in trials for IBS (Whorwell, 
Prior and Faragher 1984; Guthrie et al. 1993). In spite of this Whitehead 
(Whitehead 2004) advises on assessing whether a treatment is plausible by 
assessing the expectation of benefit through a treatment credibility 
questionnaire, and monitoring differential dropout rates. Should differential 
dropout occur the researcher can then seek to explore why this is so; is it 
because one treatment was less effective than the other, was it less 
acceptable to patients, or did patients not believe it would help them. 
In summary supportive listening was believed to be the most appropriate 
treatment to control for the time and attention given to patients in a 
homeopathic consultation. However IHT involves the prescription of a 
99 
 
 
 
homeopathic remedy and therefore the issue of structural equivalence needs 
to be considered. This will be discussed in the next section. 
5.3.1 Structural equivalence and the inclusion of a placebo tablet 
As already mentioned structural equivalence is an important aspect of ACs, 
and when thinking about structural equivalence in terms of IHT, the 
homeopathic remedy must be taken into account. As already discussed in 
section 5.2, to provide maximum structural equivalence, if one group 
receives a medication then all groups should receive a medication.  
In the searches for ACs, an RCT studying non-cardiac chest pain (Jones et 
al. 2006) was identified that compared hypnotherapy to supportive listening 
plus a placebo tablet. The authors justified the inclusion of the placebo tablet 
as being to boost any placebo effects in the supportive listening arm. The 
inclusion of a placebo tablet in a trial of IHT could be used to provide 
structural equivalence between IHT (where the patient receives a 
homeopathic remedy), and supportive listening. In this case both groups 
would receive time and attention from the therapist plus a medication, be it 
placebo or otherwise. The tablet used for the placebo could be sac-lac, the 
base tablet for a homeopathic remedy (consisting of lactose plus a binder); 
therefore the tablet would appear the same as a homeopathic remedy. 
However what and what not to tell participants about a placebo tablet poses 
an ethical dilemma. The effectiveness of the action of the placebo tablet 
ultimately rests on what patients are told about, as patients’ beliefs will help 
to determine whether it has an effect. However what patients are told will 
have an ethical dimension. This will be discussed in Chapter 6, which 
focuses on the methodology of the study. The next section discusses the 
final element of an AC, that of who will provide the AC. 
5.3.2 Who provides the attention control 
Who would deliver the AC is another area that needs careful consideration. 
In the CBT trials shown in Table 5-1 the same group of people delivered the 
experimental and control treatments. A trial of IHT has the added 
complication that the homeopaths providing the IHT may not have had any 
formal training in supportive listening, whereas therapists trained in CBT are 
likely to have formal training in a wide range of counselling skills, including 
supportive listening. It is important that whoever delivers the AC is able to 
present it as a credible therapy and one aspect of this will be the confidence 
the person feels in delivering the therapy. The downsides of homeopaths 
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delivering the AC could be; inexperience and a vested interest in not 
allowing the supportive listening to appear credible thus introducing a bias 
into the trial. However using the same team of therapists to deliver both the 
interventions would lessen the variability due to therapist, but in reality 
homeopaths would never be asked to deliver supportive listening and thus 
this would not enhance the external validity of the trial. Weighing these 
things up, and with the thought that one of the most important aspects of an 
AC is that it appears credible, it would be better if a nurse or someone with 
basic counselling skills provided the supportive listening. When choosing 
such a person, care needs to be taken to ensure that both the homeopaths 
and the supportive listening provider have a fairly similar demeanour. There 
is the possibility of bias if one was a warm and empathetic person and the 
other(s) rather cold. In this scenario it would not be a test of the therapy but 
rather a comparison of different types of people.  
This chapter has provided a discussion on the issues to consider when 
deciding on an AC for IHT. The chapter began with an investigation into how 
other researchers have constructed ACs, and the factors to consider when 
designing such a control before identifying a potential AC for IHT, namely 
supportive listening. However if IHT plus usual care was compared to 
supportive listening plus usual care it would not be known whether either of 
these treatments offered any benefit over usual care. This is important 
because it would be of no advantage to offer people a treatment that did not 
provide any additional benefit over their existing treatment. 
Once a potential control (supportive listening) and a condition (IBS) had 
been identified, the next step was to decide on the methodology of the trial. 
The next chapter will therefore explain the reasons why the trial was 
conducted in the way it was.  
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6 Methodology 
The conclusion from Chapter 3 was that a trial of IHT for IBS was needed. 
However as concluded in Chapter 4, the design of such a trial is not simple. 
Considering possible designs it was concluded in Chapter 5 that a trial 
comparing IHT plus usual care to both, supportive listening plus usual care, 
and usual care alone, was the most suitable design. In this design 
supportive listening would act as an attention control (AC), controlling for the 
time and attention the patient gets from the homeopath, and usual care 
would act as a baseline comparator. Thus it would be possible to assess not 
only whether IHT plus usual care was any different to supportive listening, 
but also whether IHT was any different to usual care alone. If a usual care 
arm had not been added this would not have been known. No matter how 
IHT performed in relation to supportive listening, it is a waste of resources to 
offer people with IBS IHT on top of their usual care if this elicited the same 
results as would be achieved with usual care alone. This chapter builds on 
the conclusions about the most appropriate study design and describes why 
the cohort multiple RCT design (cmRCT) was chosen. This PhD study was 
part of a wider trial assessing the clinical and cost effectiveness of IHT, this 
chapter describes the relationship between this PhD study and the wider trial 
before moving on to explain decisions made about the inclusion of a placebo 
tablet in the supportive listening arm, along with the choice of outcome 
measures. In addition it explores the rationale for including a qualitative 
element to this study and explains the reasons why individual interviews with 
participants in the RCT were selected for the qualitative part of the study. 
6.1 Randomised controlled trial of homeopathic treatment 
for irritable bowel syndrome 
In designing an RCT of IHT it is important to consider what the trial is trying 
to answer. In the case of this PhD the aim was to: 
 Determine whether IHT, as it is delivered in practice, is any different 
to spending time with an empathetic practitioner.  
Chapter 4 discussed various trial designs and their appropriateness in 
assessing homeopathic treatment. The aim of this study was to carry out a 
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trial that was both rigorous (had low susceptibility to bias and high internal 
validity), and that would be true to how IHT is delivered in practice. 
Therefore it was concluded at the end of Chapter 5 that a pragmatic design 
would be the most suitable. Pragmatic trials are designed to assess how 
effective an intervention is, as it is delivered in everyday practice 
(MacPherson 2004). 
The next consideration was what to use as a comparator or control. Chapter 
5 discussed the idea of ACs and how to design an AC for IHT. At the end of 
Chapter 5 it was concluded that supportive listening would provide a suitable 
AC for IHT. Therefore the eventual study design was that of a three armed 
pragmatic RCT comparing: 
 Usual care 
  IHT plus usual care 
 Supportive listening plus usual care 
 A usual care arm was included in the trial to provide a baseline for 
comparison, thus it would be possible to assess whether IHT was the same 
as, better, or worse than usual care.  
The trial reported in this thesis is part of a wider trial looking at the clinical 
and cost effectiveness of IHT compared to usual care, in the treatment of 
IBS. The wider trial is seeking to answer the question, “Is IHT a cost 
effective treatment for IBS?” A previous trial (Relton 2009) comparing IHT 
plus usual care to usual care alone for fibromyalgia was carried out by the 
same team who are conducting the wider trial. In Relton’s fibromyalgia trial a 
significant positive effect associated with IHT was found. In a subsequent 
systematic review of homeopathy for fibromyalgia (Perry 2010), it was 
suggested that Relton’s trial would have been more meaningful if the 
homeopathic package of care had been compared to a package of care that 
controlled for the non-specific effects of the therapeutic setting. This was 
because comparing IHT against usual care could have led to a positive 
outcome for IHT due to the extra attention those in the IHT arm received, 
rather than due to the homeopathic remedy. In addition to this, when the 
team from the wider trial met with Professor Whorwell, (a gastroenterologist 
and researcher) he suggested that a third arm should be included in the 
wider trial (Raw 2010). The team, knowing that my area of interest was, “a 
time and attention control for IHT,” asked me to design an AC arm to include 
103 
 
 
 
in their wider trial. Thus this study became part of a wider trial. Figure 6-1 
shows the relationship between this study and the wider trial. For the 
statement of providence from the protocol for the wider trial Appendix 4. 
 
 
For the purpose of this piece of research the main area of interest is in the 
comparison of IHT to AC at 26 weeks, however to provide a baseline for 
comparison a usual care arm was also included. This will allow a distinction 
to be made between the “placebo” effect and the natural history of the 
condition. Thus if both the IHT and AC arms proved to be the same in terms 
of effectiveness (at 26 weeks) it was possible to address the supplementary 
question regarding whether there are any differences in outcomes for the 
active treatment arms compared to usual care. 
The main area of interest to the wider trial is the clinical effectiveness and 
cost effectiveness outcomes of patients with IBS treated with IHT plus usual 
care, compared to those treated with usual care alone, 52 weeks after 
recruitment to the trial.  
6.1.1 Setting and team 
The trial took place at Barnsley Hospital NHS Foundation Trust, where both 
the IHT and the supportive listening were delivered. A consultant 
gastroenterologist and gastroenterology registrar formed part of the team for 
both this and the wider study. Two homeopaths who had previously been 
involved in a trial of IHT for fibromyalgia and who were already working at 
Barnsley Hospital provided the IHT. 
  Homeopathic treatment   
26 week outcomes   
 52 week outcomes and cost effectiveness analysis  
    
  
  
Part of this study 
Not part of this study 
Figure 6-1: Relationship between this study and the wider trial 
Usual care Attention placebo 
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6.1.2 Funding 
The trial was funded by Barnsley Hospital small grants fund, Friends of 
Barnsley Hospital and the Homeopathy Research Institute. The Homeopathy 
Research Institute is a charity that is working to facilitate scientific research 
in the field of homeopathy. Potential sources of bias introduced by a 
homeopathic charity funding this trial and how they were addressed is 
discussed in Chapter 8. The trial was registered with the International 
Standard Randomised Controlled Trial Number Register (ISRCTNR), 
registration number: ISRCTN90651143. 
6.1.3 Research question and hypotheses 
Research Question 
What is the difference between IHT and supportive listening for irritable 
bowel syndrome when compared against usual care? 
Aim 
To test whether IHT plus usual care is any different to: 
 supportive listening plus usual care 
 usual care alone. 
Primary hypothesis  
Ho: There is no difference between IHT and supportive listening when 
measured by change in IBS symptom severity score (IBS- SSS) between 
baseline and 26 weeks where IBS is defined by a score of ≥ 100 on the IBS-
SSS. 
H1: There is a difference between IHT and supportive listening for patients 
with IBS when measured by change in IBS-SSS between baseline and 26 
weeks. 
Secondary hypothesis 
Ho: There is no difference between IHT and usual care when measured by 
change in IBS symptom severity score (IBS-SSS) between baseline and 26 
weeks where IBS is defined by a score of ≥ 100 on the IBS-SSS. 
H1: There is a difference between IHT and usual care for patients with IBS 
when measured by change in IBS-SSS between baseline and 26 weeks. 
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The primary hypothesis is looking at the explanatory question “is IHT 
functionally equivalent to time and attention?” The rationale for the primary 
hypothesis being the need to test the common assumption that IHT is 
nothing more than a placebo treatment and that IHT is equivalent to 
“supportive listening.”  
As already explained the main area of interest in this thesis is whether or not 
IHT is any different to supportive listening, however to put these results into 
context, a comparison was made against usual care. Therefore the 
secondary hypothesis looked at the pragmatic question “is IHT more 
effective than usual care?” Thus a comparison was made as to whether IHT 
is any different to usual care. 
The study used a Cohort Multiple RCT (cmRCT) design, the next section 
explains why this design was chosen rather than that of a standard RCT i.e. 
a two arm parallel group trial. 
6.1.4 The cohort multiple RCT design 
This trial used a cmRCT design (Relton et al. 2010). This is a recently 
developed design, similar to the Zelen design (Zelen 1979), where 
participants are randomly allocated to either the control or experimental 
group(s) prior to being told about and consenting to the experimental 
treatment. In the Zelen design consent is only sought from those allocated to 
the experimental treatment. Consent is not sought from those allocated to 
the control group and they are not told that they are involved in a 
comparative study. However in the cmRCT design a cohort of participants 
are invited to take part in an observational study entailing the completion of 
questionnaires at various time frames. Consent to “take part in an 
observational study” is sought from everybody who is invited to join the 
cohort. Those that do not consent do not form part of the cohort. This cohort 
is formed prior to the randomisation process and from the cohort people can 
be randomly selected to the “offer of treatment.” Those who are not 
randomly selected to an offer of treatment, are not told about treatments that 
they have not been offered, as per the Zelen design. The process then 
proceeds in a similar manner to the Zelen design. Schematics of the Zelen 
design and the cmRCT design are shown below (Figure 6-2 and Figure 6-3).  
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Analysed as experimental treatment Analysed as standard 
treatment 
Experimental group: experimental 
treatment 
Control group: standard 
treatment 
Seek consent 
Consent given 
Experimental treatment 
Consent denied 
Standard treatment 
Experimental treatment Standard treatment 
Standard treatment 
Random allocation 
Figure 6-2: Schematic diagram of Zelen design 
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In both designs if an intention to treat analysis is being used then everybody 
who was offered the experimental treatment is analysed as being in the 
experimental treatment group. This is regardless of whether they consented 
to the experimental treatment (Zelen 1979; Relton et al. 2010).  
An important difference between the cmRCT design and the Zelen design is 
the possibility of using the cohort for further RCT studies, with the advantage 
of being able to directly compare the different RCT studies, obviating the 
need for indirect comparisons and the accompanying complexities. 
The cmRCT design was chosen over the Zelen design for this study 
because baseline data was needed for all participants. This was to allow the 
baseline characteristics of the participants to be compared across the three 
arms to check that the randomisation had worked in terms of baseline 
comparability. Any differences could then be adjusted for in an adjusted 
  
  
  
    
 
  
      
Analysed as experimental treatment Analysed as standard 
treatment 
Experimental group: experimental 
treatment 
Control group: standard 
treatment 
Seek consent 
Consent given 
Experimental treatment 
Consent denied 
Standard treatment 
Experimental treatment Standard treatment 
Standard treatment 
Random allocation 
Recruit to cohort 
Assess for eligibility to RCT 
Identify population 
Figure 6-3: Schematic diagram of cmRCT design 
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analysis, see Chapter 7 for a further discussion on statistical analysis. 
Obtaining this baseline data would not be possible using the Zelen design, 
whereas in the cmRCT design, because participants have consented to fill in 
questionnaires at various time frames, baseline data can be obtained from 
these questionnaires. In addition baseline data was needed for the cost 
effectiveness analysis to be carried out as part of the wider trial. 
Participants could have been recruited and randomised in the same way as 
in a “standard” randomised trial where consent is sought from eligible 
participants, and following consent they are randomised to one of the arms 
of the trial. However the cohort design was the preferred option for the study 
team for the wider trial. There are pros and cons with both the standard RCT 
and the cmRCT design. The cmRCT design aims to replicate real world 
health care where participants are not told about treatments they are not 
going to receive (Relton et al. 2010). The advantage of participants not being 
told about treatments they are not being offered, apart from replicating real 
world healthcare, is that there is less chance of resentful demoralisation. 
Resentful demoralisation is where participants assigned to the control group 
become resentful for not receiving the experimental treatment (the usual 
case) or when participants in the experimental group become resentful of the 
control group, e.g. if the experimental treatment is perceived as inferior to 
the control treatment (Torgerson and Torgerson 2008). Resentful 
demoralisation can result in non-compliance or withdrawal from the trial. A 
disadvantage of the cmRCT design is that, because participants are not told 
about treatments they may receive, they may agree to be in the cohort but 
not actually be interested in receiving any treatment for their condition. This 
may then lead them to not taking up the treatment they are offered. Whilst 
this is what occurs in real life, this may not be desirable in a trial assessing 
the effectiveness of an intervention, unless the aim of the trial was to assess 
the effectiveness of the intervention in the real world. This means that 
neither of these options is perfect. As the cmRCT is a recent design and so 
far only one published trial has used this method (Relton 2009), this study 
will be able to provide further information about how the cmRCT model 
works in practice. The IBS cohort recruited for this study was termed the 
Barnsley Irritable Bowel Syndrome Cohort or BIBSC. 
6.1.5 The placebo tablet 
As discussed in Chapter 5, to provide structural equivalence between the 
IHT arm and the supportive listening arm, including a placebo tablet in the 
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supportive listening arm was considered. However as mentioned in Chapter 
5, the inclusion of a placebo tablet has an ethical dimension. This section 
provides a more focussed discussion on ethics of including a placebo tablet 
in the RCT. 
The definition of a placebo in the Oxford English Dictionary is “ a medicine or 
procedure prescribed for the psychological benefit to the patient rather than 
for any physiological effect” (Oxford Dictionaries 2011). With the implication 
being that it is the patients belief that the “placebo” will help them that leads 
to any benefits, rather than some inherent activity of the medicine or 
procedure themselves. The rationale for the inclusion of the tablet was to 
serve the purpose of making the IHT and supportive listening as equivalent 
as possible by ensuring that both arms contain the beliefs and expectations 
that being prescribed a medication entails. Secondly it would help to ensure 
that patients return to collect their medication, thus returning for their 
supportive listening consultations.  
In the searches for ACs detailed in Chapter 5 a RCT studying non-cardiac 
chest pain (Jones et al., 2006) was identified that compared hypnotherapy to 
supportive listening plus a placebo tablet. The authors justified the inclusion 
of the placebo tablet as being to boost any placebo effects in the supportive 
listening arm. The inclusion of a placebo tablet in a trial of IHT could be used 
to provide structural equivalence between IHT (where the patient receives a 
homeopathic remedy) and supportive listening. In this case both groups 
would receive time and attention from the therapist plus a medication, be it 
placebo or otherwise. The tablet used for the placebo could be sac-lac, the 
base tablet for homeopathic remedies (consisting of lactose plus a binder), 
therefore the tablet would appear the same as a homeopathic remedy. 
However the inclusion of a placebo tablet in the supportive listening arm 
leads to a question regarding what to tell participants in the supportive 
listening arm to ensure that the researcher’s duty to provide informed 
consent is met (World Medical Association 2008). In one previous trial the 
participants in the supportive listening arm were told they were being given 
“a medication that may help their condition” (Jones et al., 2006). The 
“medication” in question was an inert tablet and none of the patients were 
given an active medication (Whorwell, 2010). Ethically this can be difficult to 
implement because it could be argued that the participants are being misled. 
In a discussion on this issue Whitehead (Whitehead, 2004) page S162, 
gives the following advice, “to be able to state in the consent form that the 
110 
 
 
 
pills could help, at least a few of the patients should receive an active drug.” 
The theory being that the patients given the active medication would be 
receiving a medication that might help and everyone in that arm of the trial 
would have a chance of receiving the active medication. However what 
Whitehead doesn’t explain, or explore, is what people would be told about 
the tablet they would receive. If they were told “you have x chance of 
receiving an active medication and x chance of receiving a placebo,” and the 
chance of receiving an active medication was very low, the overall “placebo 
effect” of the tablet could be reduced, when compared to an arm where 
everyone is told they were being given a “medication that may help them”. 
Thus there is a possibility that this reduction in overall “placebo effect” could 
negate any advantage in including the placebo tablet. However, if they were 
simply told that they would receive “a medication which may help their 
condition,” with the thought that including an active medication makes this 
statement true, and therefore fulfils the requirement for informed consent, it 
is difficult to see how this would be any different to not including the active 
medication. This is because it is believed that Whitehead’s suggestion fails 
to take into account the fact that placebos can be effective (Beecher, 1955). 
Therefore it would not be misleading to say that the placebo tablets could 
help, as there is the possibility the tablets could help, either because people 
believe that taking a tablet might help, or because they are told they might 
be effective.  
The approach of giving some people an active medication was considered, 
however giving an active medication to some participants would lead to an 
increase in the number of participants required in the supportive listening 
arm. This is because the supportive listening arm would now consist of the 
number of participants calculated in the power calculation (who would be 
given supportive listening plus placebo) plus the extra people who would be 
given supportive listening plus active medication. Increasing the number of 
participants in the supportive listening arm was considered not to be feasible 
due to the funding limitations of the trial.  
Another thought was that the patients in the supportive listening arm could 
be given a low-dose multivitamin. This would be unlikely to improve their 
condition but it could be described as “a medication that may help your 
condition.” And thus potentially still act as a placebo – but it may not be 
inactive and thus not in fact a placebo. Furthermore introducing a 
multivitamin would lead to the introduction of a new variable into the trial. 
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This is becasuse it is not known whether a multivitamin would have an effect 
on IBS. Therefore the supportive listening arm could then be getting an 
active medication that those in the homeopathic arm would not be getting. It 
was decided that it was better to keep the trial as simple as possible rather 
than introducing more variables which can lead to difficulty in analysis. Thus, 
although having the placebo medication would provide structural 
equivalence, substituting it with something that could prove to be an active 
treatment in its own right could over-complicate matters. The potential 
difficulties identified were, in the interpretation of results, where effects may 
be due to non-specific effects of the treatments, or due to something specific 
about IHT and or the supportive listening arm (i.e. the multivitamin). 
Taking all this into account it was decided that, in the application to the 
research ethics committee, a placebo tablet would be included in the 
supportive listening arm of the trial. The rationale for its inclusion would be 
explained, that is to provide structural equivalence with the IHT arm. 
Another factor that was considered was whether whoever was prescribing 
the placebo tablet would be comfortable in presenting it as a credible 
treatment. Without this any placebo effects of the tablet could be lost and 
there would be no point in including it in the trial. Therefore in addition to the 
ethical questions over giving a placebo tablet, there is also the difficulty as to 
who would give out the tablets. In trials by Whorwell’s group in Manchester 
(Whorwell, Prior and Faragher 1984; Calvert et al. 2001; Jones et al. 2006) 
the placebo has been given by the person providing the supportive listening, 
however this relied on this person being comfortable in providing the placebo 
and telling the participants that this is “a medication that may help.” In the 
trial of non-cardiac chest pain (Jones et al., 2006) a research assistant 
provided the supportive listening. In this trial it was decided that providing 
ethical approval for the placebo tablet could be obtained, then the people 
delivering the supportive listening would give out the placebo tablets, and 
the rationale for the inclusion of the placebo tablet would be explained to the 
supportive listening providers. However owing to the concerns of the 
research ethics committee, a placebo tablet was not included in the 
supportive listening arm. A full discussion for the reasons behind this 
decision can be found in Chapter 8.  
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6.1.6 Outcome measures 
Primary outcome measure 
The primary outcome measure was the IBS Symptom Severity Scoring 
System (IBS-SSS) (Francis, Morris and Whorwell 1997). The IBS-SSS is a 
global measure consisting of 5 questions that are scored on a 100 point 
visual analogue scale. All scores contribute equally leading to a possible 
total score of 500, with a higher score equalling greater severity (< 175 
represents mild IBS, 175-300 represents moderate severity and >300 
represents severe IBS). (Francis, Morris and Whorwell 1997) 
IBS-SSS was chosen as it is the measure most commonly used to assess 
improvement in IBS and therefore its use allowed comparison between this 
and other IBS trials. Furthermore in a systematic review of outcome 
measures used in clinical trials for IBS it was ranked by Bijerk (Bijkerk et al. 
2003) as the best outcome measure based on psychometric and 
methodological properties for a detailed IBS symptom assessment. The 
Adequate Relief question (Mangel et al. 1998) which measures improvement 
in symptoms with the single question "Did you have adequate relief of IBS-
related abdominal pain or discomfort?" was also felt to be a good choice 
when assessing global symptomatology as an outcome (Bijkerk et al. 2003). 
However it does not give a detailed IBS symptom assessment and cannot 
be used to assess baseline IBS severity. 
With participant burden as consideration, it was decided to use only one IBS 
specific outcome measure, because an assessment of the baseline IBS 
symptoms was needed, the IBS-SSS was chosen. 
Secondary outcome measures 
When choosing secondary outcome measures it is important to consider 
what additional value they will give to the study. To allow comparability 
between this and other trials, and in order to identify the most appropriate 
outcome measures, a search of IBS RCTs that used an AC was conducted 
in AMED (Allied and Complementary Medicine) (1985 to June 2010), 
Embase (1996 to 2010 Week 22) and Ovid Medline (1996 to May Week 4 
2010). The search terms used were “specific effect”, “context effect”, 
“irritable bowel”, “irritable colon”, “Spastic colon”, “functional bowel disease” 
and “functional colonic disease” and the MeSH terms irritable bowel 
syndrome, colonic disease and functional colonic disease. This search was 
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conducted in 2010 prior to the choice of the secondary outcome measures. 
Full details of the search are given in Appendix 5 
From the results of this, and consideration as to what additional value the 
outcome measure would bring to the study, the following outcomes were 
chosen.  
1. Hospital anxiety and depression scale (HADS) (Bjelland et al. 2002). 
Although improvement in IBS is of primary importance, patients suffering 
from IBS often report a greater incidence of anxiety and depression and 
lower feelings of general wellbeing than the general population (Ten Berg et 
al. 2006). Therefore any improvement in these areas could also imply a 
positive effect of treatment. The scale chosen to assess anxiety and 
depression was the hospital anxiety and depression scale (HADS). Although 
there are a variety of scales that can be used, HADS is a validated measure 
for assessing anxiety and depression and its use in IBS trials is well 
documented (Kennedy et al. 2005; Lu et al. 2005; Smith 2006). Coupled with 
this is the fact that HADS is a self report measure, takes a short time to 
complete (2-5 minutes), and can be used to assess both anxiety and 
depression, rather than solely depression or solely anxiety (Snaith 2003). 
2. EuroQol-5D (EQ-5D) (Williams 1990). The EQ-5D is a standardised 
instrument used to measure health related quality of life. It consists of two 
parts, the first being five questions (dimensions), used to explain a person’s 
state of health for each dimension and the second, a visual analogue scale 
used by the patient to score their overall health. This was chosen because it 
was considered that including a global measurement scale to assess 
whether participants’ general wellbeing improved would give valuable 
information. It was also needed for the cost effectiveness element of the 
RCT, which is outside the scope of this PhD study. Although there are 
disease specific quality of life measures available for IBS, such as the IBS 
quality of life measure (IBS-QoL) (Patrick et al. 1998), these do not provide 
the information needed for the cost effectiveness element of the wider trial. 
To reduce participant burden in filling out questionnaires it was decided to 
choose only one health related quality of life measure. There are alternative 
health related quality of life measures that could have been chosen such as 
the SF6 D (Brazier et al. 1992). However the EQ-5D was chosen over these 
because it is short, therefore reducing participant burden in completing 
questionnaires, and widely used, thus allowing comparability of other 
treatment trials for IBS. 
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For patients in the IHT and supportive listening arms the following additional 
outcomes were collected by postal questionnaire at 6 months. 
3. Consultational and Relational Empathy (CARE) (Mercer et al. 2004). 
CARE is a measure of the practitioners empathy as perceived by the 
patients. This was included to explore further the concept of time and 
attention, give some indications about how patients perceived the therapists, 
and allow an exploration as to whether there was any correlation between 
participants’ perceptions of the therapists and outcome. 
4. Expectation of benefit: This measures the patients expectation of benefit 
and credibility based on a validated measure originally designed by 
Borkovec (Borkovec and Nau 1972) and modified by Drossman (Drossman 
et al. 2003) for IBS. It was included to assess the credibility to the patients of 
the two treatments for IBS. Based on a 10 point scale the patient answers 
the following two questions (i) how confident would you be that this 
treatment would be successful in reducing your bowel symptoms? (ii) How 
logical does this type of treatment seem to you for helping bowel symptoms? 
The intention was to measure this after the second appointment for those in 
the active treatment arms. This measure was chosen because the use of 
Borkovec and Nau’s credibility scale is recommended in order to test the 
integrity of trials of psychological interventions (Irvine et al. 2006). However it 
was considered that Drossman’s modified version for IBS would be more 
suitable than the original version.  
5. Each participant’s exposure to treatment was recorded e.g. the number of 
sessions with either a homeopath or “supportive listening” provider. 
Exposure to treatment was recorded to allow the uptake of both treatments 
to be compared. It may have been that uptake was far greater for one of the 
treatments, which could have been due to:  
 Patients feeling better and therefore requiring less sessions. 
 Patients not finding the treatment acceptable/useful and so failing to 
come back for follow-ups. 
If was also thought that, if no significant difference in the outcomes was 
found between IHT and supportive listening, it would be useful to note 
whether either of the two options was more acceptable to patients than the 
other. 
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6.2 Qualitative Interviews 
This section discusses the methodology used for the qualitative part of this 
study. It begins with explaining the rationale behind including a qualitative 
element and the reasons behind choosing to carry out semi-structured 
interviews. It then moves on to discuss the aims and objectives of this study 
and how these influenced the sampling strategy, interview schedule and 
analysis method.  
6.2.1 Why include a qualitative element 
To provide the optimum understanding of the effects of complex 
interventions, such as IHT, a combination of quantitative and qualitative 
research methods are sometimes used (Walach et al. 2006). This is 
because RCTs are able to give information about whether or not a treatment 
is clinically effective but they cannot give information as to why this is the 
case. Therefore in order to better understand aspects of complex 
interventions qualitative interviews nested in trials have been used to provide 
information that can not be picked up by the trial outcome data (Thompson 
et al. 2011; Brien, Leydon and Lewith In press). Verhoef et al (Verhoef, 
Casebeer and Hilsden 2002) argued that including a qualitative element 
exploring patients’ experience of CAM treatment should be considered when 
conducting CAM research. This is to aid the understanding of why the 
intervention may work, such as how the patient’s beliefs and expectations 
influence the treatment “working” and what patient’s understanding of a 
treatment “working” is. To this end one particularly useful approach is to nest 
qualitative studies within a RCT (Bernie 2003).  
In this study, the RCT will be able to examine whether IHT is similarly 
effective to supportive listening, when compared against standard care, 
however it will not be able to say why this is or isn’t so. To better understand 
the effects of IHT, it would be informative to explore the patient’s perspective 
of what it was about the treatment, if anything, that they perceived to have 
helped them. A qualitative element to this study would be able to explore 
whether the patients believed the homeopathic remedy exerted any effects 
or whether there something inherent in the way the homeopathic 
consultation was conducted that they found particularly helpful. Did being 
listened to help them? Or was it something else? In order to create a fuller 
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picture the therapist’s point of view could also be investigated. This would 
seek to understand how they perceived the treatment to have helped (if it 
helped) and during analysis determine whether they had a similar 
perspective to the patients. 
One method of carrying out this qualitative work is to conduct in-depth 
qualitative interviews with participants and therapists from both treatment 
arms of the RCT. Individual interviews offer the possibility of gaining a 
deeper understanding into what the patient perceived to have happene 
along with the ability to pick up nuances of the treatments that cannot be 
picked up by questionnaires (Rubin and Rubin 2005). Another option would 
have been to record the homeopathic consultations and the supportive 
listening consultations and analyse them using a form of conversation 
analysis. Conversation analysis is the study of conversations with its focus 
being on the processes involved in social interaction and how talk makes 
things happen (Greenhalgh et al. In press). It aims to understand how 
specific actions are achieved through talking, e.g., asking questions, 
providing advice, eliciting symptoms histories, rather than exploring 
participants understanding of how treatments worked or didn’t work (Drew, 
Chatwin and Collins 2001). Moreover conversation analysis cannot provide 
information about what people think. Instead it aims to understand 
communication within the interaction (such as a consultation) and how 
opportunities for participation are opened up or closed down. It would 
therefore not answer the questions posed by this PhD study whose aim is to 
explore the participants’ views on the treatment they received. Another 
option would have been to use focus groups, however focus groups are 
more suited to situations where the intention is to understand participants 
attitudes and where interactions between participants will help understand 
the research issue (Ritchie and Lewis 2003). Individual interviews are more 
able to gain detailed information on individuals reports, with a greater 
opportunity for clarification and deeper understanding, especially of complex 
systems (Ritchie and Lewis 2003). Accordingly in-depth individual interviews 
were chosen.  
The nature of the interview then needed to be decided; structured, semi-
structured or unstructured. Unstructured interviews are used to gain a 
general flavour of participants views or experiences of a topic whilst 
structured interviews are used when the researcher is interested in one core 
idea (Rubin and Rubin 2005). This study required more than just a general 
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flavour of participants’ views, but was not just interested in one core idea, 
such as the participants’ views of the remedy. Consequently individual semi-
structured interviews were chosen as a means to explore patients views on 
their treatment and gain a deeper understanding of what the patient 
perceived to have happened. Furthermore semi-structured interviews allow 
the same general areas of interest to be explored with each interviewee, 
whilst at the same time allowing a degree of flexibility to go with the 
participant rather than adhering strictly to the same pre-prepared list of 
questions with each participant, as is the case with structured interviews. 
Carrying out these interviews also had the possibility of adding to the body of 
knowledge regarding IHT. Previous studies have tried to assess the 
elements of the consultation from the homeopath’s perspective (Eyles et al. 
2010), and from the participant’s perspective (Brien, Leydon and Lewith In 
press). However so far no studies have been carried out that explore the 
patient’s or the homeopath’s perceptions of the whole intervention of “ IHT.” 
i.e. explored the perceptions of both the homeopathic consultation and the 
remedy, and what aspects of these led to any benefit.  
6.2.2 Research question  
What, if any, elements of their treatment do patients and therapists in the 
Barnsley Irritable Bowel Syndrome Cohort (BIBSC) study perceive as 
leading to changes (or lack of) in their IBS and general health?  
6.2.3 Aim of the study 
To explore patients views of what they found helpful about the treatment 
they received, and what led to changes in their IBS and general health, in a 
purposive sample of patients who received IHT, and a purposive sample of 
patients who received supportive listening. 
To explore therapists’ views of what patients found helpful about the 
treatment they provided, and what they perceive to have led to changes in 
the IBS symptoms and general health of patients taking part in the RCT. 
6.2.4 Objectives 
In order to answer the research question this research therefore explored 
the following questions: 
For patients 
 Whether any aspects of their IBS or general health had changed 
during their treatment  
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 What they thought had led to these changes 
 What elements of their treatment they thought helped /didn’t help 
 What the patients liked/didn’t like about the treatment they received 
 Whether they felt the treatment worked for them 
 What their understanding of a treatment working is 
For therapists 
 Whether they felt the IBS symptoms or general health of the patients 
had changed during their treatment 
 What they thought had led to these changes 
 What elements of the treatment they provided they thought had 
helped /didn’t help 
 Whether they felt the treatment they provided worked 
 What their understanding of the treatment they provided working is. 
6.2.5 Construction of a topic guide 
Semi-structured interviews offer the possibility of exploring IHT from the 
patient’s perspective, thus gaining an insight into what they feel has helped 
or not helped them (Rubin and Rubin 2005). Semi-structured interviews can 
be used to gather patients’ perspectives on the different elements to be 
explored and whether or not they feel it is one particular aspect of the 
treatment that helped or whether it was the whole package (King and 
Horrocks 2010). To this end a topic guide to the areas of questioning was 
needed (King and Horrocks 2010). To allow flexibility in the interviews the 
topic guide covered broad areas that needed to be addressed rather than 
focusing in on specific questions (Rubin and Rubin 2005). The aim of the 
qualitative part of this study, was to explore patients’ and practitioners’ views 
of what they felt was helpful about the treatment they received (or provided), 
and what led to any changes in their or their patients IBS and general health. 
Therefore, the questions were seeking to explore whether the treatments 
were helpful, in what way the treatments were helpful, and what it was that 
led participants to their conclusions. Table 6-1 shows the broad questions 
that were asked and what each question is seeking to understand.  
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Question  Area to be explored 
Tell me about the treatment you 
received 
Opening question to elicit the patients’ initial views. 
What changes have there been 
since you started the 
treatment? What do you think 
has led to the change? 
To determine if there had been any change. If so what 
the participant perceived had led to the changes. Did they 
perceive the change to be due to the treatment they 
received or something else that has happened in their 
life? Did they attribute it to a particular aspect of the 
treatment? 
Did you feel the treatment 
worked for you? If yes, in what 
way did it work? (Ask for 
examples). If no, what would 
the treatment working have 
been? 
What were the participants’ perceptions of a treatment 
working? Did they perceive the treatment to have worked 
for them? (The participants symptoms may have changed 
since starting treatment, but a change in symptoms may 
not be perceived as a treatment working).  
What did you find 
helpful/unhelpful about the 
treatment? (Ask for examples) 
 
The patient may not have felt the treatment worked as 
per their definition of a treatment working but they may 
have found the treatment helpful. What did participants 
perceive as a treatment being helpful and did they equate 
a treatment being helpful with a treatment working? They 
may have been better able to cope with their IBS 
following treatment even though the symptoms 
themselves may not have changed. 
What did you like/dislike about 
the treatment? 
 
To explore without explicitly asking whether they enjoyed 
spending time with and talking to an empathetic 
practitioner, was this important to them? Was there 
anything they disliked about the treatment, did those who 
disliked aspect(s) of the treatment do worse than those 
who didn't?  
Would you use this treatment 
again? Why? 
 
Did the participant feel strongly enough about the 
treatment to use it again, is it something they would 
recommend? They may feel better but would not use the 
treatment again, if not why not? 
What expectations did you 
have of the treatment? Did it 
meet these expectations? Did 
the therapist give you idea of 
what you could expect from the 
treatment? 
To understand the participants’ expectations and any 
expectations that the therapist gave them. This was 
mapped with the RCT results to see if there was any 
relationship between expectations and outcome. 
How would you describe the 
therapist? 
 
To gain an insight into the participants’ perceptions of the 
therapist and whether this related to whether they felt the 
treatment worked or whether they felt the treatment was 
helpful. The aim being to better understand the 
relationship between the participant and the therapist and 
the impact this had on whether a treatment works 
Did the therapist suggest any 
lifestyle changes or other 
therapies? Did you follow this 
advice? What was the 
outcome? 
To find out whether the therapists made other lifestyle 
suggestions and whether the participant felt these were 
helpful? Were any improvements down to advice given 
by the therapist rather than specifically due to the 
treatment they'd received? 
In IHT arm: 
What was your experience of 
taking the remedy? 
 
To explore the participants perceptions of taking the 
remedy. Was the remedy related to any of the changes or 
was it something else about the treatment such as the 
talking aspect? 
Table 6-1: Interview questions and what they were seeking to explore 
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6.2.6 Sampling strategy and size 
The aim of quantitative sampling methods is to obtain a representative 
sample of the population being studied thus allowing results to be 
generalised back to that population. However the aim of qualitative sampling 
is different (Thompson 1999). Qualitative research sets out to understand 
issues relating to human behaviour, and therefore requires a sample that is 
likely to cover all the areas of interest, from as broad a range of standpoints 
as possible, from a sample that addresses the particular needs of the 
individual question (Mays 1996). There are different types of sampling that 
can be used. Convenience sampling, as its name suggests seeks to sample 
the most accessible members of the population being studied (Mason 1996). 
Whilst theoretical sampling requires the building of theories from the 
emerging data and then selecting a new sample which will allow the theory 
to be explored and elaborated further (Ritchie and Lewis 2003). Finally in 
purposive sampling the researcher actively selects a sample of people that 
are likely to cover the range and diversity of experiences. A sampling frame 
is often used to aid this (Ritchie and Lewis 2003). 
In this study it was intended that a purposive sample of approximately 16 
patients would be interviewed, 8 people from each of the two active 
treatment arms of the trial. Purposive sampling was chosen because this 
research is setting out to understand how different people viewed the 
treatment they received. It is not setting out to develop a theory or theoretical 
model of the treatment, rather it requires a range of experiences and views. 
It was planned that a sampling frame (see Section 6.2.7.2) would be used to 
purposively select participants to ensure that the data reflected the range 
and diversity of treatment experience. The RCT aimed to recruit 33 people to 
each arm. It was estimated that with loss to follow up, potential under 
recruitment, and ineligibility to take part in the interviews, there would be 
roughly 20 people in each arm of the trial eligible to take part in the 
interviews. Therefore to gather the range of people identified in the sampling 
frame it was expected that it would be sufficient and feasible to recruit 8 
people from each arm. 
Four therapists provided treatments as part of the BIBSC study, two 
providing supportive listening and two providing IHT. To reflect the diversity 
of therapists’ experiences it was the intention was to sample all four 
therapists. 
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In summary the sample size was decided on based on the following criteria: 
 It was anticipated that this number would generate data with sufficient 
breadth and depth to give enough information for key themes in 
people’s experiences to be identified.  
 It would be feasible to undertake given the constraints of time and 
resources for the study. 
6.2.7 Participants 
6.2.7.1 Inclusion and exclusion criteria 
To be included in the sample participants must have taken part in the RCT.  
Inclusion criteria for patients 
 Participated in either the supportive listening or IHT arm of the RCT. 
This is because the interviews were focusing on peoples experiences 
of their treatment in the RCT. 
 Attended at least 2 treatment sessions. Participants will need to have 
experienced at least two sessions to understand what the treatment 
they were offered involved.  
Inclusion criteria for therapists 
 Provided either supportive listening or IHT in the RCT because the 
interviews focused on therapists views of the treatment they provided 
in the RCT. 
6.2.7.2 Sampling frame for patients 
The intention was that participants who met the above inclusion criteria 
would be purposively sampled from each of the two active treatment arms. 
This was to ensure that there was a mix of people who experienced benefit 
and who did not experience a benefit, from each treatment arm of the RCT. 
It was also planned to recruit a mixture of men and women. This was 
because it was thought that men may have a different perspective of 
treatment to that of women. A previous study comparing IBS patients 
managed in primary and secondary care, found despite there being a 
greater number of female IBS sufferers, one of the factors associated with 
consulting in secondary care was being male (Smith et al. 2004). Therefore 
it is likely that there is some difference associated with gender in the 
treatment of IBS. Table 6-2 shows the sampling frame for this study. 
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Treatment  IHT 
n=6-8 
Gender Male  
n=3-4 
Female  
n=3-4 
Did the treatment work? Yes  
n=1-2 
Maybe/No 
n=1-2  
Yes  
n=1-2 
Maybe/No 
n=1-2 
Treatment Supportive listening 
n=6-8 
Gender Male  
n=3-4 
Female  
n=3-4 
Did the treatment work? Yes 
n=1-2 
Maybe/No 
n=1-2  
Yes 
n=1-2 
Maybe/No 
n=1-2  
Table 6-2: Sampling frame for interviews 
Treatment is defined as having worked if following treatment the patient has 
a decrease of 50 or more in the IBS symptom severity score (Francis, Morris 
and Whorwell 1997). 
Due to a lower than anticipated recruitment into the RCT the number of 
participants in the IHT and supportive listening arms of the trial were too low 
to purposively sample. Therefore an amendment was sent to the research 
ethics committee. Permission was given to invite to interview all those who 
had attended at least two IHT or supportive listening consultations. A copy of 
this permission letter is given in Appendix 10. 
6.2.8 Analysis method 
The choice of analysis method is influenced by the aims and objective of the 
research, what the research findings are intending to do and the 
researcher’s own philosophical stance (Richards 2005). In this study the 
findings are intending to provide a greater understanding about what 
participants’ believed to have been helpful about treatment, and what, if 
anything they believed to have led to an improvement in IBS symptoms 
and/or general health. In this case the aim is not solely to report the views of 
the respondents but to provide an understanding of how the participants 
came to their conclusions.  
Framework analysis is a method developed for use in the area of applied 
policy research (Ritchie and Spencer 1994). In applied policy research the 
objectives are set by specific requirements. This means that the results of 
the research are targeted to give answers that provide a greater explanation 
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or understanding of the issues being addressed. In addition the timescales in 
applied policy research tend to be relatively short being months not years. 
Hence framework has been developed to fit these criteria (Ritchie and 
Spencer 1994).  
Framework was chosen as the analysis method for this research. This is 
because the main aim of the research involved providing an understanding 
of participants’ views rather than trying to generate a theory about 
participants’ views. In grounded theory, the aim is to use the data to produce 
a plausible theory, grounded in the data (Braun and Clarke 2006). In addition 
to this, grounded theory requires an iterative process of data collection and 
analysis, whereby the results of the initial data collection are used to inform 
further sampling. This is followed by further analysis and checking of the 
theory being generated until saturation is reached (Richards and Morse 
2006). Saturation occurs when no new ideas are brought up in the data 
collection process (King and Horrocks 2010). The structure of this qualitative 
study did not allow for such a process. Therefore framework was felt to the 
most appropriate means of analysing this study. 
As far as possible throughout the conduct of this research the author has 
attempted to take the stance of the unprejudiced observer. The position of 
the unprejudiced observer requires acknowledgement that whilst it is 
impossible not to have any prejudices, through being aware of one’s 
prejudices, and questioning one’s self and one’s thoughts and actions, one 
can aim to perceive without projection (Vithoulkas 1998). A fuller discussion 
of this and the impact it has had on this research can be found in Chapters 8 
and 10. 
This chapter described the methodology for both the quantitative and 
qualitative studies, explaining how this PhD study related to a wider trial of 
the clinical and cost effectiveness of IHT for IBS, along with a rationale for 
why the cmRCT design was used. The option of including a placebo tablet in 
the supportive listening arm of the trial was explored and the choice of 
outcome measures explained. The RCT will be able to give information 
about whether or not IHT works, but it will not be able to say why this is so, 
hence it was decided that a qualitative element should be included in this 
study. This chapter explored in more detail the reasons behind this decision 
and explained why semi-structured interviews were chosen and the 
reasoning behind the sampling strategy and interview schedule. The next 
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chapter details the methods for both the quantitative and qualitative studies 
and explains how each of these studies was carried out.
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7 Methods 
This chapter describes the methods used in both the RCT and the qualitative 
study. It explains how the studies were conducted, following on from the 
previous chapter which explained why the studies were conducted in the 
way they were. This chapter is split into two sections, a section on the 
methods for the RCT and a section on the methods for the qualitative 
interviews. 
7.1 Randomised controlled trial  
7.1.1 Design 
A full description of the design of this study is given in Chapter 6, whilst an 
overview of the design is given here. This study is a three armed 
prospective, parallel group, individually randomised trial comparing:  
 Usual care alone 
 IHT plus usual care 
 Supportive listening plus usual care 
The study used the Cohort Multiple RCT Design (Relton et al. 2010). A 
discussion on the features of this design in given in Chapter 6.  
In this study eligible participants who consented to take part in the 
observational study made up the Barnsley IBS cohort (BIBSC). From the 
BIBSC some people were randomly allocated to the “offer of intervention” 
(IHT or supportive listening) or to the usual care arm of the trial. The 
recruitment and randomisation processes are discussed in more depth in 
Section 7.1.4. 
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7.1.2 Treatment 
Patients allocated to either the IHT or the supportive listening arm were 
offered five consultations, one every five weeks for five months. The 
consultations were spaced at these intervals because in usual homeopathic 
practice patients will be seen every four to six weeks. Patients were offered 
five consultations because it is generally considered, by homeopaths, that 
on average patients will need this number of consultations for a measurable 
benefit to be observed. The consultations for both IHT and supportive 
listening were 60 minutes. Thus each of these two arms received the same 
amount of direct face-to-face contact with a therapist (if they attended all 
appointments). Figure 7-1 shows the treatment and data collection schedule. 
Usual care included any drug treatments or other supportive regimes that an 
NHS patient with IBS would usually have access to.  
 
 
 
Both homeopaths and supportive listening therapists were supervised by 
supervisors with an allegiance to that therapy. This means that homeopaths 
were supervised by supervisors who are also homeopaths and supportive 
listening therapists were supervised by counselling supervisors.  
52 weeks 26 weeks Baseline 
Postal questionnaires sent 
Treatment visit 
Figure 7-1: Treatment and data collection schedule 
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7.1.2.1 Individualised homeopathic treatment 
Two homeopaths with a 5 year history of working at Barnsley Hospital 
delivered the IHT. They were both registered with the Society of 
Homeopaths (SoH) and had previous experience of trials of IHT. Clinical 
homeopathy and IHT have different prescribing strategies, however both 
homeopaths involved in this study are classical homeopaths (IHT 
practitioners) and are registered with the Society of Homeopaths. The 
homeopaths were able to choose from any of over 1,300 different possible 
remedies from the homeopathic pharmacopeia.  
7.1.2.2 Supportive listening 
Supportive listening was delivered by qualified psychotherapists with at least 
five years clinical experience, employed by Barnsley Hospital NHSFT, 
chosen as having a warm empathic manner likely to foster a positive 
relationship between them and the patient. There were no nurses or similar 
health professionals that had been trained in basic counselling skills based 
at Barnsley hospital available, and it was a requirement from the local 
research ethics committee that the people providing the supportive listening 
were members of the British Association for Counselling and Psychotherapy 
(BACP) or the United Kingdom Register of Counsellors and 
Psychotherapists (UKRCP). During the supportive listening session patients 
were able to talk about their physical symptoms as well as any emotional 
issues and possible ways of coping with these better. Supportive listening 
provided the patient with the opportunity to feel heard and with the 
opportunity to express themselves in a non-judgemental environment. 
Participants were encouraged to talk about their physical symptoms as well 
as any emotional issues and to discuss how these might be coped with in a 
better way. 
Prior to the commencement of the trial counsellors who were interested in 
providing the supportive listening were interviewed and the nature of the 
intervention explained to them. After the two counsellors had been recruited 
to the study there was a further session where the nature of the supportive 
listening intervention was reiterated. At this point they had the opportunity to 
ask any questions about what was expected of them. 
It was the intention that a check would be carried out to ensure that the 
counsellors delivering the supportive listening were delivering supportive 
listening rather than cognitive behavioural therapy (CBT) or some other 
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psychotherapeutic intervention. This was to be done by assessing a random 
selection of the taped supportive-listening sessions. In this check the 
assessor would be looking for instances where the counsellor used 
techniques that did not fall within the supportive listening criteria such as 
interpreting information rather than responding reflectively. 
7.1.3 Inclusion and exclusion criteria 
There were two levels of inclusion in the wider trial, inclusion in the BIBSC 
and inclusion in the RCT. This thesis is concerned with the RCT, however to 
meet the inclusion criteria for the RCT the participants need to have first met 
the inclusion criteria for the BIBSC study. Hence the criteria are described 
below. 
Inclusion Criteria for BIBSC study 
 Irritable bowel syndrome diagnosis according to ROME III diagnostic 
criteria for IBS. This is the criterion commonly used to define IBS in 
treatment trials. 
 Adults aged 18 and over. 
 Consent to take part in the BIBSC Study. 
 Able to understand written English. 
Everyone who completed a questionnaire and met these inclusion criteria 
was eligible for the BIBSC study. Those eligible for the BIBSC study were 
then assessed to determine whether they met the inclusion and exclusion 
criteria for the RCT. Due to the potential for the BIBSC to be used for future 
RCTs exploring IBS the inclusion criteria were broad. Thus, depending on 
what an RCT was addressing, each RCT that used the cohort could have 
different inclusion criteria. For example, the RCT in this PhD study was 
looking at all patients with IBS, but a future RCT may only be interested in 
patients with diarrhoea prevalent IBS. By having broad criteria for the cohort, 
different populations can be sampled for each RCT, hence there may be 
different inclusion criteria for the cohort, and for the RCT, with the latter 
being more restrictive.  
Inclusion criteria for the RCT 
 Score of 100 or greater on the IBS Symptom Severity Score, this 
score is often taken as the cut off for symptomatic IBS. 
Exclusion criteria for the RCT 
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 Current diagnosis of haemophilia or cancer 
 Major gastrointestinal surgery in previous 6 months 
 Currently receiving homeopathic treatment. If a significant number of 
participants in the “supportive listening” arm of the trial were already 
receiving homeopathic treatment, the effectiveness of IHT compared 
to supportive listening could be underestimated.  
 Pregnant or breast-feeding 
 Patients not fluent in English. Patients need to be able to converse 
with the therapist if selected to one of the active treatments. 
Apart from “currently receiving homeopathic treatment” and not being fluent 
in English, these are the standard exclusion criteria used in trials of IBS. 
These groups are excluded because it is perceived that taking part in a trial 
may present a risk to people with the above conditions. Whilst it is unlikely 
that either IHT or supportive listening would cause a worsening of symptoms 
to the above groups, or any harm to pregnant or breast-feeding women, in 
the interests of safety it was felt prudent to exclude the above groups.  
7.1.4 Recruitment 
Patients were recruited through NHS primary and secondary care settings 
as follows. 
Primary care: Potential participants were identified via GP databases, a 
method used successfully to recruit IBS patients to an acupuncture study 
(Reynolds, Bland and MacPherson 2008). The intention was that potentially 
eligible participants would be identified through searching the database of 
four GP practices for patients aged 18 and over with a diagnosis of IBS or 
given medications used to treat IBS symptoms and who have consulted their 
GP for IBS within the last two years.  
Secondary care: Potential participants were identified by gastroenterology 
clinicians at Barnsley Hospital using the same criteria as for the GP 
database searchers i.e. having a diagnosis of IBS or being prescribed 
medication used to treat IBS. 
All participants remained under the care of their GP and/or consultant. Once 
identified, potential participants were sent a letter inviting them to take part in 
the observational study and asking them to complete a questionnaire, which 
included screening questions according to the ROME III diagnostic criteria. 
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See Appendix 6 and 7 for copies of the GP letter, questionnaire and 
participant information sheet. Once patients returned the questionnaire, if 
they fulfilled the inclusion criteria and consented, they were entered in to the 
BIBSC study. Those who were eligible for inclusion into the BIBSC study 
were then assessed by the researcher and a gastroenterologist to determine 
whether or not they met the inclusion and exclusion criteria for the RCT. 
Figure 7-2 shows a CONSORT diagram of this process (Schulz et al. 
2010).The completed diagram is given with the results in Chapter 9.  
 
In the RCT there was uneven randomisation to the three arms in a 4:1:1 
ratio of usual care alone: IHT plus usual care: supportive listening plus usual 
care. Due to the limited funding available for this trial, it was decided to use 
unequal randomisation to reduce the number of participants needed in the 
treatment arms, thus reducing the overall costs of the treatment arms. The 
impact of this on the power of the study to detect a difference between IHT 
and supportive listening is given in Section 7.1.5. 
Of those that were eligible for the RCT participants were randomly selected 
to the offer of IHT, the offer of supportive listening or usual care. The random 
Returned questionnaires (n=x) 
Excluded (n= x) (give reasons) 
Excluded (n= x) (give reasons) 
Assessed for eligibility to Cohort (n= x)  
Assessed for eligibility to RCT (n= x) 
I 
I 
 
Excluded (n= x) (give reasons) 
 
 
Randomised (n= x) 
I 
I 
 
Questionnaires sent (n=x) 
 
 
 
Figure 7-2: CONSORT diagram of the recruitment process 
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selection was achieved thorough the shuffling of a pack of opaque sealed 
envelopes containing the allocation. Questionnaires from participants who 
consented and met the eligibility criteria were taken one at a time. At the 
same time a sealed opaque envelope containing the allocation was taken 
from the top of the shuffled pack. The envelope was opened and the 
allocation noted. This was carried out by an independent administrator at the 
University of Sheffield. It is important that the randomisation process is 
adequately concealed to prevent selection bias. This occurs when there are 
systematic differences between the participants in the comparison groups, 
which can lead to over-estimation or under-estimation of the treatment effect 
(Torgerson, 2008).     
Figure 7-3 shows the relationship between the cohort and the RCT.  
 
 
Those randomly selected to the offer of IHT and those randomly selected to 
the offer of supportive listening were sent participant information sheets, 
detailing what the treatment involved, and a consent form to sign (see 
Appendix 7 for participant information sheets and consent forms). If they 
signed and returned the consent form an appointment was made for them 
with the relevant practitioner. Figure 7-4 gives an example of the CONSORT 
diagram that was used to summarise the data for the randomisation process. 
The completed diagram is shown in Chapter 9.
B. Members of the cohort. 
 
C. Usual 
care group 
for the 
RCT.  
A. People who weren’t eligible to take part in 
the cohort or who didn’t fill in the questionnaire. 
D1. Participants 
randomly selected 
to homeopathic 
treatment. 
D2. 
Participants 
randomly 
selected to 
supportive 
listening. 
Figure 7-3: Relationship between Cohort and RCT 
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Allocated to supportive listening 
(n=x) 
 Received allocated intervention 
(n=x) 
 Did not receive allocated 
intervention (n=x) (give reasons) 
Lost to follow-up (n= x) 
 (give reasons) 
 
Analysed (n=x)  
Excluded from analysis (n=x)  
(give reasons) 
Analysed (n=x) 
Excluded from analysis (n=x) 
 (give reasons) 
 
Analysed (n=x)  
Excluded from 
analysis (n=x) (give 
reasons) 
Allocated to homeopathic treatment 
(n=x) 
 Received allocated intervention 
(n=x) 
 Did not receive allocated 
intervention (n=x) (give reasons) 
 
Allocated to usual 
care (n= x) 
 
Randomised (n=x) 
 
Lost to follow-up (n= x) 
 (give reasons) 
 
Figure 7-4: CONSORT diagram of randomisation process 
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7.1.5 Sample size 
The sample size calculation was based on the primary outcome for the wider 
trial, which is the change in IBS-SSS between baseline and 26 weeks (a 
discussion on why change score was used is given Section 7.1.8.1), with the 
primary research question for the wider trial being “What is the clinical and 
cost effectiveness of IHT + usual care compared to usual care alone?” 
Therefore the primary comparison for the wider trial was between IHT and 
usual care, thus it was necessary to power the trial to assess whether there 
was any difference between IHT and usual care, for this reason the trial was 
powered for an independent t-test between IHT and usual care, for the 
change in IBS-SSS between baseline and 26 weeks.  
As the sample size was powered for the primary research question, which 
was to compare two treatments using an independent test, the sample size 
was not based on the global test, ANOVA for comparing more than two 
groups. A calculation could have been carried out assuming the use of 
ANOVA taking into account the 3 arms of the trial. This would have led to a 
smaller sample size but would not have powered the trial for a comparison 
between the two treatment groups of interest in the primary research 
question. This is because it would only have been able to power the study to 
find a difference across the three arms of the trial and not to detect a specific 
difference between two pre-specified groups (Munyombwe 2010). 
A power calculation was carried out using sample size determination 
software called PS Power (Dupont and Plummer 2009), using a reduction of 
50 points on the IBS-SSS, which has been reported to be a clinically 
relevant change (Francis, Morris and Whorwell 1997). A standard deviation 
of 85 was chosen. There were no previous trials of IHT for IBS that had used 
the IBS-SSS. Therefore a statistician was consulted who advised the use of 
a standard deviation from another similar trial. Three IBS trials that had used 
the IBS-SSS were used to obtain an estimate standard deviation (Kaptchuk 
et al., 2008; Moss-Morris et al., 2010; Ringstrom et al., 2010). This was done 
by taking the average of the standard deviations for the change in IBS-SSS 
in these three previous trials, which was 85. Assuming use of an 
independent t-test to compare groups, power 80%, significance level 5%, 
clinically relevant difference of 50 on the IBS-SSS, and standard deviation of 
85, ratio of usual care to IHT of 4:1, 29 participants were required for the IHT 
arm and 116 for the usual care arm, for this comparison. In a previous IBS 
study (Reynolds, Bland and MacPherson 2008) it was found that there was a 
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13% loss to follow up, taking this into account gave an estimated sample 
size of 33 for the IHT and supportive listening arms and 132 for the usual 
care arm. In terms of the adequacy of this sample size for adjusted analysis 
using multivariable regression analysis, the above power calculation leads to 
a sample size for the IHT arm plus the usual care arm plus the supportive 
listening arm of 198. To determine the number of regression coefficients that 
could be used in an ANCOVA the 10 cases per predictor rule of thumb was 
used. This means that for every predictor used in the ANCOVA model there 
should be 10 participants who experienced the outcome of interest. This 
means if the ANCOVA model was used to determine whether there were 
any differences between the three arms in this trial, adjusting for age, sex 
and initial IBS-SSS, this would give a total of 6 predictors (including the 
intercept). Therefore 60 participants would be needed.  
A separate power calculation was carried out to determine the sample size 
required to answer the research question for this PhD study which is “Is 
individualised IHT any different to “supportive listening” in the treatment of 
Irritable bowel syndrome?” Based on the previous assumptions, except 
assuming a ratio of 1 to 1 of supportive listening to IHT and a 13% loss to 
follow up, a sample size of 53 in the IHT arm and 53 in the supportive 
listening arm was required.  
Due to limited funds it was decided to aim to recruit 198 participants in total, 
allowing for 33 participants in each of the active treatment arms and 132 in 
the usual care arm, thus powering the trial to determine if IHT is any different 
to usual care in terms of reduction of IBS symptoms as measured by IBS-
SSS. This meant that the study would be underpowered for the comparison 
between IHT and supportive listening. However it was intended to proceed 
while trying to identify additional funding. Hence if sufficient extra funding 
was secured then the aim would be to recruit 53 people to each of the active 
treatment arms, thus powering the trial to determine if IHT is any different to 
supportive listening, in terms of reduction of IBS symptoms as measured by 
IBS-SSS. A calculation was carried out in PsPower (Dupont and Plummer 
2009) to determine what effect size could be detected between IHT and 
supportive listening with a 1:1 ratio, 80% power, alpha of 0.05 and 33 people 
in each group. This gave an effect size of 59.53, meaning that with 33 
people in each group, the study was powered to detect an effect size of 59.5 
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or more. This is almost 10 points more than the minimal clinically relevant 
change of 50, associated with the IBS-SSS.  
As previously described in Section 7.1.4, participants were recruited to the 
BIBSC via primary and secondary care, however an estimate of how many 
questionnaires to send out was needed. To do this a rough calculation was 
carried out working backwards from the required sample size for the RCT. 
As previously stated, a power calculation estimated that the total number of 
people needed for the RCT was 198.The first step was to use this figure to 
estimate the number of members the BIBSC would need, in order, that there 
would be 198 members eligible for the RCT. It was unknown how many 
members of the BIBSC would meet the eligibility criteria for the RCT, so a 
conservative estimate of 30% was taken, (the GP database recruitment 
criteria meant that it was likely that those sent a questionnaire would have 
IBS, therefore this was conservative). This gave a figure of 660 people. 
From this figure an estimation was made of the number of people to send a 
questionnaire to, to result in the BIBSC containing 660 members. Based on 
a previous study, (Hillila, Farkkila and Farkkila 2010) that achieved a 70% 
response rate to a postal survey of IBS patients, it was anticipated that, the 
response rate would be circa 60%. This led to the requirement of a total of 
1100 questionnaires to be posted to potentially eligible participants. 
7.1.6 Data collection 
Data was collected via questionnaires sent to the participants at baseline, 26 
weeks and 1 year after sending the baseline questionnaire. However only 
data collected at baseline and 26 weeks is included in this study. This is due 
to the time limitations associated with PhD study, and agreement within the 
team, that the one year data would be analysed separately.  
 (Details of NHS and resource use as measured by medication and visits to 
healthcare professionals were also collected to facilitate an economic 
analysis as part of the wider study.) 
Table 7-1 gives details of which outcome measures were collected at which 
time frames, it should be noted that the 52 week data is outside the scope of 
this study, however it has been included in the table for reasons of clarity. 
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 Baseline 26 weeks 52 weeks Other 
IBS-SSS     
HADS     
EQ-5D     
Medication 
usage 
    
Number of 
healthcare visits 
    
Expectation of 
benefit 
   After 2nd appointment in 
active treatment arms 
CARE     
Exposure to 
treatment 
   Collected by therapist in 
active treatment arms 
Table 7-1: Time frames at which outcome measures will be collected 
7.1.7 Ethical considerations 
The ethical considerations for this study were: 
 The ethics of conducting trials of homeopathy 
 The inclusion of a placebo tablet in the supportive listening arm 
 The informed consent process in trials using the cmRCT model 
 Adverse events 
 Confidentiality and data storage 
 A full discussion on these is given in Chapter 8. 
7.1.8 Analysis  
7.1.8.1 Statistical Analyses 
Descriptive Statistics 
Continuous data was summarised by mean and standard deviation, provided 
it was normally distributed. Data was tested for normality through plotting 
histograms of the data. In the case of data not being normally distributed the 
median and inter-quartile range were quoted. Ordinal data was summarised 
by median and inter quartile range. Table 7-2 gives details of the data 
summarised. 
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 Usual Care  
 
IHT Supportive 
listening 
Gender Male     
Female    
Age Mean (sd)    
Missing    
Employment 
 
Employed    
Unemploye
d 
   
Unknown    
Number of 
prescribed 
medicines 
Mean(sd)    
Missing    
IBS-SSS Mean (sd)    
 Median 
(IQR) 
   
 Missing    
HADS-D Mean (sd)    
 Median 
(IQR) 
   
 Missing    
HADS-A Mean (sd)    
 Median 
(IQR) 
   
 Missing    
EQ-5D Global Mean (sd)    
Table 7-2: Summary of baseline data 
Inferential Analyses  
The intention was to perform univariate analysis subgroup analysis using 
independent t-tests or the Mann Whitney U test for change in IBS-SSS 
between baseline and 26 weeks and change in HADS between baseline and 
26 weeks. 
It was also planned to carry out an adjusted analysis of change in IBS-SSS 
between baseline and 26 weeks across all groups, using ANCOVA, with 
outcome variable; change score and predictors; initial score. 
Statistical analyses were performed using PASW Statistics version 17, on an 
intention to treat basis (ITT) using a 2 sided 5% significance level. intention-
to-treat analysis was used to maintain the baseline comparability (Bowers 
2008). The challenge of using an intention-to-treat analysis with this type of 
design is that the people who are offered an intervention may not actually be 
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interested in having it. This happens in standard randomised controlled trials 
but the difference with the cmRCT design is that when participants 
consented to take part in the observational study they weren’t consenting to 
take part in an RCT of different treatments. Thus there may be a greater 
chance than with a standard RCT of participants not being interested in the 
treatment offered. Participants not taking up the offer of treatment may lead 
to a Type II error, where there is no difference found between the treatments 
when there is really a difference between the treatments, in those who 
accepted and complied with, the intervention. It was thought likely that the 
number of people who didn’t have the treatment they are assigned to would 
be higher than in standard RCT, however it was considered that the results 
would tell the real life ‘effect’ of the interventions, if allocated and 
recommended to an unselected population. However high rates of non-use 
of the allocated intervention may lead to high Type II error rates. This would 
also indirectly provide information on the acceptability of the intervention to 
patients. 
An alternative to an ITT analysis is a per-protocol analysis. This method 
includes in the analysis only those who actually had the treatment they were 
assigned to (Kirkwood and Sterne 2003). For the results of a per-protocol 
analysis to be unbiased the probability of taking up the treatment must be 
random, and there should be no other differences between those who took 
up the treatment and those who didn’t, thus ensuring that baseline 
randomisation is held (Hewitt, Torgerson and Miles 2006). However it was 
considered likely that in this RCT there could be fundamental differences 
between those who took up the treatment and those who didn’t, meaning 
that a per-protocol analysis had the potential of being biased. Therefore the 
baseline data for those who took up the offer of treatment and those who 
didn’t take up the offer of treatment were compared. This was not subject to 
formal testing but was tabulated and accompanied by a written narrative. 
A description of the outcome measures used in this study and the rationale 
for choosing them is given in Chapter 6. 
Primary analysis 
The primary analysis was change in IBS-SSS between baseline and 26 
weeks.  
The percentage of participants in each arm who achieved a decrease in IBS-
SSS score of ≥ 50 and the percentage of participants in each arm whose 
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IBS-SSS score increased by ≥ 50 was reported. A decrease in 50 points on 
the IBS-SSS is the minimal clinically relevant change for this measure 
(Francis, Morris and Whorwell 1997). 
The reasons for choosing the IBS-SSS as the primary outcome measure are 
given in Chapter 6. The reasons for choosing change in IBS-SSS between 
baseline and 26 weeks as the primary outcome are discussed below.  
The IBS-SSS is self scored on a series of visual analogue scales (VAS). 
There is no consensus as to how VAS data should be analysed. Some hold 
the view that VAS data is ordinal and that it is inappropriate to calculate 
means and standard deviations for such data (Bowers 2008). Whereas 
others suggest that means can be used as long as they are used with 
caution and data is checked for normality (Campbell 1999). On consideration 
of these two approaches it was decided that the best strategy was to check 
for normality of the data and then use parametric tests, as long as the data 
proved to be close to normally distributed, however if this was found not to 
be the case then non-parametric tests would be used.  
There were a number of options for analysing the data, these were: 
i) Comparison of 26 week IBS-SSS score’s 
ii) Comparison of percentage change in IBS-SSS score’s from baseline to 26 
weeks 
iii) Regression model which outcome post-treatment score adjusted for 
baseline score (Analysis of Covariance) ANCOVA with treatments and other 
confounders as covariates 
iv) Regression model of change score adjusted for baseline and other 
confounders 
v) Comparison of change in IBS-SSS score from baseline to 26 weeks 
Theoretically because the participants had been randomised, the average 
scores in each of the groups at baseline should be approximately equal, 
therefore any differences found between the groups at 26 weeks should be 
due to the treatment that they have received. If this was the case the 
estimated treatment effect would be the same whichever method is used. 
However Vickers (Vickers 2001) cautions against the use of percent change 
because it has lower statistical power than both change between baseline 
and 26 weeks and 26 week score alone. Change score was chosen over 
end point score because the majority of trials that have used the IBS-SSS 
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measure have used a change score. Therefore using change score would 
allow greater comparability between this and other trials. However Vickers 
(Tu, Baelum and Gilthorpe 2008) suggest a better approach is to use 
analysis of covariance (ANCOVA), a form of regression which adjusts each 
person’s follow up score for their baseline score, with the advantage of being 
unaffected by baseline differences. In this study it was intended that both 
univariate and adjusted analysis (using ANCOVA) would be performed. This 
would be done to see if whether there are any effects of confounders. If the 
randomisation had worked then the treatment effects should be similar for 
both unadjusted and adjusted analysis. Prior to carrying out the ANCOVA 
analysis the normality assumption was tested using a residual analysis and 
the residuals checked to ensure that they are independent and had constant 
variance. This was done using a histogram of residuals and a plot of 
residuals against plotted values. A residual is the difference between the 
observed value of the dependent variable and the predicted value of the 
independent variable (Katz 2006). 
Secondary analysis 
The secondary outcome measures are: 
 Hospital anxiety and depression scale (HADS) (Bjelland et al. 2002) 
 Consultational and relational empathy (CARE) (Mercer et al. 2004) 
 EuroQol-5D (Williams 1990) 
 Expectation of benefit: based on a validated measure originally 
designed by Borkovec (Borkovec and Nau 1972) and modified by 
Drossman (Drossman et al. 2003) for IBS.  
 Exposure to treatment 
A discussion on the reasons for choosing these outcome measures is given 
in Chapter 6. 
Anxiety and depression 
Change in HADS between baseline and week 26 was calculated. As with the 
IBS-SSS there were a variety of options for analysing the data: 
i) 26 week HADS score  
ii) Percentage change in HADS score from baseline to 26 weeks 
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iii) Regression model which outcome post-treatment score adjusted for 
baseline score (Analysis of Covariance) ANCOVA with treatments and other 
confounders as covariates 
iv) Regression model of change score adjusted for baseline and other 
confounders 
v) Change in HADS score from baseline to 26 weeks 
In previous trials of IBS change scores have been used (Atkinson et al. 
2004; Simren et al. 2004). A discussion on the use of change scores or 
endpoint scores concluded that the results were similar in both depending on 
the nature of the data (Vickers and Altman 2001). Therefore to allow 
comparability with other trials change in HADS was chosen.  
HADS is an ordered categorical (ordinal) scale, in which respondents are 
asked to tick one answer out of a choice of four possible answers per 
question. It comprises of 14 questions, 7 of which are designed to assess for 
anxiety and 7 for depression. Question responses are analysed by assigning 
numerical scores to the ordered categories, with 0 equating to good and 3 
equating to poor. Once numerical scores have been assigned, those scores 
equating to the depression questions are summed, and those equating to 
the anxiety questions are summed. A numerical score is then provided for 
the depression component and another number provided for the anxiety 
component. Possible total scores range from 0 (the best state) to 21 (the 
worst state). These summed scores are often treated as if they were from a 
continuous distribution that is normally distributed (Boyce et al. 2003; 
Atkinson et al. 2004) yet as with the IBS-SSS scores it can be debated as to 
the appropriateness of this assumption. However in this study the same 
approach as for the IBS-SSS was taken i.e. the data was checked for 
normality. As long as it proved to be normally distributed the data was 
treated as continuous and parametric tests were used. Adjusted analyses 
(using ANCOVA) were also performed. Prior to carrying out the ANCOVA 
analysis the normality assumption was tested using a residual analysis and 
the residuals were checked to ensure that they are independent and have 
constant variance using a histogram of residuals and a plot of residuals 
against plotted values. 
Empathy of practitioner 
The CARE measure at 26 weeks was used to compare how the patients 
perceived the empathy of the practitioner they saw (in the IHT and 
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supportive listening arms), to see if there was any correlation between 
empathy of the practitioner and outcome for the patient.  
It was intended that the relationship between empathy of practitioner and 
clinically significant change in IBS-SSS score was to be tested using logistic 
regression analysis. A change in IBS–SSS of ≥ 50 was defined as a 
responder, with the outcome being a clinically relevant change in IBS, and 
the predictors being CARE score and baseline IBS-SSS. It was thought 
likely that those with a higher initial IBS-SSS score were more likely to have 
a clinically relevant change than those with a lower initial score, hence it was 
proposed that initial IBS-SSS score would be included in the model.  
7.1.8.2 Descriptive analyses 
Health related quality of life 
Health related quality of life was measured using the EQ-5D questionnaire 
3L (3 level), measured at baseline and after 26 weeks. There are two types 
of the EQ-5D questionnaire, the 3L and the 5L, both ask the same 
questions. The difference being the 3L has 3 possible classes/levels of 
severity for each question whilst the 5L has 5 possible levels of severity. EQ-
5D results were presented at both time points as the proportion of reported 
problems for each level for each dimension as recommended by the 
EuroQol group (EuroQol Group 2011). EQ-5D VAS was presented as mean 
and standard deviation for each time point unless the data was skewed, in 
which case they were presented as median values along with 25th and 75th 
percentiles, again as recommended by the EuroQol group (EuroQol Group 
2011). Permission was sought to use the EQ-5D, which was granted without 
incurring any costs. This was because of the small scale of this study and 
the fact that it was not being carried out by a pharmaceutical company or 
any other profit-making stake-holder (see Appendix 8). 
No statistical tests were carried on the EQ-5D data and exposure to 
treatment data due to concerns about multiple testing. The issue with 
multiple testing or multiple comparisons is that the more attributes that are 
compared the more likely it is that a difference will be found in at least one of 
the attributes. Most tests are carried out to the 95% confidence level i.e. 1 
time in 20 a difference will be found when there is not really a difference, so 
the more tests that are carried out the more chance there is that a difference 
will be found when there isn’t really a difference. Therefore the confidence in 
results where multiple comparisons have been carried out should be weaker. 
A solution to this problem is through the use of a correcting factor to correct 
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for the multiple comparisons, an example of this is the Bonferroni correction 
(Bland and Altman 1995). However the Bonferroni correction is rather 
conservative (Petrie and Sabin 2005). For this reason it was decided that in 
this study statistical tests would only be used to compare the primary 
outcome and HADS. This is because IBS-SSS, the primary outcome 
measure, is measuring the severity of the persons IBS-SSS, which is the 
main area of interest to this study. HADS was chosen because more people 
with IBS suffer with stress and anxiety than in the general population (Ten 
Berg et al. 2006) and an improvement in this may indicate a positive effect of 
treatment.  
 
Exposure to treatment 
The exposure to treatment of each of the two active treatment arms was 
measured through recording the number of appointments each patient 
attended. From this average number of IHT appointments and average 
number of supportive listening appointments attended were calculated and 
reported.  
 
Credibility of treatment 
Credibility of treatment was measured using a questionnaire developed by 
(Borkovec and Nau 1972) and adapted for IBS patients by (Drossman et al. 
2003). This was measured after two appointments for IHT and supportive 
listening arms. From this the median credibility scores for IHT and supportive 
listening were compared.  
Other comparisons 
Comparisons of age, sex, IBS type and IBS-SSS score were made between 
those eligible for the RCT and randomly selected to IHT who took up the 
offer and those randomly selected to IHT who didn’t take up the offer. This 
was to see if there are any differences between any of the characteristics of 
these people. No formal testing was carried out on this data, instead the 
information was tabulated and accompanied by a written narrative.  
The same comparisons were carried out between those agreeing to 
supportive listening and those who declined it. 
7.1.8.3 Missing data 
There are three types of missing data, missing completely at random 
(MCAR), missing at random (MAR) and missing not at random (MNAR) 
144 
 
 
 
(Little and Rubin 1987). MCAR means that there are no predictors as to why 
the data is missing, an example of this would be if a questionnaire had got 
lost in the post (Shih 2002). MAR is when the missingness depends on 
observed data and not on the unobserved data e.g. if there was a missing 
IBS-SSS score and the reason for it being missing depends on employment 
status of the participant (Sterne et al. 2009). MNAR is when the missing data 
is neither MCAR nor MAR i.e. the reasons for missingness depends on the 
missing observations (Sterne et al. 2009). An example of this would be 
where the IBS-SSS score is missing and the fact that the score is missing 
depends on the value of the score i.e. if a person had not returned their 
questionnaire because they had a high IBS-SSS. 
To explore the reasons for missingness in this RCT the number of 
participants with missing data at 26 weeks was summarised along with 
reasons for missing data where available. For each outcome measure for 
each arm (IHT, supportive listening and usual care) the number of non-
responders was calculated. The baseline characteristics for those with 
missing data were examined along with the reasons for missing data - where 
available. These were compared between the different arms. The aim was to 
assess whether the data was likely to be MCAR, MAR or MNAR. Missing 
data can be dealt with according to which type of missingness is present. In 
the case of MCAR then the fact that the data is missing will not have an 
impact on the overall result and a complete case analysis can be carried out 
(Shih 2002). If the data is MNAR, then a complete case analysis, along with 
a sensitivity analysis, where the missing data is inputted using multiple 
imputations, can be carried out and the results compared (Sterne et al. 
2009). To determine whether the missing data in this study was likely to be 
MCAR, MAR or MNAR a logistic regression model was used to investigate 
whether missingness was associated with any demographic factors for IBS-
SSS score and for HADS score (full details of this model are given in 
Chapter 9). If the data was found to be MCAR then a complete case analysis 
alone would be carried out, however if the data was MNAR, then the 
intention was for missing data to be inputted using multiple imputations 
(MICE) (Little and Rubin 1987) and the results compared between this and a 
complete case analysis. 
 
 
145 
 
 
 
7.2 Qualitative Interviews 
As explained in Chapter 6, semi-structured in-depth interviews were 
conducted with participants in the IHT and supportive listening arms of the 
RCT. Interviews were also carried out with the therapists who provided the 
IHT and supportive listening. This section provides details of the methods 
used in these interviews, beginning with explaining how potential participants 
were identified and recruited.  
7.2.1 Identification and Recruitment 
Potential participants were sampled on completion of their 26 week BIBSC 
study questionnaire. Those identified as potential participants were at that 
stage only identifiable by the study number assigned to them as part of the 
BIBSC study. The principal investigator who had access to the document 
containing codes linking the BIBSC study numbers with names and 
addresses used this document to identify the names and addresses of 
potential participants. Once names and addresses had been identified, 
potential participants were sent an invitation letter along with a participant 
information sheet and consent form to sign and return. If they wished to take 
part they were asked to mail the researcher to arrange a convenient time for 
the interview to take place. 
There were four therapists providing the treatments (two providing 
supportive listening and two providing IHT) in the RCT, all of whom were 
invited to take part in this study. The principal investigator had access to 
their names and contact details and sent them an invitation letter along with 
the participant information sheet and consent form to sign and return, copies 
of these are given in Appendix 9. 
7.2.2 Study procedure 
Participants were asked to take part in one interview which lasted one to one 
and a half hours. The focus of the interview was on the patient’s or 
therapist’s experience of the treatment they received or provided and what 
they found helpful or unhelpful about the treatment.  
Interviews took place in the participant’s homes or at another mutually 
convenient location. Funding was not available to cover participants travel 
expenses, and this was stated in the information sheet. 
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The interviews followed an in depth semi-structured format starting out broad 
and narrowing down to ensure that all the necessary topics had been 
covered by the end of the interview.  
Two interviews were conducted initially as an internal pilot. The intention 
being to reflect on these and decide whether the topic guide required any 
modifications. Minor amendments to phrasing of questions would then be 
made as necessary prior to carrying out the remaining interviews. In the 
event it was decided that it was not necessary to change the topic guide. 
Field notes were made whilst the interview was taking place or immediately 
after and interviews transcribed as soon as possible after they had taken 
place. Field notes contained a brief description of the setting for the interview 
along with a description of the participant and the main topics they raised, 
these were made as an aide-memoire. 
7.2.3 Analysis 
The qualitative data was analysed using framework analysis, the reasons 
why this methods of analysis was chosen are given in Chapter 6. Framework 
analysis consists of five key stages: 
 Familiarisation, where the researcher familiarises themselves with the 
data through listening to the interviews and reading through 
transcripts. During this stage the researcher makes notes and jots 
down observations on recurrent themes and important issues. 
 Identifying a thematic framework. In this stage the researcher 
identifies key issues, concepts and themes in the data, using the 
notes and observations they made during the familiarisation process. 
 Indexing, in this stage the researcher applies the thematic framework 
to the data. Transcripts are read and coded according to the themes 
and concepts that were identified in the thematic framework.  
 Charting. The indexed data is arranged into charts with headings and 
subheadings comprising of the themes identified in the thematic 
framework. It is important at this stage to ensure that the initial source 
of the data is clearly identifiable to allow it to be checked with the 
original source if required. 
 Mapping and interpretation. Once all the data has been charted 
according to the core themes, key characteristics of the data are 
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explored. The researcher reviews, compares and contrasts the charts 
searching for patterns and connections, whilst at the same time 
seeking for explanation for these patterns within the data. 
The results of this analytic process differ depending on the research 
question and the study aims, in this study the aim was to explore patients’ 
and therapists’ perceptions about IHT or supportive listening and provide an 
understanding of what people believed, if anything, was helpful about these 
treatments and what, if anything led to changes in IBS symptoms and overall 
health. 
The exact details this analysis process are given in Chapter 10, which 
reports the results of the qualitative study. The reason the analysis is 
documented in detail in the results section rather than in the methods 
section is because the analysis involved an iterative process. In this process 
the results from the first stage of the analysis were used to inform the 
second stage of the analysis etc. Therefore knowledge of the results was 
needed in order to provide a detailed description of the analysis process, 
understandable to the reader.  
In summary, this chapter has detailed the methods used in both the RCT 
and the nested qualitative study, providing information on how each of these 
studies was conducted. The next chapter will discuss ethical concerns 
associated with the RCT and qualitative study along with the potential for 
author bias when planning, conducting and analysing the work contained in 
this thesis.  
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8 Ethical Considerations 
This chapter discusses the ethical considerations of both the RCT and the 
qualitative study, along with a section discussing the potential for author bias 
in this study. 
Ethical approval for the formation of the Barnsley Irritable Bowel Syndrome 
Cohort (BIBSC) and the subsequent RCT was made in a single application 
to Leeds (East) Research Ethics Committee, reference 10/H1306/73. Ethical 
approval for the qualitative study was made to Leeds (Central) Research 
Ethics Committee, reference 11/YH/0178. See Appendix 10 for approval 
letters. 
8.1 Ethical considerations in research 
Research ethics are concerned with the planning, conduct and reporting of 
research. In research involving human participants, the researcher needs to 
ensure that the participants’ moral and legal rights are protected (World 
Medical Association 2008). This involves ensuring that participants are fully 
informed about the possible risks and benefits of taking part in the research, 
enabling them to give consent having fully understood the implications of 
taking part. There should be no coercion in this process and the participants 
autonomy and privacy should be respected at all times (Royal College of 
Nursing Research Society 2011). Any risks associated with the research 
should be minimised, and participants should not be exposed to 
unacceptable risks. In addition to this, the research should be scientifically 
valid and have the potential to lead to an enhancement of knowledge or 
health (Emanuel, Wendler and Grady 2000). To ensure that this is the case 
the research protocol should be subject to independent review. In light of 
these requirements, the next section discusses the ethical concerns 
particular to the RCT study.  
8.2 Ethical considerations in the RCT 
The main ethical consideration for the RCT was the potential inclusion of the 
placebo tablet in the supportive listening arm. In particular there were 
difficulties around its inclusion without telling participants what it was. Other 
ethical considerations were: 
 The ethics of conducting trials of homeopathy 
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 The informed consent process in trials using the Cohort Multiple RCT 
(cmRCT) model 
 Adverse events 
 Confidentiality and data storage 
An application made to Leeds (East) Research Ethics Committee in 
September 2010 led to a number of concerns being identified by the 
research ethics committee’s (REC), in particular: 
 The ethics of carrying out a RCT investigation of homeopathic 
treatment 
 Inclusion of a placebo tablet in the supportive listening arm of the 
RCT 
 Informed consent in the cohort multiple RCT (cmRCT) model 
These considerations, and the ways in which they were addressed, are now 
discussed. 
8.2.1 The ethics of trials of homeopathy 
The REC were unconvinced of the value of carrying out a trial of 
homeopathic treatment, stating: “the committee felt that homeopathy is a 
placebo but if the researcher was clear about the issues around homeopathy 
then maybe it is ethically acceptable for a person to take part.” They also 
said: “the committee agreed the study could be approved if … the 
researcher explains that no clinical randomised trials have shown that 
homeopathy works.” 
This feedback presented a dilemma as to what information to give 
participants about homeopathic treatment. As discussed in Chapter 4, there 
have been five meta-analyses of homeopathic treatment, four of which 
showed a favourable effect. The REC’s conclusion that “no clinical 
randomised trials have shown homeopathy works” fails to take into account 
this evidence for homeopathic treatment. This, combined with the popularity 
of homeopathic treatment (Thomas, Coleman and Nicholl 2003), suggests 
that it is important that research continues to be carried out in an attempt to 
determine how homeopathic treatment differs from spending time with an 
empathetic practitioner. 
Taking the above into account, and to meet the REC’s requirements in terms 
of the information given to potential participants, the participant information 
sheet for the homeopathic treatment arm was amended by including the 
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following sentence. “Homeopathic treatment involves a consultation with a 
homeopath followed by the prescription of a homeopathic remedy. It has 
been available on the NHS since 1948; however there is no clear proof as to 
whether or not it works. Whilst some patients report a benefit with 
homeopathic treatment we don’t know whether this is the case for more than 
a handful of people. In this study we are trying to find out if homeopathic 
treatment improves IBS symptoms”. 
It was considered that this sentence acknowledged the lack of clarity over 
the effectiveness of homeopathic treatment without deeming it ineffective, 
which could undermine participants’ confidence in the treatment. 
8.2.2 Inclusion of a placebo tablet 
It was intended that the supportive listening arm of the trial would include a 
placebo tablet, as described in Chapter 6. However on submission of the 
protocol for the RCT to the REC, the REC asked what participants would be 
told if they asked what was in the placebo tablet. It was suggested that the 
placebo tablet would be called a milk sugar tablet (the base ingredient of 
homeopathic remedies). In a trial of hypnotherapy for non-cardiac chest pain 
(Jones et al. 2006), that had included a supportive listening plus placebo 
tablet arm, people had been told that the tablet was an anti-acid despite 
being a placebo (Whorwell 2010). However, due to changes in what 
participants can now be told in trials it had already been realised that it 
would be impossible to directly lie to participants about what the placebo 
tablet contained. Despite this the REC expressed concern that telling people 
that they were being given a milk sugar pill had the possibility of reducing 
any placebo effects as it would be apparent that this was an inactive tablet. 
Reducing the expectations of those in the “supportive listening plus placebo” 
arm could therefore potentially reduce the effect size for the supportive 
listening arm. The REC’s suggestion was that the participants were told that 
they were being given a “dummy pill.”  
This suggestion was not considered desirable because it was highly likely to 
lead to a loss of credibility in the tablet. Indeed, some would consider it no 
longer to be a ‘placebo’ suggesting that a placebo only works because of 
what people believe that it is, or the meaning people attach to it (Moerman 
2002). Following the logic of this REC, it would appear that there is a belief 
that placebos per se are unethical, as they fundamentally rest on deceiving 
patients in order to work. This is a belief that is based on the argument that 
placebos should not be used because they always require some kind of 
deception (Marusic 2004). However it could equally be said that it would not 
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be untruthful to say that a “placebo” may help, because it may indeed help, 
even if this is through the “placebo effect” rather than through any 
physiological means. 
The REC’s comments provided an impetus to reflect on the role of the 
placebo tablet. The aim of including the placebo tablet was to control for the 
non-specific effects of being prescribed a medication. However without it the 
trial would be comparing two credible NHS treatments, supportive listening 
and IHT, against usual care. This led to the realisation that a decision had to 
be made as to whether the study should be looking at credible NHS 
treatments or answering explanatory questions. 
In the scenario whereby two credible NHS treatments were compared the 
placebo tablet would be removed from the trial altogether and IHT and 
supportive listening for IBS would be compared. This would mean that the 
trial would be comparing two treatments that could potentially be obtained on 
the NHS and removed the issues around what to tell people about the 
placebo medication.  
This scenario did also mean that those in the IHT arm received a tablet 
whilst those in the supportive listening arm did not, thus reducing the 
similarity in the treatment experiences. Nonetheless, without the placebo 
tablet it was considered that it would still be possible to determine whether 
IHT was better than giving a patient time and attention. Thus it was decided 
to remove the placebo tablet from the supportive listening arm. 
8.2.3 Informed consent process in the Cohort Multiple RCT 
design 
The intention was that potential participants in the Barnsley Irritable Bowel 
Syndrome Cohort (BIBSC) would be sent a participant information sheet 
explaining the purpose of the study along with an invitation letter and a 
questionnaire with a consent form on the back. It was made clear in the 
participant information sheet that a decision not to take part would in no way 
affect any of their current or future treatments. Those interested in taking 
part needed to complete and return the questionnaire and sign the consent 
form. Those randomly selected to be offered either supportive listening or 
homeopathic treatment would then be sent a participant information sheet 
containing details of the treatment they had been offered along with a further 
consent form to sign and return. It was made clear in the participant 
information sheets that a decision not to take part would not affect their 
inclusion in the BIBSC study.  
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In the cmRCT design people are not told about treatments they are not 
going to be offered, the reason being that telling people about treatments 
they are not being offered could lead to participant disillusionment (resentful 
demoralisation (Torgerson and Torgerson 2008)), if the participant does not 
get the treatment they wanted. This may then lead them to falsely report 
their outcomes, become uncooperative, non-compliant or even withdraw 
from the study, which could threaten the validity of their outcomes and thus 
introduce bias into the trial (Torgerson 1998). The rationale for the cmRCT is 
that it offers a more pragmatic approach whereby information and consent 
processes aim to mimic those undertaken in real world health care. This 
means that participants are only informed about the treatment they are being 
offered and not about other treatments that they have not been offered. Thus 
all participants in the cohort consent to provide observational data, whilst 
only those who are offered an active treatment consent (or not) to the 
treatment they have been offered.  
To follow the cmRCT model, in this study participants who were randomly 
selected to the offer of a treatment were not going to be told that there was 
another treatment arm. However the REC stated that “It must be clear that 
the cohort understands the nature of what will happen and that they may be 
offered interventions and explain what these interventions are.” 
To resolve this issue it was felt that there were three options for the way 
forward: 
 Provide the REC with further rationale for the use of the cmRCT 
model.  
 Explain in the participant information sheet for the BIBSC that there is 
a possibility that members of the BIBSC may be randomly selected to 
be offered a treatment. 
 Carry out a standard RCT without the formation of a wider cohort 
(BIBSC). 
Reflecting on these options and given the time constraints of the wider trial it 
was decided to go with the second option and explain at the outset that there 
was the possibility of members of the BIBSC being randomly selected to be 
offered a treatment.  
It was noted that the same REC had previously approved a study that used 
the cmRCT model, however in that instance ethical approval for the 
formation of the cohort was applied for and granted first and then 
subsequently permission for each RCT trial using the cohort was applied for 
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separately. This suggests that a “staged” application for ethical approval 
may be more straightforward. 
8.2.4 Adverse events 
An adverse event is an unfavourable change in health that occurs either, 
whilst a patient taking part in a clinical trial that involves receiving a 
treatment, or within a pre-specified period of time after completion of the 
treatment. The procedure for dealing with any adverse events in the RCT 
was as follows. In the event of a patient reporting concerns to either the 
homeopaths or supportive listening providers they were advised to talk to 
their GP or consultant. The homeopaths and supportive listening providers 
enquired at each appointment whether the patient had experienced any 
unusual or unexpected events and any such events were recorded by the 
clinician. All patients remained under the care of their GP or hospital 
consultant. 
8.2.5 Confidentiality and data storage 
To ensure participant confidentiality all data was stored in accordance with 
data protection requirements made under The Data Protection Act (The 
National Archives 1998). This act requires that data be stored securely and 
for no longer than necessary. To this end all data was kept either in a locked 
filing cabinet in a secure office, or in the case of electronic data on a secure 
server with a password protected computer and files. No data was stored on 
a home computer or laptop. 
On inclusion into the study participants were given a code. Codes and the 
corresponding names were kept in a separate document stored on a secure 
server and accessed by a password protected computer that only the 
research team had access to. Audio recordings of the supportive listening 
sessions were down-loaded onto a password protected computer and stored 
on a secure server and deleted from the recording device. 
8.3 Ethical considerations for the qualitative study 
The main ethical issues for the qualitative study were: 
 The informed consent procedure 
 Participants withdrawal and subsequent use of data 
 Safety of participants and researcher 
 Confidentiality and data storage 
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Each of these will be discussed in turn below. 
8.3.1 Informed consent procedure 
Potential participants were sent a participant information sheet explaining 
the purpose of the study along with an invitation letter and consent form. It 
was made clear in the participant information sheet that those who were not 
interested in taking part in the interviews were still able to remain in the 
BIBSC study and that a decision not to take part would in no way affect any 
of their current or future treatments. Those interested in taking part needed 
to mail, phone or e-mail to express their interest and arrange a convenient 
time for the interview to take place. When the potential participant made 
contact to arrange an appointment time there was the opportunity for them to 
ask any questions and seek further clarification about what the study would 
entail. 
Signed consent forms were collected at the start of the interviews following 
discussion with the interviewer. 
8.3.2 Participant withdrawal and subsequent use of data 
Participants were informed of their right to withdraw at any time and without 
giving a reason. This was explained in the participant information sheet and 
reiterated prior to starting the interview. 
If a participant chose to withdraw during the interview process they were 
asked whether they consented to have any data already collected being 
included in the study. If they did not agree to this, all data collected during 
the interview was destroyed. However if they consented to the data already 
collected being included, the data collected up to the point of withdrawal was 
included in the study. 
8.3.3 Assessment of Safety 
Participants 
a) Patients 
There was a slight risk that patients may find talking about their treatment 
distressing. In order to minimise this, and to help to make sure that patients 
were prepared for the interview, an outline of areas that the interviews would 
cover was provided in the participant information sheet.  
If a participant became distressed during the interview, the interview was 
stopped and the interviewer asked the participant if they wanted to continue. 
If the answer was yes, the interviewer took a short break before continuing. 
If the answer was no, the interview was stopped at that point and the 
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participant thanked for their participation. Assistance was given to help the 
participant identify appropriate sources of support, or if necessary a 
recommendation made that they contact their GP.  
b)  Therapists 
There was a slight risk that the therapist may feel uncomfortable talking 
about the treatment they provided. However the therapists had all expressed 
an interest in providing feedback about the RCT and talking about 
participants’ reaction to the treatment they received, so it was felt that this 
was unlikely. However an outline of the areas that the interview would cover 
was provided in the participant information sheet, in order to ensure that the 
therapists were prepared for the interview.  
Researcher 
The researcher was travelling alone and conducting interviews in the 
participants’ homes. To ensure the researcher’s safety at all times the 
University’s lone worker policy was followed and a risk assessment 
completed. This covered information such as providing a third party with 
details of the interview times and locations and procedures for getting help in 
the unlikely event of a problem arising during an interview.  
8.3.4 Confidentiality and data storage 
All data was stored in accordance with data protection requirements and 
was kept either in a locked filing cabinet in a secure office or in the case of 
electronic data on a secure sever with a password protected computer and 
files. 
Participants’ names and contact details were stored in a locked office and 
only accessed by the research team. Electronic (anonymised) data was 
stored on password-protected secure computers in the research team 
members’ locked offices.  
Audio recordings of the interviews were downloaded onto a password 
protected computer and deleted from the recording device.  
All data will be stored for two years after completion of the PhD viva, which 
will allow time for any academic challenge to be made. All data will be 
deleted after this time.  
On inclusion in the study participants were given a code. Codes and the 
corresponding names were kept in a separate document stored on a secure 
server and accessed by a password protected computer that only the 
research team had access to. 
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Any quotations used in the final report or any other publications were 
anonymised through giving the participants a pseudonyms. 
Any comments made by the participants about the therapists were 
anonymised to ensure that it was not possible for individuals to be identified 
by the therapists.  
8.4 Author bias 
The author of this thesis is a professional homeopath and a member of the 
Society of Homeopaths. As such there is a potential for the author to be 
biased in terms of a desire to find homeopathy to be effective. Part of the 
homeopathic training involves learning, as far as it is possible, to take the 
stance of the unprejudiced observer (Kent 1984). This means 
acknowledging that it is impossible not to have any prejudices, but that 
through being aware of one’s prejudices it is possible to question one’s self 
and one’s thoughts and actions. The author has attempted to do this 
throughout this study, by questioning decisions made, and reflecting whether 
or not they have been made as a result of a prejudiced stance. 
Another way in which bias was minimised was the writing of an analysis plan 
for the RCT prior to conducting any analysis of the data. This was to ensure 
that results were not based on post hoc analyses that were designed to 
show homeopathic treatment in the best light possible. In addition a 
statistician was consulted throughout, with regard to both the analysis plan 
and subsequent analysis. As a further quality control check, the protocol for 
the study was peer reviewed by two independent reviewers prior to 
submission to the REC.  
One of the funders of this study, the Homeopathy Research Institute (HRI), 
is a charity that provides funding for homeopathy research. This could have 
introduced a potential conflict of interest had they been involved in the 
design, analysis, writing or dissemination of the study results. However the 
HRI solely provided part of the funding for this study and had no involvement 
in the writing of the analysis plan, subsequent analysis and conduct of the 
study. Funding was given prior to the research commencing and not on the 
production of a positive result. 
In summary, this chapter has briefly explored the principles governing 
research ethics before moving on to discuss the ethical concerns relating to 
the RCT and qualitative study. In particular it explains why it was decided not 
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to include a placebo tablet in the supportive listening arm and the REC’s 
concerns about trials of homeopathic treatment. 
The results of the RCT are discussed in the next chapter. 
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9 Results 
This chapter reports the results from the RCT. The analysis of the results 
was conducted as per the analysis plan described in Chapter 7.  
9.1 Recruitment 
Between January 2011 and June 2011, 596 people, from four GP surgeries 
and one secondary care unit, were sent a questionnaire and an invitation to 
take part in the Barnsley Irritable Bowel Syndrome Cohort Study (BIBSC). Of 
these, 154 people returned questionnaires, 115 of whom met the eligibility 
criteria for the BIBSC. Those eligible for the BIBSC were screened for 
eligibility for the RCT. 94 people met all the RCT inclusion criteria and none 
of the exclusion criteria. The Consolidated Standards of Reporting Trials 
(CONSORT) diagram (Schulz et al. 2010), Figure 9-1 shows the flow of 
participants through the recruitment process. The overall response rate was 
26% (154/596) with 19% (113/596) of those sent a questionnaire being 
eligible to take part in the BIBSC study and 16% (94/596) being eligible to 
take part in the RCT.  
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9.1.1 Randomisation 
A total of 94 people were randomised and allocated to usual care (n=60), 
IHT plus usual care (n=16) or supportive listening plus usual care (n=18). Of 
these 12/18 (75%) took up the offer of IHT and 9/18 (50%) took up the offer 
of supportive listening. Where possible the reasons for not taking up the 
offer of treatment were sought, however this was not always possible. 
Reasons given included: too many other appointments, poor health, unable 
to take time off from caring duties, being deaf and happy to live with IBS. 
Returned questionnaires (n=154) 
Excluded (n= 1) 
 Questionnaire returned but not 
completed (n=1) 
Excluded (n= 40)  
 Not meeting ROME III criteria 
(n=18) 
 Failed to consent to use of data 
(n=14) 
 Failed to consent to be contacted 
(n=8) 
Assessed for eligibility to Cohort (n= 153)  
Assessed for eligibility to RCT (n= 113) 
I 
I 
 
Excluded (n= 19) 
 In another trial (n=2) 
 Seeing homeopath (n=3) 
 Colitis (n=3) 
 Failed to score >100 on IBSS 
(n=7) 
 Cancer (n=2) 
 Crohn’s disease (n=1) 
 Gastrointestinal surgery (n=1) 
 
 
Randomised (n= 94) 
I 
I 
 
Questionnaires sent (n=596) 
 
Figure 9-1: CONSORT diagram for recruitment 
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One person cited each of the reasons listed. Full details of the randomisation 
process are reported in the randomisation CONSORT diagram (Figure 9-2). 
A record of mailing dates for the initial questionnaires was kept, which 
allowed participants to be mailed a 26 week questionnaire exactly 26 weeks 
after they were mailed the initial questionnaire.  
IBS-SSS data was collected at 26 weeks for 85 of the 94 people 
randomised. Those who did not return their 26 week questionnaire were 
contacted by telephone and asked if they would answer questions from the 
IBS-SSS over the telephone. Table 9-1 gives a summary of questionnaire 
returns for each arm. Those who did not complete their 26 week 
questionnaire and were unable to be contacted by telephone have been 
defined as lost to follow up at 26 weeks, with 9 people being lost to follow 
up. The percentage in brackets refers to the percentage of total people 
recruited that were allocated to each intervention.  
 Usual care 
N=60 (64%) 
IHT  
N=16 (17%) 
Supportive listening  
N=18 (19%) 
Number randomised 60 16 18 
Number who took up 
offer of treatment 
N/a 12 9 
Withdrawn from trial 
prior to treatment 
0 0 0 
Withdrawn from trial 
treatment 
0 0 0 
Completed 26 week 
questionnaire 
51 15 11 
Contacted by phone for 
IBS-SSS 
3 1 4 
Total who gave IBS-SSS 54 16 15 
Loss to follow up 26 
weeks 
6  0 3  
Table 9-1: Summary of participant flow 
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Allocated to supportive listening (n= 18) 
 Received allocated intervention (n=9 ) 
 Did not receive allocated intervention (n= 9 ) 
No time as carer (n=1) 
Too many other appointments (n=1) 
Deaf (n=1) 
Lives with IBS (n=1) 
Unknown (n=5) 
Lost to follow-up (n= 3) 
 Did not return questionnaire n=3) 
 
Analysed (n=15)  
Excluded from analysis (n= 3) 
Analysed (n= 16 ) 
Excluded from analysis (n= 0) 
 
Analysed (n= 51)  
Excluded from analysis (n=9) 
 Did not return 
questionnaire (n-9) 
 
Lost to follow-up (n= 0) 
 
Allocated to IHT (n=16) 
 Received allocated intervention n=( 12 ) 
 Did not receive allocated intervention (n= 4 ) 
Poor health (n=1) 
Unknown (n=3) 
 
Allocated to usual care (n= 60) 
 
Randomised (n= 94) 
 
Figure 9-2: CONSORT diagram of the randomisation process 
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All of those recruited lived in the Barnsley area and described themselves as 
of white British origin. The mean age of participants was 49 (standard 
deviation 14.70). The majority (83%) of the participants were female. Most 
(53%) of the participants were employed. The remainder were either not 
employed (44%) or did not provide this information (3%). Table 9-2 gives 
details of the baseline characteristics of the participants in each arm of the 
trial. 
 Usual Care  
N=60 
IHT N=16 Supportive 
listening N=18 
Gender Male  12 (20%) 0 (0%) 4 (22%) 
Female 48 (80%) 16 (100%) 14 (78%) 
Age Mean (sd) 51.71 (14.20)  48.19 (13.45) 42.50 (16.17) 
Missing 2 0 2 
Employment 
 
Employed 28 (46.7%) 11 (68.8%) 11 (61.1%) 
Unemployed 31 (51.7%) 5 (31.3%) 5 (27.8%) 
Unknown 1 0 2 
Number of 
prescribed medicines 
Mean (sd) 4.60 (4.18) 2.56 (2.31) 2.94 (2.71) 
Missing 0 0 0 
IBS-SSS Mean (sd) 250.87 (78.60) 280.38 (79.43) 291.61 (74.38) 
 Median (IQR) 243.50 
(188.00-324.00) 
275.00 
(205.00-344.25) 
289.50 
(224.75-340.00) 
 Missing 0 0 0 
HADS-D Mean (sd) 5.82 (3.69) 5.88 (4.54) 6.94 (4.91) 
 Median (IQR) 6.00 (2.25-8.00) 3.50 (3.00-9.50) 6.00 (2.75-10.25) 
 Missing 0 0 0 
HADS-A Mean (sd) 10.13 (4.74) 11.13 (4.49) 10.11 (4.80) 
 Median (IQR) 10.00 (6.25-
14.00) 
10.50 (7.50-
15.25) 
11.50 (6.50-
14.00) 
 Missing 0 0 0 
EQ-5D Global Mean (sd) 58.25 (25.39) 59.00 (15.64) 62.57 (23.46) 
Table 9-2: Baseline patient characteristics 
It can be seen from the baseline characteristics that there were fewer men in 
the IHT arm (n=0, 0%) compared to the supportive listening (n= 4, 22%) and 
usual care arms (n=12, 20%). The initial mean IBS-SSS was lower for those 
in the usual care arm (250.87) compared to those in the IHT arm (280.38) 
and supportive listening arm (291.61). However the mean IBS-SSS for each 
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of the arms all lie within the confidence intervals for the other arms, i.e. the 
mean IBS-SSS for the usual care arm is 250 and the confidence intervals for 
the mean IBS-SSS for the IHT and supportive listening arms are 205.00 to 
344.25 and 224.75 to 340.00 respectively. Formal testing of ‘comparability’ 
was not undertaken as this has low power to detect differences in samples 
formed in randomised trials and any imbalances (which will, be definition, 
have occurred by chance) will be accounted for in the analysis. 
9.1.2 Care providers 
Two homeopaths and two counsellors provided IHT and supportive listening 
respectively, at Barnsley Hospital NHS Foundation Trust. Table 9-3 shows 
the number of participants treated by each care provider. 
Care provider Number of participants 
randomized 
Number of participants treated 
Homeopath 1 10 8 
Homeopath 2 6 4 
Listener 1 14 7 
Listener 2 4 2 
Table 9-3: Number of participants treated by each care provider 
Both of the homeopaths are registered with the Society of Homeopaths and 
have over five years clinical experience. Both of the listeners are qualified 
counsellors, registered with the British Association for Counselling & 
Psychotherapy and have over five years clinical experience. 
9.1.3 Adherence to treatment 
Whilst none of those in the treatment arms of the trial asked to withdraw 
from the trial, not all the participants attended all of the 5 treatment sessions 
that they were offered. Table 9-4 shows how many sessions people 
attended in each arm of the trial.  
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Number of sessions attended IHT 
(n=16) 
Supportive listening 
(n=18) 
0 4 9 
1 0 0 
2 0 0 
3 0 2 
4 0 2 
5 12 5 
Table 9-4: Number of appointments attended 
9.1.4 Adverse effects 
No adverse effects were reported. However one participant in the IHT arm 
suffered an allergic reaction and sought medical attention, the reaction was 
not thought, by the doctor the participant consulted, to be due to the IHT.  
9.1.5 Outcome Data 
Table 9-5 gives details of participants in each of the three arms at 26 weeks. 
The higher IBS-SSS the more severe the IBS. All calculations are based on 
an intention to treat analysis unless otherwise stated. 
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Usual care 
N=60 
IHT N=16 Supportive 
listening N=18 
Number of 
appointments 
Mean (sd) Not applicable 3.75 (2.24) 2.17 (2.31) 
IBS-SSS 26 
weeks  
Mean(sd) 237.3 (110.22) 210.44 (112.40) 262.0 (120.72) 
Median(IQR) 221.0 (164.50-
325.00) 
180.0 (146.25-
274.00) 
235.0 (184.00-
380.00) 
Missing 7 0 3 
Change in IBS-
SSS 26 weeks 
Mean (sd) -10.5 (78.770 -69.9 (114.75) -45.7 (87.56) 
Median (IQR) 6 (-64-41.00) -57.5 (-200-6) -38.0 (-128-33) 
Missing 7 0 3 
HADS 26 weeks Mean(sd) 13.9 (7.37) 17.27 (6.28) 15.3 (8.52) 
Median(IQR) 13.0 (9-18) 15.0 (13-23) 13 (8-23) 
Missing 9 1 7 
Change in HADS 
26 weeks 
Mean (sd) -1.78 (4.64) -0.2 (7,57) -0.18 (4.75) 
median(IQR) -2.0 (-5-2) 0.0 (-2-3) 2 (-5-3) 
Missing 9 1 7 
CARE score Mean  43.0 (10.48) 44.50 (3.87) 
Median (IQR) 50.0 (33.00-
50.00) 
43.50 (41.50-
48.50) 
Missing* 3 5 
Therapeutic 
rationale 
Mean logical  5.83 (2.55) 4.00 (1.73) 
effective 5.5 (2.65) 5.00 (1.58) 
Median 
(IQR) 
logical 3.00 (3.00-5.50) 6.00 (5.00-7.75) 
effective 5.00 (3.50-6.50) 6.00 (5.00-7.00) 
Missing* 2 4 
Table 9-5: Patient characteristics at 26 weeks 
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*This is the number of participants who attended at least two appointments 
but did not return their therapeutic rationale form. Those who declined the 
offer of treatment are not included in this number. 
The outcomes for the EQ-5D dimensions were dichotomised into those that 
reported problems and those who did not report any problems. 
Dichotomising the dimensions in this manner is one of the ways that results 
from the EQ-5D dimensions can be reported as per instructions in the EQ-
5D manual (EuroQol Group, 2011) (Cheung 2009). In the EQ-5D 3L (the 
version used in this trial) participants have the option of ticking one of three 
boxes for each of the dimensions. Table 9-6 shows the options for the 
mobility dimension. In the case of the mobility dimension those that ticked 
the top box would be defined as having no problems and those that ticked 
either the middle or bottom box would be defined as having problems. The 
same applied for the other 4 dimensions.  
Mobility Please tick one 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
Table 9-6: EQ-5D mobility dimension 
Table 9-7 gives details of the number of people who reported problems for 
each of the EQ-5D dimensions, at baseline and 26 weeks. 
 
167 
 
 
 
EQ-5D dimension Usual care IHT Supportive 
listening 
 Before After Before After Before After 
Mobility  No problems 45 37 10 12 15 7 
Problems 15 13 5 3 3 3 
Missing 0 8 1 1 0 4 
Self care  No problems 50 44 15 15 18 9 
Problems 9 16 0 0 0 1 
Missing 1 8 1 1 1 4 
Usual activities No problems 35 30 11 9 13 7 
Problems 25 20 5 6 5 3 
Missing 0 8 0 1 0 4 
Pain/ 
discomfort  
No problems 9 6 0 2 5 1 
Problems 50 44 16 12 13 10 
Missing 1 8 0 2 0 3 
Anxiety/ 
Depression 
No problems 24 22 6 4 11 4 
Problems 36 27 10 11 7 6 
Missing 0 9 0 1 0 4 
EQ-5D VAS Mean (sd) 62.57 
(23.46) 
63.41 
(23.31) 
59 
(15.64) 
69.07 
(17.35) 
58.25 
(23.39) 
63.09 
(24.38) 
Median (IQR) 68.0 
(47-82) 
69 
(46-80) 
60  
(50-70) 
72.5 
(61-81) 
63.5 
(39-80) 
70 
(40-85) 
Missing 2 7 1 2 7 9 
Table 9-7: EQ-5D scores before and after treatment 
Following dichotomisation the percentage of participants who reported 
problems was calculated for each dimension (mobility, self care, quality of 
life, pain and anxiety and depression), for each arm of the trial, both at 
baseline and after 26 weeks.  
For clarity and to follow the two pre-specified comparisons, the percentage 
of patients who reported problems in the usual care arm (UC) compared to 
those in the IHT arm (HT) (Figure 9-3) and the percentage of patients who 
reported problems in the IHT arm (HT) compared to those in the supportive 
listening arm (SL) (Figure 9-4). 
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Figure 9-3:EQ-5D dimensions of usual care arm compared to IHT arm 
 
Figure 9-4: EQ-5D dimensions of IHT compared to supportive listening 
9.1.6 Missing data 
Participants were sent a 26 week questionnaire and one reminder. 
Participants who did not return their 26 week questionnaire were contacted 
by telephone and asked if they would give their 26 week IBS-SSS over the 
telephone. Table 9-8 gives details of return rates for the 26 week 
questionnaires and phone IBS-SSS. Details are given as n/N where n is the 
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number of people who performed that action and N is the total number of 
people in that arm of the trial.  
 Returned 26 week 
questionnaire 
Phone IBS-SSS 
given 
No 26 week data 
Usual care 51/60 (85%) 3/60 (5%) 6/60 (10%) 
IHT 15/16 (93.75%) 1/16 (6.25%) 0/16 (0%) 
Supportive listening 11/18 (61.11%) 4/18 (22.22%) 3/18 (16.67%) 
Table 9-8: Return rates for the 26 week questionnaire 
As explained in Chapter 7, there are three types of missing data, missing 
completely at random (MCAR), missing at random (MAR) and missing not at 
random (MNAR).  
 
Missing 26 week IBS-SSS 
To assess whether it is likely that the missing 26 week IBS-SSS is MCAR, 
MAR or MNAR a comparison of baseline data was made between those who 
didn’t return their 26 week IBS-SSS and those who did. The data on those 
who didn’t return their 26 week questionnaire includes those whose IBS-SSS 
was sought by telephone but who didn’t return their 26 week questionnaire. 
Table 9-9 gives these comparisons. Comparisons between those who 
returned their 26 week IBS-SSS and those who did not return their 26 week 
IBS-SSS were also made for the usual care and supportive listening arms, 
everyone in the IHT arm returned their 26 week IBS-SSS. This was to see if 
there were any differences between the arms of the trial.  
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 Across all arms Usual care Supportive listening 
Did 
return 
(N=85) 
Did not 
return 
(N=9) 
P Did 
return 
(N=54) 
Did not 
return (N=6) 
Did 
return 
(N=15) 
Did not 
return 
(n=3) 
Sex  % female 82.1 90.0 0.532 72.2 85.7 73.3 100 
Missing 0 0  0 0 0 0 
Age Mean 50.64 
(13.87) 
38.67 
(18.28) 
0.02 53.04 
(13.00) 
42 (19.55) 44.71 
(16.03) 
27.00 
(5.66) 
Missing 3 1  2 0 0 1 
IBS-SSS Mean 264.64 
(82.18) 
255.70 
(47.60) 
0.617 247.72 
(81.90) 
274.71 
(43.30) 
307.67 
(70.79) 
211.33 
(18.77) 
Median  254.00 
(189.25–
336.75) 
248.00 
(214.75–
306.75) 
 243.00 
(181.00-
326.50) 
262.00 
(237.00-
318.00) 
313.00 
(267.00-
434.00) 
215.00  
Missing 0 0  0 0 0 0 
EQ-5D Mean 61.88 
(22.63) 
55.40 
(21.80) 
0.396 63.13 
(23.69) 
58.86 (23.33) 60.77 
(26.61) 
47.33 
(19.14) 
Median  67.50 
(49.75-
80.00) 
62.50 
(38.25-
72.50) 
 68.50 
(48.00-
84.25) 
65.00(42.00-
80.00) 
70.00 
(42.00-
82.00) 
50 
Missing 10 0  7 0 2 0 
Employed % 
employed 
51.2 77.8 0.147 43.4 71.4 64.3 66.7 
Missing 2 1  1 0 1 1 
HADS Mean 16.60 
(7.73) 
14.2 
(7.28) 
0.354 16.15 
(7.39) 
14.43 (8.04) 17.73 
(9.14) 
13.67 
(6.66) 
Median  16.00 
(11.00-
22.50) 
13.50 
(8.25-
19.25) 
 17.00  
(11.00-
22.00) 
10.00  
(9.00-23.00) 
16.00 
(11.00-
24.00) 
6 
Missing 0 0  0 0   
Table 9-9: Baseline comparisons between those who did and did not return their 26 
week IBS-SSS 
It can be seen that those who returned their 26 week IBS-SSS were older 
(mean age 51) than those who did not (mean age 38) and were more likely 
to be employed (51.2%) than those who did not (77.8%).  
Student’s T-tests were used to calculate p values for the differences in age, 
IBS-SSS, EQ-5D and HADS between those who did and those who did not 
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return their 26 week IBS-SSS. Pearson’s chi-square test was used to 
determine if the differences between those who did and did not return their 
IBS-SSS in terms of employment status and gender were statistically 
significant. From these tests only age (p=0.02) was found to be statistically 
significant (p<0.05). Therefore age appears to be related to whether 
participants returned their 26 week IBS-SSS. Younger people were less 
likely to return the questionnaire.  
In the usual care arm it can also be seen that fewer of those who returned 
their 26 week questionnaires were employed, 43.4% compared to 71.4% of 
those who didn’t return their score. This difference was smaller in the 
supportive listening arm with 64.3% of those who returned their 26 week 
IBS-SSS being employed compared to 66.7% of those who didn’t return their 
score. Those in the supportive listening arm who did not return their 26 week 
IBS-SSS were younger (mean age 27) than those who did (mean age 45), 
this was also true for the usual care arm, with the mean age of those who 
did not return their 26 week IBS-SSS being 42 and the mean age of those 
who did return their 26 week IBS-SSS being 53.  
These comparisons show that there appears to be a correlation between 
missing IBS-SSS and age. This means that it unlikely that the data in MCAR. 
 A higher percentage of those in the supportive listening arm (20%) did not 
return their 26 week IBS-SSS compared to those in the IHT (0%) and usual 
care arms (13%). Pearson’s chi-square test was used to determine if the 
differences in the response rate were statistically significant. Table 9-10 
shows the cross tabulation of missing 26 week IBS-SSS and allocation. 
Table 9-11 shows the results for Pearson’s chi-square. It can be seen that 
the p value was 0.265; therefore there is no evidence of a correlation 
between allocation and missing 26 week IBS-SSS. 
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 26 week IBS-SSS not missing 26 week IBS-SSS missing Total 
Allocation usual care 53 7 60 
IHT 16 0 16 
Supportive listening 15 3 18 
Total 84 10 94 
Table 9-10: Cross tabulation of missing 26 week IBS-SSS by allocation 
 
 
Value Df p 
Pearson Chi-square 2.66 2 0.27 
Table 9-11: Pearson’s Chi-square for missing IBS-SSS by allocation 
A logistic regression model was also carried out to determine if any of the 
factors that may have affected missingness of data were significant for IBS-
SSS. 
A logistic regression model was set up with 26 week IBS-SSS as the 
dependent variable. This is a binary variable as it the data is either missing 
or not, in this model missing 26 week IBS-SSS was coded as 1 and not 
missing IBS-SSS was coded as 0. Covariates chosen as possible predictors 
of missingness were: age and IBS-SSS as continuous variables, and 
employment and allocation as categorical variables. These were chosen 
because in the above comparisons there are appeared to be some 
differences between the employment status and age of responders and non-
responders. As already reported, there was a difference between the 
percentage of people in the supportive listening arm who returned their IBS-
SSS and the percentage of people in the IHT arm, hence allocation was 
included in the model. Finally initial IBS-SSS was chosen as it was thought 
possible that returning 26 week IBS-SSS may be related to initial IBS-SSS. It 
should be noted that the number of events (i.e. number of missing data 
points) for IBS-SSS was only 10. Therefore following the rule of 1 predictor 
per 10 events only 1 allows for 1 predictor to be included in the regression 
equation (Peduzzi et al. 1996). This means that the results of the regression 
should be viewed with caution. However the regression was carried to 
determine whether it backed up the results obtained from the comparisons 
made above. The results from the regression are shown in Table 9-12. 
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Predictor Β SE β Wald’s x
2
 df P e
β 
odds 
ratio 
Constant 0.875 2.269 0.149 1 0.700 2.399 
Age -0.060 0.031 3.740 1 0.053 0.942 
Employment (employed = 1, 
not employed =0) 
0.590 0.919 0.412 1 0.521 1.805 
IBS-SSS -0.003 0.005 0.473 1 0.492 0.997 
Allocation   0.232 2 0.890  
Allocation (1) usual care =1 0.458 0.950 0.232 1 0.630 1.581 
Allocation (2) IHT = 1 -18.986 9552.556 0.000 1 0.998 0.000 
Table 9-12: Regression model for missing 26 week IBS-SSS 
 
None of the p values in this model were less than 0.05, therefore the 
regression model indicated that none of: employment status, sex, age and 
baseline IBS-SSS were significant predictors to missing IBS-SSS in this 
small study. The Cox and Snell pseudo r2 was 0.113 which indicates that the 
model does not provide a good explanation as to why the data is missing. 
This may be due, in part, to the low event rate for this data, meaning that 
these results should be viewed with caution as there may be insufficient 
power to detect predictors.  
From the results obtained from the comparisons between missing IBS-SSS 
and baseline data and the regression it can be seen that there is a potential 
correlation between missing 26 week IBS-SSS and age. In terms of dealing 
with this missing data it is believed that the data is not MCAR. However the 
missingness is not substantial. A statistician was consulted for advice as to 
how to deal with the missing data and it was advised that if the variables 
associated with missingness are included in an ANCOVA then this will 
balance the analysis. Hence in the ANCOVA model for the primary outcome 
age and employment status will be included.  
Missing 26 week HADS 
To assess whether it is likely that the missing data for 26 week HADS is 
MCAR, MAR or MNAR a comparison of baseline data was made between 
those who didn’t return their 26 week HADS and those who did, Table 9-13.  
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 Across all arms Usual care IHT Supportive listening 
Did return 
(N=77) 
Did not return 
(N=17) 
P Did return 
(N=51) 
Did not return 
(N=9) 
Did return 
(N=15) 
Did not 
return 
(N=1) 
Did return 
(N=11) 
Did not 
return (n=7) 
Sex  % female 83.1 82.4 0.940 80.4 77.8 100 0 72.7 85.7 
Missing 0 0  0 0 0 0 0 0 
Age Mean 52.07 (13.95) 37.31 (11.97) 0.00 54.18(13.18) 38.22 (12.38) 47.93 
(13.89) 
52.00 47.90 (16.78) 33.50 (11.06) 
Missing 3 1  2 0 0 0 1 1 
IBS-SSS Mean 259.77 (80.20) 281.47 (73.38) 0.308 246.08 (80.82) 278.00 (61.39) 280.73 
(82.21) 
275 294.64 (61.77) 286.86 
(96.30) 
Median  248.00 (188.00-
328.50) 
267.00 
(221.50-
328.50) 
 243.00 (176.00-
326.00) 
262.00 (225.50-
334.50) 
275.00 
(198.00-
351.00) 
275 313 (265.00-
343.00) 
267.00 
(215.00-
339.00) 
Missing 0 0  0  0 0 0 0 
EQ-5D Mean 62.10 (22.31) 57.18 (23.51) 0.423 62.66 (24.00) 62.00 (21.97) 59.64 
(16.02) 
50 63.22 (24.09) 51.86 (27.43) 
Median  60.00 (49.00-
80.00) 
62.00 (46.00-
77.50) 
 68.50 (46.00-
84.00) 
65.00 (51.00-
80.00) 
62.00 
(50.00-
70.25) 
50 70.00 (42.00-
84.50)  
62.00 (27.00-
75.00) 
Missing 10 0  7  1 0 2 0 
Employed % 
employed 
45.5 88.2 0.00 39.2 88.9 66.7 100 45.5 85.7 
Missing 2 1  1 0 0 0 1 1 
HADS Mean 16.04(7.71) 17.71 (7.67) 0.421 15.75 (7.49) 17.11 (7.27) 17.47 (7.90) 10 15.45 (8.91) 19.57 (8.48) 
Median  15.00 (10.50-
21.00) 
18.00 (10.00-
23.00) 
 16.00 (10.00-
21.00) 
18 (9.5-23.00) 15.00 
(12.00-
24.00) 
10 15.00 (10.00-
21.00) 
18.00 (16.00-
28.00) 
Missing 0 0  0 0 0 0 0 0 
Table 9-13: Comparison of baseline data between those who did and did not return their 26 week HADS 
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It can be seen from that those who returned their 26 week HADS were older 
(mean age 52), than those who did not (mean age 37) and fewer of those 
who returned their 26 week HADS were employed (45.5%), compared to 
88.2% of those who did not return their score. A Student’s t-test was used to 
calculate a p value for the differences in age and (p<0.01) was found to be 
statistically significant. Pearson’s chi-square test was used to determine if 
employment status was a significant predictor of failing to return 26 week 
HADS. The p value (p<0.01) indicated that employment status was a 
statistically significant predictor. Therefore age and employment status are 
related to whether participants returned their 26 week HADS.  
In the usual care arm it can also be seen that fewer of those that returned 
their 26 week HADS were employed (39.2%) compared to 88.9% of those 
who didn’t return their score. The same was observed in the supportive 
listening arm with 45.5% of those who returned their 26 week HADS being 
employed compared to 85.7% of those who did not return their score. Those 
in the supportive listening arm who did not return their 26 week HADS were 
younger (mean age 34), than those who did (mean age 48), this was also 
true for the usual care arm, with the mean age of those who did not return 
their 26 week HADS being 38, and the mean age of those who did return 
their 26 week HADS being 54.  
These comparisons show that there appears to be a correlation between 
missing HADS and employment status and missing HADS and age. This 
means that it unlikely that the data in MCAR.  
In terms of allocation, 17.65% of those in the usual care arm did not return 
their 26 week HADS, 6.67% of those in the IHT arm and 63.64% of those in 
the supportive listening arm. Pearson’s chi-square test was carried out to 
determine if the difference in these results was statistically significant.  
Table 9-14 shows the cross tabulation of missing 26 week IBS-SSS and 
allocation.  
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 26 week HADS not missing 26 week HADS missing Total 
Allocation usual care 51 9 60 
IHT 15 1 16 
Supportive listening 11 7 18 
Total 77 17 94 
Table 9-14: Cross tabulation of missing 26 week HADS by allocation 
Table 9-15 shows the results for Pearson’s chi-square, it can be seen that 
the p value was 0.03, therefore there is a correlation between allocation and 
missing 26 week HADS. 
 
 Value df P 
Pearson Chi-square 7.16 2 0.03 
Table 9-15: Pearson’s Chi-square for missing HADS by allocation 
A logistic regression model was also carried out to determine if any of the 
factors that may have affected missingness of data were significant for 
HADS. There were a greater number of people with missing 26 week HADS 
than there was for missing 26 week IBS-SSS. This is because only the 26 
week IBS-SSS was sought over the telephone from those who did not return 
their 26 week questionnaire.  
A logistic regression model was set up with 26 week HADS as the 
dependent variable. This is a binary variable, the data is either missing or 
not, in this model missing 26 week HADS was coded as 1 and not missing 
HADS was coded as 0. Covariates chosen as possible predictors of 
missingness were: age and IBS-SSS as continuous variables, and 
employment and allocation as categorical variables. These were chosen 
because in the above comparisons there are appeared to be differences 
between the employment status and age of responders and non-responders. 
As already reported, there was a difference between the percentage of 
people in the supportive listening arm who returned their HADS and the 
percentage of people in the IHT arm, hence allocation was included in the 
model. Finally initial IBS-SSS was chosen as it was thought possible that 
returning 26 week HADS may be related to initial IBS-SSS. It should be 
noted that the number of events (i.e. number of missing data points) for 
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HADS was only 17. Therefore following the rule of 1 predictor per 10 events 
only allows for 1 predictor to be included in the regression equation. This 
means that the results of the regression should be viewed with caution. 
However the regression was carried to determine whether it backed up the 
results obtained from the comparisons made above. The results from the 
regression are shown in Table 9-16. 
Predictor Β SE β Wald’s x
2
 Df p e
β 
odds 
ratio 
Constant -0.033 1.586 0.000 1 0.983 0.968 
Age -0.057 0.028 4.207 1 0.040 0.945 
Employment (employed = 1, 
not employed =0) 
2.447 1.120 4.771 1 0.029 11.549 
Allocation   3.954 2 0.139  
Allocation (1) usual care =1 -0.867 0.752 1.330 1 0.249 0.420 
Allocation (2) IHT = 1 -2.423 1.239 3.824 1 0.051 0.089 
Table 9-16: Results from regression model for missing HADS 
The regression model indicated that age and employment status are 
significant predictors of missing HADS scores at the 0.05 level. Employment 
p=0.029 and age p=0.040. The Cox and Snell pseudo r2 is 0.244 indicating 
that the model does not provide a good explanation of the missing data and 
it is therefore likely that there are other factors associated with missingness. 
The lack of fit of the model may in part be due to the low level of events and 
these results should be treated with caution. However as both the p values 
for the comparisons and the p values in the regression model show that age 
and employment status are predictors of missing 26 weeks HADS then it is 
likely that these are indeed predictors. From these results it is believed the 
data is not MCAR. However the as with the missing 26 week IBS-SSS 
missingness is not substantial. As with the missing 26 week IBS-SSS a 
statistican was consulted for advice as to how to deal with the missing 26 
week HADS data. It was advised that if the variables associated with 
missingness are included in an ANCOVA then this will balance the analysis. 
Hence in the ANCOVA model for the primary outcome age and employment 
status will be included.  
9.1.7 Primary outcome 
 The primary outcome for this RCT was change in IBS-SSS between 
baseline and 26 weeks. 
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Complete case analysis using t-tests 
Figure 9-5 shows the range of the change in IBS-SSS for each of the three 
arms using available data. It can be seen that there is a large variation in the 
change that people experienced in all of the three arms regardless of how 
missing data is dealt with. The length of boxes indicate the inter-quartile 
range and the horizontal lines at the end of the vertical lines extending out of 
the boxes represent the upper and lower limits of the change in IBS-SSS.  
 
Figure 9-5: change in IBS-SSS by allocation for available data 
The change in IBS-SSS for each of the three arms was checked for 
normality by plotting histograms of the change in IBS-SSS for each arm, 
plotting normal Q-Q plots, and using Kolmogorov-Smirnov (Massey 1951) 
and Shapiro-Wilk (Shapiro and Wilk 1965) tests for normality. The results of 
the Kolmogorov-Smirnov and Shapiro-Wilk tests are given in Table 9-17. A 
tick in the box means indicates no significant departure from normality and a 
cross indicates a significant departure from normality. The histograms are 
shown below (Figure 9-6, Figure 9-7 and Figure 9-8). 
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Treatment  Kolmogorov-Smirnov Shapiro-Wilk 
Usual care   
IHT   
Supportive listening   
Table 9-17: Results from tests for normality for change in IBS-SSS 
 
Figure 9-6: Distribution of change in IBS-SSSd for usual care 
 
Figure 9-7: Distribution of change in IBS-SSS for IHT 
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Figure 9-8: Distribution of change in IBS-SSS in supportive listening arm 
As can be seen from the histograms the distribution of change in IBS-SSS 
does deviate from normality. However due to the change in IBS-SSS 
containing negative numbers it was not possible to apply a natural 
logarithmic transformation to the data to see if this improved the 
approximation to normality.  
For the available data analysis, despite the deviation from normality seen in 
the histograms, because the Kolmogorov-Smirnov and Shapiro-Wilk tests 
did not show a significant departure from normality, it was assumed that the 
change scores were close enough to normality to carry out parametric tests. 
Therefore Student’s t-tests were used to compare the following, for change 
in IBS-SSS 
 IHT plus usual care versus usual care alone,  
 Supportive listening plus usual care versus IHT plus usual care.  
Student’s t-tests make the assumption that the variability of each group is 
approximately equal. Levene’s test for equality of variance examines 
whether this assumption has been met. In all of the tests this assumption 
was met. The result for Levene’s test for each of the comparisons is given 
below in Table 9-18 (when p value < 0.05, the test is not met).  
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Comparison Levene's test Levene's test 
met F Significance 
IHT versus usual care 
3.77 0.057 
Yes 
IHT versus supportive listening 0.95 0.34 Yes 
Table 9-18: Results from Levene's test  
Carrying out a Student’s t-test to compare the change in IBS-SSS for usual 
care alone and IHT plus usual care gave change in IBS-SSS of -10.45 and -
69.94 respectively with a mean difference -59.48 (95% confidence interval 
(CI) –109.65 to -9.32); t(67) = -2.37, (p=0.021), i.e. the change in IBS-SSS 
was 59.48 points greater in the IHT arm compared to the usual care arm. 
The confidence intervals of the difference do not cross zero (and the p value 
is < 0.05) hence we can conclude that this difference was statistically 
significant. The results are shown in Table 9-19. It can therefore be 
estimated that there is a difference in outcomes between usual care and IHT 
when the outcome is change in IBS-SSS. The plausible range of the 
difference between IHT and usual care is likely to be between 9 and 109 
points.  
The results of a Student’s t-test comparing IHT to supportive listening gave 
change in IBS-SSS of -69.94 and -45.67 respectively with a mean difference 
-24.27 (95% confidence interval (CI) –51.09 to 99.63); t (29) = -0.66, 
(p=0.52).Therefore it can not be concluded that there is a difference in 
outcomes between IHT supportive listening when the outcome is change in 
IBS-SSS. The results are shown in Table 9-19. 
T-test for equality of means 
Comparison t df Sig. (2-
tailed) 
Mean 
difference 
Std. Error 
difference 
95% confidence interval of 
the difference 
Lower Upper 
UC vs HT -2.37 67 0.021 -59.48 21.13 -109.65 -9.32 
HT vs SL 0.66 29 0.52 24.27 36.85 -51.09 99.63 
Table 9-19: Results from t-tests comparing change in IBS-SSS 
Adjusted analysis  
A one way ANOVA was conducted using the complete data. The 
independent variable was allocation which had three levels: usual care, IHT 
and supportive listening. The dependent variable was change in IBS-SSS. 
The covariates chosen were age, employment status and initial IBS-SSS. 
Age and employment status were chosen because in the exploration of the 
missing data, age and employment status were found to be potential 
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indicators of missingness of 26 week IBS-SSS. Initial IBS-SSS was included 
as a covariate because it is thought likely that there will be a relationship 
between change in IBS-SSS and initial IBS-SSS.  
The homogeneity-of-regression assumption was tested. This test evaluates 
the interaction between the covariate and the independent variable(s) in the 
prediction of the dependent variable. This is important because a significant 
interaction between the covariate and a factor would suggest that the 
differences of the dependent variable between groups may vary as a 
function of the covariate. Therefore if the interaction is found to be significant 
then the results of the ANCOVA would not be meaningful and an ANCOVA 
should not be carried out (Katz 2006). 
The results from the tests between allocation and age, allocation and 
employment, and allocation and initial IBS-SSS were not significant. 
Allocation and age: F (3,69) = 0.29, p=0.83. 
Allocation and employment: F (3,69) = 0.66, p=0.58 
Allocation and IBS-SSS: F (3,69) = 1.05, p=0.38 
Following this the underlying assumption of homogeneity of variance was 
tested using Levene’s test of equality of error of variances the result showed 
that this assumption had been met.  
F (2,81) = 1.809, p=0.17 i.e. P>0.05. 
The results from this ANCOVA showed that there were no significant 
differences between the groups due to allocation. F (2,73) = 1.83 p= 0.167 
η2 = 0.048. A summary of the ANCOVA results are given in Table 9-20. 
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Source Sum of 
squares 
Df Mean square F ratio Sig Partial Eta 
squared 
Corrected model 51838.985
a
 5 10367.797 1.312 .268 .082 
Intercept 2095.420 1 2095.420 .265 .608 .004 
Covariate – IBS-SSS 2506.684 1 2506.684 .317 .575 .004 
Covariate -
employment 
10496.376 1 10496.376 1.328 .253 .018 
Covariate -age 2690.263 1 2690.263 .340 .561 .005 
Allocation 28979.227 2 14489.613 1.834 .167 .048 
Residual error 576818.913 73 7901.629    
Total 700842.000 79     
Corrected Total 628657.899 78     
Table 9-20: Summary of ANCOVA results for change in IBS-SSS 
The parameter estimates for the ANCOVA model are given in Table 9-21. 
Parameter 
B 
Std. 
Error T Sig. 
95% Confidence 
Interval 
Partial Eta 
Squared 
Lower 
Bound 
Upper 
Bound 
Intercept -31.977 68.788 -.465 .643 -169.070 105.117 .003 
IBSSSS -.077 .136 -.563 .575 -.349 .195 .004 
Employment 26.765 23.222 1.153 .253 -19.517 73.047 .018 
Age -.521 .893 -.583 .561 -2.300 1.258 .005 
[allocation=UC] 23.078 29.262 .789 .433 -35.242 81.397 .008 
[allocation=HT] -26.437 33.724 -.784 .436 -93.648 40.774 .008 
[allocation=SL] 0
a
 
      
Table 9-21: Parameter estimates for ANCOVA 
a. This parameter is set to zero because it is redundant. 
(UC = usual care, HT = IHT and SL =supportive listening) 
In summary the results of the ANCOVA showed that the main effect of 
allocation on change in IBS-SSS was not significant when adjusted for age, 
employment status and baseline IBS-SSS. 
Percentage of participants achieving a clinically relevant change in 
IBS-SSS 
A reduction of 50 points on the IBS-SSS is taken to be a clinically relevant 
improvement in IBS. (Francis, Morris and Whorwell 1997). Table 9-22 shows 
the percentage of participants in each arm of the trial that achieved a 
clinically relevant change in their IBS symptoms.  
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 Usual care IHT Supportive listening 
Decrease in 50 points in IBS-SSS 25.0% 62.5% 38.9% 
Increase in 50 points in IBS-SSS 18.3% 18.8% 16.7% 
Missing 16.7% 0% 11.7% 
Table 9-22: Percentage of participants who achieved a clinically relevant change in 
IBS-SSS 
It can be seen that a greater percentage of people in the IHT arm achieved a 
clinically relevant change in IBS-SSS than in either the usual care or 
supportive listening arms. However the percentage of people in each of the 
arms who achieved a clinically significant worsening of symptoms appears 
similar. No formal tests were carried out on these comparisons.  
In summary, for the primary outcome, which is change in IBS-SSS between 
baseline and 26 weeks, it can be estimated that there is no difference in 
outcomes between IHT and supportive listening. This was true when both an 
adjusted analysis that takes into account all the available information on 
patients is included and when Student’s t-test is used to compare IHT and 
supportive listening.  
In terms of IHT compared to usual care, Student’s t-test found a statistically 
significant difference between IHT and usual care, however no difference 
was found between any of the three arms in the adjusted analysis.  
9.1.8 Secondary Outcomes 
9.1.8.1 Hospital Anxiety and Depression  
Complete case analysis 
The change in HADS by allocation was plotted (Figure 9-9). It can be seen 
that there are two outliers in the IHT arm. The source for the data for these 
outliers was checked to ensure that no errors had been made in data entry. 
The data entered was found to be correct.  
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Figure 9-9: Change in HADS by allocation  
To ensure that the conditions for t-tests were met the change in HADS for 
each of the three arms was checked for normality by plotting histograms of 
the change in HADS for each arm, plotting normal Q-Q plots and using 
Kolmogorov-Smirnov and Shapiro-Wilk tests for normality. The results of the 
Kolmogorov-Smirnov and Shapiro-Wilk tests are given in Table 9-23. A tick 
in the box indicates no significant departure from normality and a cross a 
significant departure from normality.  
Treatment Kolmogorov-Smirnov Shapiro-Wilk 
IHT   
Supportive listening   
Table 9-23: Results from tests for normality for change in HADS 
Figure 9-10, Figure 9-11 and Figure 9-12 show histograms of the distribution 
of change in HADS for usual care, IHT and supportive listening respectively. 
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Figure 9-10: Distribution of change in HADS for usual care 
 
Figure 9-11: Distribution of change in HADS for IHT 
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Figure 9-12: Distribution of change in HADS for supportive listening 
The results of the Kolmogorov-Smirnov and Shapiro-Wilk showed the data to 
be normally distributed. The histograms look to be approximately normally 
distributed, therefore it was taken that the assumption of normality required 
for parametric tests was met and t-tests were carried out comparing usual 
care to IHT and IHT to supportive listening.  
Levene’s test was used to check whether the assumption of equality of 
variance required for t-tests has been met. In both the comparison of usual 
care to IHT and IHT to supportive listening this assumption was met, see 
Table 9-24. 
Comparison Levene’s test Levene’s test 
met F Significance 
IHT vs usual care 
2.199 0.143 
Yes 
IHT vs supportive listening 0.537 0.471 Yes 
Table 9-24: Results from Levene's test for change in HADS 
Carrying out a Student’s t-test to compare the change in HADS for usual 
care and IHT gave change in HADS scores of -1.78 and -0.20 respectively 
(where the greater the negative score the greater the improvement) with a 
mean difference -1.58 (95% confidence interval (CI) –1.59 to 4.76); t(64) = -
1.00, (p=0.323), i.e. the change in HADS was 1.58 points greater in the 
usual care arm compared to the IHT arm. This was not statistically 
significant at the conventional 5% level. Therefore there was no difference in 
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the change in HADS scores for those in the usual care arm compared to 
those in the IHT arm. 
The results of a Student’s t-test comparing IHT to supportive listening gave 
change in HADS scores of -0.20 and -1.81 respectively with a mean 
difference -0.02 (95% confidence interval (CI) –5.34 to 5.38); t(24) = 0.007, 
(p=0.99). There is no evidence of difference between the improvement in 
those in the IHT arms compared to those in the supportive listening arm. The 
results are shown in Table 9-25. 
T-test for equality of means 
Comparison t df Sig. (2-
tailed) 
Mean 
difference 
Std. Error 
difference 
95% confidence interval of 
the difference 
Lower Upper 
UC vs HT 0.996 64 0.323 1.584 1.591 -1.593 4.762 
HT vs SL 0.007 24 0.994 0.01818 2.598 -5.344 5.380 
Table 9-25: Results for t-tests for change in HADS 
ANCOVA 
A one way ANCOVA was conducted. The independent variable allocation 
had three levels: usual care, IHT and supportive listening. The dependent 
variable was change in HADS. The covariates chosen were age, 
employment status and initial HADS. Age and employment status were 
chosen because they appeared to be predictors of missingness. Initial HADS 
was chosen because it was thought that there may be a link between initial 
HADS and change in HADS. Initial IBS-SSS was not chosen because it is 
thought that there may be a link between initial HADS and initial IBS-SSS; 
therefore only one of these measures was chosen as a covariate.  
The homogeneity-of-regression assumption was tested. This test evaluates 
the interaction between the covariate and the independent variable(s) in the 
prediction of the dependent variable. This is important because a significant 
interaction between the covariate and a factor would suggest that the 
differences of the dependent variable between groups may vary as a 
function of the covariate. Therefore if the interaction is found to be significant 
then the results of the ANCOVA would not be meaningful and an ANCOVA 
should not be carried out (Katz 2006). 
The results from the tests between allocation and age and allocation and 
employment were not significant. However the results from the tests 
between allocation and initial HADS were significant indicating that there is 
an interaction between initial HADS and change in HADS.  
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Allocation and age: F (3.62) = 0.34, p=0.80 
Allocation and employment status: F (3,62) = 1.87, p=0.14 
Allocation and initial HADS: F (2,69) = 7.71 p=0.00 
Due to the interaction between initial HADS and change in HADS the 
ANCOVA model was constructed with only employment status and age as 
covariates. Interactions between each of the covariates and change in 
HADS were checked for and this time no significant interactions were found. 
The results are shown below.  
Allocation and age: F (3.65) = 0.43, p=0.73 
Allocation and employment status: F (3,65) = 0.06, p=0.98 
Following this the underlying assumption of homogeneity of variance was 
tested using Levene’s test of equality of error of variances. The result 
showed that this assumption had been met.  
F (2,69) = 1.48, p=0.23 i.e. P>0.05. 
The results from this ANCOVA showed that there were no significant 
differences between the groups due to allocation. F (2,67) = 0.53, p= 0.591 
η2 = 0.02. A summary of the ANCOVA results are given in Table 9-26. 
Source Sum of 
squares 
Df Mean square F ratio Sig Partial Eta 
squared 
Corrected Model 105.917
a
 4 26.479 .936 .449 .053 
Intercept 27.257 1 27.257 .963 .330 .014 
Covariate -
Employment 
.135 1 .135 .005 .945 .000 
Covariate -Age 38.947 1 38.947 1.377 .245 .020 
allocation 29.950 2 14.975 .529 .591 .016 
Error 1895.583 67 28.292    
Total 2114.000 72     
Corrected Total 2001.500 71     
Table 9-26: Summary of ANCOVA results for change in HADS 
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Parameter B Std. Error T Sig. 
95% Confidence Interval 
Partial Eta 
Squared 
Lower 
Bound 
Upper 
Bound 
Intercept 3.208 3.002 1.069 .289 -2.783 9.200 .017 
Employment -.100 1.445 -.069 .945 -2.984 2.784 .000 
Age -.061 .052 -1.173 .245 -.164 .043 .020 
[allocation=UC] -1.615 1.968 -.820 .415 -5.543 2.314 .010 
[allocation=HT] -.361 2.271 -.159 .874 -4.894 4.173 .000 
[allocation=SL] 0
a
       
Table 9-27: Parameter estimates for ANCOVA for change in HADS 
a. This parameter is set to zero because it is redundant. 
(UC = usual care, HT = IHT and SL =supportive listening) 
 
The parameter estimates for the ANCOVA are shown in Table 9-27. 
It can be seen from the results from the t-tests and the results from the 
ANCOVA that there does not appear to be a difference in outcomes in terms 
of change in HADS.  
9.1.8.2 Empathy of practitioner 
The intention was to see if there was any correlation between the perceived 
empathy of the practitioner (as measured by the CARE measure) and the 
outcome for the patient in terms of improvement in IBS symptoms. However 
due to a combination of lower than anticipated participants recruited to the 
trial, lower than anticipated uptake of treatment (particularly in the supportive 
listening arm) and failure to return the CARE measure, there was not 
enough data to carry out any modelling. This is because, following the 10 
cases per predictor rule of thumb (Peduzzi et al. 1996), only one regression 
coefficient (including the intercept) could be included in the model. This 
means that there is not enough data for any predictors to be included in the 
model and hence no modelling could be carried out. Table 9-28 gives details 
on the numbers of people who returned their CARE measure. 
  IHT (N=16) Supportive listening (N=18) 
Took up offer of treatment 12 9 
Returned CARE measure 9 4 
Table 9-28: Return rate for CARE measure 
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Exposure to treatment 
The mean number of appointments attended by those who took up the offer 
of IHT was 5 (SD=0) and the mean number of appointments attended by 
those who took up the offer of supportive listening was 4.33 (SD=0.87). 
Further details on how many appointments each participant attended are 
given in section 9.1.3 Adherence to treatment. 
9.1.8.3 Credibility of treatment 
The intention was that the practitioners would give the participants the 
credibility of treatment measure after their second appointment for the 
participant to complete and return. However the practitioners providing the 
supportive listening did not like the wording of this measure and did not 
follow instructions about giving the credibility questionnaires to the 
participants. The result was that not all the participants in the supportive 
listening arm of the trial completed a questionnaire and those questionnaires 
that were completed did not contain the participants’ study ID. Therefore it 
was impossible to link the completed credibility questionnaires to participants 
as was the intention. The results from the therapeutic rationale question 
were given earlier in Table 9-5.  
As can be seen there were no differences in how effective the participants in 
the IHT arm (median score 6.00 (IQR: 5.00-7.00)) and those in the 
supportive listening arm (median score 5.00 (IQR: 3.50-6.50)) thought the 
treatment would be. However there was a slight difference between how 
logical participants in the IHT arm thought the treatment was (median score 
6.0 (IQR: 5.00-7.75)) compared to those in the supportive listening arm 
(median score 3.00 (IQR: 3.00-5.50)). This was not tested for statistical 
significance for the reasons described in Chapter 7.  
9.1.8.4 Other comparisons 
The baseline data of those who took up the offer and those who did not take 
up the offer of treatment was compared. Sixteen people were offered IHT 
and 12 people took up the offer, 18 people were offered supportive listening 
and 9 people took up the offer. Table 9-29 shows the comparisons between 
those who took up the offer of treatment and those who didn’t take up the 
offer of treatment. 
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 IHT Supportive listening 
Took up offer 
n=12 
Didn’t take up offer 
n=4 
Took up offer 
n=9 
Didn’t take up offer 
 n=9 
Age  Mean (sd) 43.75 (13.23) 43.75 (13.77) 40.88 (16.56) 44.13 (19.25) 
Missing 0 0 1 1 
Employment % employed 58.3 100 66.7 56.6 
Missing 0 0 1 1 
Medication % taking medication 83.3 75 100 77.8 
Missing 0 0 0 0 
Sex % female 100 100 66.7 88.9 
Missing 0 0 0 0 
IBS-SSS Mean 275.92 (86.67) 293.75 (60.74) 296.11 (84.28) 287.11 (67.88) 
 Median 272.50 (190.50-344.25) 275.00 (251.00-355.25) 284.00 (221.50-336.50) 295.00 (228.00-347.50) 
 Missing 0 0 0 0 
HADS Mean 15.92 (8.07) 20.25 (7.14) 20.00 (8.28) 14.11 (8.62) 
 Median 14.00 (10.50-19.00) 20.25 (12.75-25.50) 18.00 (13.00-28.00) 15.00 (6.50-20.50) 
 Missing 0 0 0 0 
EQ-5D Mean 64.42 (14.63) 45.33 (13.61) 51.63 (29.82) 64.88 (19.78) 
 Median 67.00 (51.00-70.75) 50.00 (30.00-56.00) 57.50 (23.75-80.50) 68.50 (51.75-79.75) 
 Missing 0 0 1 1 
Table 9-29: Comparisons between those who took up the offer of treatment and those who did not
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58% of those who took up the offer of IHT were employed, compared to 
100% of those who didn’t take up the offer of IHT. It therefore seems likely 
that employment status had an impact on whether or not those offered IHT 
took up the offer. The same difference was not seen in the supportive 
listening arm where 66.7% of those who took up the offer were employed 
compared to 56.6% of those who didn’t take up the offer. Aside from 
employment status, there were no other major differences between those 
who took up the offer of supportive listening and those who didn’t. 
To summarise, for the primary comparison of interest in this study, the 
change in IBS-SSS between baseline and 26 weeks using Student’s t-test, 
no difference was found between IHT and supportive listening.  
The next chapter reports the results of the qualitative interviews. 
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10 Results from Qualitative study 
Interviews were carried out to obtain information about what, if anything, 
participants in the active treatment arms of the RCT believed to have helped 
with their IBS symptoms and general health. The purpose was to provide a 
greater understanding of what aspects of IHT lead to any improvements in 
participant’s health and what aspects of supportive listening lead to any 
improvement in participant’s health.  
Face-to-face interviews were conducted by the author between October 
2011 and January 2012. The interviews were semi-structured, lasted 
between 50 and 90 minutes and generally took place in the participant’s 
home. The interview schedule is given in Chapter 6. All the therapists who 
provided either the IHT or the supportive listening in the RCT were also 
invited to interview. The purpose was to provide an understanding as to 
whether they believed the treatment they provided had helped and if so what 
they thought it was about the treatment that had helped. 
10.1 Participants 
Twelve participants in the IHT arm met the eligibility criteria of having 
attended at least two IHT appointments. All twelve were invited to be 
interviewed and five consented to interview. Nine participants in the 
supportive listening arm met the eligibility criteria and were invited to be 
interviewed. Three consented to interview, although one was subsequently 
too ill to be interviewed (with a non-IBS related condition), therefore two 
interviews were carried out. For clarity the participants who had received an 
active treatment in the RCT will be referred to as “patients” and the 
participants who had provided the treatments will be referred to as 
“therapists” from this point forwards. 
10.1.1 Patients  
All the patients interviewed lived in the Barnsley area and described 
themselves as being of white British origin. Patient characteristics are given 
in Table 10-1. Participants’ names have been changed to protect their 
anonymity. 
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Name Age Gender Treatment 
received 
Number of 
treatment sessions 
attended 
Sheila 42 Female IHT 5 
Paula 58 Female Supportive 
listening 
5 
Mike 42 Male Supportive 
listening 
5 
Cynthia 55 Female IHT 5 
Elizabeth 50 Female IHT 5 
Sam 26 Female IHT 5 
Rachel 51 Female IHT 5 
Table 10-1: Patient characteristics 
  
10.1.2 Therapists 
All the therapists who provided treatment in the RCT were invited to 
interview (two homeopaths and two counsellors) and all four consented. One 
of the listening providers, however, was subsequently unable to attend an 
interview due to a change in work commitments. Therapists’ characteristics 
are given in Table 10-2. 
Name Therapy provided Qualification Number of 
years in practice 
Cath Homeopathy Member of the Society of 
Homeopaths 
12 
Joanne Homeopathy Member of the Society of 
Homeopaths 
10 
Angela Supportive 
listening 
Member of the British 
Association for Counselling 
& Psychotherapy (BACP) 
7 
Table 10-2: Therapist characteristics 
10.2 Analysis of the interviews 
In the assessment of quality in qualitative research there is no consensus as 
to the criteria that should be used and how these criteria should be applied 
(King and Horrocks 2010). However documenting the analysis process in a 
detailed manner has been acknowledged as a means of ensuring 
dependability of the analysis (Mays and Pope 1995; Thomas and Magilvy 
2011). Therefore in the interests of transparency and dependability the 
analysis process is explained in depth in the following sections. 
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Dependability is similar to the term “reliability” used in quantitative research. 
It occurs when another researcher can follow the decision trial that the 
original researcher used and would be able to come to a similar not 
contradictory conclusion. The process is described in the results section 
rather than the methods section because the analysis was a process that 
occurred in four stages. In order to provide a comprehensive description of 
the process it was necessary to explain how the findings from one stage led 
to the analysis of the next stage. The goal of the analysis was to try to 
explain why and how the treatments had or had not worked.  
The four stages to this analysis process were: 
 Generating and coding themes 
 Charting themes to make connections between them 
 Using themes to map out individual patient journeys 
 Looking across the patient journeys and themes to develop a typology 
of different ways in which the treatment was perceived to have 
worked 
A full description of what these stages consisted of will be presented in 
Sections 10.2.1 to 10.2.4. 
10.2.1 Transcription and coding of interviews 
All interviews were recorded and transcribed verbatim. The researcher 
transcribed the first three interviews. The research ethics committee’s 
opinion was sought on having subsequent interviews transcribed by an 
employee of the University of Leeds, which was approved. After the first 
interview was transcribed a coding framework of themes was constructed 
through reading the transcript and identifying themes that were relevant to 
the research aims; which were to explain why and how the treatment had or 
had not worked. This process was guided by the aims of the research, 
issues raised by the respondent and the topic guide (described in Chapter 
6). The themes identified as important within the interviews were:  
 the treatment worked 
 the treatment didn’t work 
 the treatment was helpful 
 effect of the homeopathic remedy 
 description of the treatment 
 description of the therapist 
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 expectations of treatment 
 use treatment again? 
 things they tried 
 reasons for taking part 
 recommend treatment to others 
The themes have been presented in the order in which they were discussed 
in the interviews. These themes emerged through the initial familiarisation 
phase of reading through the transcripts and were important because they 
would give an insight into what if anything the patients believed had worked, 
how they felt it had worked, in what way, and why. Although the “treatment 
worked” and the “treatment was helpful” initially appear to be related they 
have been split because though participants may have found the treatment 
helpful, it may not necessarily have worked in terms of reducing their IBS 
symptoms. After transcribing the interviews were then coded into these 
themes. Table 10-3 gives an explanation of what these themes meant and 
an example of a quote from the interviews that fitted each theme. 
During the process of reading and categorising the interviews into the 
themes listed above, new themes that did not fit into the above list, but that 
represented key aspects of the participants’ experiences of treatment were 
added to the framework. After the addition of a new theme transcripts 
already coded were re-read to determine if there was anything in that 
transcript that fitted into the new theme. This carried on in an iterative 
process until all the interviews had been coded. The additional themes 
added were:  
 other health problems  
 effect of treatment wore off 
 lay theories of why treatment worked 
 quality of the talking 
 reasons why it had to be the homeopathic remedy 
 relationship with food 
 set back due to life events 
Table 10-4 gives the additional themes, with an explanation of what the 
theme meant along with an example quote for each theme.
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Theme  Explanation Example 
Treatment worked 
 
Descriptions of the 
treatment working. 
“Yes that one was definite. I think I've been showing signs of er, you know 
improvement but nothing to the level of that particular evening and taking that one 
which is and I didn’t expect that. I don’t know whether C. (homeopath) expected it 
but it happened. And then when I went back to see her and said, oh that was 
unbelievable” (Elizabeth – IHT) 
“I mean erm pause erm the sort of clinical side of it erm I don’t probably hasn’t had 
any effect. But on the sort of mental side it has” (Mike – supportive listening) 
Treatment didn’t work 
 
Descriptions of the 
treatment not working 
“Er it’s (IBS) actually got, got worse “ (Mike – Supportive listening) 
Treatment helpful Descriptions of how 
the treatment helped 
them 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“You know, so but yes it helped talking to somebody that knew summat, that you 
could talk, talk about it, you know cos your tell your friends ... say to them like, oh I've 
got this problem if I need to go to toilet. I've got to go to toilet, but you can’t go into 
detail, because its not nice. You know like and I just when I go, I go and that’s it, but 
like talking to C (homeopath), it were like talking because she understood the feelings 
and the pain and anxiety of what you’re doing, you know like urgency of going to 
toilet and what kind of poo. You know you had to be careful who were in the next 
cubicle because you made such a noise, and smell’s horrendous absolutely horrible.” 
(Cynthia – IHT) 
“ I’ve lost that control erm again and err talking to counsellor basically that’s what it is 
I’m losing control. You now what I mean everything everything’s just a mess at the 
moment but talking to somebody has really helped I suppose.” (Mike – supportive 
listening)  
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Theme Explanation Example 
Effect of the remedy What happened after 
taking the remedy.  
“I think it was a couple of days after I took the first tablet and I started going to the 
toilet, oh no I got home and she said it wont happen today its not like a miracle cure. 
I’m not giving you a laxative and the following morning I got up and went to the 
toilet.” (Sheila – IHT) 
Description of the 
treatment 
 
Descriptions that were 
given of the 
treatment. Any advice 
that was given 
lifestyle, diet etc 
“Well I wasn’t too sure what to expect when I first went to have me first meeting with 
C. And I was a bit like oh that was quite er, different in so much as it was very much 
getting understanding of me, and my life style of people around me, and it was more 
of a probing to get to know me, the personality, the character.” (Elizabeth –IHT) 
“Well we just talked really it was just a talking there was no set thing about it I mean I 
thought we were just going to talk about bowels but we didn’t really we just just just 
talked really about like you talk in counselling you just talk don’t you.” (Paula – 
supportive listening) 
Description of the 
therapist 
 
How the behaved, 
what they were like. 
 
 
 
 
 
 
 
 
 
 
 
 
“She were really good. And like I say, you did, we did go into depth with things. But er, 
I didn’t mind because I'm one of them what, with me being depressed and that been 
to counsellor and things like that so I've learnt to open up. Erm but er no she were 
brilliant, she were really good, from first moment I were at ease with her. She were 
brilliant , yes can't say owt wrong.” (Rachel – IHT) 
“Somebody you felt confident to talk to, made you feel comfortable as I said she er 
showed she cared to me it didn’t felt it were just a job to her.” (Mike – supportive 
listening) 
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Theme Explanation Example 
Expectations of 
treatment 
 
Any expectations they 
had of the treatment 
before receiving it.  
“No well I knew of it. You know and I had a little bit I suppose one of those what’s that 
all about. is it just a case of it's in the head, and is it a placebo and really is it one of 
those. So I was probably at best a cynic.” (Elizabeth – IHT) 
“I suppose with A (counsellor) I went there open minded erm not expecting too 
much” (Mike – supportive listening) 
Use treatment again? 
 
Whether or not they 
would use the 
treatment again.  
“I would go back, I would continue because I did feel the benefit” (Sam – IHT) 
Well I suppose If my bowels started really bad again and it were offered to me yeah 
I’d have a go at it (Paula – supportive listening) 
Things they tried 
 
Other things they had 
tried for their IBS, 
either during the trial 
or in the past. 
“I’d got that point so I went and I saw a urr nutritionist and they suggested I do a 
complete detox so I had 3 months of apple juice what was it apple juice and cayenne 
pepper and garlic and all sorts of stuff to do a complete detox and then build the 
system back up again.” (Sheila – IHT)  
“I mean over the years I’ve tried sort of taking certain food things out like milk and 
fibre, things like that but it just hasn’t done anything for me” (Mike – supportive 
listening) 
Reasons for taking part  
 
Why they agreed to 
take part in the trial. 
 
 
 
 
 
 
 
“It wan’t costing me anything I have I have lost a husband with skin cancer an I have 
think an all these years after that they’re going to be a pill now that they can swallow 
and I think any anybody that can help anything in anyway to make the future better 
for other people should do it if they can.” (Paula – supportive listening) 
“Um I I was fed up with having it and I don’t want surgery” (Shiela – IHT) 
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Theme Explanation Example 
Recommend the 
treatment to others 
 
Whether or not they 
would recommend the 
treatment to others. 
“Oh I would tell them to go and have a talk and get to know a bit about it yes 
definitely yes. Cos like you say it's er, they can’t they can’t pin point it down of food 
allergies or stress. So there’s got to be summat that’s got to come forward on 
somebody, somebody must be able to pick summat up. “ (Cynthia – IHT) 
“I’d say yeah recommend it .In fact one of friends who goes to school she actually got 
er all the information about it. Er and when she applied for it she got the listening and 
she turned it down, and she said is it good? I said, yeah to be honest yeah, I said if you 
get offered it again honestly go for it” (Mike – supportive listening) 
Table 10-3: Explanation of initial themes
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Theme Explanation Example 
Other health problems 
 
Description of other 
health problems and the 
effects of treatment on 
them. 
“Oh gosh yes I mean if any thing I felt, I mean I'm erm I'm fifty one I'm going 
through the change as well. So I remember saying to C. once flippin hot 
sweats you know and all of that. And er, don’t know why but the Nux Vom 
even helped with that, I don’t know whether it picks up you know the body 
whatever, cos I said to her you know I went though a period where it was 
like, oh gosh and always in the evening and always when you go to bed and 
er, I just mentioned it to her because you talk about you know lots of 
different things.” (Elizabeth – homeopathc treatment) 
Effect of the treatment 
wore off 
 
They were better whilst 
they were having the 
treatment but the effects 
of the treatment wore off.  
“Before I'm met C. It were bad and then, it like the six months were fine and 
then we are back to square one again. You know it's just the time what I 
were going to C. and talking and gettin' them little tablets it did a world of 
good. But after that then we were back to square one.” (Cynthia – IHT) 
Lay theories why 
treatment worked 
 
How they thought the 
treatment worked, what it 
was about the treatment 
that led to any effects. 
 
 
 
 
 
 
 
 
 
“It seemed to be that she looked at me as a whole, rather than just what I 
was actually specifically there for, she did look at other things and helped 
me with that and I suppose things have a knock on effects don’t they, I do 
believe that if there is one thing wrong in the body then other things get out 
of balance a little bit. So I think it did seem to regulate and like give that 
harmony I suppose” (Sam – IHT) 
“It were just pure talk about whatever and whether this works to I mean 
yeah, I suppose if you think about it if you got all these things on your mind 
and that contributes to your bowels getting irritable and starting off. If year 
go to somebody and just talk and just let it all out then I suppose it probably 
does ease it. I don’t know.” (Paula – supportive listening) 
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Theme Explanation Example 
Quality of the talking 
 
Description of the talking 
aspect of the treatment, 
what it consisted of and 
how it was conducted. 
“Being able to talk she believed straight away if you know what I mean. She 
weren’t there just cos she were being paid I felt like she were being there 
cos she cared. You know what I mean, she listened and then when she were 
talking she were giving a little bit of feedback like saying, Er saying things like 
look at the good points you knew she’s were listening.” (Mike – supportive 
listening) 
Reasons why it had to be 
the remedy 
 
Reasons why it had to be 
the remedy that had led 
to any effects. 
Erm, because the first time she gave me something and I said well it did and 
it did wonderfully. The next time she gave me something different. And then 
and after a week I rang her up and said I don’t know what you’ve given me 
but it makes me feel ill and its not done anything. So she sent so she sent me 
the original one again. (Sheila – IHT) 
Relationship with food 
 
The effect of food on their 
IBS symptom. 
“I know it's not what I eat because I've not pinpointed it to anything, 
because I've tried that myself before I started going to C. Whether it were 
milk whether it were bread or whether it were owt in particular you know, 
and it's not it's just one of them things it just does it. So you know I just can’t 
pin point it, it's not tomatoes pips or it's not apples or owt. I've tried and 
tried and it just does it on it's own like you know I just no control over it 
really.” (Cynthia – IHT) 
Set back due to life events 
 
Descriptions of situations 
where life events led to a 
set back in their IBS. 
“You know what I mean, boosted me up I must admit I had 5 sessions with 
her up sort of the last session doing really well. erm but then sort of the last 
session because I’ve got the tribunal Thursday. It’s really sort of knocked me 
back.” (Mike – supportive listening) 
Table 10-4: Additional themes 
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10.2.2 Charting themes 
Once all the data had been categorised into these themes, charts were 
constructed. In these charts the themes were broken down into subthemes, 
for example “treatment worked” was broken down into nine subthemes, as to 
how people knew the treatment had worked e.g. two of the subthemes for 
“treatment worked” were: coping better with life and “reduction in 
medication”. A full list of the sub themes for “treatment worked is shown in 
Table 10-5.  
Sub theme Explanation  
Non specific “worked” 
 
Non specific statements relating to the 
treatment working  
Other health problems better 
 
Improvements in other health problems 
they may have been suffering with 
Quantifying the improvement 
 
Putting facts and figures to the 
improvement 
Improvement in frequency of toilet 
 
An increase or decrease in the number 
of visits to the toilet, depending on 
whether they had constipation or 
diarrhea prevalent IBS 
Coping with better with life 
 
Ways in which they were coping better 
with their life 
Easy 
 
The ease at which the treatment worked 
Reduction in medication 
 
Reduction in the amount of medication 
they were taking 
Certainty 
 
How certain they were that the 
treatment had worked 
Improvements mentally and emotionally 
 
Improvements in their mental and 
emotional state 
Table 10-5: Subthemes of "treatment worked" 
Charts are tables that contain quotes (or summarised quotes) for each 
participant for each of the themes or subthemes. Participants may have 
more than one quote for each subtheme and therefore all quotes relevant to 
that subtheme are summarised separately rather than synthesising the 
quotes to produce one synthesised quote for each participant for each sub 
theme. Table 10-6 shows the basic structure of a chart. For clarity it is vital 
that participants are kept in the same order for each chart when more than 
one chart is being constructed (Srivastava and Thomson 2009).  
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 Sub 
theme I 
Sub theme 
II 
Subtheme 
III 
Subtheme 
IV 
Sub theme 
VI 
Participant I      
Participant II      
Table 10-6: Basic structure of a chart 
In this study the unit of analysis was the person rather than the mechanism 
or theory. Therefore a separate chart was prepared for each theme of 
interest. Two themes were chosen for full charting, these were, “lay theories 
about how the treatment worked” and “the treatment worked.” These were 
chosen because following coding and familiarisation of the data they were 
found to cover important points that would aid the understanding of what it 
was about the treatment people found helpful. “Treatment didn’t work” was 
not used because there was only one quote from Mike in this theme, which 
is given in Table 10-3. Charts were draw up for these two key subject areas 
and entries made for all respondents on each chart. To do this all the quotes 
from all the participants regarding the treatment working were printed off and 
re-read. After re-reading all the quotes regarding the treatment working, the 
theme, the treatment working was broken down into subthemes and each 
sub theme given a title. A chart was constructed with the participants’ names 
down one side and the titles of the sub themes along the top. The quotes 
were then placed in the appropriate box. This was repeated for the theme 
“lay theories as to why the treatment worked.” The sub themes chosen for 
this theme are shown in Table 10-7. 
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Sub theme Explanation  
Body working the way it’s supposed to 
 
Statements relating to the body working 
properly and in the way it is supposed to 
work 
Holistic The treatment looked at them as a 
whole rather than breaking them down 
into little pieces 
Letting it out Offloading, letting off pressure etc. 
Realisation of self 
 
When they realised things about 
themselves that either helped them to 
deal with their IBS or led to them 
realising what was causing the IBS 
Sorting out head 
 
Statements relating to sorting their 
head out thinking things through, 
getting things straight in their mind 
Action of the remedy 
 
A physical or emotional reaction that 
they ascribed to being due to the 
remedy  
Combination of remedy and talking 
 
Talking and the remedy both had led to 
effects 
Not the talking 
 
Ways in which they knew it had to be 
something other than the talking that 
had led to any effects 
Table 10-7: Sub themes for "lay theories as to why the treatment worked" 
In the process of charting themes are often joined together or separated as 
links are made between themes. In constructing the charts in this study it 
was realised that the theme of the remedy had not been fully explored and 
further links between the remedy and lay theories about the treatment and 
the treatment working could be made. Therefore all quotes relating to the 
remedy were re-read and studied and then incorporated into the charts 
where appropriate. 
Once the charts had been constructed they were printed off and shared with 
a supervisor with the purpose of identifying gaps, areas that could be further 
explored and discussing each others understandings of the themes to bring 
further insights into the data. Following this discussion the charts were 
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examined to see where there were gaps e.g. which of the subthemes had 
not been filled in for which of the participants. The interview transcripts were 
then re-read to determine if there was anything that had been missed and 
that fitted the gaps. Any such information was transferred to the appropriate 
place in the chart.  
Finally patients reported changes in health (during the interview) were 
compared with change in their IBS-SSS scores, EQ-5D overall health state 
(global assessment) and their HAD score. A higher EQ-5D score indicates a 
higher perceived level of overall health, whilst a higher HADS indicates a 
worsening of symptoms. This is shown in Table 10-8. These comparisons 
were made to explore complementary perspectives (Barbour 2001) about 
how the patients viewed their health and whether or not anything had 
changed following treatment.  
Six of the patients interviewed reported (during the interview) that their IBS 
had improved, five in the IHT arm and one in the supportive listening arm. 
IBS-SSS scores confirmed that three of the five in the IHT arm had achieved 
a clinically relevant improvement in their IBS, one had not changed and one 
had achieved a score that indicated a clinically relevant worsening of their 
IBS. A change in IBS-SSS of 50 or more is taken to be clinically relevant 
(Francis, Morris and Whorwell 1997). One person in the supportive listening 
arm achieved a clinically relevant improvement in their IBS; this was in 
agreement with their report during their interview that their IBS was better. 
The IBS-SSS score for the person in the supportive listening arm who 
reported that their IBS was the same or possibly worse, was in agreement 
with this statement, in that the IBS-SSS showed that there had been no 
significant change in their IBS. 
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Name Perceived benefit from treatment reported 
during interview 
Reported 
Improvement in IBS 
during interview 
Clinically 
relevant 
Improvement in 
IBS-SSS (change 
of at least 50) 
EQ-5D score HADS 
Before After Before After 
Sheila IBS improved 
All other health problems better  
Yes Yes 71 80 12 13 
Paula IBS better Yes yes 64 78 15 14 
Mike Mood better 
Being in a trial helped with self confidence 
Better able to deal with things 
No No 20 40 33 28 
Cynthia IBS improved 
Space to talk about mum (who had died)  
More confident going out (during treatment) 
Yes*  Yes 50 67 24 25 
Elizabeth IBS and other health problems improved 
More aware of body and what causes IBS 
Yes No 75 65 7 17 
Sam Pain better 
Helped reduce stress in life 
Realised don’t have to be perfect all the time 
Yes No 60 83 10 13 
Rachel IBS improved  
Mood improved 
More confident going out 
Yes Yes 30 70 37 23 
Table 10-8: Patients’ outcomes from RCT 
* Improvement during treatment but wore off when treatment finished
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Sam and Elizabeth reported an improvement in their IBS symptoms at 
interview; however this was not apparent in their IBS-SSS. In Elizabeth’s 
case her baseline and after treatment scores were approximately the same, 
whereas Sam’s score after treatment was significantly worse than her score 
at baseline. In Elizabeth’s case the homeopath reported that a significant 
event had occurred shortly after Elizabeth finished treatment which led to her 
going into a “bad depression”. This could account for the lack of change in 
her IBS-SSS and the worsening in her HAD score (7 at baseline and 17 at 
26 weeks). This difference in scores and reported changes allowed for an 
exploration as to why this should be so. Which, in the case of Elizabeth, led 
to a greater understanding of her patient journey. 
Comparing data in this way and exploring discrepancies can potentially lead 
to a greater understanding of the data and a fuller explanation of why things 
have occurred. 
Mike who said he felt better mentally, but not physically, did not have a 
clinically significant improvement in his IBS-SSS, however his HAD score 
dropped from 33 at baseline to 28 at 26 weeks. His EQ-5D score (a measure 
of the patients perception of their overall health state) increased from 20 to 
40. An increase in EQ-5D indicates an increase in the patient’s perception of 
their overall health. These changes confirm Mike’s view on what had 
improved during treatment.  
Rachel felt significantly better mentally following treatment and had been 
able to reduce her anti-depressant medication. Her HAD score bears this 
out. It reduced from 37 to 23 indicating an improvement in her anxiety and 
depression levels.  
In summary the patients’ views on whether or not they had improved were 
generally reflected in the results from the RCT and comparing them allowed 
greater understanding of how the patients had or had not been helped by the 
treatment they received. Except for Elizabeth, everybody scored higher in 
the EQ-5D rating of their overall health, indicating that everyone perceived 
their health state to be better following treatment. Everyone who took part in 
the interviews said that they felt better following treatment. It is useful to see 
that, although in some cases their IBS-SSS score had not improved, overall 
they felt better. This gives a further insight into how the participants viewed 
their health. 
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10.2.3 Mapping patient journeys 
After the charting had taken place, to further understand the data, the 
patients’ experiences of their IBS and the treatment they received was 
mapped. This involved constructing diagrams for each patient that mapped 
the history of their IBS and what elements, if any, about the treatment they 
felt had helped them. The data used to construct the charts came from the 
interviews. The charts included any information they gave on what they 
believed to have caused their IBS and any elements that they felt 
aggravated it and anything that they had done prior to taking part in the trial 
that they believed had had an effect on their IBS. These charts built on the 
themes already identified in the early steps of the analysis. Therefore also 
included was their perception on whether or not their IBS and/or general 
health had improved since taking part in the trial, and if so, in what way it 
had improved. Finally, what it was about the treatment that they perceived to 
have led to any benefits, was also mapped. Figure 10-1 to Figure 10-7 show 
the maps for each of the participants. 
 
 
 
Definitely 
remedy and 
not the talking. 
Didn’t need 
that had 
friends that 
could talk to 
Remedy helped 
symptoms on many 
levels. IBS not 
completely gone 
but significantly 
better other health 
problems 
completely better 
IBS for many years, 
mainly diet related, 
possibly connected 
to stress 
Had IBS 
for last few 
years 
Much better, has 
only had one mild 
attack since 
beginning treatment 
in the trial. Doesn’t 
know why, could be 
the listening or 
giving up white 
bread 
Went to weight 
watchers™ to 
lose with as 
having trouble 
with knees. Told 
to stop eating 
white bread 
Started 
in trial 
Last six months 
have been very 
stressful and been 
better despite this 
Figure 10-1: Sheila, IHT 
Figure 10-2: Paula, supportive listening 
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IBS following 
a trip to 
Egypt 
Remedy helped with symptoms. 
After taking it would be on the 
toilet constantly for 1-2 days, 
after that fine for 3 weeks 
Better whilst 
seeing 
homeopath but 
has relapsed 
since finishing 
treatment 
Figure 10-4: Cynthia, IHT 
Treatment led to many 
realisations about IBS and how it 
affected his life  
IBS for 
7 years 
Depression  Unable to work 
Mental state 
improved but 
physical symptoms 
the same 
Since completing treatment 
recent stressful event made him 
feel worse but not as bad as 
would have done without 
treatment 
Diverticular 
disease for 
14 years 
Figure 10-3: Mike, supportive listening 
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Believed that 
combination of 
talking, techniques 
and remedy that led 
to improvement 
Continued with 
homeopathic 
treatment after 
trial finished 
IBS for 
a few 
years 
Started 
Cambridge 
diet 
IBS wasn’t any 
better, led to 
realisation that 
IBS was stress 
related 
Treatment 
helped deal 
with stress 
better and also 
IBS symptoms 
No IBS episodes 
that can 
remember 
Remedy had 
a dramatic 
effect 
IBS improved and 
general health much 
better during treatment 
More recently 
IBS 
Talking helped 
realise how 
much stress put 
on self trying to 
be perfect 
Realised 
stress 
contributing 
to IBS 
Believed talking and 
the remedy were the 
best combination for 
her, it might be 
different for others 
Had stressful time 
with work during 
treatment but didn’t 
lead to aggravation of 
IBS 
Stomach always 
weak point 
Abdominal 
migraines 
as a child 
Figure 10-5: Elizabeth, IHT 
Figure 10-6: Sam, IHT 
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10.2.4 Developing typologies 
The patient maps and charts were shared with a supervisor. This led to a 
discussion about the different patients’ journeys and the similarities and 
differences between them. It was apparent that some patients shared similar 
patterns in terms of whether or not their IBS had improved and what they 
attributed this to. Sheila and Rachel, who had both experienced a significant 
improvement, believed their improvement was directly related to the 
homeopathic remedy, whilst Mike who had received supportive listening, 
believed the talking had led to an improvement in his mental state. Elizabeth 
and Sam, who both received IHT, felt that it was a combination of the 
remedy and talking that had led to improvements in their IBS. Paula who 
received supportive listening was very uncertain about what had led to an 
improvement in her IBS symptoms. Discussing these four types led to the 
idea that they could be thought of as four typologies. A typology is a way of 
classifying a population or a phenomena such as beliefs into different 
sectors (Ritchie and Lewis 2003). Each sector can be characterised and is 
differentiated from the others by its own characteristic elements meaning 
that each individual can only be assigned to one typology. If the distinction 
between the typologies allows for individuals to be assigned to multiple 
typologies then the typologies need further defining. The typologies defined 
an ideal type, i.e. a more generic description of the four types that allowed 
for differences between the patients who fitted into a type, yet not allowing 
the patients to fit into multiple types. The typologies were identified as: 
Typology one: Talking helps 
Typology two: I’m better but I don’t know why 
IBS started in 
last few years 
Believed it was 
down to the remedy  
Significantly 
better following 
treatment and 
able to go out 
again 
After taking 
remedy had 
indigestion then 
better the next day 
Figure 10-7: Rachel, IHT 
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Typology three: It was the remedy 
Typology four: It was the remedy and the consultation 
For these typologies to hold all patients should be able to be located to a 
typology. When there is a case that does not fit it should be interrogated to 
determine whether there is a missing dimension in the typologies or whether 
another typology needs to be defined (Ritchie and Lewis 2003). In this study 
Cynthia didn't appear to fit neatly into any of these types. Therefore either 
another typology needed to be defined or the existing typologies broadened. 
On re-reading the transcript from the interview with Cynthia and studying her 
patient journey it was realised that Cynthia believed the remedy had helped 
her, but after her treatment had finished, her IBS returned to its pre-trial state 
and the benefits hadn’t lasted. This led to the inclusion of Cynthia into 
typology three and also the realisation that what was important was what 
patients believed any improvement was due to. Whilst it is useful to know 
that the benefits hadn't lasted, in terms of these typologies it wasn't 
important. Crucial to deciding to which typology a person belonged was what 
they perceived, if anything, to have benefitted them rather than whether the 
benefit was sustained. 
Once the initial typologies had been identified they needed to be further 
developed. To do this the themes related to the consultation and talking 
(letting it out, self realisation and sorting out head) were compared. This was 
to provide a greater understanding of any differences in people's beliefs 
about the "talking" in the two treatment arms and between the typologies. 
Areas of difference and overlap were identified and noted. 
Although in this study the participants from the homeopathic treatment arm 
fell into different typologies from those in the supportive listening arm, the 
typologies were not simply driven by the nature of the intervention. It is 
possible that a person in the homeopathic treatment arm could believe that it 
was the consultation that had helped them and the remedy had no effect. A 
person with this belief would fit into typology one. Alternatively a person in 
the homeopathic treatment arm could also have felt better but not have been 
certain why this was so, therefore fitting into typology two. 
Table 10-9 gives a brief description of the typologies and which typology 
each of the participants fitted into and the treatment they had received.  
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Typology Name Treatment Description of typology 
Typology 
1:Talking helps 
Mike  Supportive 
listening 
The participant felt better for 
having talked to someone. 
Typology 2: 
Something’s 
worked but I 
don’t know what 
Paula Supportive 
listening 
Unsure of what had helped, the 
participant was better but they 
didn't know whether it was due 
to the treatment or something 
else 
Typology 3: It 
was the remedy 
Sheila, 
Cynthia, 
Rachel 
IHT  The participant was better and 
believed this was solely due to 
the action of the remedy 
Typology 4: It 
was the remedy 
and the 
consultation 
Elizabeth, 
Sam 
IHT The participant felt better and 
thought that this was due to 
the action of the remedy and 
talking to someone 
Table 10-9: Description of typologies 
Once these themes had been read and compared all the quotes relating to 
the consultation, the remedy and whether the treatment had worked were 
organised by the typology the patient had been ascribed to. Views about the 
consultation, the remedy and whether the treatment had worked were 
compared across and between typologies. The charts were also revisited 
and data re-read to further expand the typologies. During this time the 
interviews with the therapists were listened to and read to identify areas that 
reinforced what the patients believed and areas where they disagreed. In 
particular the therapists’ views on the talking aspect of the treatment were 
studied to determine if there were areas of overlap between what the 
patients and the therapists believed about how talking could lead to a 
benefit, and what the homeopaths and counsellors believed. The data from 
the charts, quotes and the therapists was reflected on to produce the 
typologies, and a chart constructed which contained a summary of each 
typologies views of what may have helped i.e. the consultation, the remedy 
or something else, see Table 10-10. 
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 Consultation Remedy Other 
Typology one Shared emotions in a 
safe environment 
Believed 
Insights into connection 
between mind and 
body 
n/a n/a 
Typology two Offloading to someone 
neutral 
Talking about worries 
could help reduce 
worries and IBS 
symptoms 
n/a Lifestyle 
change 
such as 
change in 
diet may 
help 
Typology 
three 
Talking about problems 
was useful but had no 
therapeutic effect on 
IBS 
Some remedies helped 
other didn’t 
Sudden improvement 
after taking remedy 
Effect of remedy wore off 
Repeating the same 
remedy helped 
Initial aggravation of 
symptoms after taking 
remedy 
n/a 
Typology four Detailed exploration of 
symptoms led to a 
better understanding of 
what was causing IBS 
Talking helped to 
reduce stress 
Speed of change (quick) 
after taking the remedy 
Effect of the remedy 
worse off but repeating it 
helped 
Aggravation of symptoms 
after taking the remedy 
before an improvement  
n/a 
Table 10-10: Summaries of what each typology believed had helped, from patient’s 
perspective 
10.3 Typology one: Talking helps 
This typology believed that talking is beneficial and that it had helped them in 
some way, whether it was solely on a mental/emotional level, solely on a 
physical level, or a combination of both. They were very certain that they had 
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benefitted from the talking and were very clear in expressing this. One 
person, who had received supportive listening fitted in to this typology (Table 
10-9). 
“ Erm but yeah I must admit that work with A has helped a lot. A lot 
emotionally wise it really has. It helped me enjoy the better days, if anything, 
now it might not sound a lot to some people but for me, and I suppose 
anybody else that’s like myself its a big thing.” Mike (patient, supportive 
listening) 
One of the aspects in which talking helped was that the consultation 
provided a safe place to share emotions. For Mike this was important 
because it gave him the opportunity to talk about what was troubling him, the 
anxieties and doubts without fear of comeback. Talking about these issues 
relieved the pressure he felt was building up inside him.  
“Face to face, just listening it helps brilliantly. You know what I mean, I could 
let everything out. You know what I mean, all worries how I were feeling and 
it were just nice it were, like ‘pop the lid’ cos I feel like friends and family they 
get fed up of hearing. You know what I mean its like, aint feeling so well like 
me wife A” why don’t you tell me?” “cos I’m sick of repeating myself”, feel 
like I’m repeating myself so like I hide everything.” Mike (patient, supportive 
listening) 
Letting out all the doubts and worries not only allowed him to release the 
pressure that was building up but also aided him in recognising how much 
IBS had affected his life.  
“Being able to talk to somebody let it all out erm makes you realise how 
much it has affected me. I aint being silly. Sort of it’s not my fault I haven’t 
got no control over it, erm and talking to her its made me realise how much 
its affected me, my lifestyle. How I live, me family, everything else.” Mike 
(patient, supportive listening) 
Angela, one of the counsellors who provided the supportive listening, also 
recognised the importance of being able to share thoughts and feelings that 
the patient may not have been able to share before. She believed that 
people had found this opportunity to share and reflect useful and had led to 
improvements in how the participants felt. 
“I think it was a place to actually reflect emotions and feelings that they were 
unable to share with anybody, whether it was family, because of the fear of 
burdening family, there was a fear of perhaps medical appointments were 
not always er, long enough in terms of sharing exactly emotionally how they 
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felt, and some of what they shared there was some, would have been with 
other people embarrassment in sharing, but we were in the session because 
of the confidentiality and because of the er, confidentially of core conditions 
that were offered they actually went with the process. And were quite happy, 
and within the supportive listening er, were able to sort of really reflect on 
themselves, and their positives and the could do’s, rather than could not 
do’s. Is often the could not’s that block people.” Angela (counsellor) 
Another aspect of being listened to that helped his typology was that what 
they were saying was believed. Mike had struggled with people not believing 
that he was genuinely poorly and so being believed by someone helped to 
reduce his feelings of self doubt and wondering whether he was really as 
poorly as he said he was. No one in any of the other typologies mentioned 
the importance of being believed; however Joanne one of the homeopaths 
also recognised how important being believed was to the patients. 
“One of the things er, that’s of value within the homeopathic consultation is 
that space for somebody to actually listen about your symptoms er and not 
dismiss them as being (in the mind) most of the patients said that people 
have said, oh it's in your mind. Your stress, you know. So I think again there 
is something that I acknowledged about just the space of somebody being 
able to sit down and someone listen and er, accept and believe that what 
they are saying is right.” Joanne (homeopath) 
For Mike talking about how IBS had affected his life also helped with his self 
doubt in that talking things through allowed him to make realisations about 
the changes he had had to make to his lifestyle because of his IBS. An 
example is where he talks about how he now has to take his children to 
school in the car because he no longer has the energy to walk.  
“Think of you know what I mean cos you keep talking and waffling and things 
come out like simple things like taking my kids to school 200 yards away. 
Have to use car now so that’s one thing that’s a total life change.” Mike 
(patient, supportive listening) 
The final way in which this typology felt that the talking had helped them was 
in making the connection between the mind and body. By talking things 
through they made the realisation that IBS is not just a physical problem but 
a mental problem as well. Feeling better mentally could therefore lead to 
feeling better physically which in turn could lead to further improvements in 
how they felt mentally. 
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“I must admit that side of it has helped a lot. I think you can, it helps you 
enjoy the better days. If you can get rid of that. Er emotional side that er 
psychological side er depression get rid of that. It helps you deal with better 
days and I don’t know if you had more sort of enjoyed better days more 
whether then the symptoms start to ease a little bit because some of it some 
days have got to be triggered through being fed up.” Mike (patient, 
supportive listening) 
All these aspects of talking helping were synthesised into a diagrammatic 
representation for this typology which is shown in Figure 10-8.
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Figure 10-8: Typology one, talking helps 
Treatment 
IBS 
Improvement in 
mental state but not 
physical state 
Talking helps 
It provides a safe place 
to share emotions which 
helped with self 
confidence 
How does it help?  
Being believed  
Made conscious the 
changes to lifestyle 
because of IBS  
Recognised that IBS is 
a genuine illness, 
leading to reduction in 
self blame and doubt  
Talking provides insight into the 
link between mind and body and 
the realisation that IBS is not just 
a physical problem  
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10.4 Typology two: I’m better but I don’t know why 
This typology did not know what had led to an improvement in their IBS. 
They did not know if the treatment they had received had helped, it might 
have done but they weren’t really sure. This was in part due to their 
uncertainty about what had caused them to have IBS. They thought it could 
have been due to stress or it could be due to some other factor such as diet. 
This uncertainty led them to an uncertainty about why they were better. If it 
had been stress that had been causing the IBS then it could have been 
talking that helped. However, if it was down to some other lifestyle factor 
such as eating a particular food, then stopping eating that could have 
helped. One person who had received supportive listening fitted into this 
typology (Table 10-9).  
They thought that having someone to talk to could help with reducing stress, 
particularly if their IBS was triggered by having something on their mind. If 
this was the case then talking to somebody could ease it.  
“It were just pure talk about whatever, and whether this works to, I mean 
yeah I suppose, I suppose if you think about it, if you got all these things on 
your mind and that contributes to your bowels getting irritable and starting 
off. If you go to somebody and just talk, and just let it all out, then I suppose 
it probably does ease it, I, I don’t know.” Paula (patient, supportive listening) 
The difference between this typology and typology one was the uncertainity 
in typology two about whether or not it was the talking that had helped. 
Improvements could have been due to the talking or they could have been 
due to some lifestyle factor such as diet. In the case of Paula she was on a 
diet and cut out white bread at the same time as taking part in the RCT. She 
wonders whether it was the cutting out white bread that led to the 
improvement she experienced. 
“I don’t buy white bread anymore I only buy wholemeal bread an,an it just 
registers that that’s the one thing I did do an I’ve been aright just had one 
mild bout. So was it the wholemeal bread. I just do not eat white bread at all. 
So it makes you wonder dunit?” Paula (patient, supportive listening) 
They acknowledged that they had found the talking helpful but didn’t really 
know whether this had any effect on their IBS. Talking probably would be 
helpful, but whether or not it could help to lead to an improvement in their 
IBS symptoms, they weren’t really sure. 
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“I probably did find it helpful ,but I think anybody that went to see somebody 
that, that they had no, erm, that they didn’t know and they could just talk to 
and they listened without people butting in putting their you know penneth in 
about what happens would find it helpful to just unload wouldn’t the?” Paula 
(patient, supportive listening) 
Angela, one of the therapists who provided the supportive listening, also felt 
the supportive listening sessions provided an opportunity to share and reflect 
on thoughts and feelings. Her experience was that patients were able to 
share thoughts that they had not shared with anyone before and this was 
important.  
“It was a place for them to share, and reflect also. Er and I suspect, well I 
know some of the reflections and these were people who er, were not ,not 
young people they were several decades in terms, had certainly not shared 
er some of their feelings and thoughts processes, and the challenges to their 
own dignity that they had felt in relation to their treatment and how it 
impacted on daily life. In terms of very much limiting them.” Angela 
(counsellor) 
It should be noted that of the people interviewed only Paula reported that 
she had made another change/done something differently that she felt could 
have led to her improvement. No one in the other typologies mentioned 
doing anything else (such as making a dietary change) that they felt had 
have helped with their IBS during the trial. This may be because they 
genuinely hadn’t done anything else that had helped with their IBS or it could 
be that they had made changes but had forgotten that they had made them. 
Although they were asked about other things they may have done that could 
have led to an improvement it is still possible that they had forgotten. 
This typology is represented diagrammatically in Figure 10-9. Which shows 
the two main aspects of this typology which are; the possibility that talking 
could have helped and the possibility that it could have been something else 
that helped.
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Explanation Treatment 
IBS Symptoms improved Unsure 
The talking  
A lifestyle 
change 
Unloading to 
someone who 
doesn’t give advice 
is helpful 
If worries are 
contributing to IBS 
then talking about 
them could help 
reduce symptoms  
If IBS is caused by or 
exacerbated by diet, 
then changing diet 
could reduce 
symptoms 
It could have 
been due to 
Figure 10-9: Typology two, uncertain what had led to benefit 
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10.5 Typology three: It was the remedy 
People belonging to the third typology believed it was the remedy that had 
helped them and that the talking was incidental. Three people all of whom 
received IHT fitted into this typology (Table 10-9). They were very certain 
that it was the remedy that had helped.  
“It had to be the remedy. I know were were chatting but we were more 
chatting about all and sundry. Rather than and it wasn’t chatting about how 
to treat it and how I might think about treating myself internally it was just 
chatting, erm and history of what symptoms I’ve had. For years like I’ve 
always always had dry skin” Sheila (patient, IHT) 
The interviews with the homeopaths were studied to find similarities or 
differences between the patients’ understanding of why it had to be the 
remedy and the homeopaths’ understanding. Four points were identified that 
led the patients to the belief that it had to be the remedy that had helped 
them. These were: the speed at which changes took place, a worsening of 
symptoms before an improvement in symptoms, not all remedies were 
beneficial and if the effects of a remedy wore off repeating that remedy led to 
continued benefit. Although these four points were identified by patients the 
patients in this typology didn’t necessarily experience all four.  
The first point that led people to thinking that it had to be the remedy was the 
speed at which the changes took place. In the case of Sheila she noticed a 
sudden improvement within a couple of days of having taken the remedy. 
“So it’s definitely had a sudden improvement, which is why how I know it was 
the homeopathic remedy.” Sheila (patient, IHT) 
Cath, one of the homeopaths, felt that improvements due to talking would 
take more time, taking place over a few consultations rather than 
immediately. 
 “I did feel with these it was so easy you know sort of there wasn’t time for it 
to be that really (the talking)” Cath (homeopath) 
The suddenness of the changes, therefore, were important in people’s 
understanding of why it had to be the remedy rather than talking. However 
the speed of action of the remedy didn’t always lead to an immediate 
improvement. The second reason that people believed the remedy to have 
had an effect was because they experienced a brief worsening of their 
symptoms prior to improvement. Cynthia and Rachel noticed that they were 
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worse the day they took the remedy after which they would experience an 
improvement in their symptoms.  
“I mean I would be all day on toilet, up and down, up and down, and then 
after that then, it were just a normal, it were a just a normal poo, and a 
normal carry on, you know without thinking, oh I daren't eat that ....you knew 
you were going to be fine..” Cynthia (patient, IHT) 
“they give me bad indigestion and heartburn, I had to sit up all night. But, two 
or three days like that it's worse, then months, a couple of months I've had 
(of being better)... it's been brilliant.” Rachel (patient, IHT) 
A third reason why participants felt it had to be the remedy was that different 
remedies had different effects. They may have been given a remedy that 
helped them and then subsequently been given a different remedy that they 
felt didn’t do anything or they may have been given a remedy that had no 
effect and then on being given a different remedy noticed a dramatic 
improvement. Rachel experienced a big improvement soon after one of the 
remedies she was given, having found the first remedy not to have any 
effect. 
 “The other ones they didn’t seem to do much, but soon as I had that one... I 
don’t know but I put it down to that. Them tablets.” Rachel (patient, IHT) 
The use of the word “soon” in this quote from Rachel also demonstrates the 
speed with which the remedy acted. In contrast Sheila was given something 
initially that had a big effect but when the homeopath changed the remedy at 
the next consultation she felt that the new remedy didn’t do anything. 
 “Erm because the first time she gave me something and I said well it did 
wonderfully. The next time she gave me something different. And then and 
after a week I rang her up and said I don’t know what you’ve given me but it 
makes me fell ill and its not done anything.” Sheila (Patient, IHT) 
Experiencing different actions with different remedies was important in 
people’s understanding of what it was that helped them. The fact that some 
remedies helped while others didn’t, was confirmatory that the remedy had 
had an effect. Participants then would ask for a repeat of the remedy that 
they felt had helped them when its action wore off. In classical homeopathy it 
is recognised that the action of a remedy may wear off and thus it may need 
to be repeated (Kent 1984). Cath the homeopath saw the fact that patients 
asked for repeats of remedies to be confirmatory of the action of the remedy.  
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“They did because they asked for repeats. So and I think if you ask for 
repeat and you get the benefit then, that's fairly confirming.” Cath 
(homeopath) 
Joanne, the other homeopath, approached treating the patients slightly 
differently to Cath, who tended to give the participants one remedy at a time. 
Joanne tended to give them one remedy that fitted their whole symptom 
picture (a constitutional remedy) along with what she termed an acute 
remedy to help with any flare ups they may have. The acute remedy was to 
be taken if and when a flare up occurred, therefore this remedy would only 
be taken if they had a flare up. Thus the constitutional remedy aimed to 
reduce or eliminate the number of IBS attacks, along with improving the 
patients overall health, whilst the acute remedy taken at the beginning of an 
attack aimed to shorten its length. Joanne experienced participants asking 
for a repeat of the remedy they felt had helped them and often this was the 
constitutional rather than the acute remedy.  
“It was really interesting that people came back and said just that. You know 
I have been okay. But I would like some more of that (the constitutional 
remedy), that remedy because it's been a really stressful month.” Joanne 
homeopath, talking about the constitutional remedy which was aimed at 
helping to prevent participants getting the IBS symptoms in the first place.  
Cynthia noticed that when the tablets were wearing off her symptoms came 
back, she would then be better again after repeating the remedy.  
“As you were getting to end of your three weeks it were coming back, so you 
knew then your tablets had worn off.” Cynthia (patient, IHT) 
Participants experienced a combination of these factors and it was this that 
led them to the conclusion that it was the remedy that had led to the effects 
rather than anything else. These observations fitted with the homeopaths 
beliefs. It is likely that it is not just one but a combination of these factors 
which are interrelated that led to the belief that is was the remedy that led to 
any effect. Figure 10-10 is a diagrammatic representation of these factors. 
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10.6 Typology Four: It was the remedy and the consultation 
These participants believed it was the combination of the consultation and 
the action of the remedy that led to an improvement in their symptoms. Two 
people who had received IHT fitted into this typology (Table 10-9). Their 
beliefs about how the consultation had helped them centred around how the 
style of the consultation developed their insight into what led to them getting 
IBS. Crucial to this was a better understanding of their bodies. This 
understanding they perceived to have come about through talking about 
their symptoms with the homeopath and the exploration of their character 
that is part of the homeopathic consultation. This is subtly different to 
typology one in that in typology one the perceived benefits were around the 
themes of off loading, letting off steam and how discussing the impact of IBS 
on their life had led them to make realisations about how having IBS had 
affected their mental state. Whereas in typology four because the 
homeopathic consultation requires an in-depth understanding of bodily 
complaints and how the patient experiences them the self-exploration it 
Explanation Treatment 
IBS IBS and other health 
problems improved 
It was the remedy  
When a remedies 
beneficial effect wore off 
repeating it led to 
continued improvement 
Not all remedies 
were beneficial  
Aggravation of 
symptoms after taking 
remedy, before 
improvement 
Sudden 
improvement in 
symptoms after 
taking remedy 
How did they know 
it was the remedy? 
Figure 10-10: Typology three, it was the remedy 
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promoted appeared to be on a deeper level. Mike (typology one) and Sam 
and Elizabeth’s (typology three) experiences were subtly different. For Mike 
supportive listening facilitated an exploration of the impact of IBS on his life 
both physically and emotionally. 
 
“So I suppose if I can get head sorted out and enjoy the good days there’s 
always a good chance that I’d have more frequent good days...And they 
might be more prolonged and I know won’t obviously cure it. But it might give 
me better days and longer days er might even take the edge of flare ups 
they might not be as severe. Because there’s nothing else sort of driving it if 
you know what I mean.” Mike (patient, supportive listening) 
However Sam started exploring aspects of her character that could have 
contributed to her getting ill.  
“I have never realised that I'm somebody who just has to have such control 
over everything, and have to do everything above and beyond, and I think 
I'm not helping myself at all putting all this stress on myself. And like I said it 
has helped me look at that and try and take a little bit more of a light hearted 
view, and I can remember one day I had been sat in the garden just feeling 
really content just in the house. My boyfriend was watching football or 
something here I was in the garden, the dog was just pottering about. I just 
thought this is brilliant. I could just do this for ever. And I can remember 
getting these feelings of contentment I said to her, I really feel content at the 
moment, and she said it could be you know with me not putting so much 
pressure and worry on myself that I'm realising well what you have got to 
around you is amazing you know stop rushing about and just take stock of 
what you have.” Sam (patient, IHT) 
In the case of Sam and Elizabeth IHT was accompanied by a deep reflection 
of themselves and their symptoms. This in turn led to a greater 
understanding of themselves. Both Sam and Elizabeth felt a benefit from 
understanding themselves better.  
“So I think with her trying to, she also pointed out to me that I am vey much 
that I everything has to be perfect, I don’t like to under do anything. I'm not 
happy with myself and I never cottoned onto this. And I just always wanted 
everything to be perfect. And I do believe yes perfect is not always existing, 
but I always want the best of what every I do, and I think she actually helped 
me in a way realise that you can sometimes just drop below that and it's 
nothing bad is going to happen, and I think that took some of the stress 
away.” Sam (patient, IHT) 
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“cos I think by talking things through you have a better understanding erm, 
and how your body reacts and feels and, what is it that makes it feel that 
way, if that makes sense.” Elizabeth (patient, IHT) 
Another aspect of this understanding themselves better was the realisation 
of the need to reduce stress in their lives which could in turn led to a 
reduction in symptoms. This is similar to typology one where the talking also 
helped them to make connections between their mental/emotional state and 
their IBS symptoms. However the difference between these typologies being 
that in typology one although they had made some realisations they had yet 
to act on them.  
“If you can get rid of that. Er emotional side that er psychological side, er 
depression get rid of that, it helps you deal wi with better days and I don’t 
know if you had more sort of enjoyed better days more whether then the 
symptoms start to ease a little bit because some of it some days have got to 
be triggered through being fed up.” Mike (patient, supportive listening, 
typology one)  
Elizabeth and Sam both attributed their IBS in part to stress, although they 
only realised this through taking part in the trial. Having made this 
connection they felt that reducing their stress reduced their IBS symptoms.  
“But I'm getting better I'm understanding it now. Which is helping everything 
because I think if I can lower my stress then I'm going to lower the risk of 
these outbreaks. So I think that’s a big thing for me. Learning to relax. And 
sitting still and I think I did that more during the treatment.” Sam (patient, 
IHT) 
“I think I get a natural build up and then the way it sort of like releases itself 
is in the stomach form of the IBS. So it was an interesting time.” Elizabeth 
(patient, IHT) 
Sam also felt that offloading and talking helped to reduce her stress levels. 
The consultation therefore was a key aspect of treatment for people in this 
typology. The homeopathic consultation helped them to understand 
themselves more and make changes, such as reducing stress, these 
changes helped with their IBS. The act of talking and offloading could also 
help them to reduce their stress levels. However despite their understanding 
of how the consultation had helped them they still believed that the remedy 
had had an additional effect. It was both these aspects combined that led to 
their improvements. As Elizabeth summarises when reflecting on the 
dramatic effect of one of the remedies she took  
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“I think I think the whole combination. I think you know if I go through it now, 
and think you know what if I had just gone along and somebody had given 
me some nux vom would have had the same impact, you know I don’t know 
whether it would. Because I don’t think I would have been aware of me and 
my symptoms and the causes. And all of those things, I don’t think maybe it 
would have had the same impact.” Elizabeth. (patient, IHT) 
In terms of how they knew the remedy had had an effect their reasoning was 
similar to those in typology three who believed it was solely the remedy that 
had had any effect. 
Elizabeth noticed a dramatic improvement in her symptoms after taking one 
particular remedy.  
“So that was a big, I mean talk about er, take something instantly have a 
reaction then the feeling of like wow. That was yes.” Elizabeth. (patient, IHT) 
She had never experienced anything like this before, even with conventional 
medicine. The sudden improvement was preceded by a brief worsening of 
her symptoms both of which she attributed to the remedy.  
“Within two hours of taking this pill, I felt rubbish, pants. I felt my stomach felt 
bloated. I felt headachy and I felt oh my god I'm having a reaction but the 
next day when I woke up. I was great.” Elizabeth (patient, IHT) 
The combination of worsening of symptoms followed by a dramatic 
improvement confirmed to Elizabeth that it was the remedy that had had the 
effect.  
Sam also noticed a prompt reaction after taking a remedy aimed at 
supporting her in stopping the contraceptive injection. This quick reaction 
dropped off after the trial had concluded. 
“so when she did that and she did give me something to help with, er, 
stopping the injection even that I didn’t expect anything to happen for 
months and she got something happening two or three days later... and I 
never thought anything could be so effective so quickly. But I know it's 
definitely slowed back down since I'm not seeing her.” Sam (patient, IHT) 
This is similar to Cynthia’s experience of being better whilst having treatment 
and then getting worse again once the treatment stopped. They both 
ascribed this worsening to no longer taking the remedies. 
Like those in typology three (it was the remedy) both Elizabeth and Sam 
experienced sudden improvements, or a worsening of symptoms followed by 
an improvement, which they believed were due to the remedy. In Sam’s 
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case this wasn’t sustained after concluding treatment. This was further 
evidence of it being the remedy that caused the effect. Since concluding the 
trial Elizabeth has continued to seek IHT and when she feels things are 
slipping she asks for a repeat of the remedy that had the dramatic effect.  
“And also I think I know that if I do need any medicine. I just say to C. I need 
some of that ... and yes. You know err, and I, I continue down the 
homeopathic route definitely. I have not gone back to the doctors, not gone 
back there at all. Erm I've not needed to.” Elizabeth (patient, IHT) 
This typology is the most complex of the four typologies, not only are there a 
combination of interrelated reasons as to what it was about the consultation 
that helped, but also a combination of reasons as to why they believe the 
remedy played a part. Joanne, one of the homeopaths, saw an improvement 
in the patients’ anxiety symptoms and their physical symptoms. Her view 
was that the listening could have helped with the patient’s anxiety or stress, 
and although these symptoms can be linked with the physical symptoms, 
she felt that supportive listening would have been less helpful with the 
physical symptoms, especially if they were not solely related to stress. This 
fits in with this typologies view that it is both the consultation and the remedy 
that has helped.  
In summary the patients in this typology saw this whole process as 
intertwined and saw a need for both the remedy and the talking to help with 
their IBS symptoms. 
“I don’t know, I would say definitely both because er with the treatment I felt 
the effects on different things in the body, but I think the talking helped as 
well.” Sam (patient, IHT) 
In homeopathic thinking a correctly chosen remedy should cover the totality 
of the patient’s symptoms, including mental and emotional symptoms, and a 
well chosen remedy should lead to the reduction in unhelpful behaviour 
patterns that lead to physical symptoms, such as the need for perfection as 
described by Sam (Sankaran 1999). In addition homeopaths are taught to 
discuss with the patient possible maintaining causes, i.e. things that are 
hindering the patient in getting well, this could include poor situations or 
relationships (Roberts 2001). In Sam’s case this could be her tendency to 
seek perfection in everything she does. Cath explains this linking of a 
patient's symptoms and what she perceives to be causative factors and how 
she feeds this back to her patients. 
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“So what I will do is I will give a remedy and then if it's a good effect I will 
explain what I gave and why. And explaining that I had linked this emotional 
symptom and that physical symptom. So that’s kind of giving them the 
feedback. That you know either you know you can look at your lifestyle or 
you will know if you are majorly stressed you are likely to get a return of 
symptoms and you are likely to need another remedy.” Cath (Homeopath) 
Thus to homeopaths the remedy and the talking are deeply interconnected, 
and those in Typology Four believed both these aspects led to a benefit.  
Figure 10-11 gives a diagrammatic representation of typology four.
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What was it 
about the 
consultation? 
How did they 
know it was 
the remedy? 
Explanation Treatment 
+ IBS 
IBS and 
general health 
improved 
Remedy Consultation 
Recognised the 
need to reduce 
stress  
Speed of 
changes after 
taking remedy  Aggravation of symptoms 
after taking remedy 
before improvement  
Talking things 
through helps to 
reduce stress 
The effects of the remedies 
wore off over time but 
repeating them helped 
Detailed exploration of 
symptoms led to a better 
understanding of what 
caused IBS symptoms 
Figure 10-11: Typology four, it was the remedy and the consultation 
234 
 
 
 
10.7 Rigor in qualitative research 
In the interests of carrying out this study in a rigorous manner, a supervisor 
was met with to discuss the study throughout the data collection and 
analysis. The supervisor carried out an independent review of three of the 
interview transcripts and the initial coding and thoughts and ideas were 
shared. The supervisor also carried out an independent review of the 
charting, mapping and typology development, sharing views on where 
further exploration of the data was warranted. This led to a deeper 
understanding of the typologies and the patients’ individual journeys. In 
addition this independent analysis increased the likelihood of credibility of 
the analysis. As a further quality control check, the results of the qualitative 
analysis were shared with another supervisor who had not been involved in 
the initial sharing process; this led to further discussion about the data and 
allowed the data to be explored from an additional view point.  
As stated earlier there is no consensus on how best to assess the quality or 
rigor of qualitative studies. Whilst some authors have published evaluation 
tools (Long and Godfrey 2004), others have been more cautious about the 
use of tools and checklists (Barbour 2001). This is because of the potential 
for checklists to be used prescriptively without thought as to whether fulfilling 
that check box is appropriate to the study in question. Another more radical 
position held by extreme relativists is the view that each research study is 
unique and just as valid in its own right (Mays and Pope 2000). In terms of 
this PhD study, the view was held that the best way of enabling others to 
assess the rigor of this study was to be transparent about how the study was 
conducted and the results analysed, thus allowing other researchers to 
clearly understand how and why the conclusions were reached. Therefore, 
in the interests of transparency, the results and how the author came to 
these results were fully described. The purpose of this is to leave a decision 
trail, as advocated by Koch (Koch 2006), so that the reader is able to audit 
for themselves the actions of the researcher. This decision/audit trail has 
been made clear in the description of the analysis of the results. It is the 
audit trail that allows the reader to be confident that the results are credible 
and plausible. Furthermore a description of the population surveyed and the 
treatment they received has been given to allow future researchers and 
readers to determine how transferable they believe the data to be (Thomas 
and Magilvy 2011). The sharing of the data with supervisors, providing a 
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clear audit trial and description of how these results were arrived at, gives 
added confidence in the trustworthiness of the analysis process and results 
of this study. From these processes it can be seen that the results are 
consistent with the data and how they have been arrived at. 
Field notes were made throughout the research process in the form of 
memos. Some of these were simply to provide an aide memoire after an 
interview had taken place whereas others contained reflections on the 
research process. Throughout the study the author was conscious of her 
dual role as that of a researcher and also as a homeopath. In this PhD the 
author did not provide any of the IHT. However throughout the duration of 
the study she was working half a day a month as a professional homeopath 
providing private healthcare. During the interviews the author did not reveal 
that she was a homeopath. This was in the belief that patients would be freer 
to discuss the treatment they had received if they didn’t feel that the 
researcher was aligned to any particular therapy. However had any of the 
patients asked the researcher about this, she would have given an honest 
answer. This question was not asked by any of the patients, however one of 
the therapists did ask at the end of the interview.  
The author is aware that her role as a homeopath could lead to a biased 
view in this study, to minimise the impact of this, she has tried (as far as it is 
possible), throughout to take the view of the unprejudiced observer. In the 
homeopathic consultation the homeopaths ideal is to take the stance of the 
unprejudiced observer. Meaning that, as far as possible, they observe the 
patient’s state without bringing in their own thoughts or ideas. As Kent in his 
lectures on homeopathic philosophy says “let me beg of you... to lay aside 
all that you have heretofore imagined or presumed, the whims and notions, 
and “what I thought about it,” page 56 (Kent 1984). To achieve this, the 
homeopath needs to explore and recognise their own prejudices. The idea 
being that through knowing their prejudices they work to leave them at the 
door of the consulting room, during the consultation they seek to understand 
the patients experience, rather than what the homeopaths thinks the patient 
is experiencing. Thus the author, as a trained homeopath, has aimed to take 
the stance of the “unprejudiced observer” when carrying out these 
interviews. This stance fits with that of the realist perspective as described 
by Cohen and Crabtree (Cohen and Crabtree 2008). Different authors have 
described the realist stance in different ways, however Cohen and Crabtree 
describe it thus, “we cannot separate ourselves from what we know; 
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however, objectivity is an ideal researchers strive for through careful 
sampling and specific techniques” Page 333 (Cohen and Crabtree 2008). To 
aid with taking the stance of the “unprejudiced observer,” throughout the 
duration of this study the researcher has reflected on times when she may 
have been biased and re-assessed actions, whilst thinking have I done this 
because it is the right thing to do, or have I done it because of a biased 
standpoint? That is, because I am a homeopath, am I making assumptions 
about IHT. The quote below from one of the memos demonstrates this 
process. This memo was made after interviewing one of the homeopaths 
who had provided IHT.  
“This interview was harder than the others because I was trying to be the 
unprejudiced observer as much as possible and also not start talking in 
homeopathic terms which would have meant something to the two of us but 
may not have meant anything to non homeopaths. Through the interviews I 
have tried to be as unbiased as possible and tried not to lead people in to 
saying how good homeopathic treatment is. In this interview I was trying very 
hard to not turn the session into one where we both praised homeopathic 
treatment, rather I was trying to explore what other things may have led to 
improvement in people and understand the way this homeopath talked to her 
patients. All homeopaths are different and I wanted to understand this 
homeopaths views.” Memo made after interviewing Cath, one of the 
homeopaths. 
To enable a deeper analysis of the data both the author and a supervisor 
read through three transcripts and discussed codes. The purpose was not to 
agree but to understand where disagreements lay and to understand 
multiple viewpoints. The idea being that this would facilitate a more through 
and deeper analysis of the data. Throughout the analysis phase the author 
and a supervisor met to share ideas and thoughts about the data. Data from 
the interviews regarding if and how the patients believed their IBS and 
general health had changed was compared with the patients’ questionnaire 
data from the RCT. Thus qualitative data and quantitative data were 
compared. This allowed similarities and differences between what the 
qualitative and quantitative results to be compared. Where there were 
differences, explanations as to why this should be so were sought from the 
data. An example of this is the case of Elizabeth who when interviewed said 
her IBS was significantly better but her IBS-SSS did not back this up. On 
further exploration of her interview, interviews with the therapist, and 
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questionnaire data, it was found that she had had a significant change in 
circumstances shortly after completing treatment and before completing the 
26 week questionnaire, which led to depression. Both therapists and patients 
were interviewed which allowed the therapists views on the treatment to be 
compared with the patients views, so that, areas of agreement and 
disagreement could be compared, allowing an overall interpretation to be 
developed that took into account the views of both the therapists and the 
patients.  
In terms of rigor in qualitative research, Mays and Pope (Mays and Pope 
1995) advocate showing how studies fit with other empirical work. Eyles  
Eyles et al. 2010) has carried out a study looking at homeopaths’ 
perceptions of the homeopathic consultation, described in Chapter 4. The 
views of participants in this study were compared with the views of 
homeopaths identified by Eyles to check if there were any areas of overlap. 
In this study the category “Self realisation” was about making links between 
the mind and body that lead to realisations about their IBS and themselves. 
One of the themes identified by Eyles (Eyles et al. 2010) in her study on 
homeopaths views of the homeopathic consultation was that of the 
consultation allowing the patients to form insights and connections between 
their symptoms. This connection was thus noted in both this study and Eyles 
study.  
Comparing this study to a study by Brien (Brien, Leydon and Lewith In 
press) on patient perceptions of the homeopathic consultation, it was noted 
that participants in both studies found self disclosure in the homeopathic 
consultation challenging. This theme was found in people from the IHT arm 
(Sam and Elizabeth) but not found in supportive listening arm. With the 
patients questioning why the homeopath needed all that information, they 
felt a bit uncomfortable revealing so much to a stranger, although ultimately 
they saw a benefit in the downloading.  
“I mean like I said at first I really didn’t probably appreciate talking about 
everything. But then afterwards I realised it's a help because of this because 
of that. At first I felt like not that I was being told off. But it was questioning 
why do you do that, why do you enjoy doing this. And like things like I love 
spending time with my family and my nephew and niece I love to be with. 
Cos we are very close and I've always been there. And done things with 
them. And I said like you know I try and see the every week or every other 
week. And well why. I thought because I like to. And I felt like at first does 
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that mean I'm not meant to like doing that. And it started making me question 
myself. Like but I think it's just she needs to understand what I do, what I 
don’t do. My emotions are with different scenarios. And then once I start 
pinning it together I appreciated it more. But again I didn’t realise that to 
begin with why is she was asking me all these questions. I didn’t understand 
that. So I think that put me off, that was what put me off.” Sam (IHT) 
“I think when you meet somebody for the first time and you start talking 
about you and in depth about you, your family that's a bit weird at first 
because you are talking to a complete stranger, who you have never known 
before. So er, and I suppose I probably am a little bit guarded. So you are a 
bit like what's all this about you know, I'm sort of thinking what’s all this about 
but hang on this is part of the treatment, then we need to, we need to go with 
it.” Elizabeth (IHT) 
Brien (Brien, Leydon and Lewith In press) in her interviews with people who 
had received IHT for rheumatoid arthritis also found that participants found 
self disclosure challenging. It is likely that this is due to something specific 
about the types of questions that are asked by homeopaths to elicit the 
information required to prescribe a remedy. In this study, although patients 
could have found self disclosure challenging because IBS can be 
embarrassing to talk about, Brien’s (Brien, Leydon and Lewith In press) 
study was about rheumatoid arthritis. It is unlikely therefore that the issue 
around self disclosure is solely related to the condition, but instead, is more 
generic to IHT.  
It is possible that there is a response bias in this sample. All the interviewees 
reported some benefit. It is unlikely that everyone in the study believed that 
they had benefitted from the treatment they received because some did not 
attend all five treatment sessions. When one of the participants in the 
supportive listening arm was telephoned for her IBS-SSS she said that whilst 
it was nice to talk to someone she didn’t feel it had benefitted. Therefore it is 
probable that those who did not experience any benefit did not consent to 
being interviewed. In the letters sent out to participants inviting them to take 
part in the interviews they were told that the researcher was interested in 
hearing from people who did and did not experience a benefit from taking 
part in the study. Everyone who attended at least two consultations was 
invited to interview therefore everyone who had received treatment was 
given a chance to take part what ever their experience. However the only 
patients that agreed to take part in this study were RCT participants who had 
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completed all their treatment sessions. It is likely that people who completed 
all their treatment sessions are more likely to have continued with the 
treatment because they perceived it to be benefitting them. Despite this the 
study was able to capture a range of views about what it was about the 
treatment that people had found helpful and why.  
This chapter described the results of the qualitative study, explaining each 
step of the analysis process and how the results of each step informed the 
analysis of the next step. The end result was the identification of four 
different typologies that explained what the patients viewed to have been 
helpful about the treatment they received. The next chapter discusses the 
results from the systematic review, quantitative and qualitative studies, 
exploring what the results of these studies mean in terms of the 
effectiveness of IHT for IBS, in relation to usual care and supportive 
listening.  
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11 Discussion 
This thesis had two aims: the first was to carry out a systematic review of the 
effectiveness of homeopathic treatment in the treatment of IBS, and the 
second was to carry out a trial exploring the effectiveness of IHT in the 
treatment of IBS. The trial of IHT for IBS had two components: an RCT to 
explore whether IHT is effective in treating IBS and a qualitative study 
exploring patients’ perspectives of what, if anything, led to any effectiveness 
of IHT for IBS. This chapter discusses the results of each of the three 
components of this PhD separately before examining the overall results. The 
chapter begins with a discussion of the systematic review and the 
challenges involved with carrying out a systematic review into homeopathic 
treatment, before reviewing the types of studies identified and their 
implications in terms of the evidence base of homeopathic treatment. 
Following on from the discussion on the systematic review, the methodology 
and results of the RCT are considered. The use of the cohort multiple RCT 
(cmRCT) methodology had a significant impact on this study and the 
reasons for this are explored and their implications examined. The results of 
the RCT and the outcome measures used are reviewed in light of these 
factors and conclusions drawn about the information the RCT provided. 
Following this, the qualitative study and its findings are debated, before 
moving on to a consideration of the overall outcomes from this study, taking 
into account the results of all three components. Finally, the strengths and 
limitations of the study along with areas for future work are discussed.  
11.1 Systematic review 
The systematic review aimed to assess the evidence of the effectiveness of 
homeopathic treatment for IBS and to determine whether or not there was a 
need to conduct a further study to explore the effects of homeopathic 
treatment for IBS. Therefore the studies identified, the searching process 
used to identify them, and the information they gave, is discussed in this 
section. The section begins with a discussion of the searching process.  
11.1.1 Searching process and studies identified 
No filters were used in the search process. Filters can be used to provide 
more efficient searches through only identifying a particular type of study 
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and filtering out all other studies. For example, a search that was only 
interested in RCTs could use a filter that would only identify RCTs. In this 
review no filters were used because it was anticipated that only a small 
number of studies would be identified. In fact only 57 studies were identified 
without the use of filters. Had filters been employed, fewer studies would 
have been identified and the issue as to whether or not the filters had been 
too restrictive would have been of concern. Considering the search terms 
used in this review, it is possible that the sensitivity of the search could have 
been improved by using terms of remedies in combination with IBS. 
However the use of such terms would be difficult as there is no one 
homeopathic remedy used in the treatment of IBS, rather any of the over     
1 000 homeopathic remedies in the materia medica can be used as a 
treatment for IBS, dependent on the patient’s individual symptoms.  
In terms of the types of studies identified by the systematic review, there 
were three RCTs of homeopathic treatment: one case series (Gray 1998) 
and three audits (Mathie and Robinson 2006; Greeson et al. 2008; 
Thompson et al. 2008). However the majority of the studies found in the 
searches were discussion pieces and case studies. It is unsurprising that 
case studies were identified, because case studies are commonly used to 
aid homeopathic prescribing through gaining insights into remedies and how 
they can be used. The symptoms in the repertory, the book used by 
homeopaths to match symptoms up to remedies, come from both proving 
symptoms (symptoms exhibited by a well person who has taken a 
homeopathic remedy for the purpose of eliciting the symptoms of that 
remedy), and cured cases. Therefore case studies provide a valuable means 
for homeopaths to further their knowledge. However the purpose of this work 
was not to further knowledge on IBS and homoeopathic treatment, it was to 
evaluate the quality of the evidence that exists for homeopathic treatment 
being more beneficial than alternative options for care and to potentially 
estimate the size of impact of homeopathic treatment on IBS symptoms. 
Discussion pieces focused on the symptoms of IBS, the types of remedies 
that may be appropriate and in some cases on new treatment regimens. 
One such study is a study by Gamble (Gamble 2008) that discussed the 
reasoning behind using a particular combination remedy in the treatment of 
IBS in Australia. 
No cohort studies were identified and only three RCTs were identified. There 
are a variety of reasons as to why only three RCTs were identified, one of 
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which could be that very few RCTs of homeopathic treatment for IBS are 
carried out. This is possibly in part due to financial constraints and difficulties 
in obtaining funding for homeopathic research, meaning that the research 
focuses on less costly studies. Furthermore it is the opinion of some 
homeopaths that homeopathic treatment is effective, and research should 
therefore be conducted into improving practice through gaining a greater 
understanding of remedies, rather than conducting expensive RCTs. 
Another reason why so few RCTs were identified could be that trials have 
been carried out and then have not been published; it can be more difficult 
for trials with negative results to be published as discussed in Chapter 3. It 
could also be the case that more trials had been published but not in places 
where they could be accessed, possibly because they were published in little 
known journals that are not indexed. Finally, trials could have been 
published in places where they should have been found, but in fact were not 
found. In this systematic review measures were taken to maximise the 
number of studies found as described in Chapter 3, however it is always 
possible that some RCTs were not identified. Despite the paucity of 
evidence for homeopathic treatment for IBS, there is a need for the 
effectiveness of safe non-pharmacological therapies to be evaluated in the 
treatment of IBS (Manheimer et al. 2012). Homeopathic treatment is one 
such treatment. This systematic review identified two RCTs (Rahlfs and 
Mossinger 1976; Rahlfs and Mossinger 1979) that compared homeopathic 
remedies with a placebo remedy in the treatment of IBS. A further RCT that 
compared homeopathic treatment as an alternative to usual care, to usual 
care (Owen 1990) was identified. This study was not eligible for inclusion 
due to the fact that it had not used a global IBS measure as an outcome, 
rather it asked participants to choose and then score their top four symptoms 
before and after treatment. The symptoms the participants chose were not 
reported in the trial and it appeared that the symptoms they chose did not 
have to be related to their IBS. Owen’s study failing to meet the inclusion 
criteria led to the exclusion of a third of the available evidence. Had the 
rationale behind Owen’s choice of outcome measure been convincing and 
had Owen’s study been of high quality, in terms of how the study had been 
conducted and reported, it may have been worth considering a retrospective 
protocol change in order to include Owen’s study. However there was no 
convincing argument as to why Owen had chosen the outcome measure that 
they had, and no information was given on the symptoms people had 
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chosen. This meant that the symptoms people chose could have had no 
relation to IBS, and therefore a retrospective protocol change was not made.  
Data from Rahlfs and Mössinger 1976 and Rahlfs and Mössinger 1979 were 
pooled to give a combined effect size. This showed a statistically significant 
improvement in global IBS symptoms for homeopathic remedies as 
compared to a placebo tablet; standardised mean difference 0.56, 95% 
confidence interval 0.23, 0.90. However, the applicability of these findings 
are hampered by the poor quality of the reporting of the studies. 
Consequently, it is impossible to determine whether or not a significant 
degree of bias exists. The exact details of the randomisation methods were 
not given in either Rahlfs and Mössinger 1976 (Rahlfs and Mossinger 1976) 
or Rahlfs and Mössinger 1979 (Rahlfs and Mossinger 1979). However 
Rahlfs and Mössinger 1979 (Rahlfs and Mossinger 1979) give a clear 
description of the blinding of participants along with clear details about how 
the medication was blinded and the steps taken to ensure that participants 
were not able to determine which arm of the study they were assigned to. 
This description gives some confidence in the manner in which this study 
was conducted. However it cannot be certain as to whether or not all 
aspects of this study were conducted with the same rigour. These studies 
were carried out before the introduction of the CONSORT guidelines (Schulz 
et al. 2010) which may account for why important information about the flow 
of participants through the trial is missing. In Rahlfs and Mössinger 1979 
(Rahlfs and Mossinger 1979) it is possible that there was some selection 
bias in terms of deciding to exclude some of the participants from the 
analysis for not adhering to the protocol, yet including others. The effect of 
selection bias is that of increasing the effect size and therefore it is possible 
that the effect size of Rahlfs and Mössinger 1979 (Rahlfs and Mossinger 
1979) was inflated.  
11.1.2 Implications for practice 
In both Rahlfs and Mössinger 1976 (Rahlfs and Mossinger 1976) and Rahlfs 
and Mössinger 1979 specified homeopathic remedies were used for the 
treatment of IBS, i.e. these were studies of clinical homeopathy rather than 
individualised or classical homeopathic treatment. Trials such as Rahlfs and 
Mössinger 1976 (Rahlfs and Mossinger 1976) and Rahlfs and Mössinger 
1979 (Rahlfs and Mossinger 1979) are designed to assess whether or not it 
is the homeopathic remedy that provides any effectiveness of treatment, 
rather than any other aspect of homeopathic treatment, such as the 
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consultation. In the meta-analysis of these two studies a statistically 
significant effect associated with the homeopathic remedies was found. 
However due to the low quality of reporting of these studies it cannot be 
certain as to whether or not these trials were of high quality or not. Therefore 
it is difficult to assess whether these results would be replicated in everyday 
practice. Thus it is recommended that Rahlfs and Mössinger’s trial (Rahlfs 
and Mossinger 1976; Rahlfs and Mossinger 1979) is repeated using current 
reporting guidelines (Schulz et al. 2010), to determine whether or not their 
findings are replicable. Whilst this study would be worth repeating for a 
European audience, where clinical homeopathy is more prevalent, it could 
be of less interest to a UK audience where specific remedies for specific 
conditions are less likely to be used. 
In the conclusion the results of the systematic review showed that there was 
a need for a trial, which was subsequently carried out. The results of this trial 
are discussed in the next section. 
11.2 Randomised controlled trial 
11.2.1 Recruitment to the Barnsley Irritable Bowel Syndrome 
Cohort and the RCT 
The study aimed to recruit 198 patients to the RCT, however during the 6 
months recruitment phase from January 2011 to June 2011, 115 eligible 
participants were recruited to Barnsley Irritable Bowel Syndrome Cohort 
(BIBSC), of these 94 were eligible participants for the RCT. Recruitment was 
via a questionnaire mailed out to potential participants identified through 
primary and secondary care. In primary care GP databases were searched 
for participants who had a diagnosis of IBS or were taking medication for 
IBS. In secondary care patient records were screened to identify potentially 
eligible participants. Full details of how participants were recruited are given 
in Chapter 7. A previous mail out study in Scandinavia achieved a 70% 
return rate (Hillila, Farkkila and Farkkila 2010), from this it had been 
anticipated that this study would achieve a 60% return rate (in terms of 
number of patients who returned the questionnaire), however the actual 
return rate for this study was between 18-30%, dependent on the GP 
surgery.  
There were a number of reasons for this lower than anticipated recruitment: 
the difficulty in obtaining agreement from the GP surgeries to carry out the 
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screening and mail out of questionnaires, the lower than anticipated 
response rate from those mailed and the differences in how patients were 
identified by the GP surgeries. Prior to the commencement of the study four 
GP practices had agreed to identify potential participants for this study. One 
of these GP surgeries carried out an initial screening of its patients to give 
an estimate of the number of IBS sufferers within its practice. Using this as a 
rough guide it was estimated that a sufficient number of IBS patients would 
be identified by the four GP surgeries who had agreed to take part and the 
consultant gastroenterologists in secondary care. However the number of 
patients who actually had IBS was found to be much lower than the initial 
inspection of the GP database would suggest. This was partly because 
some of the IBS patients identified were not currently suffering from IBS, and 
consequently were not eligible to take part in the BIBSC or RCT. In addition 
to this not all the GP practices coded patients in the same way. One practice 
in particular appeared to have given diagnosis of IBS for one off incidences 
of food poisoning and other similar causes of self-limiting diarrhoeal 
symptoms. This meant that although this particular practice sent out more 
questionnaires than any of the other practices, only three percent of those 
who returned questionnaires proved to be eligible for the RCT. Furthermore, 
although prior to the commencement of the study four GP practices had 
agreed to taking part, there was a delay in starting the study due to the 
difficulty in obtaining ethical approval (Chapter 8 outlines these). This meant 
that by the time the study was ready to start the situation at the GP surgeries 
had changed and not all of those originally identified were able to recruit 
patients. 
Other studies using the cmRCT methodology have also had a less than 
expected return rate and it has since been estimated that 15% of those 
invited to take part in the cohort will take up the offer  (Raw 2010). This may 
be because people are recruited via mailing from GP databases rather than 
during an appointment that involves a personal contact. It may also be due 
to the length of the questionnaire or confusion over the consent process 
(described in 11.2.3). The information on expected return rate, coupled with 
the recruitment rate achieved in this study, means that to recruit the required 
number of participants between 8 and 10 GP practices would need to carry 
out the GP database recruitment alongside the secondary care recruitment.  
When it became apparent that there was a possibility that this study would 
fail to meet its recruitment target, attempts were made to increase the 
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recruitment rate by contacting additional GPs and asking if they would be 
able to recruit from their databases. In addition further gastroenterologists 
were contacted and asked to search their lists; this led to an increase in the 
recruitment rate but meeting the target still proved to be a problem. 
11.2.2 Possible sources of bias in the recruitment process 
Whilst GP recruitment aimed to recruit a cross section of the public who 
suffer from IBS, it is to be questioned as to how representative the sample 
is. When using a recruitment method based on participants filling out and 
returning a questionnaire, participants will require a certain level of literacy to 
be able to complete the questionnaire. Making the questionnaire easy to 
read and understand, and as simple to complete as possible, will help with 
this (Edwards et al. 2009). However when using outcome measures that 
consist of a validated questionnaire, the questionnaire that most closely fits 
with the study and its aims may not be the one that is simplest to complete. 
Therefore, in the recruitment method used in this study there is a potential 
conflict when choosing an appropriate outcome questionnaire. Thus, when 
using questionnaire-based recruitment it is difficult, if not impossible, to 
prevent the fact that there will be some potentially eligible participants who 
are not able to complete the questionnaire. It is believed that a potential 
difficulty with the questionnaire used in this study was the fact that the 
outcome questionnaires that it was comprised of did not all follow the same 
format. I.e. the EQ-5D required participants to tick boxes, whilst the IBS-SSS 
required participants to mark their score on a line scale, whilst the 
information required for the cost analysis required participants to write 
numbers in boxes. Working this out could prove too time consuming for 
some potential participants and may have prevented them from completing 
the questionnaire. In addition, for this study the participants needed to be 
screened for IBS prior to being recruited to the BIBSC. Part of the cmRCT 
methodology involves the identification of potential participants from GP 
databases and their subsequent assessment for eligibility via a 
questionnaire to fill in and return (Relton et al. 2010). It is almost inevitable 
with this recruitment method that participants who respond will have a 
certain level of comprehension, which means that some members of the 
population will be excluded. The reading ease of the initial questionnaire was 
found to be 79.8%, when tested with the Flesch Reading Ease test, (the 
higher the percentage the easier the document is to read), this score 
indicates that the document was fairly easy to read (Flesch 1948). However, 
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as already discussed, the fact that the questionnaire comprised of various 
outcome questionnaires, each requiring different responses, could have led 
to confusion, resulting in difficulty in completing the questionnaire. 
Furthermore only people who visit their GP with IBS symptoms will have 
been identified as potentially eligible. It is possible that there are people 
within the population who suffer with IBS but have never visited their GP 
about their symptoms (Jones 2008). In addition, it is likely that there will 
people who are able to read and understand the questionnaire but are not 
interested in taking part in the study, or do not want the hassle of having to 
fill in a questionnaire. Trying to make the questionnaire as short and simple 
as possible reduces the burden on potential participants. In theory more 
people would complete a shorter simpler questionnaire than would complete 
a long complex questionnaire. In this study an association was found 
between failure to complete the 26 week questionnaire and being in 
employment. This meant that people who were employed were less likely to 
complete the 26 week questionnaire, compared to those who were not 
employed. In order to maximise the return rate of the 26 week questionnaire, 
systematic reviews of how to increase return rates of questionnaires were 
accessed (Edwards et al. 2002; Nakash et al. 2006) and where possible 
measures that had been found to be beneficial were taken, such as 
handwriting the participants name, using proper stamps and using a 
University of Leeds header on the questionnaires and accompanying letters.  
Although the recruitment method used in this study aimed to recruit a cross-
section of people with IBS in the community, it will, by its nature, have failed 
to include some sections of the population with IBS. This means that the 
people included will not be truly representative of the general population with 
IBS living in the Barnsley area. It was observed that fewer men returned the 
questionnaire than women, however, although the total number of 
questionnaires sent out is known, the GP surgeries were not able to give a 
breakdown by sex of the questionnaires they sent out. This means that it is 
unknown as to whether or not a greater percentage of women returned their 
questionnaires compared to men. However IBS is more prevalent in women 
than men (Smith et al. 2004), in Smith et al’s cross sectional observation 
survey 84% of the subjects were women. The greater prevalence of IBS in 
women may account for fewer of the returned questionnaires being from 
men. In the randomisation process no men were randomised to IHT, this 
was a chance occurrence that may have had an impact on the results. It is 
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possible that men would have had a different view of IHT and possibly have 
had different results to women. The lack of men in the IHT arm could 
therefore have introduced a bias into the study in terms of the results of the 
IHT arm, however the fact that there are fewer men in the study overall is 
considered to replicate the real world. It may have been beneficial to stratify 
randomisation by gender, which would have ensured that some men would 
have been randomised to IHT. This would be worth considering in any future 
studies. 
11.2.3 Administration of the BIBSC 
The cmRCT design is a new design, which means that necessarily there will 
be developments in the way in which it is implemented. The observations of 
this study may be important in future developments of the cmRCT design. In 
particular studying some of the difficulties associated with the administration 
of BIBSC may prove useful in refining the cmRCT design. In this study, the 
cmRCT methodology was complicated to manage. This was because there 
proved to be multiple levels of consent, which hadn’t been anticipated prior 
to commencement of the study. On the face of it the consent process was 
seemingly simple, with participants having the option to consent to one or all 
of three separate options: the data they supplied being used, to be contacted 
again and for the study team to look at their medical records. Yet in practice 
this consent process was complex to interpret. This complexity led to a 
considerable amount of time being needed to assess what participants had 
consented to, and what obligations had been made to the participants in 
terms of sending them future questionnaires. Additionally recruitment to the 
RCT was a two stage process: first participants were screened for eligibility 
to the BIBSC and then if eligible they were screened for eligibility to the 
RCT. One of the eligibility criteria for the BIBSC was to meet the Rome III 
criteria for IBS and one of the eligibility criteria for the RCT was to score over 
100 on the IBS-SSS. It was found that, although some people did not meet 
the Rome III criteria, they did score over 100 on the IBS-SSS. This highlights 
the discrepancy between different measures and the difficulty in making a 
diagnosis in conditions such as IBS, where its presence is not determined 
through a physical test (Talley and Spiller 2002). 
In this study there were six levels of consent and eligibility: 
Group 1: consented and eligible for both RCT and BIBSC 
Group 2: consented and eligible for BIBSC 
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Group 3: consented but not eligible for BIBSC or RCT 
Group 4: did not consent to be contacted again  
Group 5: did not consent to use of data or be contacted again, therefore 
nothing could be done. 
Group 6: did not consent to use of data but consented to be contacted again. 
People in group three, i.e. those who had consented, but were not eligible to 
take part in the BIBSC study, needed to continue to be sent questionnaires. 
This was because there was no mechanism by which participants were told 
whether or not they were eligible for the BIBSC study, thus everyone who 
had consented would be expecting to receive future questionnaires. 
However the purpose of collecting data on these people has to be 
questioned, especially with respect to whether or not this data will be used in 
any way. If the data is not used then the ethics of collecting data from these 
people has be explored. In the initial patient information sheet and invitation 
letter everyone was told that if they consented to take part in the study they 
would be sent questionnaires at various time frames. This meant that 
everyone who consented to take part in the study would be expecting further 
questionnaires, unless they were informed that they were not eligible to take 
part in the study, in which case they would not be sent any further 
questionnaires. However as it stands the cmRCT design continues to collect 
data from all those who return their questionnaire, regardless of whether or 
not they are eligible for the BIBSC study. Thus there is an ethical dilemma 
as to what to do with these people. Is it more ethical to carry on sending 
them questionnaires and not use the data, or is it more ethical to stop 
sending them questionnaires. Along with the question of ethics, there are 
cost implications associated with sending questionnaires out to people 
whose data cannot be included in the study. This is an important issue and 
one that needs to be considered both in terms of ethical and financial 
considerations. For the future it would be useful to carry out a study 
exploring how patients understand the consent process employed in this 
study, and from this, identify how it could be simplified.  
In addition to the ethical and financial issue of people in group three, there is 
the issue of those in group six. These people failed to consent to the use of 
the data that they had provided, however they did consent to be contacted 
again. The data from these participants could not be used, but like those in 
group three there was the obligation to continue to send these participants 
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questionnaires. The failure to consent to the use of the data was thought to 
be either due to an error on their part, or a lack of understanding of how the 
data would be used. This is because it seems contradictory to go to the 
trouble of filling out a questionnaire and then failing to allow its contents to 
be used.  
In summary there were six levels of eligibility and consent for this study, 
which made the BIBSC and the RCT complicated to administer and 
maintain. This means that using the cmRCT methodology in a small scale 
study with limited finances is not simple. It would have been less complex to 
use an already established cohort, assess for eligibility and then randomly 
select, rather than set up a cohort at the same time as conducting the study. 
This would become feasible if the cmRCT model became widely established 
and thus more cohorts available to recruit from. Alternatively, the complexity 
of the cmRCT design may not have been necessary; the more usual way of 
addressing simple questions such as that posed in this study is to follow a 
straightforward parallel randomised controlled trial design. In this case the 
GP could mail out the questionnaire; potential participants would be given a 
phone number to call if they were interested in taking part in the study. 
Those who called the number could then have been screened over the 
phone using the Rome III criteria, and if found to be eligible sent a shorter 
questionnaire to fill in. It is also possible that the cmRCT design could be 
modified so that the GP’s mail out the questionnaire and a pre-screening 
process is employed as described above. This would lead to people who are 
not eligible for the cohort being screened out in the initial stage, thus 
removing the problem of the obligation to continue sending questionnaires to 
people who are not eligible to take part in the cohort. Whilst this is feasible 
for a small scale study such as that conducted in this PhD, if a large scale 
cohort of thousands of people was desired, then people phoning for their 
eligibility to be assessed may not prove to be feasible.  
11.2.4 Uptake of offer of treatment 
Those randomly selected to be offered IHT or supportive listening were sent 
an invitation letter, participant information sheet and consent form to sign 
and return. Participants were telephoned a week after posting the letters to 
ensure that they had received the letter. All participants were telephoned 
unless they had already returned a signed consent form.  
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A difference was found between the uptake of treatment between the two 
arms, with fewer participants taking up the offer of supportive listening 
(50%), than those taking up the offer of IHT (75%). The reason for this is 
unclear, because it was a positive opt-in to treatment there was no 
mechanism by which reasons for failing to uptake the offer were routinely 
sought. Where possible, participants were asked for reasons, however due 
to the low numbers, diversity of replies and possibility of participants not 
wishing to divulge the reason for not taking up the offer, no overall theory as 
to why this difference occurred could be made. Furthermore because of the 
small numbers of participants in both groups, what appears to be a large 
difference in the uptake between the two groups may simply be due to 
chance. Despite this, it is possible that more people may have taken up the 
offer of IHT because it was easier to see how IHT may help, whereas for 
supportive listening it was less obvious to see how it would help. Paula, who 
took up the offer of supportive listening, was initially sceptical of how it may 
help.  
“I must admit that at first when I read it I thought whatever’s talking about it 
going to do, an how ridiculous, and I thought no, just try, just fill it in and try.” 
Paula (patient, supportive listening) 
If adhering to the cmRCT methodology in its strictest form, when participants 
are recruited to the cohort, no mention is made about any treatments that 
may be offered. Participants are purely recruited to join an observational 
cohort. Only those randomly selected to be offered a treatment are told 
about the treatment that they are being offered; they are not told about any 
other treatments that other participants may be receiving. However due to 
the research ethics committees concerns about this model, in the letter 
inviting people to take part in the BIBSC study, a brief mention was made 
about the fact that they may be offered a treatment. The treatments that may 
be offered were not described in great detail and participants would have 
had to have read the participant information sheet to realise that there was 
the possibility of receiving a treatment. The text included in the BIBSC 
participant information sheet was; 
“About 1 in 20 people who have chosen to participate in this study will be 
randomly selected to be offered a treatment. We currently want to test the 
effectiveness of the following two treatments: 
1. Homeopathic treatment 
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2. Supportive listening 
Inclusion in the study does not necessarily mean that you will be offered 
one of the above treatments. If you are randomly selected to be offered one 
of the treatments you will be sent a separate letter and an information sheet 
with further details describing the treatment offered.” 
It is possible then, that the participants did not return the study questionnaire 
expecting to be offered a treatment and were not treatment seekers, rather 
they had other reasons for returning the questionnaire, such as wanting to 
help others with IBS. This may have led to a lower uptake of the treatment 
options than would have been the case if people had enrolled in the study 
with the express desire to receive a treatment. However this does not 
explain why less people took up the offer of supportive listening than took up 
the offer of IHT.  
To reduce the problem of participants not taking up the offer of treatment, a 
question could have been included in the initial questionnaire that gave a list 
of treatments, and people asked to tick any treatment that they would be 
interested in receiving. One of the exclusion criteria for the RCT could then 
be - not being interested in homeopathic treatment and supportive listening. 
This would reduce the problem of people not being interested in the 
treatment they were offered. However people who stated that they were 
interested in homeopathic treatment and supportive listening may be 
systematically different from those who didn’t state that they were interested. 
This may reduce the generalisability of the results. In addition offering 
people a list of treatments to tick may lead to people being disappointed if 
they weren’t offered a treatment, leading to resentful demoralisation, one of 
the problems that the cmRCT was designed to avoid. 
The homeopaths and counsellors who provided the treatments found that 
even when people had returned their signed consent form, some people 
were not able to attend appointments. This was a particular problem for 
those who worked and were unable to get time off work to take part in the 
study. One of the homeopaths noted that in a previous study on homeopathy 
for fibromyalgia, a significant number of the participants were unable to 
work. This was due to being too ill, which resulted in these people being 
more able to attend appointments. It may also be that due to the nature of 
IBS; some participants may not have wanted to approach their employer for 
time off work. One participant from the supportive listening arm, who took 
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part in the qualitative interviews, described a situation when she had felt ill at 
work.  
“ Er you can’t keep nipping to the loo, with all these fellers and I don’t want to 
say anything, erm and I thought, and I did take something and I did, I did 
manage but if I’d started not to manage at work, I’d have told I was sick or 
something, I wouldn’t have told em that (I had IBS).” Paula (patient, 
supportive listening) 
This illustrates the reluctance some people have about telling their 
workplace that they have IBS. Therefore there were potential barriers to 
people accepting the offer of treatment. It is likely that these barriers were 
similar across both treatment groups and does not explain why the uptake 
should be lower in the supportive listening arm. It is possible that people 
thought that supportive listening would not help them and therefore were 
less keen to take up the offer, but this is not certain.  
The expectation of benefit and credibility of the treatments to participants 
was assessed using a scale developed by Borkovec and Nau (Borkovec and 
Nau 1972) and modified for IBS, by Drossman (Drossman et al. 2003). It 
was intended that all participants in the supportive listening and IHT arms 
would be given this questionnaire at their second appointment. However this 
measure was not consistently applied across the two treatment groups. All 
twelve people who received IHT returned the credibility questionnaire, yet 
only five of the nine people who received supportive listening returned their 
questionnaire. This discrepancy may in part be due to the different attitudes 
of the therapists providing the treatments. The counsellors who provided the 
supportive listening expressed concerns about the credibility of the 
questionnaire, in that they did not agree with the content of the questions. In 
particular they did not like the use of the word logical in the question, “How 
logical does this type of treatment seem to you for helping functional bowel 
symptoms?” It could therefore be that not all participants in the supportive 
listening arm were given the form by the counsellors, or the counsellors 
portrayed the form in a negative light when giving it to the participants, 
(possibly reducing the desire of the participants to fill out the form), or the 
participants did not return the form for another reason.  
Furthermore it could have been that the counsellors were unable to disguise 
their strong feelings about the content of this questionnaire, and this in some 
way affected the participants desire to complete the questionnaire. One of 
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the counsellors reported that the participants did not understand the 
questions; however this is surprising as none of the people in the IHT arm 
appeared to have had any difficulties with the questions. To prevent the 
possibility of therapists having an undue influence over the return of the 
expectation of benefit questionnaire it would have been prudent to have 
posted the questionnaires out to the participants, rather than relying on the 
therapists to give them out.  
The rationale for giving out the questionnaires at the second appointment 
was to assess how credible the participants found the treatment they were 
receiving once they had had some experience of the treatment. However it 
may also have been useful to post a copy of the expectation of benefit 
questionnaire with the offer of treatment letter. If participants then returned 
the expectation of treatment questionnaire regardless of whether they took 
up the offer, information may have been gained as to why less people took 
up the offer of supportive listening than took up the offer of IHT. It is of 
course possible that those not interested in taking up the offer of treatment 
would not have returned the form anyway but without trying it this is 
unknown.  
11.2.5 Attendance at appointments 
All twelve people (100%) who took up the offer of IHT attended all five 
appointments whilst five of the nine people (55.6%) who took up the offer of 
supportive listening attended all five appointments. The reasons for this 
difference are unknown. Furthermore, due to the small numbers in both 
arms of this study, all conclusions about the apparent differences in 
response rate and attendance rate are tentative. It could be that those in the 
IHT arm felt a benefit from the treatment and therefore continued with it, 
whilst some of those in the listening arm decided not to carry on with 
treatment because they did not feel a benefit. It could also have been that 
those in the supportive listening arm did not like the treatment, but this is not 
clear. Fewer people randomised to the supportive listening arm returned 
their 26 week questionnaires (12 out of 18) compared to those randomised 
to IHT (15 out of 16), which suggests that there was something different 
about the IHT arm compared to the supportive listening arm, although the 
exact nature of this difference is not certain. This differential return rate is 
discussed in further detail in Section 11.2.8. One thing that could have 
affected this is the therapists themselves. Their potential impact is discussed 
in the next section. 
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11.2.6 Impact of who delivered the treatment 
Due to concerns expressed by the research ethics committee, trained 
counsellors delivered the supportive listening rather than someone trained in 
basic listening skills. In this study, prior to applying for ethical approval, 
attempts had been made to identify nurses working at Barnsley Hospital who 
had been trained in basic listening skills, and who may have been able to 
deliver the supportive listening. Due to the fact that no suitable practitioners 
were found, it was felt that the best option was to have trained counsellors 
delivering the supportive listening, as the research ethics committee 
advised. This could have led to the provision of an enhanced supportive 
listening because the counsellors are likely to have a greater knowledge of 
counselling skills than someone trained in basic listening skills. To address 
this the counsellors were specifically asked to provide supportive listening 
rather than counselling, however it is possible that the counsellors provided 
a form of counselling rather than supportive listening. As a check, it had 
been intended that a researcher at University of Leeds would assess a 
random selection of listening sessions, as described in Chapter 6. However 
it was not possible to identify an appropriate researcher within the time 
scales of this study. This check would have allowed an assessment to be 
made as to whether or not supportive listening or a more advanced form of 
counselling was being delivered. 
Another potential issue was the fact that the homeopaths were providing 
“their” treatment as they would deliver it in everyday practice. Yet the 
counsellors providing supportive listening were not providing “their” 
treatment as they would deliver it in everyday practice, both being person 
centred counsellors who would normally use a variety of techniques in their 
normal practice. It could therefore have been the case that the counsellors 
providing the supportive listening may not have had the same level of affinity 
with supportive listening as the homeopaths had with IHT. This could have 
led to an unconscious belief in the counsellors that supportive listening 
would not help the participants, which could in some way have been 
conveyed to the participants. This is merely supposition, however it is a 
possibility that is worth considering. Furthermore the homeopaths had been 
involved in the project from its inception and the idea of assessing IHT for 
IBS had, in part, been their idea. Therefore there was the potential for the 
homeopaths to have a greater affinity with the study than the counsellors, 
who were recruited to the trial once ethical approval had been received from 
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the research ethics committee. A greater affinity with the trial may have led 
to greater enthusiasm for the trial, which could in some way been conveyed 
to the participants, thus providing them with added impetus for remaining in 
the trial and returning questionnaires, which may in part explain the 
differential return rate.  
None of this can be certain; however what can be concluded is that IHT was 
more acceptable to patients in this trial that supportive listening was. The 
reasons for this are unclear but could be related to some of the points 
discussed above such as: the credibility of the treatment, or the enthusiasm 
of the therapist providing the treatment. However the possibility that this was 
merely due to chance cannot be ignored. 
11.2.7 Impact of recruitment on results 
As already stated the recruitment was lower than anticipated. To put the 
lower recruitment into context, the power of the t-test between usual care 
and IHT was calculated retrospectively to determine what the actual power 
of the study was for this comparison. As with the power calculations carried 
out prior to the commencement of the study, this was calculated in PS 
Power (Dupont and Plummer 2009). The calculation was based on 16 
people in the IHT arm and 60 in the usual care arm, with a standard 
deviation 85, alpha of 0.05 and difference of 50 points.  
PS Power gave the power as 0.539.Therefore the actual power to detect a 
difference between IHT and usual care for this study was 54%, lower than 
the 80% that was desired. This shows that the study was underpowered to 
detect a clinically relevant difference between IHT and usual care.  
A further calculation was carried out to determine the power of the study to 
detect a difference between IHT and supportive listening. This calculation 
was based on 16 participants in the IHT arm and 18 in the supportive 
listening arm, with a standard deviation of 85, alpha of 0.05 and a clinically 
relevant difference of 50 points.  
The power was calculated to be 0.374.Therefore the power was 37%. This is 
low. In retrospect using a 4:1:1 ratio of usual care: IHT: supportive listening 
and powering the study to detect a difference between usual care and IHT 
may not have been the optimum use of resources. Had the same number of 
people been recruited, but the recruitment spread evenly across four arms, 
then the power would have been 0.623, i.e. 62.3%. This was calculated 
based on 31 people in each of the three arms, a standard deviation of 85, 
257 
 
 
 
alpha of 0.05 and a clinically relevant difference of 50 points. This would 
have resulted in a higher power than was achieved in this study. However as 
there were not sufficient funds available to carry out a fully powered trial with 
equal numbers of participants in each arm, the study was not set up for 
equal numbers in each arm. It is to be debated as to whether or not using 
the unequal randomisation was the best thing to do. If the intention is to 
recruit a large cohort of people which is then used for multiple RCTs, as the 
cmRCT methodology intends, then the use of unequal randomisation is 
based on sound principles, in terms of cost and the best use of resources. 
However with this study there was no large cohort to randomise from and 
insufficient funding to recruit and maintain a large cohort of people with IBS. 
Therefore in retrospect for this particular study it may have been of more 
benefit to use a 1:1:1 ratio. However it should be borne in mind that 
whatever the ratio that had been used the trial would have under-recruited 
and therefore been underpowered. The issue with an underpowered trial is 
the fact that it may find no significant benefit of the experimental treatment 
over the control treatment when in reality there is a difference, i.e. a false 
negative. Whilst it has been said that underpowered trials are unethical 
because they cannot answer the question they set out to address (Halpern, 
Karlawish and Berlin 2002), it cannot be guaranteed that a trial will recruit 
the desired number of people. However it is important that steps are taken to 
minimise the chance of under recruitment. In this trial the recruitment rate 
was estimated prior to conducting the study and GPs approached in 
advance as discussed in 11.2.1. This led to an assessment being made as 
to whether it was feasible to recruit the required number of participants 
before carrying out the study. This was done to minimise the chances of the 
study being underpowered.  
Despite this study being underpowered, it is still able to make a contribution 
to the evidence base of homeopathic treatment for IBS. Rahlfs and 
Mössinger 1976 (Rahlfs and Mossinger 1976) and Rahlfs and Mössinger 
1979 (Rahlfs and Mossinger 1979) recruited 72 and 119 participants 
respectively; this study is a similar size, and makes a modest contribution to 
the body of evidence for homeopathic treatment in the treatment of IBS. This 
study also contributes to the knowledge of the use of the cmRCT design in 
practice, as discussed in Section 11.2.3.  
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11.2.8 Return rate of questionnaire 
Over all three arms, after one questionnaire and one reminder were sent out, 
the return rate for the 26 week questionnaire was 81.9 %. Given the low 
return rate for the initial questionnaire, this was a surprisingly high number. 
However a prospective cohort study assessing development of IBS (Spence 
and Moss-Morris 2007) experienced similar findings with a relatively low 
return rate of the initial questionnaire (52%) followed by a good response to 
a follow up questionnaire (94%). This leads to the belief that once people 
had decided to take part in a study such as the BIBSC study, they are 
committed to returning their questionnaires. Nonetheless there were 
differences between the arms in terms of return rate, 85% of those in usual 
care returned their 26 week questionnaire, 93.75% of those in IHT arm and 
61.11% in supportive listening arm. The low return rate in the supportive 
listening arm compared to the other two arms was particularly worrying, as 
this may have resulted in a bias in the results of the trial. This could have 
been either an overestimate of the effect of supportive listening, if only those 
that found the treatment effective returned their questionnaires, or an under 
estimation of the effectiveness of supportive listening, if those who didn’t 
return their questionnaires all felt better. Without knowing the reasons for 
non-return of the questionnaire this could not be known. Consequently to 
further increase the response rate, those who didn’t return their 
questionnaire were telephoned to ask if they would give their score for the 
IBS-SSS score over the phone. This action increased the return rate of IBS-
SS scores to 90.4%, broken down as follows: 90% in usual care arm, 100% 
in the IHT arm and 83.3% in supportive listening arm. Despite the 
differences in the return rate for IBS-SSS after phone calls, when the 
analysis of missing data was carried out as described in Chapter 9, 
allocation was not found to be a significant predictor as to whether IBS-SSS 
was missing. Whether or not allocation was a significant predictor of missing 
IBS-SSS prior to the telephone calls is not known because this was not 
tested in the missing data analysis. The reason for this was the desire not to 
over test the data as explained in Chapter 7, and in order to decide how to 
deal with the missing data it was more important to explore whether there 
were any predictors of missingness of IBS-SSS after the phone calls. 
Summing up all the facts about: recruitment rate, take up of offer of 
treatment, attendance of appointments and return rate of questionnaires, 
there appears to have been something different about IHT compared to 
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supportive listening, in terms of its acceptability to participants. Compared to 
IHT, a lower percentage of people took up the offer of supportive listening, a 
lower percentage of people attended all five treatment appointments and a 
lower percentage of people returned their 26 week questionnaire. Why this 
should be so remains unclear, as discussed in Section 11.2.4; it may have 
been related to the counsellors who provided the supportive listening being 
less enthusiastic and having less affinity for the trial, yet this does not 
explain the differential acceptance of offer of treatment as the counsellors 
had not had any contact with the participants at this point. Therefore 
although it can be concluded that IHT was more acceptable to participants, 
why this should be so is at this point unknown. It could be that as already 
discussed it was easier for participants to perceive how IHT may help them. 
It would be useful if any future trials of IHT compared to supportive listening 
are carried out, that they incorporate a means for routinely asking 
participants why they have not taken up the offer of treatment. However this 
may be ethically difficult as it has the potential to put the participants in an 
uncomfortable situation, in which they may not feel able or willing to tell the 
truth. 
To test the sensitivity of the results, the missing IBS-SSS data was inputted 
assuming best and worst case scenarios i.e. the maximum IBS-SSS was 
inputted for all the people for whom there was missing 26 week IBS-SSS 
(worst case) and the minimum IBS-SSS was inputted for all the people for 
whom there was missing 26 week IBS-SSS (best case). An ANCOVA was 
conducted for each of these scenarios. As was calculated in Chapter 9, the 
independent variable was allocation which had three levels; usual care, IHT 
and supportive listening. The dependent variable was change in IBS-SSS. 
The covariates were age, employment status and initial IBS-SSS. Assuming 
the worst case scenario led to the difference between the groups associated 
with allocation just being statistically significant, F (2,82) = 3.14 p= 0.049 η2 = 
0.71. Whereas when assuming a best case scenario, no statistically 
significant difference was found between the groups, F (2,82) = 0.089 p= 
0.915 η2 = 0.02. This indicates that whilst the results are sensitive to the 
worst case scenario, even in the worst case scenario the difference between 
the groups is only just significant. Therefore it can be concluded that the 
missing IBS-SSS data is unlikely to have made a significant change in the 
results.  
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11.3 What the results of the RCT mean 
11.3.1 IBS-SSS 
The primary outcome was the change in IBS-SSS between baseline and 26 
weeks. T-tests were carried out to compare IHT to usual care and IHT to 
supportive listening. An ANCOVA adjusting for age, employment status and 
initial IBS-SSS was also carried out. 
Although the change in IBS-SSS was greater for the IHT arm, the spread of 
data for change in IBS-SS was large; at least 300 points for all three arms. 
I.e. some people experienced an improvement of over 200 points while 
others worsened by over 100 points. This shows that people’s reactions in 
terms of change in their IBS symptoms were not homogenous, this lack of 
homogeneity in reactions was true across all arms. 
The results for the ANCOVA and the t-tests were not in agreement, with the 
ANCOVA test finding no differences according to allocation. i.e. there were 
no differences in the groups. However the results from the Student’s t-tests 
indicated that there was a statistically significant difference between IHT and 
usual care but not between homoeopathic treatment and supportive 
listening. This illustrates how it is possible for different tests to give different 
answers. Furthermore it also demonstrates the importance of stating upfront 
what the primary test method and comparison will be to prevent intentional 
or unintentional use of the result which best fits the investigators theory. In 
this study the primary comparison was the comparison of IHT with 
supportive listening using a Student’s T-test, in which no statistically 
significant differences were found. 
The results of the ANCOVA are contradictory to the views of Ernst and Lee 
(Ernst and Lee, 2008), that pragmatic trials of homeopathic treatment 
compared to usual care are bound to find a positive result. The results of this 
PhD study indicate that it is possible that pragmatic trials do not always find 
a positive result. However this study was underpowered and therefore it 
cannot be known whether or not this result would be replicated in a fully 
powered trial. 
In relation to the results of the RCT it must be borne in mind that the study 
was underpowered to detect a difference which means that the study is at 
risk of a type II error, where no difference is found when a difference really 
exists. The lack of power of the study may be why no difference was 
261 
 
 
 
detected between IHT and supportive listening, or it may be that there is 
genuinely no difference between the two treatments. It could also be that the 
intervention only works in a selected sub-group of people and not the rest of 
the population studied, i.e. there are responders and non-responders. If this 
was the case the effectiveness of the intervention in the responders would 
swamped by its lack of effectiveness in the non-responders, with the 
average effect not being applicable to either the responders or the non-
responders. Without carrying out a further fully powered RCT comparing IHT 
and supportive listening it cannot be known whether or not the failure to 
identify a statistically significant difference was due to the study being 
underpowered. It could also be the case that the counsellors delivered 
counselling rather than supportive listening and this led to a greater 
effectiveness of the supportive listening because it wasn’t actually supportive 
listening that was being delivered, as already discussed in Section 11.2.6. 
In exploring the IBS-SSS and what the scores say about the three 
treatments it is of interest to look at the results depicting the percentage of 
people in each arm who achieved a clinically relevant improvement or 
deterioration. In all three arms the percentage of people who deteriorated to 
a clinically relevant degree was similar with 18.3% of those in the usual care 
arm; 18.8% of those in the IHT arm and 16.7% of those in the supportive 
listening arm experiencing a clinically relevant deterioration. This indicates 
that having one of the treatments in this study appears not to have a 
protective effect in terms of preventing people from deteriorating to a 
clinically relevant degree. It therefore appears that neither IHT nor 
supportive listening provide a means of preventing some people from getting 
significantly worse. Whether this tells us more about the nature of IBS or 
more about the treatments on offer is unclear at this point.  
However in terms of the percentages of people who improved to a clinically 
significant level there appeared to be a difference between the groups; with 
62.5% of those in the IHT arm improving to a clinically significant level, 
38.9% of those in the supportive listening arm and 25% of those in the usual 
care arm. This data was compared but no formal statistical tests were 
carried out to prevent over testing of the data as explained in Chapter 7. The 
large difference between the IHT and supportive listening and usual care 
arms is of interest. It may be that because fewer people took up the offer of 
supportive listening and less people attended all five appointments, a lower 
percentage in the supportive listening arm achieved a clinically relevant 
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change. Or it could be that because people weren’t seeing an improvement 
they did not carry on attending the supportive listening appointments; this is 
not known. These results again highlight the importance of deciding in 
advance what are going to be the outcome measures and tests carried out.  
11.3.2 Hospital anxiety and depression scores (HADS) 
In terms of HADS the mean change indicated an improvement for all three 
arms, but this change was minimal in the IHT and supportive listening arms, 
where the mean change was -0.2 and -0.18 respectively. The change in 
HADS between baseline and 26 weeks was compared for usual care and 
IHT, and IHT and supportive listening using t-tests. The change in HADS 
between baseline and 26 weeks was also compared across all three arms 
using ANCOVA adjusted for age, employment status and initial IBS-SSS. No 
differences were found between any of the comparisons, t-tests or 
ANCOVA. There were a high number of people who were experiencing 
anxiety and/or depression in this study, this is to be expected, as a link 
between IBS and depression has already been reported (Ten Berg et al. 
2006). Contrary to expectation though was the finding that although the 
mean change in IBS-SSS in the IHT arm indicated a clinically relevant 
change in IBS-SSS, there was only a minimal improvement in HADS. Given 
the link between IBS and anxiety and depression it would be expected that 
an improvement in IBS-SSS would be accompanied by an improvement in 
HADS. However a study exploring the impact of physical activity on IBS also 
found that although physical activity led to an improvement in 
gastrointestinal symptoms it did not lead to an improvement in symptoms of 
anxiety and depression (Morlin et al. 2008). This suggests that the link 
between IBS and anxiety and depression is complex. It is hard to know 
whether anxiety and depression causes IBS, whether anxiety and 
depression is a manifestation of IBS, whether anxiety and depression in IBS 
patients results from their having IBS, or a mixture of two or more of the 
above. 
11.3.3 CARE measure 
In terms of empathy of practitioner, the median score (Inter quartile range) 
for IHT 50.0 (33.00-50.00) compared to 43.50 (41.50-48.50) for the 
supportive listening arm. However due to the low number of people who 
returned this form and the lower than anticipated recruitment rate it was not 
possible to explore any correlations between CARE scores and outcome, as 
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discussed in Chapter 9. It had been thought that use of the CARE measure 
would provide an insight into how people viewed the therapist they saw, 
along with the possibility of determining whether or not there was a 
correlation between outcome and how the practitioners were viewed. 
Although participants were asked in the qualitative interviews about the 
practitioners, not everybody who attended treatment was interviewed; 
furthermore it is considered that it would be easier for a participant to rate 
the therapist in a negative light in a questionnaire completed in their own 
home compared to in an interview with a researcher (Fisher 1993). 
11.3.4 EQ-5D 
In the EQ-5D domains, of the people that responded there were fewer 
people who had no problems at 26 weeks than had no problems at baseline. 
This is contrary to what would be expected. This was true for all domains in 
the usual care and supportive listening arms. However in the IHT arm in the 
domains of mobility and pain, a greater number of people said they had no 
problems at 26 weeks than said they had no problems at baseline. In the 
IHT arm, in the domain of self-care, the number of people who experienced 
no problems was the same at 26 weeks as it was at baseline. 
It would have been expected that had people’s overall health improved, 
there would be a greater number of people reporting no problems after 26 
weeks, compared to baseline. As IHT aims to treat the “whole person” it 
would be expected that if the treatment was effective it would not just lead to 
a benefit in terms of IBS symptoms but also a benefit in terms of any other 
health complaints and an improvement in overall wellbeing. The fact that it is 
only in the IHT arm that even the same number of people are reporting no 
problems at 26 weeks indicates that it is possible that IHT may have in some 
way improved other areas aside from IBS. Despite this the HADS for those 
in the IHT arm did not indicate a particular benefit of IHT in terms of 
reduction of anxiety and depression.  
The fact that fewer people in the usual care and supportive listening arms 
were experiencing no problems in all domains at 26 weeks compared to 
baseline could in part be due to the amount of missing data. However even if 
everyone with missing data had reported no problems, this still would not 
have led to a greater or even the same number of people reporting no 
problems at 26 weeks, compared to baseline, across all domains. Therefore 
it remains unclear as to why fewer people should be reporting no problems 
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at 26 weeks compared to baseline, especially in light of the EQ-5D VAS 
results. 
In terms of the EQ-5D VAS in all arms, the mean score had increased, with 
those in the IHT arm having increased the most. An increase in score 
indicates an improvement in overall health state. This is in contrast to the 
domains, where in the supportive listening arm it appeared on average that 
people were the same or had worsened. The results of the EQ-5D therefore 
are supplying a contradictory message.  
11.3.5 Conclusions from the randomised controlled trial 
The mean change in IBS-SSS indicated an improvement across all arms of 
the trial whether participants received a treatment or not. Those in the IHT 
experienced the greatest mean improvement, then those in the supportive 
listening arm, then those in the usual care arm. It could be that some of 
these improvements can be explained by regression to the mean, whereby 
participants who completed the baseline questionnaire did so at a time when 
their IBS symptoms were at their worst and thus IBS was on their minds, 
leading to them deciding to take part in the study. Such people are likely to 
improve anyway due to the cyclical nature of IBS, whereas those who didn’t 
complete the questionnaire may have decided not to complete it because 
they didn’t have any IBS symptoms at that time. There could also be some 
improvement due to the Hawthorn effect where people improve simply 
through the action of being involved in a trial. Mike, in the supportive 
listening arm, was proud to be involved in a trial where his experiences could 
be of benefit to other people. 
“And also what’s always given me a bit of pride in what I’m doing is helping 
other people. You know what I mean and that’s summat important to me, I 
aint selfish I’ve never been a selfish person…You know what I mean and 
she (the counsellor) says thank you for doing this and I’m no anytime cos if it 
doesn’t help me it might help somebody else and that’s how I’ve thought of it 
all the way along.” Mike (patient, supportive listening) 
The treatment may or may not have had an effect. Yet it is possible that 
feeling proud of doing something that could help others may have been 
beneficial and have led to an improvement in symptoms.  
Although no significant differences were found apart from in a t-test between 
usual care and IHT, this may be because the study was underpowered i.e. 
due to a type II error where IHT was more effective than supportive listening, 
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but the study failed to detect that. It could also be that the intervention only 
works in a selected sub-group of people and not the rest of the population 
studied, hence the effect is diluted. 
What can be concluded from these results however is that IHT is more 
acceptable to the population studied than supportive listening. This 
conclusion has been drawn from the fact that a greater percentage of people 
took up the offer of IHT and a greater number attended all five appointments. 
It is possible that if a different population was studied then a different result 
may be found. Possibly in a population that had more of an affinity with 
counselling. 
11.4 The inclusion of the results from this PhD study in the 
systematic review 
This PhD study met the eligibility criteria for inclusion into the systematic 
review as described in Chapter 3. Therefore the results from the systematic 
review were reanalysed with the addition of the results from this study. 
Comparing this study with Rahlfs and Mössinger 1976 (Rahlfs and 
Mossinger 1976) and Rahlfs and Mössinger 1979 (Rahlfs and Mossinger 
1979), all three studies assessed an outcome of global improvement in IBS, 
in IBS patients identified either through clinical practice or through using the 
ROME criteria. There may be a difference in the severity of patients’ IBS 
between Rahlfs and Mössinger’s studies and this study. This is because 
Ralhfs and Mössinger (Rahlfs and Mossinger 1976; Rahlfs and Mossinger 
1979) do not provide a baseline assessment of the severity of IBS, so it 
cannot be known to what degree the included patients were suffering. 
However unless there are significant differences between German patients 
with IBS and British patients with IBS it is likely that the participants in all 
three trials were fairly similar. In this PhD study IHT, supportive listening and 
usual care were compared, with IHT and supportive listening being provided 
as an adjunct to usual care. The homeopathic treatment was individualised 
homeopathic treatment rather than clinical homeopathy, whereas Rahlfs and 
Mössinger’s studies were assessing clinical homeopathy. The time frame of 
the studies was also different. The study length in Rahlfs and Mössinger’s 
studies was only 15 days. This is considered to be a relatively short amount 
of time in terms of homeopathic treatment, which can often take many 
months (Barry 2006). The time frame for this PhD study was 26 weeks which 
is considerably longer. Although it is tempting to combine studies in a meta-
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analysis, especially if it is likely that a significant result will be yielded, it is 
important not to combine studies when there is significant clinical 
heterogeneity, as was the case with these studies. This is because the 
results from a meta-analysis of the combined studies would not be 
meaningful due to the large degree of differences between the studies. E.g. 
they involved different types of homeopathy, were assessed at different time 
scales (2 weeks compared to 26 weeks) and were potentially comparing 
people with different levels of disease. Therefore the studies were not 
considered sufficiently similar for a meta-analysis to be carried out. However 
a comparison of the results has been made in a Forest plot. The forest plot 
is displayed in Figure 11-1. To prevent unit of analysis issues that could 
arise because this study is a three armed trial, the number of participants in 
the homeopathic treatment arm was divided in half as was the case for the 
placebo arm in Rahlfs and Mössinger 1976. This is because there are two 
comparisons involving the homeopathic treatment arm, one comparing 
homeopathic treatment to usual care and the other comparing homeopathic 
treatment to supportive listening. In Figure 11-1, Peckham et al 2012a is the 
comparison of IHT to supportive listening and Peckham et al 2012b is the 
comparison of IHT with usual care. 
The standardised mean was calculated because although all three studies 
used the same outcome, different scales were used in each of the studies. It 
can be seen that of the three studies only Rahlfs 1979 showed a statistically 
significant effect of homeopathic treatment. 
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Figure 11-1: Forest plot of three studies 
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From the Forest plot it can be seen that the current evidence is inconclusive 
as to whether or not homeopathic treatment may provide a benefit in IBS. 
When the standardised mean difference (between IHT and usual care) is 
calculated for the RCT reported in this thesis, no difference is found between 
IHT and usual care; this is in contrast to the results from the t-test comparing 
IHT and usual care, yet agrees with the results found in the ANCOVA. This 
illustrates how different statistical tests can give different results for the same 
data.  
In light of the findings of this systematic review, it is recommended that 
further studies are carried out to assess the effectiveness of homeopathy, 
both of IHT and clinical homeopathy. The choice of control for clinical 
homeopathy is less challenging than for IHT. In the case of clinical 
homeopathy when a pre-specified remedy, thought to have an affinity with 
the condition under investigation is to be assessed, a placebo medication 
provides an appropriate choice of control. However the situation differs for 
the evaluation of IHT, where the decision as to what is an appropriate control 
is challenging because of the interconnected nature of the homeopathic 
remedy and the homeopathic consultation, meaning that it is difficult to 
separate the two as discussed in Chapter 4. Furthermore the traditional 
parallel group RCT, where one arm gets a homeopathic consultation plus 
homeopathic remedy and the other gets a homeopathic consultation plus a 
placebo remedy, fails to take into account any effectiveness specific to the 
homeopathic consultation such as the remedy matching process. 
11.5 Qualitative study 
This section will focus on the qualitative study, beginning with a discussion 
on recruitment to the qualitative study, before discussing the different 
typologies and the participants’ views on the homeopathic remedy. Finally 
the views of the homeopaths and counsellor are used to explore how 
different therapists could have had different impacts on outcomes. This is 
the first study that explores patients’ perceptions of IHT for IBS and 
compares them with patients’ perceptions of supportive listening for IBS.  
11.5.1 Impact of recruitment on the results 
Due to under recruitment in the RCT it was not possible to use a sampling 
frame to purposively select participants for the qualitative study, as there 
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were insufficient numbers. Therefore everyone who had received at least 
two treatment sessions was invited to attend an interview.  
Of those participants who met the eligibility criteria for the interviews, 41.7% 
of those eligible from the IHT arm and 33% of those eligible from the 
supportive listening arm consented to be interviewed. This led to five people 
from the IHT arm and two people from the supportive listening arm being 
interviewed. Three people from the supportive listening arm had consented 
to be interviewed, however one of these people was subsequently too ill to 
be interviewed. From the analysis of those interviewed it was possible to 
identify four different typologies within those interviewed. However due to the 
relatively low numbers of people interviewed, especially in the supportive 
listening arm, it may be that these are not an exhaustive list and had more 
people been interviewed additional typologies would have been identified. 
The lack of people interviewed from the supportive listening arm highlights a 
potential problem for qualitative studies nested within RCTs, in that if the 
RCT under recruits there is a potential for insufficient eligible participants for 
the qualitative study. Therefore when carrying out a nested qualitative study 
it would be useful to estimate the minimum number of participants required 
in the quantitative study to give an adequate number of participants in the 
qualitative study. 
11.5.2 Patients perceptions of treatment 
Overall participants in this study had not used IHT in the past. Only Sheila 
said that she had previously used a homeopathic remedy, which she had 
bought over the counter. Thus the participants had little prior knowledge of 
homeopathy. Apart from Paula (supportive listening, typology two) all 
participants experienced a benefit that they attributed to the treatment they 
had received. Paula experienced a benefit but she did not feel she could 
directly attribute it to the treatment she had received. She could see how the 
treatment could have helped, but she was reluctant to say that it had 
definitely helped, as it could have been due to something else. Despite this 
all participants, including Paula, saw some value in the treatment they 
received and all participants said that if they were offered the treatment in 
the future they would take up the offer. This included those who had 
worsened in terms of their IBS-SSS. 
The findings from this study build on previous qualitative research into the 
homeopathic consultation. By providing information on participants’ 
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perceptions of the whole intervention of IHT, this study presents a broader 
view of what it is about IHT that patients believe to be of benefit, or not. The 
homeopathic consultation has in the past been compared to counselling and 
psychotherapeutic consultations (Chanda and Furnham 2008). Whilst 
previous studies have identified ways in which the homeopathic consultation 
differs from counselling and psychotherapeutic consultations (Eyles et al. 
2010), this is the first study that has directly compared IHT with a counselling 
type consultation. A difference identified by Eyles was the in-depth enquiry 
into bodily complaints experienced in the homeopathic consultation. Whilst 
this is undoubtedly an essential element in IHT (Thompson 2006), none of 
the patients interviewed in this study spoke of this aspect of the consultation. 
This may have been because the questions were designed to elicit 
information on what the patient perceived to have been of benefit and 
patients did not have a specific viewpoint on the in-depth enquiry into bodily 
complaints. A difference identified in this PhD study between the 
homeopathic consultation and supportive listening was the depth to which 
some of those in the IHT arm explored the mind-body connection. Whilst 
those in the supportive listening arm were aware of this connection, they did 
not take it a step further by trying to understand what it was about them and 
their personalities that led to them getting ill. This is described in more detail 
in Chapter 10 where the experiences of Sam and Elizabeth (who received 
IHT) are compared with Mike’s (who received supportive listening). Thus, it 
appears that in some way the homeopathic consultation facilitates the ability 
for self-exploration through development of the concept of a mind-body 
connection. These concepts have previously been identified as important to 
the homeopathic consultation (Thompson and Weiss 2006; Eyles et al. 
2010; Brien, Leydon and Lewith In press) but as yet no connection has been 
made between the two.  
11.5.3 Participants views on the homeopathic remedy 
Through interviewing the participants an insight was gained into what they 
thought about the homeopathic remedy and whether they believed that the 
homeopathic remedy would help them. However, whether or not the 
homeopathic remedy itself led to any physical effects cannot be discerned in 
this study, and nor was the study designed to assess such results. However 
the study was designed to explore participants’ beliefs about the 
homeopathic remedy and the role participants believed it played in any 
improvements observed.  
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In terms of what people thought about the homeopathic remedy, no one who 
received IHT thought that the remedy had had no effect. They believed 
either: that it was the remedy and the consultation that led to a benefit, or 
that it was the remedy alone. This provides an insight into what people in 
this study believe about IHT, and the faith people had in the remedy. It may 
be that had a larger sample been available there would have been some 
people who believed that the remedy did nothing, and that any improvement 
was due to the consultation alone. It may also be that some of those who did 
not consent to being interviewed believed that the remedy did nothing. 
However the results from this study indicate that people believed that the 
remedy helped them because they perceived it to have produced changes in 
their symptoms. Possible mechanisms by which this could have occurred 
are unknown. However if Moerman (Moerman 2006) is correct in his belief 
that it is the meanings people hold that lead to improvements, then it is likely 
that the remedy will lead to an improvement regardless of whether there is 
anything intrinsically active about the remedy in the way that antibiotics are 
active. This leads to interesting questions about the potential use of a 
placebo tablet in the supportive listening arm and the fact that the research 
ethics committee’s views on placebo and how it should be described 
prevented its use. It also highlights the importance of further research into 
the mechanisms by which placebos may act. 
11.5.4 Importance of who delivered the treatment 
Interviews with the therapists gave some insights into both supportive 
listening and IHT, one of which was the importance of who it was that 
delivered the treatment and the differences between different people 
delivering treatment. It has been suggested in psychotherapy that therapist 
variability far outweighs specific factors of a treatment in terms of treatment 
effects (Messer and Wampold 2002). In this study Angela, one of the 
counsellors who provided the supportive listening, thought that having a 
trained counsellor delivering supportive listening was very different to having 
a research assistant trained in basic counselling skills delivering supportive 
listening. This was because Angela believed that being a counsellor affects 
the whole way a person conducts themselves in respect to patients.  
“A research assistant, I don’t know I'm making an assumption here so I 
might be wrong, will not have a clear code of ethics. They may be gifted one 
that they have got to work in but they won’t have the code of ethics which 
they have to embrace and actually live by.” Angela (counsellor) 
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She thought that this code of ethics would create a different understanding 
between counsellors providing supportive listening and a research assistant 
providing supportive listening, because being a counsellor affects the entire 
way she interacts with patients. Whether or not there is genuinely a 
difference between a research assistant and a counsellor delivering 
supportive listening is not known. However the counsellor believed that the 
understanding between her and the patient led to there being no barriers 
between her and the patient. This was because the patient knew that they 
would have absolute confidentiality and that their safety was paramount to 
her. Mike’s experience of his initial meeting with the counsellor demonstrates 
this lack of barriers.  
“It felt like as soon as I met her and sat down took coats off started talking it 
were, I felt erm safe with her if you know what I mean. I felt confidence with 
her I felt like I could talk, straight away like I say there were no hurdles no 
hurdles to start with no physical barriers or ought like that straight away it 
were good.” Mike (patient, supportive listening) 
This in part explains why the counsellors had a problem with the wording of 
the credibility questionnaire because they felt the wording of one of the 
questions would be detrimental to the patients. Angela felt that being a 
counsellor was a whole way of being and that counsellors had a set of 
guidelines by which they lived. To provide the best possible care for the 
patients whilst adhering to the trials protocol, Angela said that she had 
stretched the bounds of supportive listening as far as she could. This meant 
that the supportive listening in this trial was a “boosted up” version of 
supportive listening and would have been different to a trial where a 
research assistant with limited training in counselling skills had provide the 
supportive listening. Thus the interview with the counsellor gave an insight in 
to the fact that the person delivering the listening can have a significant 
impact on the treatment. This admission by the counsellor was an interesting 
admission about the fidelity of the supportive listening intervention. If in fact 
the counsellors had provided counselling rather than supportive listening, 
then they could have potentially increased the effect size of supportive 
listening, resulting in an attenuation of the difference in the effect size 
between the homoeopathic treatment group in the supportive listening 
group. This could potentially be a reason why no difference was found 
between the IHT arm and the supportive listening arm. 
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The importance of who it is that delivers the treatment was also noted in the 
IHT arm. On interviewing the homeopaths it became apparent that they used 
very different styles of practice. One of them would give just one remedy to 
the patients, whereas the other would give a constitutional remedy to help 
with their IBS and overall health, and an acute remedy to take during flare 
ups of IBS. It is likely that these different approaches would impact on the 
patients differently and that for some people having something to take during 
an acute episode would be very reassuring. Going back to Moerman’s work 
on meaning (Moerman 2002), it is likely that being given something to take 
during an acute episode would have meaning for some patients and it is 
possible that that meaning would translate into a benefit, regardless of 
whether the remedy had any physical effects on the body.  
Including interviews with the practitioners allowed a greater understanding of 
the therapies as they were delivered, and provided a means of realising the 
differences between different people delivering the same therapy. In addition 
the interviews provided a greater understanding of how homeopaths treat 
people suffering with IBS in the UK. Although homeopaths have presented 
case studies (Chimthanawala 2004) and written discussion pieces (Gamble 
2008) on how they treat IBS, this is the first study that has explored how 
homeopaths treat IBS patients, not conducted by the homeopath delivering 
the treatment.  
11.5.5 Limitations of the qualitative study 
It is possible that this study may not have identified the full range of 
typologies that exist within the population studied. This is down to two 
factors: the relatively low numbers of people interviewed, and the fact that 
the people who agreed to be interviewed may not encompass the full range 
of possible views. Everyone who agreed to be interviewed perceived, that in 
some way, the treatment had been helpful and it is unlikely that this 
constituted the full range of viewpoints. However the four typologies 
identified allow a broad understanding of how participants perceived the 
treatment they received.  
It is also possible that the methods used to reveal the themes and concerns 
of the participants in this study may not have captured all the themes and 
concerns. It is possible when conducting research that a different researcher 
may come to different conclusions. In this study methods were employed to 
reduce the chance of this occurring, and to ensure that the study was 
274 
 
 
 
conducted in a rigorous manner. These involved sharing transcripts and 
codes with a supervisor and discussing themes, patient journeys and 
typologies with supervisors. Full details of these are given in Chapter 10. 
The purpose of these were, as far as possible, to ensure that a different 
researcher was likely to come to similar not contradictory conclusions. 
11.6 Synthesising the qualitative and quantitative results  
11.6.1 The advantages of comparing the qualitative and 
quantitative results 
To fully explore the results of this study, the results of the RCT and the 
qualitative study were compared. In order to facilitate a greater 
understanding, it is important when comparing qualitative and quantitative 
results to explore areas where there is contradiction between the results 
(O'Cathain, Murphy and Nicholl 2010). In this PhD study when comparing 
the qualitative and quantitative results it was noticed that for one person 
(Elizabeth) there was a discrepancy between what she said in the interview 
and what she reported in the questionnaire. When interviewed Elizabeth said 
she had had a significant benefit from treatment, however her questionnaire 
results did not reflect this. On further exploration it was discovered that the 
failure to see an improvement in the questionnaire data could be linked to a 
significant event that caused her to become depressed, consequently when 
she filled out the questionnaire she was depressed and reported how she 
was feeling at that point in time. In the qualitative interview she discusses 
how the treatment she received led to an improvement in her health. This 
case illustrates how linking the qualitative and quantitative data can give a 
deeper insight into the individual patient. In the case of Elizabeth if only the 
quantitative data had been studied the conclusion would have been that this 
person had not improved. Just looking at the qualitative data would have led 
to the conclusion that this person was significantly helped. However by 
comparing the two together and exploring the observed discrepancy a 
deeper understanding of not only Elizabeth’s journey but also the nature of 
IBS and triggers leading to a deterioration of symptoms could be discovered. 
This also highlights the fact that questionnaires are completed at a point in 
time and therefore the answers are affected by how that person feels at that 
point, which may not necessarily reflect how any treatment they received 
has impacted on them. The process of randomisation means that 
275 
 
 
 
theoretically this effect should be evenly distributed throughout all arms of 
the trial.  
Furthermore Elizabeth’s experience demonstrates the effect a significant 
event can have on IBS and the interaction between stress and IBS. Although 
this interaction may have been reported by patients, it would not have been 
observed as clearly had solely a qualitative or solely a quantitative study 
been carried out.  
11.6.2 Different views of treatment 
Through comparing the results of the qualitative and quantitative studies, it 
can be seen that IHT was viewed differently to supportive listening. The 
typologies that people were in, in the two arms were different. Those in the 
IHT arm were in either, typology three: it was the remedy, or typology four: it 
was the remedy and the consultation, whilst those in supportive listening 
were in either, typology one: listening helps, or typology two: something’s 
worked but I don’t know what. It should be borne in mind, however, that a 
small number of people were interviewed and the results may be slightly 
different had more people been interviewed. However the results from the 
RCT indicated that people found IHT more acceptable as already explained, 
therefore combining these two findings indicates that IHT is indeed viewed 
differently to supportive listening. In part it is believed to be the remedy 
accounts for some of these differences in views, people viewed the 
homeopathic remedy as an important part of the treatment, no one felt it had 
no action and even those who valued the consultation aspect of IHT 
believed the remedy to be important.  
The homeopathic remedy is not the only way in which IHT differs from 
supportive listening, the way the talking is conducted is different in IHT. As 
described in Chapter 10, Sam and Elizabeth found the homeopathic 
consultation challenging at first, and it wasn’t what they had been expecting. 
No one in the supportive listening arm mentioned this. It may be that those 
allocated to the supportive listening arm who didn’t want to talk about 
themselves declined the offer of supportive listening. Yet people who didn’t 
want to talk about themselves who were offered IHT, may not have been 
aware of what IHT involved, and therefore may not have turned down the 
offer. Therefore there may have been more people in the IHT arm that 
weren’t comfortable talking about themselves than were in the supportive 
listening arm. The supportive listening aimed to allow the patient to talk with 
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minimal guidance and questioning. Whereas in IHT to allow the prescription 
of an appropriate remedy a detailed understanding of the patient is required 
(Vithoulkas 1998), thus it is also likely that supportive listening was less 
challenging than IHT.  
In summary, the talking in the IHT arm was slightly different to the talking in 
the supportive listening arm. In the IHT arm the talking facilitated a greater 
understanding of what caused the patient’s IBS, rather than just letting out 
their concerns, as was the case in the supportive listening arm. However in 
order to really understand the differences in the styles of the consultations, 
tapes of both the IHT and supportive listening arms would have to be 
listening to and analysed. 
11.6.3 Supportive listening as an attention control for IHT 
One of the aims of this study was to design a suitable control for IHT, in 
terms of controlling for the non-specific effects of spending time with an 
empathetic practitioner. Supportive listening was chosen as the control 
treatment, however in light of the results the question as to whether or not 
supportive listening is an appropriate control for IHT needs to be explored.  
As explained in Chapter 5, the concept of structural equivalence is important 
when considering an attention control (Baskin et al. 2003). In this study 
supportive listening was able to provide structural equivalence in terms of 
time spent with a practitioner, however fewer people in the supportive 
listening arm attended all five sessions that in the IHT arm. If the fact that 
fewer people attended all the sessions was due to a lack of credibility in the 
supportive listening then this could lead to the conclusion that supportive 
listening is not a suitable control. Unfortunately due to issues with the return 
of the credibility questionnaire it is only possible to estimate whether or not 
supportive listening was credible based on the questionnaires that were 
returned. The issue with this is that those who didn’t return the questionnaire 
may not have done so because they didn’t believe supportive listening to be 
credible. Despite this, comparing the results indicates that IHT and 
supportive listening were similar in terms of credibility. It could therefore be 
that participants did not complete the five sessions, not because the 
treatment lacked credibility but because they were not gaining the benefits 
they desired from the treatment.  
In terms of the empathy of the practitioners, this was similar in both arms, 
indicating that supportive listening is similar to IHT in terms of consultational 
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empathy. This was important as it has been suggested that therapists can 
play more of a role in improvement than the specific effects of the therapy 
itself. (Messer and Wampold 2002). However the fact that fewer people took 
up the offer of supportive listening cannot be ignored. It may be that people 
had less faith in supportive listening than IHT, or that they did not want what 
they perceived to be some sort of cognitive behavioural therapy, or they 
simply didn't understand what supportive listening was. One person wrote in 
the free text box in their initial questionnaire that they were happy to try IHT 
but did not want cognitive behavioural therapy, it is possible that they were 
not the only person that felt this way. Apart from Sheila in the IHT arm, none 
of the other participants had any experience of homeopathy or knew much 
about it, however this did not appear to deter people from taking up the offer 
of IHT.  
Assessing the results of this study, further work needs to be carried out into 
exploring the appropriateness of supportive listening as a control for IHT. 
The appropriateness of supportive listening will in part be determined by the 
condition being studied. For some conditions supportive listening may not be 
perceived as very credible. In terms of IBS further work needs to be carried 
out to assess how credible supportive listening is as a control for IHT for 
IBS. This would require exploring IBS patients views of supportive listening. 
A possible means of doing this would be by providing IBS patients with 
information about supportive listening and then asking them questions about 
whether they thought it would help with their IBS and would it be a treatment 
they would be likely to accept if they were offered it.  
11.7 Strengths and limitations 
The strength of this study is that it assesses IHT as it is delivered in practice 
without seeking to reduce IHT into component parts. In IHT the remedy and 
the consultation are deeply connected (Milgrom and Chatfield 2011). 
Therefore trying to dissemble IHT into its constituent parts may not lead to a 
full picture as to whether or not IHT is effective in the condition to be studied. 
This study has therefore compared IHT to an attention control in an attempt 
to control for spending time with an empathetic practitioner. Including a 
qualitative element to the study has given an added depth to the data, 
therefore this study gives a fuller view of IHT and supportive listening for IBS 
than would have been the case had solely a RCT been conducted. 
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Furthermore the qualitative element allowed an exploration of how the 
treatment worked rather than solely whether it worked or not. 
One of the limitations of this study is that it was underpowered and it has not 
been able to determine whether or not IHT is better than supportive listening 
in terms of change in IBS-SSS. Despite this it has shown IHT to be more 
acceptable to IBS patients than supportive listening. The under-powering of 
the RCT led to fewer eligible participants for the qualitative study and 
because of this it may be that there were other viewpoints that were not 
represented by those who participated in the qualitative interviews. 
Furthermore the people who agreed to take part in the qualitative study may 
not be representative of the population who received IHT or supportive 
listening. This is because people that didn’t find a benefit with treatment may 
not have consented to be interviewed. Everybody who was interviewed 
found some benefit from the treatment, however it is unlikely that everyone 
who received a treatment benefited.  
11.8 Contribution to the knowledge 
The systematic review conducted in this thesis makes a modest contribution 
to the overall knowledge base on IHT for IBS, in that this is the first time the 
evidence for the effectiveness of IHT for IBS has been systematically 
reviewed. Although it was not possible to give a conclusive recommendation 
as to whether or not homeopathy is effective in the treatment of IBS, it was 
able to conclude that further trials were warranted.  
The RCT has made a contribution to the knowledge regarding the design of 
trials to explore the effectiveness of IHT. It has shown that whilst it is 
possible to use a design that compares IHT to an attention control treatment, 
care has to be taken to ensure that the attention control treatment is credible 
for the condition being treated.  
This study has made a significant contribution to the knowledge regarding 
what, if anything NHS patients receiving IHT perceive to have been helpful 
about their treatment. Although a prior study has explored patients views of 
what was helpful about the homeopathic consultation (Brien, Leydon and 
Lewith In press), this is the first study to explore patients’ views on the whole 
intervention of IHT rather than solely the consultation aspect. All patients 
who were interviewed as part of this PhD study perceived the homeopathic 
remedy to have been of benefit, whilst some patients perceived an additional 
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benefit from the consultation. This provides a greater understanding of the 
perception by patients’ of IHT. The study has also provided an insight into 
the fact that the way the talking is conducted and its effects are different in a 
homeopathic consultation to a supportive listening consultation.  
11.9 Implications for practice and policy 
The results from the systematic review indicate that IHT may be superior to 
placebo, however the results from the meta-analysis should be treated with 
caution due to the low quality of reporting in the trials included in the meta-
analysis. The low quality of reporting means that the risk of bias of these 
studies could not be adequately assessed, however it is believed to be likely 
that a selection bias may exist. This could have led to an increase in the 
treatment effect for IHT. In addition to this the studies by Ralhfs and 
Mössinger (Rahlfs and Mossinger 1976; Rahlfs and Mossinger 1979) were 
both assessing clinical homeopathy, whilst the trial in this PhD was 
assessing IHT. These two forms of homeopathic treatment are very different 
and it may be that one of these forms of homeopathic treatment is more 
effective than the other. Therefore concluding that IHT is effective based on 
the results of a meta-analysis of studies of clinical homeopathy may be 
misleading. 
The results from the RCT comparing IHT to usual care and IHT to supportive 
listening do not show a conclusive benefit of IHT, however the trial was 
underpowered therefore caution should be exerted when interpreting these 
results. This is because there is a chance of concluding there is no benefit 
when really there is a benefit. This means that whilst the results do not 
clearly provide evidence for the removal of homeopathy from the NHS they 
also do not mean that homeopathy should definitely be available on the NHS 
in the treatment of IBS. Furthermore the results from the qualitative study 
indicated that patients perceived a benefit from receiving IHT. Given the 
results of this RCT, if there was already a treatment available that clearly 
benefited IBS patients, then the continued exploration of IHT for IBS may be 
unwarranted. However as this is not the case it would be beneficial to further 
explore any potential benefits of IHT for IBS.  
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11.10 Future work  
It is recommended that in the future work is carried out to further assess the 
suitability of supportive listening as a control treatment for IHT. If supportive 
listening is found to be suitable, it would be useful to carry out a fully 
powered RCT comparing usual care, IHT and supportive listening, to further 
understand the differences between homeopathic treatment and spending 
time with an empathic practitioner. However unless there was an already 
established cohort from which participants could be recruited, it would be 
preferable to carry out a parallel RCT. This is due to the logistics and 
expense of the BIBSC as described in Section 11.2.3. 
 In terms of the cmRCT design, it would be of benefit to explore the consent 
process used in the cmRCT design, with respect to what people understood 
about what they were consenting to. It is believed that some people did not 
fully understand this process. This was because the number of people who 
filled out the questionnaire but failed to consent to the use of the data, yet 
consented to be contacted again, leads to the suspicion that some people 
were uncertain about what they were consenting to. Knowledge of what 
people did and didn’t understand about the consent process would allow for 
any adjustments to be made to the explanation of the consent process, and 
the consent process itself, that would minimise confusion.  
Furthermore in addition to repeating the RCT it would be useful also to 
conduct qualitative interviews with RCT participants, as was the case with 
this PhD study. Interviewing a greater number of people could lead to further 
insights into the four typologies already identified and the discovery of 
additional typologies. In addition it would be of value to determine whether 
anyone receiving IHT would fit into typology one: listening helps rather than 
solely the two typologies that believed the remedy to be of benefit i.e. 
typology three: it was the remedy or typology four: it was the remedy and the 
consultation.  
Furthermore, it would be of benefit to the practice of IHT and its potential 
provision, to explore the notion of responders and non-responders and 
determine whether there are in fact responders and non-responders to IHT, 
and if so what are the particular characteristics that lead to a person being a 
responder.  
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Appendices 
Appendix 1 
Searches for specific and non-specific effects of homeopathic 
treatment 
Search 1 – 14th June 2012 
A search was carried out in Web of Science using the terms: 
(“specific effect*” or “context effect*” ) and homeopath* (28) 
OR 
“non specific effect” and homeopath* (6) 
The number in brackets indicates the number of studies identified. 
Search 2 – 14th June 2012 
Database: AMED (Allied and Complementary Medicine) 1985 to June 13 
2012. 
The search was modified for Embase Classic and Embase (1947 to June 13 
2012) and Ovid MEDLINE(R) (1950 to June Week 1 2012). 
Search Strategy 
Search 
number 
Search term Number of hits identified 
AMED Embase 
Classic + 
Embase 
MEDLINE 
1 “specific effect*” .mp. 
[mp=abstract, heading 
words, title]  
188 16 882 4 277 
2 “context effect*” .mp. 
[mp=abstract, heading 
words, title]  
29 914 175 
3 Exp homeopathy/  11 340 7 764 3 937 
4 1 OR 2  217 17 793 4 464 
5 3 AND 4 (14) (27) 14 27 5 
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Appendix 2 
Searches for trials of homeopathic treatment for irritable bowel 
syndome 
Search 1 – 14th June 2012 
A search was carried out in Web of Science using the terms: 
“irritable bowel syndrome” OR “irritable bowel disease” OR “irritable colon”  
AND  
“homeopath*” OR “homoeopath*” (16) 
The number in brackets indicates the number of studies identified. 
Search 2 – 14th June 2012 
Database: AMED (Allied and Complementary Medicine) (1985 to June 2012) 
The search was modified for Embase Classic + Embase (1947 to 2012 June 
14) and Ovid MEDLINE (1946 to June week 3 2012) 
Search Strategy 
Search 
number 
Search term Number of hits identified 
AMED Embase 
Classic + 
Embase 
MEDLINE 
1 irritable bowel syndrome” 
.mp. [mp=abstract, 
heading words, title] 
209 10 051 6 996 
2 irritable bowel disease” 
.mp. [mp=abstract, 
heading words, title] 
1 135  6 996 
3 “irritable colon” .mp. 
[mp=abstract, heading 
words, title] 
1 13 720 391 
4 Exp irritable bowel 
syndrome/ 
790 13 587 3 378 
5 1 OR 2 OR 3 OR 4 210  15 106 7 364 
6 Exp homeopathy/ 11 340  7 778 3 889 
7 5 AND 6 15 50 6 
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Appendix 3 
Searches for attention controls in IBS trials 
Search 1 - 21st June 2012 
Database: Ovid MEDLINE(R) (1950 to June Week 2 2012). The search was 
modified for PsycINFO (1806 to June Week 2 2012) and Embase Classic + 
Embase (1947 to June 20 2012).  
Search Strategy 
 
Search 
number 
Search term Number of hits identified 
MEDLINE  PsycINFO Embase 
Classic 
+ 
Embase 
1 exp Irritable Bowel 
Syndrome/  
3 365 681 13 561 
2 "attention* placebo".mp. 
[mp=title, abstract, 
heading word, table of 
contents, key concepts]  
113 252 169 
3 "attention* control".mp. 
[mp=title, abstract, 
heading word, table of 
contents, key concepts]  
1 350 1 939 1 776 
4 "supportive listening".mp. 
[mp=title, abstract, 
heading word, table of 
contents, key concepts]  
22 27 28 
5 “supportive 
counselling".mp. [mp=title, 
abstract, heading word, 
table of contents, key 
concepts]  
58 48 86 
6 "supportive therapy".mp. 
[mp=title, abstract, 
heading word, table of 
contents, key concepts]  
2 319 556 3 697 
7 2 OR 3 OR 4 OR 5 OR 6  3 856 2 825 5 746 
 8     1 AND 7  10 8 23 
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Search 2 -21st June 2012 
Searches  were carried out in Web of Science using the terms: 
1. “attention* placebo” AND “irritable bowel syndrome” OR “attention* 
control” AND “irritable bowel syndrome” (6) 
2. (“supportive listening*” AND “ irritable bowel syndrome”) OR 
(“supportive therapy” AND “ irritable bowel syndrome”) OR 
(“supportive counselling*” AND “ irritable bowel syndrome”) (18) 
3. “relaxation” AND “ irritable bowel syndrome” (311) 
Numbers in brackets indicate the number of studies identified in each of the 
searches. 
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Appendix 4 
Provenance statement from wider trial 
JR, CW, KK, CS originally conceived the idea for a HIBS RCT to address the 
primary research question, and obtained the initial seed funding from 
Barnsley Hospital Small Grant Fund. CS, JR, EG & CR wrote the original 
protocol. EP conceived the idea for the secondary research question. CR 
applied the ‘cohort multiple RCT’ design to the original and secondary 
research question. KT provided guidance throughout. CR & EP wrote the 
protocol. 
KT and EP are supported and funded by the University of Leeds. CR was 
supported by the University of Leeds and is now supported by the University 
of Sheffield. 
For any peer reviewed publications that derive from this study the following 
authors will be eligible for authorship: JR, CW, KK, ES, CS, KT, EP, CR, EG.
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Appendix 5 
Searches of IBS trials that had used an attention control 
Search 1 – 19th June 2010 
Database: AMED (Allied and Complementary Medicine) 1985 to June 2010. 
The search was modified for Embase (1996 to 2010 Week 22) and Ovid 
Medline (1996 to May Week 4 2010) 
Search Strategy 
Search 
number 
Search term Number of hits identified 
AMED Embase Ovid 
Medline 
1 “specific effect*” .mp. [mp=abstract, 
heading words, title] 
52 2 679 2 193 
2 “context effect*” .mp. [mp=abstract, 
heading words, title] 
0 135 88  
3 Exp irritable bowel syndrome/ 72 8 910 2 790 
4 Exp colonic diseases/ 0 184 295 90 102 
5 Exp colonic diseases, functional/ 0 8 910  4 655 
6 “irritable bowel*” .mp. [mp=abstract, 
heading words, title] 
214 7 316 5 128 
7 “irritable colon” .mp. [mp=abstract, 
heading words, title] 
1 8 924 47 
8 “spastic colon” .mp. [mp=abstract, 
heading words, title] 
4 18 9 
9 “functional bowel disease*” .mp. 
[mp=abstract, heading words, title] 
0 113 58 
10 “functional colonic disease*” .mp. 
[mp=abstract, heading words, title] 
0 3 0  
11 1 OR 2 52 2 814 2 281 
12 3 OR 4 OR 5OR 6OR 7 OR 8 OR 9 
OR 10 
217 185 169 91 226 
13 1 AND 3 0 42 23 
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Appendix 6 
Invitation to the Cohort 
         GP Address 
         Date 
 
Barnsley Irritable Bowel Syndrome Cohort Study  
 
Dear XXXX 
I warmly invite you to take part in the Barnsley Irritable Bowel Syndrome 
Cohort Study.This study will provide valuable information to help the NHS 
make decisions about what type of treatments and services to provide to 
people with IBS in the future. This study aims to recruit 600 patients from our 
GP practice and others within Barnsley PCT to obtain this information. 
Please read the enclosed Information Sheet carefully. This tells you more 
about the study and what happens if you agree to take part. If you want to 
ask any questions, please ask Dr Kapil Kapur at C/o Gastroenterology Dept, 
Barnsley Hospital NHS Foundation Trust, Gawber Road, Barnsley,S75 2EP 
or Emily Peckham School of Healthcare, Baines Wing, University of Leeds, 
LS2 9JT, 0113 3433201, Email: hcejp@leeds.ac.uk. 
I want to assure you that the information you provide the researchers with 
will be kept strictly confidential. Your name will not be mentioned in any 
reports or given to anyone outside the research team. 
If you are happy to take part in the study, please now complete the enclosed 
Questionnaire and sign the Consent Form on the back and send it back to 
the researchers. 
Thank you for sparing the time to read through this, if you choose, for taking 
part in this important research study.  
Yours Sincerely 
Dr XXXX 
Practice Name 
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Patient Information Sheet for Cohort Study 
Barnsley Irritable Bowel Syndrome Cohort Study 
We would like you to take part in a research study. Before you decide, you 
need to understand why this study is being done and what it will involve for 
you.  
Please take time to read the following information carefully. 
Talk to others about the study if you wish.  
Ask us if there is anything that is not clear or if you would like more 
information.  
Take time to decide whether or not you wish to take part.  
Thank you for taking the time to read this. 
What is the purpose of the study? 
The purpose of this study is to follow approximately 600 adults in Barnsley 
who have visited their GP or consultant with IBS type symptoms and to 
collect information about their health, general well being and any treatments 
they are receiving. This study will provide valuable up to date information on 
IBS.  
About 1 in 20 people who have chosen to participate in this study will be 
randomly selected to be offered a treatment. We currently want to test the 
effectiveness of the following two treatments: 
1. Homeopathic treatment 
2. Supportive listening 
Inclusion in the study does not necessarily mean that you will be offered 
one of the above treatments. If you are randomly selected to be offered one 
of the treatments you will be sent a separate letter and an information sheet 
with further details describing the treatment offered. It is entirely up to you 
whether or not you choose to take up the offer and it will not affect any of 
your future care or treatment within the NHS. 
Why have I been chosen? 
You have been chosen because you have had either a diagnosis of IBS or 
are taking medication commonly prescribed for those suffering from IBS. 
Do I have to take part? 
No participation is entirely voluntary. Not taking part will not affect any of 
your future care or treatment within the NHS. No one will know that you have 
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not agreed to take part in the study. Even if you take part now, you can 
decide not to take any further part in the study by not completing any further 
questionnaires that we send you. You do not have to give any reasons. 
What will happen to me if I take part? 
If you agree to take part you please complete the enclosed Questionnaire 
and return it to the researchers at the University of Leeds. This information 
will be very helpful to the researchers and the NHS.  
What do I have to do? 
Complete and return Questionnaire number 1 in the pre paid envelope 
provided. 
 Continue your life as normal, continuing to take your medication as 
before. 
What are the possible benefits of taking part? 
There are no benefits to you personally, however if you take part you will be 
helping us to advance understanding of IBS. The information we gather 
from this study may help us to treat patients with IBS in the future.  
What are the possible disadvantages of taking part? 
You will have to make time to complete the questionnaires.  
What if there is a problem? 
Any complaint about the way you have been dealt with during the study will 
be addressed. If you have a concern about any aspect of this study, you 
should ask to speak with the Patient Advice and Liaison Service (PALS) at 
Barnsley Hospital. The address is below: 
Patient Advice and Liaison Service, Main Reception, Barnsley Hospital NHS 
Foundation Trust, Gawber Road, Barnsley, S75 2EP 
Tel: 01226 730000 Ext: 2430 
Will my taking part in this study be kept confidential? 
All information that you give us will be kept strictly confidential. Your name 
will not be mentioned in any reports. Only members of the research team will 
know that you have agreed to take part in the study.  
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As we will be sending you further questionnaires we need your name and 
contact details. These personal details will be stored in locked filing cabinets 
and all electronic copies will be stored on a secure server accessed by 
password – protected computers at the University of Leeds. 
We will ask your permission to write to your GP and inform them that you are 
involved in the study and this is only for their information. 
What will happen to the results of the study? 
The data that you provide will be anonymised and may be used in the future 
to compare treatments for IBS. The results of the study will be presented at 
conferences and submitted to a scientific journal for publication. We expect 
this to happen within 6 months of the end of the study. We will also write a 
short report for all participants and this will be sent to you and your GP.  You 
will not be identified in any reports or publications. 
Who is organising and funding the study? 
Dr Kapil Kapur who is a Consultant Gastroenterologist at Barnsley Hospital 
is leading the study. The Barnsley Health and Social Care R&D Alliance 
small projects fund and Friends of Barnsley Hospital are funding the study. 
Who has reviewed the study? 
The study has been reviewed by Leeds East Research Ethics Committee 
and by the Consumers in Research Advisory Group at Barnsley Hospital. 
Contact for further information 
Dr Kapil Kapur, C/o Gastroenterology Dept, Barnsley Hospital NHS 
Foundation Trust, Gawber Road, Barnsley, S75 2EP or Emily Peckham, 
School of Healthcare, Baines Wing, University of Leeds, LS2 0113 3433201, 
Email: hcejp@leeds.ac.uk 
Thank you for taking this the time to read this information sheet. 
Please keep this copy. 
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Appendix 7 
Invitation letter for Homeopathic treatment 
 
 
 
 
School of Healthcare 
Baines Wing 
University of Leeds 
LS2 9JT 
 
Homeopathic treatment for Irritable Bowel Syndrome. 
Dear  
We are writing to invite you to take part in a study of homeopathic treatment 
for Irritable Bowel Syndrome. This study will provide valuable information to 
help the NHS make decisions about what type of treatments and services to 
provide to people with IBS in the future. 
Please read the enclosed Information Sheet carefully. This tells you more 
about the study and what happens if you agree to take part. If you want to 
ask any questions, please ask: 
 Dr Kapil Kapur C/o Gastroenterology Dept, Barnsley Hospital NHS 
Foundation Trust, Gawber Road, Barnsley, S75 2EP  
Emily Peckham School of Healthcare, University of Leeds, 0113 3433201. 
Email: hcejp@leeds.ac.uk 
We would be grateful if you could give this study some consideration and we 
will telephone you in the week commencing 14th March 2011 to discuss any 
questions you may have and, if you do wish to take part, arrange an 
appointment with a homeopath at Barnsley Hospital. 
If you decide that you are happy to take part in the study, please sign the 
enclosed Consent Form and send it back to the researchers. Thank you for 
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sparing the time to read through this and, if you choose, for taking part in this 
important research study. 
Yours Sincerely 
Kapil Kapur       Emily Peckham 
Barnsley Hospital       University of Leeds
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Patient information sheet for homeopathic treatment 
 
 
 
Information Sheet 
Homeopathic treatment for Irritable Bowel Syndrome. 
 We would like you to take part in a research study. Before you decide, 
you need to understand why this study is being done and what it will 
involve for you.  
 Please take time to read the following information carefully. 
 Talk to others about the study if you wish.  
 Ask us if there is anything that is not clear or if you would like more 
information.  
 Take time to decide whether or not you wish to take part.  
Thank you for taking the time to read this. 
What is the purpose of the study? 
We are conducting an exploratory study to evaluate whether the addition of 
homeopathic treatment to usual care improves outcomes for patients with a 
diagnosis of IBS. 
Why have I been chosen? 
You have been chosen because you previously agreed to take part in an 
observational study of patients with irritable bowel syndrome. You have been 
randomly selected from this observational study to be offered homeopathic 
treatment. 
Do I have to take part? 
No, it is up to you whether or not you decide to take part. If you do decide to 
be included you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to withdraw 
at any time and without giving a reason. A decision to withdraw at any time, 
or a decision to not be included in the study, will not affect the standard of 
care that you receive. 
What is the drug or procedure that is being tested? 
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Homeopathic treatment involves a consultation with a homeopath followed 
by the prescription of a homeopathic remedy. It has been available on the 
NHS since 1948, however there is no clear proof as to whether or not it 
works. Whilst some patients report a benefit with homeopathic treatment we 
don’t know whether this is the case for more than a handful of people. In this 
study we are trying to find out if homeopathic treatment improves IBS 
symptoms. 
What will happen to me if I take part? 
If you agree to take part in this research project, you will be given a copy of 
the signed consent form to keep. 
You will be involved in the study for 52 weeks. During this time you will be 
asked to attend Barnsley Hospital for appointments with a homeopath 5 
times. 
At the end of your second appointment with a homeopath at Barnsley 
Hospital you will be given a questionnaire to compete and return in the 
prepaid envelope provided. 
What do I have to do? 
If you agree to homeopathic treatment we will ask you to attend five 
appointments with a homeopath and take the prescribed homeopathic 
remedy. You will continue to take your medication as before. 
What are the side effects of any treatment received when taking part? 
We do not expect you to have any adverse reaction to the homeopathy 
treatment. However, you will be given your homeopaths contact number if 
you have any questions or concerns. 
What are the possible benefits of taking part? 
You may find an improvement in your condition, but this cannot be 
guaranteed. The information we gather from this study will help us to treat 
patients with IBS in the future. 
What are the disadvantages of taking part? 
You will have to make time to attend the homeopathy appointments.  
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What happens when the research study finishes? 
At the end of the study if you wish to continue homeopathic treatment you 
will be given details of how to access homeopathic treatment privately or on 
the NHS. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study will 
be addressed. If you have a concern about any aspect of this study you 
should contact the Patient Advice and Liaison Service (PALS) at Barnsley 
Hospital. The address is below: 
Patient Advice and Liaison Service, Main Reception, Barnsley Hospital NHS 
Foundation Trust 
Gawber Road, Barnsley, S75 2EP Tel: 01226 730000 Ext: 2430 
 
Will my taking part in this study be kept confidential? 
All information that you give us will be kept strictly confidential. Your name 
will not be mentioned in any reports. Only members of the research team will 
know that you have agreed to take part in the study. As we will be sending 
you further questionnaires we need your name and contact details. These 
personal details will be stored in locked filing cabinets and all electronic 
copies will be stored on a secure server accessed by password – protected 
computers at the University of Leeds. 
 
We will ask your permission to write to your GP and inform them that you are 
involved in the study and this is only for their information. 
What will happen to the results of the study? 
The results of the study will be presented at conferences and submitted to a 
scientific journal for publication. We expect this to happen within 6 months of 
the end of the study. We will also write a short report for all participants and 
this will be sent to you and your GP. You will not be identified in any reports 
or publications. 
Who is organising and funding the study? 
Dr Kapil Kapur who is a Consultant Gastroenterologist at Barnsley Hospital 
is leading the study. The Barnsley Health and Social Care R&D Alliance 
small projects fund are funding the study. 
Who has reviewed the study? 
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The study has been reviewed by Leeds East Research Ethics Committee 
and by the Consumers in Research Advisory Group at Barnsley Hospital. 
Contact for further information 
Emily Peckham, Baines Wing, School of Healthcare, University of 
Leeds,LS2 9JT 
Tel: 0113 3433201 Email: hcejp@leeds.ac.uk 
 
Thank you for taking this the time to read this information sheet.  
 Please keep this copy. 
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Consent form for Homeopathic treatment 
 
 
 
 
Consent Form 
Title of project : Homeopathic treatment for Irritable Bowel Syndrome 
Research Team ; Dr K Kapur, Mrs J Raw, Mrs C Walters, Ms Emily 
Peckham,Dr C Relton, Dr E Said, Dr CM Smith, Miss E Goodwin 
 
1. I confirm that I have read and understand the information sheet 
dated November 2010. 
 
 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason. In this case 
my medical care or legal rights will not be affected in any way. 
 
 
3. I give permission for my GP to be informed of my participation in 
the study 
 
 
4. I agree to take part in the above study. 
 
 
 
_________________ ___________  _______________ 
Name of patient  Date    Signature 
_________________ ___________  _______________ 
Researcher  Date    Signature 
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Invitation letter for supportive listening 
  
 
        School of Healthcare 
Baines Wing  
 University of Leeds
 LS2 9JT 
Supportive listening for Irritable Bowel Syndrome 
Dear  
We are writing to invite you to take part in a study of supportive listening for 
Irritable Bowel Syndrome. This study will provide valuable information to help 
the NHS make decisions about what type of treatments and services to 
provide to people with IBS in the future. 
Please read the enclosed Information Sheet carefully. This tells you more 
about the study and what happens if you agree to take part. If you want to 
ask any questions, please ask: 
 Dr Kapil Kapur C/o Gastroenterology Dept, Barnsley Hospital NHS 
Foundation Trust, Gawber Road, Barnsley,S75 2EP  
Emily Peckham School of Healthcare, University of Leeds, 0113 3433201. 
Email: hcejp@leeds.ac.uk 
We would be grateful if you could give this study some consideration and we 
will telephone you in the week commencing 14 March 2011 to discuss any 
questions you may have and, if you do wish to take part arrange an 
appointment with a counselor at Barnsley Hospital. 
If you are happy to take part in the study, please sign the enclosed Consent 
Form and send it back to the researchers. Thank you for sparing the time to 
read through this and, if you choose, for taking part in this important 
research study. 
Yours Sincerely 
Kapil Kapur       Emily Peckham 
Barnsley Hospital       University of Leeds 
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Patient information sheet for supportive listening 
 
                 
 
 
Information Sheet 
Supportive listening for Irritable Bowel Syndrome. 
 We would like you to take part in a research study. Before you decide, 
you need to understand why this study is being done and what it will 
involve for you.  
 Please take time to read the following information carefully. 
 Talk to others about the study if you wish.  
 Ask us if there is anything that is not clear or if you would like more 
information.  
 Take time to decide whether or not you wish to take part.  
Thank you for taking the time to read this. 
What is the purpose of the study? 
We are conducting a study to evaluate whether supportive listening in 
addition to your usual care will improve outcomes for patients with IBS. 
Why have I been chosen? 
You have been chosen because you previously agreed to take part in an 
observational study of patients with IBS. You have been randomly selected 
from this observational study to be offered supportive listening. 
Do I have to take part? 
No, it is up to you whether or not you decide to take part. If you do decide to 
be included you will be given this information sheet to keep and asked to 
sign a consent form. If you decide to take part you are still free to withdraw 
at any time and without giving a reason. A decision to withdraw at any time, 
or a decision to not be included in the study, will not affect the standard of 
care that you receive. 
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What will happen to me if I take part? 
If you agree to take part in this research project, you will be given a copy of 
the signed consent form to keep. 
You will be involved in the study for 52 weeks. During this time you will be 
asked to attend Barnsley Hospital for appointments with a trained 
professional 5 times. 
At the end of your second appointment with a supportive listener at Barnsley 
Hospital you will be given a questionnaire to compete and return in the 
prepaid envelope provided. 
A selection of the supportive listening appointments will be recorded on an 
audiotape. This is to ensure that the therapist is providing supportive 
listening and not a type of counselling such as cognitive behavioural therapy. 
An independent person will listen to the audiotape to confirm this. After they 
have listened to the audiotape it will be destroyed. The tape will be 
anonymised prior to the independent assessor listening to it and they will 
have no way of identifying you from the tape. 
What do I have to do? 
If you agree to supportive listening we will ask you to attend 5 appointments 
with a trained professional at Barnsley Hospital. You will continue to take 
your usual medication as before. 
What is the drug or procedure that is being tested? 
Supportive listening will provide you with the opportunity to discuss your IBS 
with a trained professional. During the sessions you will be encouraged to 
talk about your physical symptoms as well as any emotional issues and to 
discuss how these might be coped with in a better way.  
Whilst some people find talking to somebody and being supported helpful we 
don’t know if this is the case for the majority of people and we are trying to 
find out if supportive listening helps patients with IBS. 
What are the side effects of any treatment received when taking part? 
We do not expect you to have any adverse reaction to the treatment. You 
will be given a contact number if you have any questions or concerns. 
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What are the possible benefits of taking part? 
You may find an improvement in your condition, but this cannot be 
guaranteed. The information we gather from this study will help us to treat 
patients with IBS in the future. 
What are the disadvantages of taking part? 
You will have to make time to attend the supportive listening appointments.  
What happens when the research study finishes? 
At the end of the study, if you wish to continue supportive listening you will 
be given details of how to access treatment privately or on the NHS. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study will 
be addressed. If you have a concern about any aspect of this study you 
should contact the Patient Advice and Liaison Service (PALS) at Barnsley 
Hospital. The address is: 
Patient Advice and Liaison Service, Main Reception, Barnsley Hospital NHS 
Foundation Trust 
Gawber Road, Barnsley, S75 2EP 
Tel: 01226 730000 Ext: 2430 
Will my taking part in this study be kept confidential? 
All information that you give us will be kept strictly confidential. Your name 
will not be mentioned in any reports. Only members of the research team will 
know that you have agreed to take part in the study. As we will be sending 
you further questionnaires we need your name and contact details. These 
personal details will be stored in locked filing cabinets and all electronic 
copies will be stored on a secure server accessed by password – protected 
computers at the University of Leeds. 
We will ask your permission to write to your GP and inform them that you are 
involved in the study and this is only for their information. 
What will happen to the results of the study? 
The results of the study will be presented at conferences and submitted to a 
scientific journal for publication. We expect this to happen within 6 months of 
the end of the study. We will also write a short report for all participants and 
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this will be sent to you and your GP. You will not be identified in any reports 
or publications. 
Who is organising and funding the study? 
Dr Kapil Kapur who is a Consultant Gastroenterologist at Barnsley Hospital 
is leading the study. The Barnsley Health and Social Care R&D Alliance 
small projects fund are funding the study. 
Who has reviewed the study? 
The study has been reviewed by Leeds East Research Ethics Committee 
and by the Consumers in Research Advisory Group at Barnsley Hospital. 
Contact for further information 
Emily Peckham, Baines Wing, School of Heathcare,University of Leeds, LS2 
9JT 
Tel: 0113 3433201, Email: hcejp@leeds.ac.uk 
 
Thank you for taking this the time to read this information sheet.  
 Please keep this copy
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Consent for supportive listening 
 
  
 
Consent Form 
Title of project : Supportive listening Irritable Bowel Syndrome 
Research Team ; Dr K Kapur, Mrs J Raw, Mrs C Walters, Ms Emily 
Peckham, 
Dr C Relton, Dr E Said, Dr CM Smith, Miss E Goodwin 
 
1. I confirm that I have read and understand the information sheet 
dated November 2010 
 
 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason. In this case 
my medical care or legal rights will not be affected in any way. 
 
 
3. I give permission for my GP to be informed of my participation in 
the study 
 
 
4. I give permission for my supportive sessions to be recorded on 
an audiotape 
 
 
5. I agree to take part in the above study. 
 
 
 
_________________ ___________  _______________ 
Name of patient  Date    Signature 
_________________ ___________  _______________ 
Researcher  Date    Signature 
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Appendix 8 
EuroQol Agreement 
Dear Ms/Mr. Peckham,   
Thank you for registering your research at the EuroQol Group's website.  
 
As the study you registered at the EuroQol website involves low patient 
numbers (200) and is not funded by a pharmaceutical company/medical 
device manufacturer, or any other profit-making stakeholders, you may use 
the EQ-5D instrument free of charge. If this is not the case, or the situation 
changes, please inform us as the EuroQol Group Foundation has a specific 
policy for large academic studies and/or studies funded by profit making 
bodies.  
 Please note that permission granted above only relates to the paper version 
of EQ-5D. Requests to use digital representations of EQ-5D (e.g. web, 
tablet, PDA) should be made separately to 
userinformationservice@euroqol.org attaching your initial registration. 
 
Please find attached the UK English EQ-5D-3L version (word format). A brief 
user guide is downloadable from the homepage of the EuroQol website 
(www.euroqol.org).  
 Kind regards, 
 Nalinie Banarsi 
Office Assistant 
EuroQol Group Foundation 
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Appendix 9 
Invitation letter to interviews 
 
 
 
        School of Healthcare
        Baines Wing  
        University of Leeds 
        Leeds   
        LS2 9JT 
        
Dear  
I am writing to invite you to take part in a study of patient’s experiences of 
their treatment as part of the Barnsley Irritable Bowel Syndrome Cohort 
Study. 
The study involves a 1 -1 ½ hour interview with Emily Peckham a PhD 
student at the University of Leeds. During this interview you will be asked 
about the treatment you received and whether you found it helpful. We are 
interested in your experiences whether you found the treatment helpful or 
not, see the enclosed information sheet for further details.  
The interviews will be used to look at whether or not people found the 
treatment helped their irritable bowel symptoms and general health and 
what, if anything it was about the treatment that helped or didn’t help.  
If you decide that you are happy to take part in the study, please sign the 
enclosed Consent Form and Contact Information Form and send them back 
to the Emily Peckham in the prepaid envelope provided. If you have any 
queries please contact Emily Peckham at the address given or by email: 
hcejp@leeds.ac.uk, or phone 0113 3433201. 
 Thank you for sparing the time to read through this. 
Yours Sincerely 
 
Emily Peckham
335 
 
 
 
Participant information sheet for interviews 
 
 
 
Information Sheet 
Interviews exploring patients experience of treatment for Irritable 
Bowel Syndrome (IBS). 
 We would like you to take part in a research study. Before you decide, 
you need to understand why this study is being done and what it will 
involve for you.  
 Please take time to read the following information carefully. 
 Talk to others about the study if you wish.  
 Ask us if there is anything that is not clear or if you would like more 
information.  
 Take time to decide whether or not you wish to take part.  
 
Thank you for taking the time to read this. 
What is the purpose of the study? 
We are conducting interviews to find out if people receiving treatment found 
it helped their IBS symptoms.  
Who is doing the study? 
Emily Peckham a PhD student at the University of Leeds will be carrying out 
the study. 
Why have I been chosen? 
You have been chosen because you have been receiving treatment for your 
IBS as part of the Barnsley Irritable Bowel Syndrome Cohort Study. 
Do I have to take part? 
No, it is up to you whether or not you decide to take part. If you do decide to 
be included you will be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. If 
you do not wish to take part you can still remain in the Barnsley Irritable 
Bowel Syndrome Cohort Study. A decision not to take part will not affect any 
of the care you receive now or in the future. 
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What will be involved if I take part in this study? 
 You will be asked to attend one interview which will last 1 -1½ hours 
either in your home or another mutually convenient location. 
Unfortunately we do not have funds to reimburse travel expenses. 
 We will ask about the treatment you received at Barnsley hospital. We 
are interested in whether or not you found the treatment helpful, what 
was helpful/unhelpful about the treatment, did you feel the treatment 
worked (or not)? 
 There are no right or wrong answers. We just want to hear about your 
experiences, whether you found the treatment helpful or not.  
 We will ask you if we can record the interview.  
 The recording will be downloaded onto a computer and typed up.  
We will be asking questions about your expectations about the treatment 
you received and your views and experiences of receiving it. 
What do I have to do? 
If you would like to take part in this study you need to complete and return 
the enclosed consent form and contact details form to Emily Peckham at 
the School of Healthcare, Baines Wing, University of Leeds, LS2 9JT or 
by e-mail hcejp@leeds.ac.uk. 
What are the possible benefits of taking part? 
There are no benefits to you personally however data gathered from this 
study may be used in the future to help people with IBS. 
What are the disadvantages of taking part? 
You will have to make time to attend the interview.  
Can I withdraw from the study at any time? 
Yes. Your participation is voluntary and so you can withdraw (i.e. tell the 
researcher that you do not want to take part) at any time without giving a 
reason. A decision to withdraw at any time, or a decision to not be included 
in the study, will not affect the standard of care that you receive. 
Will the information I give be kept confidential? 
Yes. All information that you give us will be kept strictly confidential. Your 
name will not be mentioned in any reports. You will be given an identification 
(ID) number and your interview responses will be stored on a secure server 
accessed by a password – protected computer using this ID number instead 
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of your name. Only the researchers at the University of Leeds will be able to 
link your name to your ID number. Your contact details linking you to your ID 
number will be destroyed three months after the end of the study.  
Very occasionally, there may be a concern that a participant or someone 
they know is at risk. In this situation it may be necessary to pass on 
information to someone outside the research team. We would let you know if 
we were going to do this. 
What will happen to the results of the study? 
The results of the study will be presented at conferences and submitted to a 
scientific journal for publication. We expect this to happen within 6 months of 
the end of the study. We will also write a short report for all participants and 
this will be sent to you. Results of this study may also be used in teaching. 
You will not be identified in any reports or publications.  
Who has reviewed the study? 
The study has been reviewed by Leeds (Central) Research Ethics 
Committee.  
Contact for further information 
Emily Peckham, Baines Wing, School of Healthcare, University of Leeds, 
LS2 9JT 
Email: hcejp@leeds.ac.uk 
 
Thank you for taking this the time to read this information sheet.  
 Please keep this copy. 
 
What to do now 
If you do not want to take part – do nothing 
If you do want to take part - complete: 
 The consent form 
 The contact details form 
Then post them in the prepaid envelope provided.
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Consent form for interviews 
 
 
Participant Consent Form 
Patients experiences of treatment for IBS 
The participant should complete the whole of this sheet himself/herself 
 Please confirm the 
statements by putting your 
initials in the box below 
I have read and understood the participant information 
sheet 
 
I have had the opportunity to ask questions and discuss 
this study 
 
I have received satisfactory answers to all of my 
questions 
 
I have received enough information about the study  
I understand that I am free to withdraw from the study:- 
1 At any time 
2 Without having to give a reason for withdrawing. 
 
I understand that any information I provide, including 
personal details, will be confidential, stored securely and 
only accessed by those carrying out the study. 
 
I understand that my interview will be audio-recorded   
I understand that any information I give may be included 
in published documents but my identity will be protected 
by the use of pseudonyms 
 
I understand that relevant sections of data collected 
during the study may be looked at by individuals from the 
University of Leeds, from regulatory authorities or from 
the NHS Trust, where it is relevant to my taking part in 
this research. I give permission for these individuals to 
have access to my records. 
 
I agree to take part in this study  
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Participant Signature ……………………………                               Date  
Name of Participant   
Researcher Signature …………………………………                      Date  
Name of Researcher 
Thank you for agreeing to take part in this study 
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Research Interview Safety Protocol (Home Visit) 
Before the interview date: 
 Emily Peckham (EP) to pre-arrange call-in/call-out system with 
contact person few days before each scheduled home visit, to ensure 
availability. 
 Contact person will either be supervisor or another colleague/friend, 
who will also have this protocol.  
 A sealed envelope containing details of the address to be visited, the 
name of the person, a contact phone number for that person will be 
given to the contact person prior to the interview. 
 EP will e-mail the contact person with details of the time the interview 
is to commence, and therefore the time to expect the first phone call. 
 Contact person to confirm receipt of this email by email or text. 
Before starting the interview: 
 On arriving at the address of the interview, EP will phone contact 
person to say visit is about to start, and agree a time when the 
interview should be finished. 
 EP will explain to the interviewee before the start of the interview that 
the University insist on this call-in/call-out system, and that if the 
interview over-runs s/he will need to make a quick phone call. 
 If the interview over-runs, EP will take a break and phone contact 
person to inform them, and to agree a second finish time. 
 If, on arrival at the address, EP has any concerns re safety (location, 
environment, other persons at address, or interviewee), she will not 
proceed with the interview. Interviewee and contact person will be 
informed, EP will return to base, and attempt to re-schedule the 
interview at an alternative location. 
After the interview: 
 EP will phone contact person to inform them that she has left the 
house, at or before the pre-arranged time. 
 Contact person to shred sealed envelope. 
General points: 
 EP will endeavour to do home visit interviews during the day /early 
evening, rather than later on in the evening, or at weekends. 
 If EP is having trouble with their phone, or does not/cannot make the 
interview for some reason, or the interviewee cancels the interview, 
contact person should be informed as soon as possible. EP will 
continue to attempt to make contact until contact person confirms 
receipt of the message. 
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 In the very unlikely situation that EP is being held against their will, 
but is allowed to make/receive phone calls, researcher will used an 
agreed “code” phrase in the phone call with contact person: “OK, I 
should be back in Manchester by then”. In this event contact person 
will immediately phone the police. 
In the event that researcher does not phone at the agreed time: 
1. Contact to phone EP on mobile phone 
2. If no response, contact will phone interviewee 
3. If no response, contact to phone police to report EP missing, 
giving details of address, person interviewed, and car registration 
no. 
4. If appropriate, contact/police to contact relative  
Emily Peckham’s contact details 
.................... 
Adapted from template produced by Sheila C Youngson, July 2005 
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